<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25081539</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8392</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>45</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Human pathology</Title>
<ISOAbbreviation>Hum. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Low expression of CD112 is associated with poor overall survival in patients with hepatocellular carcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>1944-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humpath.2014.06.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0046-8177(14)00238-X</ELocationID>
<Abstract>
<AbstractText>CD112 as an important ligand of CD226 can stimulate the natural killer (NK) cell-mediated target cell lysis. Previous studies have reported that CD112 is involved in cancer initiation and progression. However, its expression and clinical significance in hepatocellular carcinoma (HCC) have never been investigated. In this study, we used immunohistochemistry to examine CD112 expression in cancer and pericancer tissues from 159 HCC cases. Western blot and immunofluorescence were used to detect CD112 expression in HCC cell lines. χ(2) Test was used to assess the association of CD112 expression with clinicopathological characteristics, whereas Kaplan-Meier survival function and Cox proportional hazards regression model were used to explore the association between CD112 expression and clinical outcome of patients with HCC. Overall, CD112 expression was significantly reduced in HCC tissues when compared with adjacent pericancer liver tissues (P &lt; .001). Western blot and immunofluorescence analyses showed that most HCC cell lines had low CD112 expression level. Furthermore, low CD112 expression was significantly associated with high serum α-fetoprotein level (P = .004) in patients with HCC. Kaplan-Meier analysis showed that patients with low CD112 expression had poorer postsurgery overall survival than those with high CD112 expression (log-rank P = .045). In conclusion, our findings demonstrate that the down-regulation of CD112 may be an important mechanism through which HCC cells evade the natural killer cell-mediated immunosurveillance, and thus, CD112 may be a useful biomarker to assess the immunologic niche of HCC. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Xiaojun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qu</LastName>
<ForeName>Ping</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yibing</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Xingchun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Yousheng</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Fange</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Dandan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Shandong Medicinal Biotechnology Centre, Shandong Academy of Medical Sciences, Jinan 250062, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China. Electronic address: zhanglu1@fmmu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>An</LastName>
<ForeName>Jiaze</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. Electronic address: anchen@fmmu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Pathol</MedlineTA>
<NlmUniqueID>9421547</NlmUniqueID>
<ISSNLinking>0046-8177</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508020">IL2RB protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053646">Interleukin-2 Receptor beta Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053646">Interleukin-2 Receptor beta Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Biomarker</Keyword>
<Keyword MajorTopicYN="N">CD112</Keyword>
<Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
<Keyword MajorTopicYN="N">Immunohistochemistry</Keyword>
<Keyword MajorTopicYN="N">Prognosis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25081541</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8392</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>45</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Human pathology</Title>
<ISOAbbreviation>Hum. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Reversed expression of GRIM-1 and GRP78 in human non-small cell lung cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1936-43</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humpath.2014.04.023</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0046-8177(14)00237-8</ELocationID>
<Abstract>
<AbstractText>Gene associated with retinoid and interferon-induced mortality 1 (GRIM-1) acts as a tumor growth suppressor via apoptosis induction. However, GRIM-1 expression in human non-small cell lung cancer (NSCLC) and its potential interaction with another apoptosis-associated protein-glucose-regulated protein 78 (GRP78)-are as yet unknown. Using 40 surgical specimens, we showed significantly lower expression of GRIM-1 in NSCLC at both protein and messenger RNA (mRNA) levels compared with that in normal tissues (P &lt; .01 and P &lt; .001, respectively). Interestingly, these tumors tended to express higher basal amounts of GRP78 protein and mRNA (P &lt; .05 and P &lt; .001, respectively). Similarly, in the NSCLC tissues, weaker staining for GRIM-1 (main intensity + to ++) but stronger staining for GRP78 (main intensity +++ to ++++) was observed. Correlation analysis showed that protein and mRNA expression or the percentage of cells immunoreactive for GRIM-1 was negatively correlated with that of GRP78 (r = -0.279, r = -0.326, or r = -0.571, respectively). Coimmunoprecipitation and transient transfection revealed that GRIM-1 interacted with GRP78 and suppressed GRP78 protein expression. In addition, there was no correlation between GRIM-1 expression and clinical characteristics, whereas GRP78 expression was significantly correlated with tumor-nodes-metastasis (TNM) stage (stage 3 + 4 versus stage 1 + 2). In conclusion, the expression of GRIM-1 and GRP78 was negatively correlated in human NSCLC tissues, and the down-regulation of GRP78 by GRIM-1 provides a possible mechanism for their interaction. This study suggests a novel potential molecular pathway inactivated during the development of NSCLC. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Hui-Mei</ForeName>
<Initials>HM</Initials>
<AffiliationInfo>
<Affiliation>Department of Pulmonary Medicine, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Zi-Feng</ForeName>
<Initials>ZF</Initials>
<AffiliationInfo>
<Affiliation>Department of Pulmonary Medicine, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Xiao-Yun</ForeName>
<Initials>XY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pulmonary Medicine, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Tong</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Pulmonary Medicine, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ke-Xu</LastName>
<AffiliationInfo>
<Affiliation>Department of Pulmonary Medicine, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Xue-Bo</ForeName>
<Initials>XB</Initials>
<AffiliationInfo>
<Affiliation>Department of Pulmonary Medicine, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>School of Life Science, University of Science and Technology of China, Hefei 230027, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Wei-Hua</ForeName>
<Initials>WH</Initials>
<AffiliationInfo>
<Affiliation>School of Life Science, University of Science and Technology of China, Hefei 230027, Anhui, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Rong-Yu</ForeName>
<Initials>RY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pulmonary Medicine, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, PR China. Electronic address: rongyuliu@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Pathol</MedlineTA>
<NlmUniqueID>9421547</NlmUniqueID>
<ISSNLinking>0046-8177</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012334">RNA, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C542388">SHQ1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C048690">molecular chaperone GRP78</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006360">Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008207">Lymphatic Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025941">Protein Interaction Mapping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012334">RNA, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">GRIM-1</Keyword>
<Keyword MajorTopicYN="N">GRP78</Keyword>
<Keyword MajorTopicYN="N">Interaction</Keyword>
<Keyword MajorTopicYN="N">Non–small cell lung cancer</Keyword>
<Keyword MajorTopicYN="N">Pathogenesis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25086956</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8392</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>45</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Human pathology</Title>
<ISOAbbreviation>Hum. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma.</ArticleTitle>
<Pagination>
<MedlinePgn>1900-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humpath.2014.05.012</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0046-8177(14)00232-9</ELocationID>
<Abstract>
<AbstractText>CXC chemokine receptor 4 (CXCR4) expression is reportedly correlated with both vascular endothelial growth factor (VEGF) expression and poor prognosis in a variety of cancers. Its relation to CXC chemokine receptor 7 (CXCR7) is also noted in several malignancies, including rhabdomyosarcoma (RMS) cell lines. However, the correlations between these chemokine receptors and angiogenic factors have not yet been adequately investigated in RMS clinical specimens. By immunohistochemistry, we assessed CXCR4, CXCR7, CC chemokine receptor 6, CC chemokine receptor 7, VEGF expression, microvessel density, and MIB-1 labeling index in 82 formalin-fixed RMS specimens, including 34 primary alveolar RMS and 44 primary embryonal RMS (ERMS). Twenty-six frozen samples were available for investigation by quantitative reverse transcription polymerase chain reaction to detect the messenger RNA expression levels of these molecules. We also evaluated their significance with respect to clinicopathological factors and patient survival rates. Primary RMS showed high expression of CXCR7 (83.1%) regardless of the histologic subtype. High cytoplasmic CXCR4 and high VEGF expression revealed significant correlations in both ERMS and alveolar RMS (P = .0051 and P = .0003, respectively). By univariate analysis of ERMS cases, the tumors with high VEGF expression showed significantly poor prognoses (P = .0017). High VEGF expression also was the independent adverse prognostic factor for ERMS. Because CXCR4, CXCR7, and VEGF are widely expressed in RMS, the combination of these antagonists may provide a potential target for molecular therapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Miyoshi</LastName>
<ForeName>Kina</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan; Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kohashi</LastName>
<ForeName>Kenichi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fushimi</LastName>
<ForeName>Fumiyoshi</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Hidetaka</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kishimoto</LastName>
<ForeName>Junji</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Research and Development of Next Generation Medicine Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Taguchi</LastName>
<ForeName>Tomoaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwamoto</LastName>
<ForeName>Yukihide</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oda</LastName>
<ForeName>Yoshinao</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Electronic address: oda@surgpath.med.kyushu-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Hum Pathol</MedlineTA>
<NlmUniqueID>9421547</NlmUniqueID>
<ISSNLinking>0046-8177</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C501896">CXCR7 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012334">RNA, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054387">Receptors, CXCR</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055806">Microvessels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012334">RNA, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054387">Receptors, CXCR</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019718">Receptors, CXCR4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018232">Rhabdomyosarcoma, Alveolar</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018233">Rhabdomyosarcoma, Embryonal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CXCR4</Keyword>
<Keyword MajorTopicYN="N">CXCR7</Keyword>
<Keyword MajorTopicYN="N">Chemokine receptor</Keyword>
<Keyword MajorTopicYN="N">Rhabdomyosarcoma</Keyword>
<Keyword MajorTopicYN="N">VEGF</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24905390</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1547-5646</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>21</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurosurgery. Spine</Title>
<ISOAbbreviation>J Neurosurg Spine</ISOAbbreviation>
</Journal>
<ArticleTitle>Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.</ArticleTitle>
<Pagination>
<MedlinePgn>386-93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3171/2014.4.SPINE13262</ELocationID>
<Abstract>
<AbstractText Label="OBJECT" NlmCategory="OBJECTIVE">Chordoma cells can generate solid-like tumors in xenograft models that express some molecular characteristics of the parent tumor, including positivity for brachyury and cytokeratins. However, there is a dearth of molecular markers that relate to chordoma tumor growth, as well as the cell lines needed to advance treatment. The objective in this study was to isolate a novel primary chordoma cell source and analyze the characteristics of tumor growth in a mouse xenograft model for comparison with the established U-CH1 and U-CH2b cell lines.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Primary cells from a sacral chordoma, called "DVC-4," were cultured alongside U-CH1 and U-CH2b cells for more than 20 passages and characterized for expression of CD24 and brachyury. While brachyury is believed essential for driving tumor formation, CD24 is associated with healthy nucleus pulposus cells. Each cell type was subcutaneously implanted in NOD/SCID/IL2Rγ(null) mice. The percentage of solid tumors formed, time to maximum tumor size, and immunostaining scores for CD24 and brachyury (intensity scores of 0-3, heterogeneity scores of 0-1) were reported and evaluated to test differences across groups.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The DVC-4 cells retained chordoma-like morphology in culture and exhibited CD24 and brachyury expression profiles in vitro that were similar to those for U-CH1 and U-CH2b. Both U-CH1 and DVC-4 cells grew tumors at rates that were faster than those for U-CH2b cells. Gross tumor developed at nearly every site (95%) injected with U-CH1 and at most sites (75%) injected with DVC-4. In contrast, U-CH2b cells produced grossly visible tumors in less than 50% of injected sites. Brachyury staining was similar among tumors derived from all 3 cell types and was intensely positive (scores of 2-3) in a majority of tissue sections. In contrast, differences in the pattern and intensity of staining for CD24 were noted among the 3 types of cell-derived tumors (p &lt; 0.05, chi-square test), with evidence of intense and uniform staining in a majority of U-CH1 tumor sections (score of 3) and more than half of the DVC-4 tumor sections (scores of 2-3). In contrast, a majority of sections from U-CH2b cells stained modestly for CD24 (scores of 1-2) with a predominantly heterogeneous staining pattern.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first report on xenografts generated from U-CH2b cells in which a low tumorigenicity was discovered despite evidence of chordoma-like characteristics in vitro. For tumors derived from a primary chordoma cell and U-CH1 cell line, similarly intense staining for CD24 was observed, which may correspond to their similar potential to grow tumors. In contrast, U-CH2b tumors stained less intensely for CD24. These results emphasize that many markers, including CD24, may be useful in distinguishing among chordoma cell types and their tumorigenicity in vivo.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Karikari</LastName>
<ForeName>Isaac O</ForeName>
<Initials>IO</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Division of Neurosurgery, and </Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gilchrist</LastName>
<ForeName>Christopher L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jing</LastName>
<ForeName>Liufang</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alcorta</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Richardson</LastName>
<ForeName>William J</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gabr</LastName>
<ForeName>Mostafa A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bell</LastName>
<ForeName>Richard D</ForeName>
<Initials>RD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kelley</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bagley</LastName>
<ForeName>Carlos A</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Setton</LastName>
<ForeName>Lori A</ForeName>
<Initials>LA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 AR047442</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AR057410</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 EB002263</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AR047442</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AR057410</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01EB002263</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Neurosurg Spine</MedlineTA>
<NlmUniqueID>101223545</NlmUniqueID>
<ISSNLinking>1547-5646</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051927">Antigens, CD24</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C075937">Brachyury protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005326">Fetal Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020825">T-Box Domain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>68238-35-7</RegistryNumber>
<NameOfSubstance UI="D007633">Keratins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051927">Antigens, CD24</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002817">Chordoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005326">Fetal Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007633">Keratins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012447">Sacrum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020825">T-Box Domain Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS639995 [Available on 09/01/15]</OtherID>
<OtherID Source="NLM">PMC4226523 [Available on 09/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BSA = bovine serum albumin</Keyword>
<Keyword MajorTopicYN="N">CD24</Keyword>
<Keyword MajorTopicYN="N">FBS = fetal bovine serum</Keyword>
<Keyword MajorTopicYN="N">FITC = fluorescein isothiocyanate</Keyword>
<Keyword MajorTopicYN="N">IMDM = Iscove's modified Dulbecco's medium</Keyword>
<Keyword MajorTopicYN="N">MFI = mean fluorescence intensity</Keyword>
<Keyword MajorTopicYN="N">NSG = NOD/SCID/IL2Rγnull</Keyword>
<Keyword MajorTopicYN="N">PBS = phosphate-buffered saline</Keyword>
<Keyword MajorTopicYN="N">PCR = polymerase chain reaction</Keyword>
<Keyword MajorTopicYN="N">U-CH1</Keyword>
<Keyword MajorTopicYN="N">U-CH2b</Keyword>
<Keyword MajorTopicYN="N">brachyury</Keyword>
<Keyword MajorTopicYN="N">chordoma</Keyword>
<Keyword MajorTopicYN="N">oncology</Keyword>
<Keyword MajorTopicYN="N">xenograft</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24971476</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1547-5646</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>21</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurosurgery. Spine</Title>
<ISOAbbreviation>J Neurosurg Spine</ISOAbbreviation>
</Journal>
<ArticleTitle>Orthotopic murine model of a primary malignant bone tumor in the spine: functional, bioluminescence, and histological correlations.</ArticleTitle>
<Pagination>
<MedlinePgn>378-85</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3171/2014.5.SPINE13205</ELocationID>
<Abstract>
<AbstractText Label="OBJECT" NlmCategory="OBJECTIVE">There is currently no reproducible animal model of human primary malignant bone tumors in the spine to permit laboratory investigation of the human disease. Therefore, the authors sought to adapt their previously developed orthotopic model of spinal metastasis to a model for primary malignant bone tumors of the spine.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A transperitoneal surgical approach was used to implant osteosarcoma (Krib-1) into the L-3 vertebral body of nude mice via a drill hole. Motor function was evaluated daily using the previously validated qualitative key milestones of tail dragging, dorsal stepping, hindlimb sweeping, and paralysis. A subset of these animals was euthanized upon reaching the various milestones, and the spines were removed, sectioned, and stained. The degree of spinal cord compression was correlated with the occurrence of milestones and assessed by a ratio between the neural elements divided by the area of the spinal canal. Another subset of animals received stably transfected Krib-1 cells with the luciferase gene, and bioluminescence was measured at 10, 20, and 30 days postimplantation.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Osteosarcoma xenografts grew in all animals according to a reliable and reproducible time course; the mean time for development of behavioral milestones was noted in relation to the day of implantation (Day 1). Tail dragging (Milestone 1) occurred on Day 19.06 (95% CI 16.11-22.01), dorsal stepping (Milestone 2) occurred on Day 28.78 (95% CI 26.79-30.77), hindlimb sweeping (Milestone 3) occurred on Day 35.61 (95% CI 32.9-38.32), and paralysis of the hindlimb (Milestone 4) occurred on Day 41.78 (95% CI 39.31-44.25). These clinically observed milestones correlated with increasing compression of the spinal cord on histological sections. The authors observed a progressive increase in the local bioluminescence (in photons/cm²/sec) of the implanted level over time with a mean of 2.17 (range 0.0-8.61) at Day 10, mean 4.68 (range 1.17-8.52) at Day 20, and mean 5.54 (range 1.22-9.99) at Day 30.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The authors have developed the first orthotopic murine model of a primary malignant bone tumor in the spine, in which neurological decline reproducibly correlates with tumor progression as evidenced by pathological confirmation and noninvasive bioluminescence measurements. Although developed for osteosarcoma, this model can be expanded to study other types of primary malignant bone tumors in the spine. This model will potentially allow animal testing of targeted therapies against specific primary malignant tumor types.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fahim</LastName>
<ForeName>Daniel K</ForeName>
<Initials>DK</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tatsui</LastName>
<ForeName>Claudio E</ForeName>
<Initials>CE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Suki</LastName>
<ForeName>Dima</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gumin</LastName>
<ForeName>Joy</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lang</LastName>
<ForeName>Frederick F</ForeName>
<Initials>FF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rhines</LastName>
<ForeName>Laurence D</ForeName>
<Initials>LD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Neurosurg Spine</MedlineTA>
<NlmUniqueID>101223545</NlmUniqueID>
<ISSNLinking>1547-5646</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008163">Luminescent Measurements</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012516">Osteosarcoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010784">Photomicrography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013125">Spinal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">VB = vertebral body</Keyword>
<Keyword MajorTopicYN="N">animal model</Keyword>
<Keyword MajorTopicYN="N">bioluminescence</Keyword>
<Keyword MajorTopicYN="N">oncology</Keyword>
<Keyword MajorTopicYN="N">osteosarcoma</Keyword>
<Keyword MajorTopicYN="N">spine tumor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25086747</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4679</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature cell biology</Title>
<ISOAbbreviation>Nat. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S.</ArticleTitle>
<Pagination>
<MedlinePgn>876-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb3011</ELocationID>
<Abstract>
<AbstractText>Metastasis remains the most common cause of death in most cancers, with limited therapies for combating disseminated disease. While the primary tumour microenvironment is an important regulator of cancer progression, it is less well understood how different tissue environments influence metastasis. We analysed tumour-stroma interactions that modulate organ tropism of brain, bone and lung metastasis in xenograft models. We identified a number of potential modulators of site-specific metastasis, including cathepsin S as a regulator of breast-to-brain metastasis. High cathepsin S expression at the primary site correlated with decreased brain metastasis-free survival in breast cancer patients. Both macrophages and tumour cells produce cathepsin S, and only the combined depletion significantly reduced brain metastasis in vivo. Cathepsin S specifically mediates blood-brain barrier transmigration through proteolytic processing of the junctional adhesion molecule, JAM-B. Pharmacological inhibition of cathepsin S significantly reduced experimental brain metastasis, supporting its consideration as a therapeutic target for this disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sevenich</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bowman</LastName>
<ForeName>Robert L</ForeName>
<Initials>RL</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mason</LastName>
<ForeName>Steven D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Quail</LastName>
<ForeName>Daniela F</ForeName>
<Initials>DF</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rapaport</LastName>
<ForeName>Franck</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Elie</LastName>
<ForeName>Benelita T</ForeName>
<Initials>BT</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brogi</LastName>
<ForeName>Edi</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Pathology Department, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brastianos</LastName>
<ForeName>Priscilla K</ForeName>
<Initials>PK</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts 02214, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hahn</LastName>
<ForeName>William C</ForeName>
<Initials>WC</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Holsinger</LastName>
<ForeName>Leslie J</ForeName>
<Initials>LJ</Initials>
<AffiliationInfo>
<Affiliation>Virobay Inc., 1360 Willow Road, Menlo Park, California 94025, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Massagué</LastName>
<ForeName>Joan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2] Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [3] Metastasis Research Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Leslie</LastName>
<ForeName>Christina S</ForeName>
<Initials>CS</Initials>
<AffiliationInfo>
<Affiliation>Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Joyce</LastName>
<ForeName>Johanna A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2] Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [3] Metastasis Research Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA126518</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA130329</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA148967</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA167863</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F31 CA167863</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54 CA126518</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54 CA148967</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Cell Biol</MedlineTA>
<NlmUniqueID>100890575</NlmUniqueID>
<ISSNLinking>1465-7392</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C116891">CST7 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015891">Cystatins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C516148">SERPINA3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015843">Serpins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D062725">Tight Junction Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D002403">Cathepsins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.27</RegistryNumber>
<NameOfSubstance UI="C028217">cathepsin S</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001859">Bone Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002403">Cathepsins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015891">Cystatins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009928">Organ Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011480">Protease Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059748">Proteolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015843">Serpins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062725">Tight Junction Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25150978</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4679</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature cell biology</Title>
<ISOAbbreviation>Nat. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>An extracellular-matrix-specific GEF-GAP interaction regulates Rho GTPase crosstalk for 3D collagen migration.</ArticleTitle>
<Pagination>
<MedlinePgn>909-17</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb3026</ELocationID>
<Abstract>
<AbstractText>Rho-family GTPases govern distinct types of cell migration on different extracellular matrix proteins in tissue culture or three-dimensional (3D) matrices. We searched for mechanisms selectively regulating 3D cell migration in different matrix environments and discovered a form of Cdc42-RhoA crosstalk governing cell migration through a specific pair of GTPase activator and inhibitor molecules. We first identified βPix, a guanine nucleotide exchange factor (GEF), as a specific regulator of migration in 3D collagen using an affinity-precipitation-based GEF screen. Knockdown of βPix specifically blocks cell migration in fibrillar collagen microenvironments, leading to hyperactive cellular protrusion accompanied by increased collagen matrix contraction. Live FRET imaging and RNAi knockdown linked this βPix knockdown phenotype to loss of polarized Cdc42 but not Rac1 activity, accompanied by enhanced, de-localized RhoA activity. Mechanistically, collagen phospho-regulates βPix, leading to its association with srGAP1, a GTPase-activating protein (GAP), needed to suppress RhoA activity. Our results reveal a matrix-specific pathway controlling migration involving a GEF-GAP interaction of βPix with srGAP1 that is critical for maintaining suppressive crosstalk between Cdc42 and RhoA during 3D collagen migration. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kutys</LastName>
<ForeName>Matthew L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892-4370, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamada</LastName>
<ForeName>Kenneth M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892-4370, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>ZIA DE000524-23</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>ZIA DE000718-07</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Cell Biol</MedlineTA>
<NlmUniqueID>100890575</NlmUniqueID>
<ISSNLinking>1465-7392</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D038982">Integrin alpha2beta1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C107953">RAC1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064067">Rho Guanine Nucleotide Exchange Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C582067">SRGAP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>124671-05-2</RegistryNumber>
<NameOfSubstance UI="C066737">RHOA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-34-5</RegistryNumber>
<NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.16</RegistryNumber>
<NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020764">cdc42 GTP-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020830">rac1 GTP-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020742">rhoA GTP-Binding Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048430">Cell Shape</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003094">Collagen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020690">GTPase-Activating Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061307">Human Umbilical Vein Endothelial Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038982">Integrin alpha2beta1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054648">Protein Phosphatase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064067">Rho Guanine Nucleotide Exchange Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020764">cdc42 GTP-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020830">rac1 GTP-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020742">rhoA GTP-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS612897 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4150836 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25150980</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4679</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature cell biology</Title>
<ISOAbbreviation>Nat. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.</ArticleTitle>
<Pagination>
<MedlinePgn>889-901</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb3021</ELocationID>
<Abstract>
<AbstractText>Cancer-associated fibroblasts (CAFs) drive tumour progression, but the emergence of this cell state is poorly understood. A broad spectrum of metalloproteinases, controlled by the Timp gene family, influence the tumour microenvironment in human cancers. Here, we generate quadruple TIMP knockout (TIMPless) fibroblasts to unleash metalloproteinase activity within the tumour-stromal compartment and show that complete Timp loss is sufficient for the acquisition of hallmark CAF functions. Exosomes produced by TIMPless fibroblasts induce cancer cell motility and cancer stem cell markers. The proteome of these exosomes is enriched in extracellular matrix proteins and the metalloproteinase ADAM10. Exosomal ADAM10 increases aldehyde dehydrogenase expression in breast cancer cells through Notch receptor activation and enhances motility through the GTPase RhoA. Moreover, ADAM10 knockdown in TIMPless fibroblasts abrogates their CAF function. Importantly, human CAFs secrete ADAM10-rich exosomes that promote cell motility and activate RhoA and Notch signalling in cancer cells. Thus, Timps suppress cancer stroma where activated-fibroblast-secreted exosomes impact tumour progression.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shimoda</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Principe</LastName>
<ForeName>Simona</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jackson</LastName>
<ForeName>Hartland W</ForeName>
<Initials>HW</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luga</LastName>
<ForeName>Valbona</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Centre for Systems Biology, Samuel Lunenfeld Research Institute, Toronto, M5G 1X5, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fang</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Molyneux</LastName>
<ForeName>Sam D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shao</LastName>
<ForeName>Yang W</ForeName>
<Initials>YW</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aiken</LastName>
<ForeName>Alison</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Waterhouse</LastName>
<ForeName>Paul D</ForeName>
<Initials>PD</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Karamboulas</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hess</LastName>
<ForeName>Franz M</ForeName>
<Initials>FM</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology and Toxicology, RWTH Aachen University, 52074 Aachen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ohtsuka</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Keio University, School of Medicine, Tokyo 160-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okada</LastName>
<ForeName>Yasunori</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Keio University, School of Medicine, Tokyo 160-8582, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ailles</LastName>
<ForeName>Laurie</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ludwig</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology and Toxicology, RWTH Aachen University, 52074 Aachen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wrana</LastName>
<ForeName>Jeffrey L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Centre for Systems Biology, Samuel Lunenfeld Research Institute, Toronto, M5G 1X5, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kislinger</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khokha</LastName>
<ForeName>Rama</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nat Cell Biol</MedlineTA>
<NlmUniqueID>100890575</NlmUniqueID>
<ISSNLinking>1465-7392</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.81</RegistryNumber>
<NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051722">ADAM Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053829">Amyloid Precursor Protein Secretases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055354">Exosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008666">Metalloendopeptidases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019714">Tissue Inhibitor of Metalloproteinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25176384</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1011-601X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>27</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Pakistan journal of pharmaceutical sciences</Title>
<ISOAbbreviation>Pak J Pharm Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Preparation, characterization and in vitro cytotoxicity assay of curcumin loaded solid lipid nanoparticle in IMR32 neuroblastoma cell line.</ArticleTitle>
<Pagination>
<MedlinePgn>1281-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Curcumin (diferuloylmethane) possesses low bioavailability due to its poor solubility, permeability and rapid metabolism. Solid Lipid Nanoparticle of curcumin was prepared by high-speed homogenization technique. Stearic acid was used as a lipid, tween 80 as surfactant and various co surfactants were used for the preparation of SLN. The prepared SLN was characterized using zeta sizer, TEM analysis and the average particle size was found to be in the range of 80 nm - 200nm. The entrapment efficiency of the SLN was ~58 to 85%. The characteristic FTIR peaks suggest that the stearic acid is compatible with curcumin. MTT assay was performed on the optimized formulation and the results are indicative that curcumin SLN showed better cytotoxicity in low dose while compared to plain curcumin. The developed Cu-SLN can find its better place in the anticancer therapy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rahman</LastName>
<ForeName>Mohamed Habibur</ForeName>
<Initials>MH</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmaceutics, PSG College of Pharmacy, Peelamedu, Coimbatore, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ramanathan</LastName>
<ForeName>Muthiah</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, PSG College of Pharmacy, Peelamedu, Coimbatore, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sankar</LastName>
<ForeName>Veintramuthu</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmaceutics, PSG College of Pharmacy, Peelamedu, Coimbatore, India.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Pakistan</Country>
<MedlineTA>Pak J Pharm Sci</MedlineTA>
<NlmUniqueID>9426356</NlmUniqueID>
<ISSNLinking>1011-601X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013229">Stearic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4ELV7Z65AP</RegistryNumber>
<NameOfSubstance UI="C031183">stearic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IT942ZTH98</RegistryNumber>
<NameOfSubstance UI="D003474">Curcumin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003474">Curcumin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053758">Nanoparticles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009447">Neuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010316">Particle Size</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012995">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017550">Spectroscopy, Fourier Transform Infrared</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013229">Stearic Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135691</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Cephalotaxus griffithii Hook.f. needle extract induces cell cycle arrest, apoptosis and suppression of hTERT and hTR expression on human breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>305</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-305</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cephalotaxus spp. are known to possess anticancer potential. In this present work, for the first time the effects of C. griffithii needle (CGN) extracts on human cancer cells were examined.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The CGN was successively extracted with petroleum ether (PE), acetone and methanol. The extracts were tested for its effect on proliferation of cancer cells (MTT assay on HeLa, ZR751 and HepG2). Extract that showed the maximum growth inhibitory effect was subjected for mechanism of action study. These included apoptosis (morphological and DNA fragmentation assay), cell cycle (flow cytometry), caspase expression (Western blot) and activity (assay kit), p53 (western blot and TP53 siRNA interference) and telomerase expression (reverse transcriptase PCR) analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the extracts, PE extract induced maximum cytotoxicity, with highest death occurred in ZR751 cells. Since, PE extract induced cell death was highest among the CGN extracts, with maximum cancer cell death occurred in ZR751 cells; we carried out mechanism study of PE extract induced ZR751 cell death. It was observed that PE extract induced ZR751 cell death was associated with cell cycle arrest and apoptosis by activating both intrinsic and extrinsic apoptotic pathways. Knock down study revealed that p53 is essential for loss of ZR751 cell viability induced by PE extract. Further, PE extract down-regulated hTERT, hTR, and c-Myc expression. Thin layer chromatography analysis indicated the presence of unique phytochemicals in PE extract.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on the observations, we concluded that PE extract of C. griffithii needle contains important phyto-components with multiple cellular targets for control of breast cancer and is worthy of future studies.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moirangthem</LastName>
<ForeName>Dinesh Singh</ForeName>
<Initials>DS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Laishram</LastName>
<ForeName>Surbala</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Borah</LastName>
<ForeName>Jagat Chandra</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kalita</LastName>
<ForeName>Mohan Chandra</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Talukdar</LastName>
<ForeName>Narayan Chandra</ForeName>
<Initials>NC</Initials>
<AffiliationInfo>
<Affiliation>Institute of Bioresources and Sustainable Development, Takyelpat Institutional Area, Imphal 795001, Manipur, India. nctalukdar@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C422952">telomerase RNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>63231-63-0</RegistryNumber>
<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.49</RegistryNumber>
<NameOfSubstance UI="C509186">TERT protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.49</RegistryNumber>
<NameOfSubstance UI="D019098">Telomerase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biochem. 1999 Sep;199(1-2):125-37</RefSource>
<PMID Version="1">10544961</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Nat Prod. 2012 Mar 23;75(3):311-35</RefSource>
<PMID Version="1">22316239</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Complement Altern Med. 2012;12:30</RefSource>
<PMID Version="1">22469333</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Oncol. 2000 Jan;12(1):74-81</RefSource>
<PMID Version="1">10687733</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Chem Pharm Bull (Tokyo). 2000 Mar;48(3):440-1</RefSource>
<PMID Version="1">10726874</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2001 Apr 5;20(15):1803-15</RefSource>
<PMID Version="1">11313928</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Med. 2001 Mar;33(2):123-9</RefSource>
<PMID Version="1">11327115</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2001 Mar;7(3):673-82</RefSource>
<PMID Version="1">11463391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Cell Biol. 2001 Nov;11(11):S22-6</RefSource>
<PMID Version="1">11684438</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Surg Oncol. 2003 May;29(4):321-6</RefSource>
<PMID Version="1">12711283</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gene. 2003 Oct 16;316:57-65</RefSource>
<PMID Version="1">14563552</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2004 Aug 20;212(1):7-14</RefSource>
<PMID Version="1">15246556</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 1983 Dec 16;65(1-2):55-63</RefSource>
<PMID Version="1">6606682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 1990 Jun;5(6):893-9</RefSource>
<PMID Version="1">1694291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Methods Mol Biol. 1995;49:423-37</RefSource>
<PMID Version="1">8563826</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phytochemistry. 1997 Feb;44(4):735-8</RefSource>
<PMID Version="1">9041720</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1997 May 30;272(22):14183-7</RefSource>
<PMID Version="1">9162048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 1999 Oct;5(10):1164-70</RefSource>
<PMID Version="1">10502820</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>CA Cancer J Clin. 2005 May-Jun;55(3):178-94</RefSource>
<PMID Version="1">15890640</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Biotechnol. 2005;5:12</RefSource>
<PMID Version="1">15885144</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2005 Jun 20;579(16):3437-43</RefSource>
<PMID Version="1">15949805</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Complement Altern Med. 2006;6:30</RefSource>
<PMID Version="1">16965632</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Protoc. 2006;1(3):1458-61</RefSource>
<PMID Version="1">17406435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phytother Res. 2007 Sep;21(9):817-22</RefSource>
<PMID Version="1">17674423</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Biophys Res Commun. 2007 Nov 23;363(3):738-44</RefSource>
<PMID Version="1">17904524</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2008 Sep;9(9):702-12</RefSource>
<PMID Version="1">18719709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Gerontol. 2009 Aug;44(8):485-92</RefSource>
<PMID Version="1">19457450</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032483">Cephalotaxus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053938">DNA Fragmentation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018515">Plant Leaves</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012313">RNA</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019098">Telomerase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4155093</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25154395</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-8140</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>206</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of cell biology</Title>
<ISOAbbreviation>J. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Sequential and ordered assembly of a large DNA repair complex on undamaged chromatin.</ArticleTitle>
<Pagination>
<MedlinePgn>589-98</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.201403096</ELocationID>
<Abstract>
<AbstractText>In nucleotide excision repair (NER), damage recognition by XPC-hHR23b is described as a critical step in the formation of the preincision complex (PInC) further composed of TFIIH, XPA, RPA, XPG, and ERCC1-XPF. To obtain new molecular insights into the assembly of the PInC, we analyzed its formation independently of DNA damage by using the lactose operator/repressor reporter system. We observed a sequential and ordered self-assembly of the PInC operating upon immobilization of individual NER factors on undamaged chromatin and mimicking that functioning on a bona fide NER substrate. We also revealed that the recruitment of the TFIIH subunit TTDA, involved in trichothiodystrophy group A disorder (TTD-A), was key in the completion of the PInC. TTDA recruits XPA through its first 15 amino acids, depleted in some TTD-A patients. More generally, these results show that proteins forming large nuclear complexes can be recruited sequentially on chromatin in the absence of their natural DNA target and with no reciprocity in their recruitment. </AbstractText>
<CopyrightInformation>© 2014 Ziani et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ziani</LastName>
<ForeName>Salim</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics and Cancer, Equipe Labellisée Ligue 2014; and Department of Development Biology and Stem Cells, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/University of Strasbourg, 67404 Illkirch Cedex, Communauté urbaine de Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nagy</LastName>
<ForeName>Zita</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics and Cancer, Equipe Labellisée Ligue 2014; and Department of Development Biology and Stem Cells, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/University of Strasbourg, 67404 Illkirch Cedex, Communauté urbaine de Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alekseev</LastName>
<ForeName>Sergey</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics and Cancer, Equipe Labellisée Ligue 2014; and Department of Development Biology and Stem Cells, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/University of Strasbourg, 67404 Illkirch Cedex, Communauté urbaine de Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Soutoglou</LastName>
<ForeName>Evi</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics and Cancer, Equipe Labellisée Ligue 2014; and Department of Development Biology and Stem Cells, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/University of Strasbourg, 67404 Illkirch Cedex, Communauté urbaine de Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Egly</LastName>
<ForeName>Jean-Marc</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics and Cancer, Equipe Labellisée Ligue 2014; and Department of Development Biology and Stem Cells, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/University of Strasbourg, 67404 Illkirch Cedex, Communauté urbaine de Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Coin</LastName>
<ForeName>Frédéric</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics and Cancer, Equipe Labellisée Ligue 2014; and Department of Development Biology and Stem Cells, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/University of Strasbourg, 67404 Illkirch Cedex, Communauté urbaine de Strasbourg, France fredr@igbmc.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cell Biol</MedlineTA>
<NlmUniqueID>0375356</NlmUniqueID>
<ISSNLinking>0021-9525</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C117669">DDB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C080998">DNA excision repair protein ERCC-5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C512380">GTF2H5 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055767">Immobilized Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C513287">RAD23B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497314">XPA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051760">Xeroderma Pigmentosum Group A Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>148710-81-0</RegistryNumber>
<NameOfSubstance UI="D051758">Transcription Factor TFIIH</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>156533-34-5</RegistryNumber>
<NameOfSubstance UI="C086984">XPC protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.-</RegistryNumber>
<NameOfSubstance UI="D004720">Endonucleases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.5.1.-</RegistryNumber>
<NameOfSubstance UI="D045643">DNA Repair Enzymes</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004260">DNA Repair</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045643">DNA Repair Enzymes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004720">Endonucleases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055767">Immobilized Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054730">Protein Interaction Domains and Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055503">Protein Multimerization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051758">Transcription Factor TFIIH</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051760">Xeroderma Pigmentosum Group A Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4151144 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25022336</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-8421</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>274</Volume>
<Issue>1-2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of neuroimmunology</Title>
<ISOAbbreviation>J. Neuroimmunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.</ArticleTitle>
<Pagination>
<MedlinePgn>161-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2014.06.019</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0165-5728(14)00190-8</ELocationID>
<Abstract>
<AbstractText>Malignant brain tumors induce pronounced immunosuppression, which diminishes immune responses generated by immunotherapy. Here we report that peripheral immunotherapy, using irradiated unmodified whole tumor cells, and systemic cyclooxygenase-2 inhibition induce cure in glioma-bearing rats (60% cure rate), whereas neither monotherapy was sufficient to cure any animal. Moreover, the combined therapy protected against secondary tumor challenges (89% cure rate) and the secondary immune response was correlated with increased plasma interferon-gamma levels and CD8(+) T cells systemically and intratumorally. In conclusion, we demonstrate that cyclooxygenase-2 inhibition is sufficient to render unmodified tumor cells immunogenic in immunotherapy of experimental brain tumors. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eberstål</LastName>
<ForeName>Sofia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden; Lund Stem Cell Center, BMC B10, Lund University, SE-221 84 Lund, Sweden. Electronic address: sofia.eberstal@med.lu.se.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fritzell</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sandén</LastName>
<ForeName>Emma</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Visse</LastName>
<ForeName>Edward</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Darabi</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Siesjö</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Neuroimmunol</MedlineTA>
<NlmUniqueID>8109498</NlmUniqueID>
<ISSNLinking>0165-5728</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052246">Cyclooxygenase 2 Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052246">Cyclooxygenase 2 Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007114">Immunization</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007156">Immunologic Memory</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CD8(+) T cells</Keyword>
<Keyword MajorTopicYN="N">COX-2 inhibition</Keyword>
<Keyword MajorTopicYN="N">Immunological memory</Keyword>
<Keyword MajorTopicYN="N">Immunotherapy</Keyword>
<Keyword MajorTopicYN="N">Malignant brain tumors</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25042352</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-8421</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>274</Volume>
<Issue>1-2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of neuroimmunology</Title>
<ISOAbbreviation>J. Neuroimmunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Increased expression of stress inducible protein 1 in glioma-associated microglia/macrophages.</ArticleTitle>
<Pagination>
<MedlinePgn>71-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2014.06.021</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0165-5728(14)00192-1</ELocationID>
<Abstract>
<AbstractText>Factors released by glioma-associated microglia/macrophages (GAMs) play an important role in the growth and infiltration of tumors. We have previously demonstrated that the co-chaperone stress-inducible protein 1 (STI1) secreted by microglia promotes proliferation and migration of human glioblastoma (GBM) cell lines in vitro. In the present study, in order to investigate the role of STI1 in a physiological context, we used a glioma model to evaluate STI1 expression in vivo. Here, we demonstrate that STI1 expression in both the tumor and in the infiltrating GAMs and lymphocytes significantly increased with tumor progression. Interestingly, high expression of STI1 was observed in macrophages and lymphocytes that infiltrated brain tumors, whereas STI1 expression in the circulating blood monocytes and lymphocytes remained unchanged. Our results correlate, for the first time, the expression of STI1 and glioma progression, and suggest that STI1 expression in GAMs and infiltrating lymphocytes is modulated by the brain tumor microenvironment. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Carvalho da Fonseca</LastName>
<ForeName>Anna Carolina</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Laboratório de Morfogênese Celular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Huaqing</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Haitao</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Xuebo</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Division of Neurosurgery, Department of Cancer Immunotherapeutics &amp; Tumor Immunology, City of Hope Beckman Research Institute, Duarte, CA 91010, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Leying</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Division of Neurosurgery, Department of Cancer Immunotherapeutics &amp; Tumor Immunology, City of Hope Beckman Research Institute, Duarte, CA 91010, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lima</LastName>
<ForeName>Flavia Regina Souza</ForeName>
<Initials>FR</Initials>
<AffiliationInfo>
<Affiliation>Laboratório de Morfogênese Celular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Badie</LastName>
<ForeName>Behnam</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Division of Neurosurgery, Department of Cancer Immunotherapeutics &amp; Tumor Immunology, City of Hope Beckman Research Institute, Duarte, CA 91010, United States. Electronic address: bbadie@coh.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA155769</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA155769</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Neuroimmunol</MedlineTA>
<NlmUniqueID>8109498</NlmUniqueID>
<ISSNLinking>0165-5728</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489791">Stip1 protein, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006360">Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019707">Receptors, Chemokine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS614512 [Available on 09/15/15]</OtherID>
<OtherID Source="NLM">PMC4152559 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Brain tumor microenvironment</Keyword>
<Keyword MajorTopicYN="N">Glioma</Keyword>
<Keyword MajorTopicYN="N">Glioma progression</Keyword>
<Keyword MajorTopicYN="N">Glioma-associated microglia/macrophages</Keyword>
<Keyword MajorTopicYN="N">Stress-inducible protein 1</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25086876</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-8421</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>274</Volume>
<Issue>1-2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of neuroimmunology</Title>
<ISOAbbreviation>J. Neuroimmunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.</ArticleTitle>
<Pagination>
<MedlinePgn>240-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2014.07.014</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0165-5728(14)00229-X</ELocationID>
<Abstract>
<AbstractText>Bone marrow-derived mesenchymal stromal cells (MSCs) target glioma extensions and micro-satellites efficiently when implanted intratumorally. Here, we report that intratumoral implantation of MSCs and peripheral immunotherapy with interferon-gamma (IFNγ) producing tumor cells improve the survival of glioma-bearing rats (54% cure rate) compared to MSC alone (0% cure rate) or immunotherapy alone (21% cure rate) by enforcing an intratumoral CD8(+) T cell response. Further analysis revealed that the MSCs up-regulate MHC classes I and II in response to IFNγ treatment in vitro and secrete low amounts of immunosuppressive molecules prostaglandin E2 and interleukin-10. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ströjby</LastName>
<ForeName>Salina</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eberstål</LastName>
<ForeName>Sofia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden. Electronic address: sofia.eberstal@med.lu.se.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Svensson</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fritzell</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bexell</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden; Translational Cancer Research, Lund University, Medicon Village 404:C3, Scheelevägen 2, SE-223 81 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Siesjö</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Darabi</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bengzon</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Neuroimmunol</MedlineTA>
<NlmUniqueID>8109498</NlmUniqueID>
<ISSNLinking>0165-5728</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015552">Injections, Intralesional</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045164">Mesenchymal Stem Cell Transplantation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059630">Mesenchymal Stromal Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Glioma</Keyword>
<Keyword MajorTopicYN="N">Immunotherapy</Keyword>
<Keyword MajorTopicYN="N">Interferon-gamma</Keyword>
<Keyword MajorTopicYN="N">Mesenchymal stromal cells</Keyword>
<Keyword MajorTopicYN="N">Rat</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25027580</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>29</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1432-2307</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>465</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Virchows Archiv : an international journal of pathology</Title>
<ISOAbbreviation>Virchows Arch.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.</ArticleTitle>
<Pagination>
<MedlinePgn>299-312</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00428-014-1630-6</ELocationID>
<Abstract>
<AbstractText>An HPV infection is involved in the etiology of about 25 % of head and neck squamous cell carcinomas (HNSCC). It has been postulated that a strong antitumoral immune response in HPV-positive tumors represents an important underlying mechanism for their good response to therapy. Recently, the Warburg phenomenon has returned to the center of attention because it affects antitumoral immune response and response to therapy. Accumulation of tumor cell-derived lactate inhibits cytotoxic T cells, as these, analogous to cancer cells, depend on glycolysis and lactate secretion for fulfillment of energy needs. Sparse information exists on the Warburg effect in HNSCC. This study aimed to characterize the metabolic and immunological features of HPV-negative and HPV-positive HNSCC. An immunohistochemical analysis of oropharyngeal carcinomas showed an enhanced antitumoral immune response (CD8/CD4 ratio) together with increased levels of proteins involved in transmembranous metabolite transportation (GLUT1 and CD147) and respiratory metabolism (COX5B) in HPV-positive tumors as compared to HPV-negative tumors. mRNA and Western blot analyses of an HPV-positive and HPV-negative HNSCC cell line revealed metabolic characteristics similar to the in vivo situation. Additionally, the HPV-negative cell line showed stronger extracellular lactate accumulation. In contrast, the HPV-positive cell line presented with better adaption to lactic acidosis suggesting an ability to metabolize lactate. Our results indicate that HPV-positive and HPV-negative carcinomas do not only differ in terms of tumor immune microenvironment, but also in terms of tumor metabolism, characterized by an increased glucose and respiratory metabolism together with decreased lactate accumulation in HPV-positive HNSCC. Therefore, targeting metabolic pathways could represent a promising adjunct in the therapy of HPV-positive HNSCC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Krupar</LastName>
<ForeName>Rosemarie</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pathology, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany, rosemarie.krupar@ukr.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Robold</LastName>
<ForeName>Katharina</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gaag</LastName>
<ForeName>Doris</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Spanier</LastName>
<ForeName>Gerrit</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kreutz</LastName>
<ForeName>Marina</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Renner</LastName>
<ForeName>Kathrin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hellerbrand</LastName>
<ForeName>Claus</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hofstaedter</LastName>
<ForeName>Ferdinand</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bosserhoff</LastName>
<ForeName>Anja K</ForeName>
<Initials>AK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Virchows Arch</MedlineTA>
<NlmUniqueID>9423843</NlmUniqueID>
<ISSNLinking>0945-6317</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C418974">FOXP3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051272">Glucose Transporter Type 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495677">SLC2A1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.1.1.27</RegistryNumber>
<NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.9.3.1</RegistryNumber>
<NameOfSubstance UI="C480024">COX5B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.9.3.1</RegistryNumber>
<NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C535575">Carcinoma, squamous cell of head and neck</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003576">Electron Transport Complex IV</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051272">Glucose Transporter Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007770">L-Lactate Dehydrogenase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D027383">Papillomaviridae</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25183503</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0231-424X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>101</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Acta physiologica Hungarica</Title>
<ISOAbbreviation>Acta Physiol Hung</ISOAbbreviation>
</Journal>
<ArticleTitle>Different signal pathways regulate IL-1β-induced mature and primary miRNA-146a expression in human alveolar epithelial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>282-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1556/APhysiol.101.2014.3.3</ELocationID>
<Abstract>
<AbstractText>It was known that IL-1β-induced rapid expression of miR-146a, which regulated the secretion of inflammatory chemokines in human A549 alveolar epithelial cells. However, little is known about the level of primary miR-146a and the downstream biogenesis of miR-146a in A549 cells. We examined the levels of primary miR-146a and mature miR-146a in A549 cells following treatment with pharmacological inhibitors of IKK-2 (TPCA-1), MEK-1/2 (PD098059), JNK-1/2 (SP600125), p38 MAPK (SB 203580) and PI-3k (LY294002). Our studies showed that exposure to PD98059, TPCA-1 and LY294002 resulted in a dose-dependent reduction in the expression of mature miR-146a while the primary miR-146a expression was not changed by any inhibitor. Western blot showed that IL-1β induced an increase of TRBP at 30 min, following by an extended expression at 24 h compared to the non-IL-1β controls in A549 cells. In conclusion, our studies indicated that miR-146a expression in alveolar epithelial cells was regulated at the post-transcriptional level via a MEK-1/2 and IKK2 pathway, and also for the first time via PI-3k pathway. The longer expression of TRBP following stimulation with IL-1β suggests that TRBP might play a role in the process of regulating the processing of primary miR-146a to mature miR-146a in human alveolar epithelial cells. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Xiaoying</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Xi'an Jiaotong University Department of Genetics and Molecular Biology, School of Medicine 76 Yanta West Road Xi'an, Shaanxi 710061 China University of Manchester NIHR Translational Research Facility in Respiratory Medicine Group, School of Translational Medicine Manchester UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Hungary</Country>
<MedlineTA>Acta Physiol Hung</MedlineTA>
<NlmUniqueID>8309201</NlmUniqueID>
<ISSNLinking>0231-424X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060565">Argonaute Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C466422">EIF2C2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C542542">MIRN146 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C486559">NCOA6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056918">Nuclear Receptor Coactivators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="C408087">DICER1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="C517918">DROSHA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="D043244">Ribonuclease III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060565">Argonaute Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056918">Nuclear Receptor Coactivators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011650">Pulmonary Alveoli</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043244">Ribonuclease III</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">alveolar epithelial cells</Keyword>
<Keyword MajorTopicYN="N">inflammation</Keyword>
<Keyword MajorTopicYN="N">lung</Keyword>
<Keyword MajorTopicYN="N">miR-146a</Keyword>
<Keyword MajorTopicYN="N">miRNA</Keyword>
<Keyword MajorTopicYN="N">miRNAs biogenesis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24970912</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1535-5667</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title>
<ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.</ArticleTitle>
<Pagination>
<MedlinePgn>1525-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.114.138925</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Tyrosine kinase receptors including vascular endothelial growth factor receptor (VEGFR) have gained significant attention as pharmacologic targets. However, clinical evaluation of small-molecule drugs or biologics that target these pathways has so far yielded mixed results in a variety of solid tumors. The reasons for response variability remain unknown, including the temporal and spatial patterns of receptor tyrosine kinase expression. Methods to detect and quantify the presence of such cellular receptors would greatly facilitate drug development and therapy response assessment. We aimed to generate specific imaging agents as potential companion diagnostics that could also be used for targeted radionuclide therapy. Here, we report on the synthesis and initial preclinical performance of (64)Cu-labeled probes that were based on the kinase inhibitor already in clinical use, vandetanib (ZD6474), as a VEGFR-selective theranostic radiopharmaceutical.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A monomeric (ZD-G1) and a dimeric (ZD-G2) derivative of ZD6474 were synthesized and conjugated with DOTA for chelation with (64)Cu to produce the probes (64)Cu-DOTA-ZD-G1 and (64)Cu-DOTA-ZD-G2. The binding affinity and specificity to VEGFR were measured using U-87 MG cells known to overexpress VEGFR. Small-animal PET and biodistribution studies were performed with (64)Cu-labeled probes (3-4 MBq) intravenously administered in U-87 MG tumor-bearing mice with or without coinjection of unlabeled ZD-G2 for up to 24 h after injection.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Receptor-binding assays yielded a mean equilibrium dissociation constant of 44.7 and 0.45 nM for monomeric and dimeric forms, respectively, indicating a synergistic effect in VEGFR affinity by multivalency. Small-animal PET/CT imaging showed rapid tumor accumulation of (64)Cu-DOTA-ZD-G2, with excellent tumor-to-normal tissue contrast by 24 h. Coinjection of the (64)Cu-DOTA-ZD-G2 with 50 nmol (60 μg) of nonradioactive ZD-G2 effectively blocked tumor uptake.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A (64)Cu-labeled probe derived from an approved oncologic drug selective for VEGFR demonstrates excellent tumor targeting, particularly for the dimeric form. The multivalent probe yielded a 100-fold improvement in receptor affinity while maintaining pharmacokinetic and biodistribution properties well suited for PET imaging in our preclinical model. These results indicate that a clinically relevant theranostic platform can be rapidly developed from known small molecules that target key cellular receptors.</AbstractText>
<CopyrightInformation>© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas zli@houstonmethodist.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Sheng</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Medicinal Chemistry, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zu</LastName>
<ForeName>Youli</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Daniel Y</ForeName>
<Initials>DY</Initials>
<AffiliationInfo>
<Affiliation>Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Zheng</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas zli@houstonmethodist.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Nucl Med</MedlineTA>
<NlmUniqueID>0217410</NlmUniqueID>
<ISSNLinking>0161-5505</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003301">Copper Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003301">Copper Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007553">Isotope Labeling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055503">Protein Multimerization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011505">Protein-Tyrosine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040262">Receptors, Vascular Endothelial Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014018">Tissue Distribution</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">64Cu</Keyword>
<Keyword MajorTopicYN="N">theranostic</Keyword>
<Keyword MajorTopicYN="N">tumor angiogenesis</Keyword>
<Keyword MajorTopicYN="N">vascular endothelial growth factor receptor (VEGFR)</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25012458</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1535-5667</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title>
<ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection.</ArticleTitle>
<Pagination>
<MedlinePgn>1506-12</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.114.140343</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Deregulated cellular metabolism is a hallmark of many cancers. In addition to increased glycolytic flux, exploited for cancer imaging with (18)F-FDG, tumor cells display aberrant lipid metabolism. Pivalic acid is a short-chain, branched carboxylic acid used to increase oral bioavailability of prodrugs. After prodrug hydrolysis, pivalic acid undergoes intracellular metabolism via the fatty acid oxidation pathway. We have designed a new probe, 3-(18)F-fluoro-2,2-dimethylpropionic acid, also called (18)F-fluoro-pivalic acid ((18)F-FPIA), for the imaging of aberrant lipid metabolism and cancer detection.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Cell intrinsic uptake of (18)F-FPIA was measured in murine EMT6 breast adenocarcinoma cells. In vivo dynamic imaging, time course biodistribution, and radiotracer stability testing were performed. (18)F-FPIA tumor retention was further compared in vivo to (18)F-FDG uptake in several xenograft models and inflammatory tissue.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">(18)F-FPIA rapidly accumulated in EMT6 breast cancer cells, with retention of intracellular radioactivity predicted to occur via a putative (18)F-FPIA carnitine-ester. The radiotracer was metabolically stable to degradation in mice. In vivo imaging of implanted EMT6 murine and BT474 human breast adenocarcinoma cells by (18)F-FPIA PET showed rapid and extensive tumor localization, reaching 9.1% ± 0.5% and 7.6% ± 1.2% injected dose/g, respectively, at 60 min after injection. Substantial uptake in the cortex of the kidney was seen, with clearance primarily via urinary excretion. Regarding diagnostic utility, uptake of (18)F-FPIA was comparable to that of (18)F-FDG in EMT6 tumors but superior in the DU145 human prostate cancer model (54% higher uptake; P = 0.002). Furthermore, compared with (18)F-FDG, (18)F-FPIA had lower normal-brain uptake resulting in a superior tumor-to-brain ratio (2.5 vs. 1.3 in subcutaneously implanted U87 human glioma tumors; P = 0.001), predicting higher contrast for brain cancer imaging. Both radiotracers showed increased localization in inflammatory tissue.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">(18)F-FPIA shows promise as an imaging agent for cancer detection and warrants further investigation.</AbstractText>
<CopyrightInformation>© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Witney</LastName>
<ForeName>Timothy H</ForeName>
<Initials>TH</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pisaneschi</LastName>
<ForeName>Federica</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alam</LastName>
<ForeName>Israt S</ForeName>
<Initials>IS</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Trousil</LastName>
<ForeName>Sebastian</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kaliszczak</LastName>
<ForeName>Maciej</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Twyman</LastName>
<ForeName>Frazer</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brickute</LastName>
<ForeName>Diana</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Quang-Dé</ForeName>
<Initials>QD</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schug</LastName>
<ForeName>Zachary</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Beatson Institute for Cancer Research, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gottlieb</LastName>
<ForeName>Eyal</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Beatson Institute for Cancer Research, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aboagye</LastName>
<ForeName>Eric O</ForeName>
<Initials>EO</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Cancer Imaging Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London Faculty of Medicine, London, United Kingdom; and eric.aboagye@imperial.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>C11589/A13222</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Nucl Med</MedlineTA>
<NlmUniqueID>0217410</NlmUniqueID>
<ISSNLinking>0161-5505</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010421">Pentanoic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>813RE8BX41</RegistryNumber>
<NameOfSubstance UI="C005566">pivalic acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005462">Fluorine Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010421">Pentanoic Acids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FDG</Keyword>
<Keyword MajorTopicYN="N">FPIA</Keyword>
<Keyword MajorTopicYN="N">PET</Keyword>
<Keyword MajorTopicYN="N">lipid metabolism</Keyword>
<Keyword MajorTopicYN="N">tumor detection</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24518207</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.</ArticleTitle>
<Pagination>
<MedlinePgn>1892-901</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.69</ELocationID>
<Abstract>
<AbstractText>Bruton's tyrosine kinase (Btk) modulates B-cell development and activation and has an important role in antibody production. Interestingly, Btk may also affect human osteoclast (OC) function; however, the mechanism was unknown. Here we studied a potent and specific Btk inhibitor, CC-292, in multiple myeloma (MM). In this report, we demonstrate that, although CC-292 increased OC differentiation, it inhibited OC function via inhibition of c-Src, Pyk2 and cortactin, all involved in OC-sealing zone formation. As CC-292 did not show potent in vitro anti-MM activity, we next evaluated it in combination with the proteasome inhibitor, carfilzomib. We first studied the effect of carfilzomib on OC. Carfilzomib did not have an impact on OC-sealing zone formation but significantly inhibited OC differentiation. CC-292 combined with carfilzomib inhibited both sealing zone formation and OC differentiation, resulting in more profound inhibition of OC function than carfilzomib alone. Moreover, the combination treatment in an in vivo MM mouse model inhibited tumor burden compared with CC-292 alone; it also increased bone volume compared with carfilzomib alone. These results suggest that CC-292 combined with carfilzomib augments the inhibitory effects against OC within the bone microenvironment and has promising therapeutic potential for the treatment of MM and related bone disease. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eda</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Santo</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cirstea</LastName>
<ForeName>D D</ForeName>
<Initials>DD</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yee</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scullen</LastName>
<ForeName>T A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nemani</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mishima</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Waterman</LastName>
<ForeName>P R</ForeName>
<Initials>PR</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Center for Systems Biology, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arastu-Kapur</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Onyx Pharmaceuticals Inc., South San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Celgene Avilomics Research, Bedford, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Celgene Avilomics Research, Bedford, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kirk</LastName>
<ForeName>C J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo>
<Affiliation>Onyx Pharmaceuticals Inc., South San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Westlin</LastName>
<ForeName>W F</ForeName>
<Initials>WF</Initials>
<AffiliationInfo>
<Affiliation>Celgene Avilomics Research, Bedford, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raje</LastName>
<ForeName>N S</ForeName>
<Initials>NS</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000178">Acrylamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C583568">N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061988">Proteasome Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>72X6E3J5AR</RegistryNumber>
<NameOfSubstance UI="C524865">carfilzomib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C082176">Agammaglobulinaemia tyrosine kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000178">Acrylamides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001862">Bone Resorption</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009842">Oligopeptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010010">Osteoclasts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061988">Proteasome Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011505">Protein-Tyrosine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24552990</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>1819-27</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.78</ELocationID>
<Abstract>
<AbstractText>Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphoblasts through poorly defined mechanisms. Normal T-cell progenitors are hypersensitive to mitochondrial apoptosis, a phenotype that is dependent on the expression of proapoptotic BIM. In a conditional zebrafish model, MYC downregulation induced BIM expression in T-lymphoblasts, an effect that was blunted by expression of constitutively active AKT. In human T-ALL cell lines and treatment-resistant patient samples, treatment with MYC or PI3K-AKT pathway inhibitors each induced BIM upregulation and apoptosis, indicating that BIM is repressed downstream of MYC and PI3K-AKT in high-risk T-ALL. Restoring BIM function in human T-ALL cells using a stapled peptide mimetic of the BIM BH3 domain had therapeutic activity, indicating that BIM repression is required for T-ALL viability. In the zebrafish model, where MYC downregulation induces T-ALL regression via mitochondrial apoptosis, T-ALL persisted despite MYC downregulation in 10% of bim wild-type zebrafish, 18% of bim heterozygotes and in 33% of bim homozygous mutants (P=0.017). We conclude that downregulation of BIM represents a key survival signal downstream of oncogenic MYC and PI3K-AKT signaling in treatment-resistant T-ALL. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Reynolds</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roderick</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>LaBelle</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [3] Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bird</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mathieu</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bodaar</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Colon</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pyati</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stevenson</LastName>
<ForeName>K E</ForeName>
<Initials>KE</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Harris</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Silverman</LastName>
<ForeName>L B</ForeName>
<Initials>LB</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sallan</LastName>
<ForeName>S E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bradner</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Neuberg</LastName>
<ForeName>D S</ForeName>
<Initials>DS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Look</LastName>
<ForeName>A T</ForeName>
<Initials>AT</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Walensky</LastName>
<ForeName>L D</ForeName>
<Initials>LD</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kelliher</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gutierrez</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">0000000202499007</Identifier>
<AffiliationInfo>
<Affiliation>1] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA167124</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08 CA151450</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA096899</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA167124</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C110430">Bcl-2-like protein 11</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C549214">MIRN19 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489427">MYC protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>RUJ6Z9Y0DT</RegistryNumber>
<NameOfSubstance UI="C531198">dactolisib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054218">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016271">Proto-Oncogene Proteins c-myc</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011804">Quinolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS566969 [Available on 03/01/15]</OtherID>
<OtherID Source="NLM">PMC4139485 [Available on 03/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24561519</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.</ArticleTitle>
<Pagination>
<MedlinePgn>1861-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.81</ELocationID>
<Abstract>
<AbstractText>Relapsed/refractory Hodgkin's lymphoma (HL) is an unmet medical need requiring new therapeutic options. Interactions between the histone deacetylase inhibitor Givinostat and the RAF/MEK/ERK inhibitor Sorafenib were examined in HDLM-2 and L-540 HL cell lines. Exposure to Givinostat/Sorafenib induced a synergistic inhibition of cell growth (range, 70-80%) and a marked increase in cell death (up to 96%) due to increased H3 and H4 acetylation and strong mitochondrial injury. Gene expression profiling indicated that the synergistic effects of Givinostat/Sorafenib treatment are associated with the modulation of cell cycle and cell death pathways. Exposure to Givinostat/Sorafenib resulted in sustained production of reactive oxygen species (ROS) and activation of necroptotic cell death. The necroptosis inhibitor Necrostatin-1 prevented Givinostat/Sorafenib-induced ROS production, mitochondrial injury, activation of BH3-only protein BIM and cell death. Knockdown experiments identified BIM as a key signaling molecule that mediates Givinostat/Sorafenib-induced oxidative death of HL cells. Furthermore, in vivo xenograft studies demonstrated a 50% reduction in tumor burden (P&lt;0.0001), a 5- to 15-fold increase in BIM expression (P &lt; 0.0001) and a fourfold increase in tumor necrosis in Givinostat/Sorafenib-treated animals compared with mice that received single agents. These results provide a rationale for exploring Givinostat/Sorafenib combination in relapsed/refractory HL.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Locatelli</LastName>
<ForeName>S L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy [2] Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cleris</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stirparo</LastName>
<ForeName>G G</ForeName>
<Initials>GG</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy [2] Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tartari</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saba</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pierdominici</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malorni</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Rome, Italy [2] Istituto San Raffaele Sulmona, Sulmona, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carbone</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Pathology Department, CRO Aviano, Aviano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Anichini</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carlo-Stella</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<Identifier Source="ORCID">0000000331440124</Identifier>
<AffiliationInfo>
<Affiliation>1] Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy [2] Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C110430">Bcl-2-like protein 11</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507699">necrostatin-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>25X51I8RD4</RegistryNumber>
<NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5P60F84FBH</RegistryNumber>
<NameOfSubstance UI="C575255">givinostat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9ZOQ3TZI87</RegistryNumber>
<NameOfSubstance UI="C471405">sorafenib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002219">Carbamates</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056572">Histone Deacetylase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006689">Hodgkin Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009336">Necrosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009536">Niacinamide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010671">Phenylurea Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24781014</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.</ArticleTitle>
<Pagination>
<MedlinePgn>1915-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2014.141</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pippa</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Hematology/Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Navarra, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dominguez</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Hematology/Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Navarra, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christensen</LastName>
<ForeName>D J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Oncotide Pharmaceuticals, Research Triangle Park, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moreno-Miralles</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Hematology/Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Navarra, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blanco-Prieto</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Navarra, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vitek</LastName>
<ForeName>M P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo>
<Affiliation>Oncotide Pharmaceuticals, Research Triangle Park, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Odero</LastName>
<ForeName>M D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>1] Hematology/Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Navarra, Spain [2] Department of Biochemistry and Genetics, University of Navarra, Navarra, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056488">Histone Chaperones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C583613">OP449 peptide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011409">Propylene Glycols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C513473">SET protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3QN8BYN5QF</RegistryNumber>
<NameOfSubstance UI="C098720">fingolimod</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.16</RegistryNumber>
<NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>NGZ37HRE42</RegistryNumber>
<NameOfSubstance UI="D013110">Sphingosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056488">Histone Chaperones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011409">Propylene Glycols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054648">Protein Phosphatase 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013110">Sphingosine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25091565</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Neuroprotective effects of melittin on hydrogen peroxide-induced apoptotic cell death in neuroblastoma SH-SY5Y cells.</ArticleTitle>
<Pagination>
<MedlinePgn>286</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-286</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Free radicals are involved in neuronal cell death in human neurodegenerative diseases. Since ancient times, honeybee venom has been used in a complementary medicine to treat various diseases and neurologic disorders. Melittin, the main component of honeybee venom, has various biologic effects, including anti-bacterial, anti-viral, and anti-inflammatory activities.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We investigated the neuroprotective effects of melittin against H2O2-induced apoptosis in the human neuroblastoma cell line SH-SY5Y. The neuroprotective effects of melittin on H2O2-induced apoptosis were investigated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylterazolium bromide assay, caspase 3 activity, 4,6-diamidino-2-phenylindole staining, a lactate dehydrogenase release assay, Western blots, and reverse transcription-polymerase chain reaction.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The H2O2-treated cells had decreased cell viability with apoptotic features and increased production of caspase-3. On the other hand, melittin treatment increased cell viability and decreased apoptotic DNA fragmentation. Melittin attenuated the H2O2-induced decrease in mRNA and protein production of the anti-apoptotic factor Bcl-2. In addition, melittin inhibited both the H2O2-induced mRNA and protein expression of Bax-associated pro-apoptotic factor and caspase-3.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that melittin has potential therapeutic effects as an agent for the prevention of neurodegenerative diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Sang Mi</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Agricultural Biology, National Academy of Agricultural Science, RDA, Suwon 441-100, Korea. sangmih@korea.kr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jung Min</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Kwan Kyu</ForeName>
<Initials>KK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Young Chae</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pak</LastName>
<ForeName>Sok Cheon</ForeName>
<Initials>SC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>20449-79-0</RegistryNumber>
<NameOfSubstance UI="D008555">Melitten</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>BBX060AN9V</RegistryNumber>
<NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053938">DNA Fragmentation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006861">Hydrogen Peroxide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008555">Melitten</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009447">Neuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051028">bcl-2-Associated X Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25169718</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Chebulagic acid from Terminalia chebula causes G1 arrest, inhibits NFκB and induces apoptosis in retinoblastoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>319</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-319</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Plants are the valuable source of natural products with important medicinal properties. Most of the approved anti cancer drugs have a natural product origin or are natural products. Retinoblastoma is the most common ocular cancer of children. Although chemotherapy is the preferred mode of therapy, a successful treatment for retinoblastoma requires enucleation. Chebulagic acid (CA) from Terminalia chebula was shown to have anti-proliferative properties in the studies on cancerous cell lines. Due to anti cancer properties of CA and due to limitation in treatment options for retinoblastoma, the present study is undertaken to understand the role of CA on the proliferation of retinoblastoma cells.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Anti proliferative potential of CA was determined by MTT assay. The expression levels of various cell death mediators in retinoblastoma cells with CA treatment were assessed by Western blotting. Flowcytometer analysis was used to estimate the mitochondrial membrane potential (MMP) and to determine the percentage of cells undergoing apoptosis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The present study showed CA inhibited the proliferation of retinoblastoma cells in a dose dependent manner. CA modulated MMP, induced release of Cytochrome c, activated caspase 3 and shifted the ratio of BAX and Bcl2 towards cell death. G1 arrest, noticed in CA treated cells, is mediated by the increase in the expression of CDK inhibitor p27. CA treatment also decreased the levels of NFκB in the nucleus. This decrease is mediated by suppression in degradation of IκBα.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CA has shown significant anti proliferative potential on retinoblastoma cells. Our findings clearly demonstrate that CA induces G1 arrest, inhibits NFκB and induces apoptosis of retinoblastoma cells.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Naresh</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gangappa</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Geetika</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Karnati</LastName>
<ForeName>Roy</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences, University of Hyderabad, Gachibowli, Hyderabad 500046, India. roykarnati@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001578">Benzopyrans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005960">Glucosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>23094-71-5</RegistryNumber>
<NameOfSubstance UI="C076178">chebulagic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-43-6</RegistryNumber>
<NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2000 Jan;18(1):12-7</RefSource>
<PMID Version="1">10623688</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Complement Altern Med. 2012;12:142</RefSource>
<PMID Version="1">22937998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2000 Aug;18(15):2881-7</RefSource>
<PMID Version="1">10920136</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neoplasia. 1999 Apr;1(1):5-15</RefSource>
<PMID Version="1">10935465</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2000 Dec 1;19(23):6351-60</RefSource>
<PMID Version="1">11101508</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biofactors. 2000;12(1-4):45-51</RefSource>
<PMID Version="1">11216504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2001 Nov 1;19(21):4182-3</RefSource>
<PMID Version="1">11689590</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Prod Rep. 2001 Dec;18(6):641-9</RefSource>
<PMID Version="1">11820762</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2002 Mar;3(3):221-7</RefSource>
<PMID Version="1">11875461</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Med Pediatr Oncol. 2002 Jun;38(6):411-5</RefSource>
<PMID Version="1">11984802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Cancer. 2002 Jul 15;87(2):129-33</RefSource>
<PMID Version="1">12107831</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Ophthalmol. 2002 Oct;13(5):331-6</RefSource>
<PMID Version="1">12218465</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2002 Dec;161(6):2229-40</RefSource>
<PMID Version="1">12466137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Med Pediatr Oncol. 2003 Mar;40(3):158-61</RefSource>
<PMID Version="1">12518344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer. 2003 Apr;39(6):808-17</RefSource>
<PMID Version="1">12651207</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biol Pharm Bull. 2003 Sep;26(9):1331-5</RefSource>
<PMID Version="1">12951481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Integr Cancer Ther. 2002 Dec;1(4):338-44</RefSource>
<PMID Version="1">14664728</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2004 Jul;3(7):803-12</RefSource>
<PMID Version="1">15252141</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anal Biochem. 1976 May 7;72:248-54</RefSource>
<PMID Version="1">942051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Chin Med. 1998;26(3-4):311-23</RefSource>
<PMID Version="1">9862019</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Coll Nutr. 1999 Oct;18(5):426-33</RefSource>
<PMID Version="1">10511324</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2005 Jan;52(1):345-53</RefSource>
<PMID Version="1">15641090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Nutr Soc. 2005 Feb;64(1):123-31</RefSource>
<PMID Version="1">15877931</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2683-91</RefSource>
<PMID Version="1">16043839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2005 Dec 20;23(36):9408-21</RefSource>
<PMID Version="1">16361640</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Asian Pac J Cancer Prev. 2005 Oct-Dec;6(4):437-48</RefSource>
<PMID Version="1">16435988</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nutr Cancer. 2006;54(1):111-42</RefSource>
<PMID Version="1">16800779</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3708-16</RefSource>
<PMID Version="1">16936077</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anticancer Res. 2006 Sep-Oct;26(5A):3485-92</RefSource>
<PMID Version="1">17094471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Biochem Biophys. 2007 Mar 15;459(2):169-77</RefSource>
<PMID Version="1">17303067</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Nat Prod. 2007 Mar;70(3):461-77</RefSource>
<PMID Version="1">17309302</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biotechnol Appl Biochem. 2007 Jul;47(Pt 3):159-67</RefSource>
<PMID Version="1">17274761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phytomedicine. 2007 Nov;14(11):755-62</RefSource>
<PMID Version="1">17293097</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phytomedicine. 2007 Nov;14(11):739-46</RefSource>
<PMID Version="1">17482444</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Prod Rep. 2007 Dec;24(6):1225-44</RefSource>
<PMID Version="1">18033577</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acc Chem Res. 2008 Feb;41(2):302-14</RefSource>
<PMID Version="1">18217720</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Prod Rep. 2008 Jun;25(3):475-516</RefSource>
<PMID Version="1">18497896</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Ophthalmol. 2008 Jun;126(6):862-5</RefSource>
<PMID Version="1">18541855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Biophys Res Commun. 2009 Mar 27;381(1):112-7</RefSource>
<PMID Version="1">19351605</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Complement Altern Med. 2009;9:15</RefSource>
<PMID Version="1">19463163</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3065-73</RefSource>
<PMID Version="1">19151399</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Ethnopharmacol. 2009 Jul 30;124(3):506-12</RefSource>
<PMID Version="1">19481594</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Physiol. 2010 Feb;222(2):433-43</RefSource>
<PMID Version="1">19918798</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Pharmacol. 2010 Dec 15;649(1-3):74-83</RefSource>
<PMID Version="1">20858479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2011 May;85(9):4386-98</RefSource>
<PMID Version="1">21307190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Complement Altern Med. 2011;11:64</RefSource>
<PMID Version="1">21849051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Ophthalmol. 2000 Apr;118(4):577-8</RefSource>
<PMID Version="1">10766148</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001578">Benzopyrans</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045304">Cytochromes c</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059585">G1 Phase Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005960">Glucosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012175">Retinoblastoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029766">Terminalia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4158129</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24821820</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1535-3699</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>239</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Experimental biology and medicine (Maywood, N.J.)</Title>
<ISOAbbreviation>Exp. Biol. Med. (Maywood)</ISOAbbreviation>
</Journal>
<ArticleTitle>A microphysiological system model of therapy for liver micrometastases.</ArticleTitle>
<Pagination>
<MedlinePgn>1170-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1535370214532596</ELocationID>
<Abstract>
<AbstractText>Metastasis accounts for almost 90% of cancer-associated mortality. The effectiveness of cancer therapeutics is limited by the protective microenvironment of the metastatic niche and consequently these disseminated tumors remain incurable. Metastatic disease progression continues to be poorly understood due to the lack of appropriate model systems. To address this gap in understanding, we propose an all-human microphysiological system that facilitates the investigation of cancer behavior in the liver metastatic niche. This existing LiverChip is a 3D-system modeling the hepatic niche; it incorporates a full complement of human parenchymal and non-parenchymal cells and effectively recapitulates micrometastases. Moreover, this system allows real-time monitoring of micrometastasis and assessment of human-specific signaling. It is being utilized to further our understanding of the efficacy of chemotherapeutics by examining the activity of established and novel agents on micrometastases under conditions replicating diurnal variations in hormones, nutrients and mild inflammatory states using programmable microdispensers. These inputs affect the cues that govern tumor cell responses. Three critical signaling groups are targeted: the glucose/insulin responses, the stress hormone cortisol and the gut microbiome in relation to inflammatory cues. Currently, the system sustains functioning hepatocytes for a minimum of 15 days; confirmed by monitoring hepatic function (urea, α-1-antitrypsin, fibrinogen, and cytochrome P450) and injury (AST and ALT). Breast cancer cell lines effectively integrate into the hepatic niche without detectable disruption to tissue, and preliminary evidence suggests growth attenuation amongst a subpopulation of breast cancer cells. xMAP technology combined with systems biology modeling are also employed to evaluate cellular crosstalk and illustrate communication networks in the early microenvironment of micrometastases. This model is anticipated to identify new therapeutic strategies for metastasis by elucidating the paracrine effects between the hepatic and metastatic cells, while concurrently evaluating agent efficacy for metastasis, metabolism and tolerability.</AbstractText>
<CopyrightInformation>© 2014 by the Society for Experimental Biology and Medicine.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>Amanda M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology, Cell Biology, Pharmaceutical Sciences, and Bioengineering, and the McGowan Institute for Regenerative Medicine, University of Pittsburgh and Pittsburgh VA Health System, Pittsburgh, PA 15213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wheeler</LastName>
<ForeName>Sarah E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology, Cell Biology, Pharmaceutical Sciences, and Bioengineering, and the McGowan Institute for Regenerative Medicine, University of Pittsburgh and Pittsburgh VA Health System, Pittsburgh, PA 15213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Taylor</LastName>
<ForeName>Donald P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology, Cell Biology, Pharmaceutical Sciences, and Bioengineering, and the McGowan Institute for Regenerative Medicine, University of Pittsburgh and Pittsburgh VA Health System, Pittsburgh, PA 15213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pillai</LastName>
<ForeName>Venkateswaran C</ForeName>
<Initials>VC</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology, Cell Biology, Pharmaceutical Sciences, and Bioengineering, and the McGowan Institute for Regenerative Medicine, University of Pittsburgh and Pittsburgh VA Health System, Pittsburgh, PA 15213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Young</LastName>
<ForeName>Carissa L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02319, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Prantil-Baun</LastName>
<ForeName>Rachelle</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Charles Stark Draper Laboratory, Cambridge, MA 02139, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Transon</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Charles Stark Draper Laboratory, Cambridge, MA 02139, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stolz</LastName>
<ForeName>Donna B</ForeName>
<Initials>DB</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology, Cell Biology, Pharmaceutical Sciences, and Bioengineering, and the McGowan Institute for Regenerative Medicine, University of Pittsburgh and Pittsburgh VA Health System, Pittsburgh, PA 15213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borenstein</LastName>
<ForeName>Jeffrey T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Charles Stark Draper Laboratory, Cambridge, MA 02139, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lauffenburger</LastName>
<ForeName>Douglas A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02319, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Venkataramanan</LastName>
<ForeName>Raman</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology, Cell Biology, Pharmaceutical Sciences, and Bioengineering, and the McGowan Institute for Regenerative Medicine, University of Pittsburgh and Pittsburgh VA Health System, Pittsburgh, PA 15213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Griffith</LastName>
<ForeName>Linda G</ForeName>
<Initials>LG</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02319, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wells</LastName>
<ForeName>Alan</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology, Cell Biology, Pharmaceutical Sciences, and Bioengineering, and the McGowan Institute for Regenerative Medicine, University of Pittsburgh and Pittsburgh VA Health System, Pittsburgh, PA 15213, USA wellsa@upmc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1UH2TR000496-01</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Exp Biol Med (Maywood)</MedlineTA>
<NlmUniqueID>100973463</NlmUniqueID>
<ISSNLinking>1535-3699</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018929">Cell Culture Techniques</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Micrometastasis</Keyword>
<Keyword MajorTopicYN="N">chemotherapeutics</Keyword>
<Keyword MajorTopicYN="N">liver</Keyword>
<Keyword MajorTopicYN="N">mammary carcinoma</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25030480</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1535-3699</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>239</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Experimental biology and medicine (Maywood, N.J.)</Title>
<ISOAbbreviation>Exp. Biol. Med. (Maywood)</ISOAbbreviation>
</Journal>
<ArticleTitle>Tissue-engineered microenvironment systems for modeling human vasculature.</ArticleTitle>
<Pagination>
<MedlinePgn>1264-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1535370214539228</ELocationID>
<Abstract>
<AbstractText>The high attrition rate of drug candidates late in the development process has led to an increasing demand for test assays that predict clinical outcome better than conventional 2D cell culture systems and animal models. Government agencies, the military, and the pharmaceutical industry have started initiatives for the development of novel in-vitro systems that recapitulate functional units of human tissues and organs. There is growing evidence that 3D cell arrangement, co-culture of different cell types, and physico-chemical cues lead to improved predictive power. A key element of all tissue microenvironments is the vasculature. Beyond transporting blood the microvasculature assumes important organ-specific functions. It is also involved in pathologic conditions, such as inflammation, tumor growth, metastasis, and degenerative diseases. To provide a tool for modeling this important feature of human tissue microenvironments, we developed a microfluidic chip for creating tissue-engineered microenvironment systems (TEMS) composed of tubular cell structures. Our chip design encompasses a small chamber that is filled with an extracellular matrix (ECM) surrounding one or more tubular channels. Endothelial cells (ECs) seeded into the channels adhere to the ECM walls and grow into perfusable tubular tissue structures that are fluidically connected to upstream and downstream fluid channels in the chip. Using these chips we created models of angiogenesis, the blood-brain barrier (BBB), and tumor-cell extravasation. Our angiogenesis model recapitulates true angiogenesis, in which sprouting occurs from a "parent" vessel in response to a gradient of growth factors. Our BBB model is composed of a microvessel generated from brain-specific ECs within an ECM populated with astrocytes and pericytes. Our tumor-cell extravasation model can be utilized to visualize and measure tumor-cell migration through vessel walls into the surrounding matrix. The described technology can be used to create TEMS that recapitulate structural, functional, and physico-chemical elements of vascularized human tissue microenvironments in vitro.</AbstractText>
<CopyrightInformation>© 2014 by the Society for Experimental Biology and Medicine.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tourovskaia</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fauver</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kramer</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simonson</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Neumann</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Nortis, Inc., Seattle, WA 98195, USA neumann@nortisbio.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1R43CA144469-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R43HL107040-01A1</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R43NS070440-01</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1UH2TR000504-01</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Exp Biol Med (Maywood)</MedlineTA>
<NlmUniqueID>100973463</NlmUniqueID>
<ISSNLinking>1535-3699</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002196">Capillaries</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018929">Cell Culture Techniques</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018920">Coculture Techniques</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D046210">Microfluidic Analytical Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D023822">Tissue Engineering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Microfluidic device</Keyword>
<Keyword MajorTopicYN="N">body-on-chip</Keyword>
<Keyword MajorTopicYN="N">microenvironment</Keyword>
<Keyword MajorTopicYN="N">microphysiological system</Keyword>
<Keyword MajorTopicYN="N">microvasculature</Keyword>
<Keyword MajorTopicYN="N">organ-on-chip</Keyword>
<Keyword MajorTopicYN="N">tissue engineering</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25041128</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1742-4658</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>281</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The FEBS journal</Title>
<ISOAbbreviation>FEBS J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity.</ArticleTitle>
<Pagination>
<MedlinePgn>3882-93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.12923</ELocationID>
<Abstract>
<AbstractText>The mechanisms underlying immune evasion by gastric cancer have not been well described due to a lack of gastric tumor models in immunocompetent mice. In the current study, we found that supernatants from MFC cells, a murine gastric cancer line, inhibited the lipopolysaccharide (LPS) induced maturation and cross-presentation of bone-marrow-derived dendritic cells (BMDCs). Moreover, MFC tumor-derived factors markedly altered the cytokine profiles of BMDCs, leading to a trend of increased levels of interleukin 4 (IL4), IL6, IL23 and transforming growth factor β, as well as decreased levels of tumor necrosis factor α. qPCR and ELISA revealed that MFC cells expressed a high level of vascular endothelial growth factor (VEGF). Downregulating VEGF expression abrogated the inhibitory effect of MFC-derived factors on the maturation and cross-presentation of BMDCs. In addition, VEGF knockdown greatly impaired the tumorigenicity of MFC cells in immunocompetent mice. Compared with parental MFC tumors, VEGF-low MFC tumors grew much more slowly and the survival of tumor-inoculated mice was significantly improved. More importantly, mice rejecting inoculated VEGF-low MFC tumor cells gained resistance to re-challenged parental tumors, which was attributed to an antitumor immunity response against parental MFC tumors. These results reveal an immunosuppressive role for VEGF in murine gastric cancer. </AbstractText>
<CopyrightInformation>© 2014 FEBS.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery and Center of Minimal Invasive Gastrointestinal Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Peiwu</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zeng</LastName>
<ForeName>Dongzhu</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qian</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lei</LastName>
<ForeName>Xiao</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Yongliang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hao</LastName>
<ForeName>Yingxue</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Huaxing</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>Yongjia</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>FEBS J</MedlineTA>
<NlmUniqueID>101229646</NlmUniqueID>
<ISSNLinking>1742-464X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007108">Immune Tolerance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">antitumor immunity</Keyword>
<Keyword MajorTopicYN="N">gastric cancer</Keyword>
<Keyword MajorTopicYN="N">immune evasion</Keyword>
<Keyword MajorTopicYN="N">vascular endothelial growth factor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25184678</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1549-5477</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Genes &amp; development</Title>
<ISOAbbreviation>Genes Dev.</ISOAbbreviation>
</Journal>
<ArticleTitle>ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis.</ArticleTitle>
<Pagination>
<MedlinePgn>1917-28</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1101/gad.245910.114</ELocationID>
<Abstract>
<AbstractText>Elevated glycolysis is a common metabolic trait of cancer, but what drives such metabolic reprogramming remains incompletely clear. We report here a novel transcriptional repressor-mediated negative regulation of glycolysis. ZBTB7A, a member of the POK (POZ/BTB and Krüppel) transcription repressor family, directly binds to the promoter and represses the transcription of critical glycolytic genes, including GLUT3, PFKP, and PKM. Analysis of The Cancer Genome Atlas (TCGA) data sets reveals that the ZBTB7A locus is frequently deleted in many human tumors. Significantly, reduced ZBTB7A expression correlates with up-regulation of the glycolytic genes and poor survival in colon cancer patients. Remarkably, while ZBTB7A-deficient tumors progress exceedingly fast, they exhibit an unusually heightened sensitivity to glycolysis inhibition. Our study uncovers a novel tumor suppressor role of ZBTB7A in directly suppressing glycolysis. </AbstractText>
<CopyrightInformation>© 2014 Liu et al.; Published by Cold Spring Harbor Laboratory Press.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Xue-Song</ForeName>
<Initials>XS</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Haines</LastName>
<ForeName>Jenna E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mehanna</LastName>
<ForeName>Elie K</ForeName>
<Initials>EK</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Genet</LastName>
<ForeName>Matthew D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ben-Sahra</LastName>
<ForeName>Issam</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Asara</LastName>
<ForeName>John M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Manning</LastName>
<ForeName>Brendan D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Zhi-Min</ForeName>
<Initials>ZM</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA; zyuan@hsph.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01CA085679</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA125144</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA167814</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Genes Dev</MedlineTA>
<NlmUniqueID>8711660</NlmUniqueID>
<ISSNLinking>0890-9369</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485514">ZBTB7A protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016147">Genes, Tumor Suppressor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006019">Glycolysis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4197949 [Available on 03/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">GLUT3</Keyword>
<Keyword MajorTopicYN="N">PFKP</Keyword>
<Keyword MajorTopicYN="N">PKM</Keyword>
<Keyword MajorTopicYN="N">ZBTB7A</Keyword>
<Keyword MajorTopicYN="N">glycolysis</Keyword>
<Keyword MajorTopicYN="N">tumor suppressor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25184681</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1549-5477</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>17</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Genes &amp; development</Title>
<ISOAbbreviation>Genes Dev.</ISOAbbreviation>
</Journal>
<ArticleTitle>Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage.</ArticleTitle>
<Pagination>
<MedlinePgn>1957-75</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1101/gad.241620.114</ELocationID>
<Abstract>
<AbstractText>BRCA1 is a breast and ovarian tumor suppressor. Given its numerous incompletely understood functions and the possibility that more exist, we performed complementary systematic screens in search of new BRCA1 protein-interacting partners. New BRCA1 functions and/or a better understanding of existing ones were sought. Among the new interacting proteins identified, genetic interactions were detected between BRCA1 and four of the interactors: TONSL, SETX, TCEANC, and TCEA2. Genetic interactions were also detected between BRCA1 and certain interactors of TONSL, including both members of the FACT complex. From these results, a new BRCA1 function in the response to transcription-associated DNA damage was detected. Specifically, new roles for BRCA1 in the restart of transcription after UV damage and in preventing or repairing damage caused by stabilized R loops were identified. These roles are likely carried out together with some of the newly identified interactors. This new function may be important in BRCA1 tumor suppression, since the expression of several interactors, including some of the above-noted transcription proteins, is repeatedly aberrant in both breast and ovarian cancers. </AbstractText>
<CopyrightInformation>© 2014 Hill et al.; Published by Cold Spring Harbor Laboratory Press.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hill</LastName>
<ForeName>Sarah J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rolland</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Adelmant</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xia</LastName>
<ForeName>Xianfang</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Owen</LastName>
<ForeName>Matthew S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dricot</LastName>
<ForeName>Amélie</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zack</LastName>
<ForeName>Travis I</ForeName>
<Initials>TI</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; The Broad Institute, Cambridge, Massachusetts 02142, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sahni</LastName>
<ForeName>Nidhi</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jacob</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Département de Virologie, Unité de Génétique Moléculaire des Virus à ARN, Institut Pasteur, F-75015 Paris, France; UMR3569, Centre National de la Recherche Scientifique, F-75015 Paris, France; Unité de Génétique Moléculaire des Virus à ARN, Université Paris Diderot, F-75015 Paris, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hao</LastName>
<ForeName>Tong</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McKinney</LastName>
<ForeName>Kristine M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>Allison P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reyon</LastName>
<ForeName>Deepak</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pathology Unit, Center for Computational and Integrative Biology, Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA; Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsai</LastName>
<ForeName>Shengdar Q</ForeName>
<Initials>SQ</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pathology Unit, Center for Computational and Integrative Biology, Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA; Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Joung</LastName>
<ForeName>J Keith</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pathology Unit, Center for Computational and Integrative Biology, Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA; Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Beroukhim</LastName>
<ForeName>Rameen</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; The Broad Institute, Cambridge, Massachusetts 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marto</LastName>
<ForeName>Jarrod A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vidal</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gaudet</LastName>
<ForeName>Suzanne</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hill</LastName>
<ForeName>David E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Livingston</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; david_livingston@dfci.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1F30CA167895-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DP1 GM105378</GrantID>
<Acronym>DP</Acronym>
<Agency>NCCDPHP CDC HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01CA080111</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01NS047572</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50CA089393</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA136512</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01HG001715</GrantID>
<Acronym>HG</Acronym>
<Agency>NHGRI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54CA112962</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Genes Dev</MedlineTA>
<NlmUniqueID>8711660</NlmUniqueID>
<ISSNLinking>0890-9369</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C093394">TONSL protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019313">BRCA1 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004260">DNA Repair</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025941">Protein Interaction Mapping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014466">Ultraviolet Rays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4197947 [Available on 03/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BRCA1 interaction screening</Keyword>
<Keyword MajorTopicYN="N">DNA damage</Keyword>
<Keyword MajorTopicYN="N">transcription</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25005874</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1559-7016</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</Title>
<ISOAbbreviation>J. Cereb. Blood Flow Metab.</ISOAbbreviation>
</Journal>
<ArticleTitle>Lipocalin-type prostaglandin D synthase scavenges biliverdin in the cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage.</ArticleTitle>
<Pagination>
<MedlinePgn>1558-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/jcbfm.2014.127</ELocationID>
<Abstract>
<AbstractText>Lipocalin-type prostaglandin (PG) D synthase (L-PGDS) is the second major protein in human cerebrospinal fluid (CSF) and belongs to the lipocalin superfamily composed of various secretory lipophilic ligand transporter proteins. However, the endogenous ligand of L-PGDS has not yet been elucidated. In this study, we purified L-PGDS from the CSF of aneurysmal subarachnoid hemorrhage (SAH) patients. Lipocalin-type PG D synthase showed absorbance spectra with major peaks at 280 and 392 nm and a minor peak at around 660 nm. The absorbance at 392 nm of L-PGDS increased from 1 to 9 days and almost disappeared at 2 months after SAH, whereas the L-PGDS activity decreased from 1 to 7 days and recovered to normal at 2 months after SAH. These results indicate that some chromophore had accumulated in the CSF after SAH and bound to L-PGDS, thus inactivating it. Matrix assisted laser desorption ionization time-of-flight mass spectrometry of L-PGDS after digestion of it with endoproteinase Lys-C revealed that L-PGDS had covalently bound biliverdin, a by-product of heme breakdown. These results suggest that L-PGDS acted as a scavenger of biliverdin, which is a molecule not found in normal CSF. This is the first report of identification of a pathophysiologically important endogenous ligand for this lipocalin superfamily protein in humans. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Inui</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan [2] Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mase</LastName>
<ForeName>Mitsuhito</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery and Restorative Neuroscience, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shirota</LastName>
<ForeName>Ryoko</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nagashima</LastName>
<ForeName>Mariko</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okada</LastName>
<ForeName>Tetsuya</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Urade</LastName>
<ForeName>Yoshihiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cereb Blood Flow Metab</MedlineTA>
<NlmUniqueID>8112566</NlmUniqueID>
<ISSNLinking>0271-678X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054834">Lipocalins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.3.-</RegistryNumber>
<NameOfSubstance UI="D019746">Intramolecular Oxidoreductases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.3.99.2</RegistryNumber>
<NameOfSubstance UI="C022466">prostaglandin R2 D-isomerase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>O9MIA842K9</RegistryNumber>
<NameOfSubstance UI="D001664">Biliverdine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017542">Aneurysm, Ruptured</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001664">Biliverdine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002532">Intracranial Aneurysm</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019746">Intramolecular Oxidoreductases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054834">Lipocalins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019032">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013345">Subarachnoid Hemorrhage</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4158676 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24821282</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-4159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>130</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurochemistry</Title>
<ISOAbbreviation>J. Neurochem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Knockdown of phosphotyrosyl phosphatase activator induces apoptosis via mitochondrial pathway and the attenuation by simultaneous tau hyperphosphorylation.</ArticleTitle>
<Pagination>
<MedlinePgn>816-25</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jnc.12761</ELocationID>
<Abstract>
<AbstractText>Phosphotyrosyl phosphatase activator (PTPA) is decreased in the brains of Alzheimer's disease (AD) and the AD transgenic mouse models. Here, we investigated whether down-regulation of PTPA affects cell viability and the underlying mechanisms. We found that PTPA was located in the integral membrane of mitochondria, and knockdown of PTPA induced cell apoptosis in HEK293 and N2a cell lines. PTPA knockdown decreased mitochondrial membrane potential and induced Bax translocation into the mitochondria with a simultaneous release of Cyt C, activation of caspase-3, cleavage of poly (DNA ribose) polymerase (PARP), and decrease in Bcl-xl and Bcl-2 protein levels. Over-expression of Protein phosphatase 2A (PP2A) catalytic subunit (PP2AC ) did not rescue the apoptosis induced by PTPA knockdown, and PTPA knockdown did not affect the level of and their phosphorylation of mitogen-activated protein kinases (MAPKs), indicating that PP2A and MAPKs were not involved in the apoptosis induced by PTPA knockdown. In the cells with over-expression of tau, PTPA knockdown induced PP2A inhibition and tau hyperphosphorylation but did not cause significant cell death. These data suggest that PTPA deficit causes apoptotic cell death through mitochondrial pathway and simultaneous tau hyperphosphorylation attenuates the PTPA-induced cell death. Phosphotyrosyl phosphatase activator (PTPA) is decreased in the brains of Alzheimer's disease (AD) and AD transgenic mouse models. Here, we investigated whether down-regulation of PTPA affects cell viability. We found that PTPA located in the integral membrane of mitochondria, and knockdown of PTPA induced cell apoptosis in HEK293 and N2a cell lines by decreasing mitochondrial membrane potential, which leads to translocation of Bax and a simultaneous release of Cyt C. In the cells with tau over-expression, PTPA knockdown inactivated PP2A to phosphorylate tau to avoid cell apoptosis which induced by PTPA knockdown. </AbstractText>
<CopyrightInformation>© 2014 International Society for Neurochemistry.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Dan-Ju</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathophysiology, Key Laboratory of Chinese Ministry of Education for Neurological Diseases, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Qiong</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Zhi-Hao</ForeName>
<Initials>ZH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Dong-Sheng</ForeName>
<Initials>DS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Qun</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jian-Zhi</ForeName>
<Initials>JZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Gong-Ping</ForeName>
<Initials>GP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Neurochem</MedlineTA>
<NlmUniqueID>2985190R</NlmUniqueID>
<ISSNLinking>0022-3042</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8L70Q75FXE</RegistryNumber>
<NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-43-6</RegistryNumber>
<NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.16</RegistryNumber>
<NameOfSubstance UI="D010749">Phosphoprotein Phosphatases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.2.1.8</RegistryNumber>
<NameOfSubstance UI="C087440">PPP2R4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>M03GIQ7Z6P</RegistryNumber>
<NameOfSubstance UI="D012844">Sincalide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000255">Adenosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045304">Cytochromes c</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003593">Cytoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009447">Neuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010749">Phosphoprotein Phosphatases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012844">Sincalide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051028">bcl-2-Associated X Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016875">tau Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Cyt C</Keyword>
<Keyword MajorTopicYN="N">PTPA</Keyword>
<Keyword MajorTopicYN="N">mitochondrial pathway</Keyword>
<Keyword MajorTopicYN="N">tau hyperphosphorylation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24832624</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-4159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>130</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurochemistry</Title>
<ISOAbbreviation>J. Neurochem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.</ArticleTitle>
<Pagination>
<MedlinePgn>826-38</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jnc.12762</ELocationID>
<Abstract>
<AbstractText>Parkinson's disease (PD) is a common neurodegenerative disease, but its pathogenesis remains elusive. A mutation in ubiquitin C-terminal hydrolase L1 (UCH-L1) is responsible for a form of genetic PD which strongly resembles the idiopathic PD. We previously showed that 1-(3',4'-dihydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline (3',4'DHBnTIQ) is an endogenous parkinsonism-inducing dopamine derivative. Here, we investigated the interaction between 3',4'DHBnTIQ and UCH-L1 and its possible role in the pathogenesis of idiopathic PD. Our results indicate that 3',4'DHBnTIQ binds to UCH-L1 specifically at Cys152 in vitro. In addition, 3',4'DHBnTIQ treatment increased the amount of UCH-L1 in the insoluble fraction of SH-SY5Y cells and inhibited its hydrolase activity to 60%, reducing the level of ubiquitin in the soluble fraction of SH-SY5Y cells. Catechol-modified UCH-L1 as well as insoluble UCH-L1 were detected in the midbrain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated PD model mice. Structurally as well as functionally altered UCH-L1 have been detected in the brains of patients with idiopathic PD. We suggest that conjugation of UCH-L1 by neurotoxic endogenous compounds such as 3',4'DHBnTIQ might play a key role in onset and progression of idiopathic PD. We investigated the interaction between ubiquitin C-terminal hydrolase L1 (UCH-L1) and the brain endogenous parkinsonism inducer 1-(3',4'-dihydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline (3',4'DHBnTIQ). Our results indicate that 3',4'DHBnTIQ binds to UCH-L1 specifically at cysteine 152 and induces its aggregation. 3',4'DHBnTIQ also inhibits the hydrolase activity of UCH-L1. Catechol-modified as well as insoluble UCH-L1 were detected in the midbrains of MPTP-treated Parkinson's disease (PD) model mice. Conjugation of UCH-L1 by neurotoxic endogenous compounds like 3',4'DHBnTIQ might play a key role in onset and progression of PD. </AbstractText>
<CopyrightInformation>© 2014 International Society for Neurochemistry.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Contu</LastName>
<ForeName>Viorica Raluca</ForeName>
<Initials>VR</Initials>
<AffiliationInfo>
<Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kotake</LastName>
<ForeName>Yaichiro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Toyama</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Okuda</LastName>
<ForeName>Katsuhiro</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miyara</LastName>
<ForeName>Masatsugu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sakamoto</LastName>
<ForeName>Shuichiro</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Samizo</LastName>
<ForeName>Shigeyoshi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sanoh</LastName>
<ForeName>Seigo</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kumagai</LastName>
<ForeName>Yoshito</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ohta</LastName>
<ForeName>Shigeru</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Neurochem</MedlineTA>
<NlmUniqueID>2985190R</NlmUniqueID>
<ISSNLinking>0022-3042</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C110419">1-(3',4'-dihydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002396">Catechols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007202">Indicators and Reagents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.2.15</RegistryNumber>
<NameOfSubstance UI="D043222">Ubiquitin Thiolesterase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.2.15</RegistryNumber>
<NameOfSubstance UI="C507533">Ubiquitin carboxyl-Terminal Hydrolase L-1, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>JIO3275WGI</RegistryNumber>
<NameOfSubstance UI="D014213">Tretoquinol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>LF3AJ089DQ</RegistryNumber>
<NameOfSubstance UI="C034221">catechol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002396">Catechols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004587">Electrophoresis, Agar Gel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004926">Escherichia coli</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007202">Indicators and Reagents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008636">Mesencephalon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009498">Neurotoxins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019032">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014213">Tretoquinol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043222">Ubiquitin Thiolesterase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">UCH-L1</Keyword>
<Keyword MajorTopicYN="N">aggregation</Keyword>
<Keyword MajorTopicYN="N">covalent modification</Keyword>
<Keyword MajorTopicYN="N">endogenous dopamine derivative</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043040</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7516</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Dynamic and static maintenance of epigenetic memory in pluripotent and somatic cells.</ArticleTitle>
<Pagination>
<MedlinePgn>115-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13458</ELocationID>
<Abstract>
<AbstractText>Stable maintenance of gene regulatory programs is essential for normal function in multicellular organisms. Epigenetic mechanisms, and DNA methylation in particular, are hypothesized to facilitate such maintenance by creating cellular memory that can be written during embryonic development and then guide cell-type-specific gene expression. Here we develop new methods for quantitative inference of DNA methylation turnover rates, and show that human embryonic stem cells preserve their epigenetic state by balancing antagonistic processes that add and remove methylation marks rather than by copying epigenetic information from mother to daughter cells. In contrast, somatic cells transmit considerable epigenetic information to progenies. Paradoxically, the persistence of the somatic epigenome makes it more vulnerable to noise, since random epimutations can accumulate to massively perturb the epigenomic ground state. The rate of epigenetic perturbation depends on the genomic context, and, in particular, DNA methylation loss is coupled to late DNA replication dynamics. Epigenetic perturbation is not observed in the pluripotent state, because the rapid turnover-based equilibrium continuously reinforces the canonical state. This dynamic epigenetic equilibrium also explains how the epigenome can be reprogrammed quickly and to near perfection after induced pluripotency. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shipony</LastName>
<ForeName>Zohar</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mukamel</LastName>
<ForeName>Zohar</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cohen</LastName>
<ForeName>Netta Mendelson</ForeName>
<Initials>NM</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Landan</LastName>
<ForeName>Gilad</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chomsky</LastName>
<ForeName>Elad</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel [2] Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zeliger</LastName>
<ForeName>Shlomit Reich</ForeName>
<Initials>SR</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fried</LastName>
<ForeName>Yael Chagit</ForeName>
<Initials>YC</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Services, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ainbinder</LastName>
<ForeName>Elena</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Services, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Friedman</LastName>
<ForeName>Nir</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tanay</LastName>
<ForeName>Amos</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE53610</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000483">Alleles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002999">Clone Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019175">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053595">Embryonic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057026">Induced Pluripotent Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079319</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7516</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>65-70</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13485</ELocationID>
<Abstract>
<AbstractText>The translational control of oncoprotein expression is implicated in many cancers. Here we report an eIF4A RNA helicase-dependent mechanism of translational control that contributes to oncogenesis and underlies the anticancer effects of silvestrol and related compounds. For example, eIF4A promotes T-cell acute lymphoblastic leukaemia development in vivo and is required for leukaemia maintenance. Accordingly, inhibition of eIF4A with silvestrol has powerful therapeutic effects against murine and human leukaemic cells in vitro and in vivo. We use transcriptome-scale ribosome footprinting to identify the hallmarks of eIF4A-dependent transcripts. These include 5' untranslated region (UTR) sequences such as the 12-nucleotide guanine quartet (CGG)4 motif that can form RNA G-quadruplex structures. Notably, among the most eIF4A-dependent and silvestrol-sensitive transcripts are a number of oncogenes, superenhancer-associated transcription factors, and epigenetic regulators. Hence, the 5' UTRs of select cancer genes harbour a targetable requirement for the eIF4A RNA helicase. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wolfe</LastName>
<ForeName>Andrew L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2] Weill Cornell Graduate School of Medical Sciences, New York, New York 10065, USA [3].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Kamini</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Yi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Computational Biology Department, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Drewe</LastName>
<ForeName>Philipp</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Computational Biology Department, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rajasekhar</LastName>
<ForeName>Vinagolu K</ForeName>
<Initials>VK</Initials>
<AffiliationInfo>
<Affiliation>Stem Cell Center and Developmental Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sanghvi</LastName>
<ForeName>Viraj R</ForeName>
<Initials>VR</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mavrakis</LastName>
<ForeName>Konstantinos J</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2] Novartis, Cambridge, Massachusetts 02139, USA (K.J.M.); The University of Arizona Cancer Center, Tucson, Arizona 85719, USA (J.H.S.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Man</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roderick</LastName>
<ForeName>Justine E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Van der Meulen</LastName>
<ForeName>Joni</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2] Center for Medical Genetics, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schatz</LastName>
<ForeName>Jonathan H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [2] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA [3] Novartis, Cambridge, Massachusetts 02139, USA (K.J.M.); The University of Arizona Cancer Center, Tucson, Arizona 85719, USA (J.H.S.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rodrigo</LastName>
<ForeName>Christina M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Center for Chemical Methodology and Library Development, Boston University, Boston, Massachusetts 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Chunying</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rondou</LastName>
<ForeName>Pieter</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Center for Medical Genetics, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Stanchina</LastName>
<ForeName>Elisa</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Teruya-Feldstein</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kelliher</LastName>
<ForeName>Michelle A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Speleman</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Center for Medical Genetics, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Porco</LastName>
<ForeName>John A</ForeName>
<Initials>JA</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Center for Chemical Methodology and Library Development, Boston University, Boston, Massachusetts 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pelletier</LastName>
<ForeName>Jerry</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada [2] Department of Oncology, McGill University, Montreal, Quebec H3G 1Y6, Canada [3] The Rosalind and Morris Goodman Cancer Research Center, McGill University, Montreal, Quebec H3G 1Y6, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rätsch</LastName>
<ForeName>Gunnar</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Computational Biology Department, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wendel</LastName>
<ForeName>Hans-Guido</ForeName>
<Initials>HG</Initials>
<AffiliationInfo>
<Affiliation>Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE56887</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>GM-067041</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM-073855</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>MOP-10653</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
<Grant>
<GrantID>R01-CA142798-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020121">5' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489897">silvestrol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance UI="D039601">Eukaryotic Initiation Factor-4A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020121">5' Untranslated Regions</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039601">Eukaryotic Initiation Factor-4A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D054856">G-Quadruplexes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059372">Nucleotide Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015513">Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054218">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014176">Protein Biosynthesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012270">Ribosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079330</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7516</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.</ArticleTitle>
<Pagination>
<MedlinePgn>105-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13572</ELocationID>
<Abstract>
<AbstractText>In BRAF(V600)-mutant tumours, most mechanisms of resistance to drugs that target the BRAF and/or MEK kinases rely on reactivation of the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway, on activation of the alternative, PI(3)K-AKT-mTOR, pathway (which is ERK independent) or on modulation of the caspase-dependent apoptotic cascade. All three pathways converge to regulate the formation of the eIF4F eukaryotic translation initiation complex, which binds to the 7-methylguanylate cap (m(7)G) at the 5' end of messenger RNA, thereby modulating the translation of specific mRNAs. Here we show that the persistent formation of the eIF4F complex, comprising the eIF4E cap-binding protein, the eIF4G scaffolding protein and the eIF4A RNA helicase, is associated with resistance to anti-BRAF, anti-MEK and anti-BRAF plus anti-MEK drug combinations in BRAF(V600)-mutant melanoma, colon and thyroid cancer cell lines. Resistance to treatment and maintenance of eIF4F complex formation is associated with one of three mechanisms: reactivation of MAPK signalling, persistent ERK-independent phosphorylation of the inhibitory eIF4E-binding protein 4EBP1 or increased pro-apoptotic BCL-2-modifying factor (BMF)-dependent degradation of eIF4G. The development of an in situ method to detect the eIF4E-eIF4G interactions shows that eIF4F complex formation is decreased in tumours that respond to anti-BRAF therapy and increased in resistant metastases compared to tumours before treatment. Strikingly, inhibiting the eIF4F complex, either by blocking the eIF4E-eIF4G interaction or by targeting eIF4A, synergizes with inhibiting BRAF(V600) to kill the cancer cells. eIF4F not only appears to be an indicator of both innate and acquired resistance but also is a promising therapeutic target. Combinations of drugs targeting BRAF (and/or MEK) and eIF4F may overcome most of the resistance mechanisms arising in BRAF(V600)-mutant cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Boussemart</LastName>
<ForeName>Lise</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France [4].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malka-Mahieu</LastName>
<ForeName>Hélène</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Girault</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2].</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Allard</LastName>
<ForeName>Delphine</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR981, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hemmingsson</LastName>
<ForeName>Oskar</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Department of Surgical and Perioperative Sciences, Umeå University, Umeå SE-90187, Sweden (O.H.); CNRS UMR3348, Institut Curie, Orsay F-91405, France (S.V.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tomasic</LastName>
<ForeName>Gorana</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Pathology Department, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Marina</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Basmadjian</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ribeiro</LastName>
<ForeName>Nigel</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thuaud</LastName>
<ForeName>Frédéric</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mateus</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Routier</LastName>
<ForeName>Emilie</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kamsu-Kom</LastName>
<ForeName>Nyam</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR981, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Agoussi</LastName>
<ForeName>Sandrine</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR981, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eggermont</LastName>
<ForeName>Alexander M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>1] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [2] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Désaubry</LastName>
<ForeName>Laurent</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>CNRS-Strasbourg University, UMR7200, Illkirch F-67400, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Robert</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vagner</LastName>
<ForeName>Stéphan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France [4] Department of Surgical and Perioperative Sciences, Umeå University, Umeå SE-90187, Sweden (O.H.); CNRS UMR3348, Institut Curie, Orsay F-91405, France (S.V.).</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039561">Eukaryotic Initiation Factor-4E</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039562">Eukaryotic Initiation Factor-4F</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039603">Eukaryotic Initiation Factor-4G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551177">PLX4032</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489897">silvestrol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance UI="D039601">Eukaryotic Initiation Factor-4A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039601">Eukaryotic Initiation Factor-4A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039561">Eukaryotic Initiation Factor-4E</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039562">Eukaryotic Initiation Factor-4F</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039603">Eukaryotic Initiation Factor-4G</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24077287</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases.</ArticleTitle>
<Pagination>
<MedlinePgn>4485-95</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.392</ELocationID>
<Abstract>
<AbstractText>Epithelial splicing regulatory protein 1 (ESRP1) binds the FGFR-2 auxiliary cis-element ISE/ISS-3, located in the intron between exon IIIb and IIIc, and primarily promotes FGFR-2 IIIb expression. Here we assessed the role of ESRP1 in pancreatic ductal adenocarcinoma (PDAC). Immunohistochemical analysis was performed using anti-ESRP1, FGFR-2 IIIb and FGFR-2 IIIc antibodies in 123 PDAC cases. ESRP1 expression vector and small interference RNA (siRNA) targeting ESRP1 were transfected into human PDAC cells, and cell growth, migration and invasion were analyzed. In vivo heterotopic and orthotopic implantations using ESRP1 overexpression clones were performed and effects on pancreatic tumor volumes and hepatic and pulmonary metastases determined. ESRP1 immunoreactivity was strong in the nuclei of cancer cells in well-to-moderately differentiated PDACs but weak in poorly differentiated cancers. Well-to-moderately differentiated cancers also exhibited high FGFR-2 IIIb and low FGFR-2 IIIc expression, whereas this ratio was reversed in the poorly differentiated cancers. Increased ESRP1 expression was associated with longer survival in comparison with low ESRP1 expression, and PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb expression and decreased migration and invasion in vitro, whereas ESRP1 siRNA-transfected KLM-1 cells exhibited increased FGFR-2 IIIc expression and increased cell growth, migration and invasion. In vivo, ESRP1-overexpressing clones formed significantly fewer liver metastases as compared with control clones. ESRP1 regulates the expression pattern of FGFR-2 isoforms, attenuates cell growth, migration, invasion and metastasis, and is a favorable prognostic factor in PDAC. Therefore, devising mechanisms to upregulate ESRP1 may exert a beneficial therapeutic effect in PDAC. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ueda</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan [2] Department of Surgery for Organ and Biological Regulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsuda</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamahatsu</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan [2] Department of Surgery for Organ and Biological Regulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uchida</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery for Organ and Biological Regulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Naito</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Korc</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, and Biochemistry and Molecular Biology, Indiana University School of Medicine and the Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ishiwata</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R37 CA075059</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37-CA-075059</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>09</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C539364">ESRP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D051497">Receptor, Fibroblast Growth Factor, Type 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017398">Alternative Splicing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021441">Carcinoma, Pancreatic Ductal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020033">Protein Isoforms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016601">RNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051497">Receptor, Fibroblast Growth Factor, Type 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS560214 [Available on 03/04/15]</OtherID>
<OtherID Source="NLM">PMC4041859 [Available on 03/04/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096484</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>4508-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.399</ELocationID>
<Abstract>
<AbstractText>Metastasis suppressors comprise a growing class of genes whose downregulation triggers metastatic progression. In contrast to tumor suppressors, metastasis suppressors are rarely mutated or deleted, and little is known regarding the mechanisms by which their expression is downregulated. Here, we demonstrate that the metastasis suppressor, NM23-H1, is degraded by lysosomal cysteine cathepsins (L,B), which directly cleave NM23-H1. In addition, activation of c-Abl and Arg oncoproteins induces NM23-H1 degradation in invasive cancer cells by increasing cysteine cathepsin transcription and activation. Moreover, c-Abl activates cathepsins by promoting endosome maturation, which facilitates trafficking of NM23-H1 to the lysosome where it is degraded. Importantly, the invasion- and metastasis-promoting activity of c-Abl/Arg is dependent on their ability to induce NM23-H1 degradation, and the pathway is clinically relevant as c-Abl/Arg activity and NM23-H1 expression are inversely correlated in primary breast cancers and melanomas. Thus, we demonstrate a novel mechanism by which cathepsin expression is upregulated in cancer cells (via Abl kinases). We also identify a novel role for intracellular cathepsins in invasion and metastasis (degradation of a metastasis suppressor). Finally, we identify novel crosstalk between oncogenic and metastasis suppressor pathways, thereby providing mechanistic insight into the process of NM23-H1 loss, which may pave the way for new strategies to restore NM23-H1 expression and block metastatic progression. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fiore</LastName>
<ForeName>L S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ganguly</LastName>
<ForeName>S S</ForeName>
<Initials>SS</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sledziona</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cibull</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics and Markey Cancer Center, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Richards</LastName>
<ForeName>D L</ForeName>
<Initials>DL</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Neltner</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Beach</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McCorkle</LastName>
<ForeName>J R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kaetzel</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Biology, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Plattner</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA116784</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA166499</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA177558</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA116784</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA166499</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C498826">4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054778">NM23 Nucleoside Diphosphate Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D016315">Proto-Oncogene Proteins c-abl</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D002403">Cathepsins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002403">Cathepsins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016147">Genes, Tumor Suppressor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008247">Lysosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054778">NM23 Nucleoside Diphosphate Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016315">Proto-Oncogene Proteins c-abl</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS550235 [Available on 03/04/15]</OtherID>
<OtherID Source="NLM">PMC3979510 [Available on 03/04/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24166502</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>4531-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.442</ELocationID>
<Abstract>
<AbstractText>Desmosomal cadherins mediate cell-cell adhesion in epithelial tissues and have been known to be altered in cancer. We have previously shown that one of the two intestinal epithelial desmosomal cadherins, desmocollin-2 (Dsc2) loss promotes colonic epithelial carcinoma cell proliferation and tumor formation. In this study we show that loss of the other intestinal desmosomal cadherin, desmoglein-2 (Dsg2) that pairs with Dsc2, results in decreased epithelial cell proliferation and suppressed xenograft tumor growth in mice. Dsg2-deficient cells demonstrated a compensatory increase in Dsc2 expression, and small interfering RNA-mediated loss of Dsc2 restored proliferation in Dsg2-deficient cells. Dsg2 downregulation inhibited epidermal growth factor receptor (EGFR) signaling and cell proliferation through altered phosphorylation of EGFR and downstream extracellular signal-regulated kinase activation in parallel with inhibited EGFR receptor internalization. Additionally, we demonstrated a central role of Dsc2 in controlling EGFR signaling and cell proliferation in intestinal epithelial cells. Consistent with these findings, analyses of human colon cancers demonstrated increased Dsg2 protein expression. Taken together, these data demonstrate that partner desmosomal cadherins Dsg2 and Dsc2 play opposing roles in controlling colonic carcinoma cell proliferation through differential effects on EGFR signaling. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kamekura</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kolegraff</LastName>
<ForeName>K N</ForeName>
<Initials>KN</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nava</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Biophysics and Neuroscience, Center for Research and Advanced Studies (CINVESTAV), Mexico DF, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hilgarth</LastName>
<ForeName>R S</ForeName>
<Initials>RS</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parkos</LastName>
<ForeName>C A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nusrat</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DK055679</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK059888</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK061379</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK064399</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK072564</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK059888</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK061379</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK072564</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK079392</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 DK007771</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051187">Desmocollins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051182">Desmogleins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2003 Nov 20;22(52):8509-18</RefSource>
<PMID Version="1">14627991</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2001 Jul;117(1):26-35</RefSource>
<PMID Version="1">11442746</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8064-9</RefSource>
<PMID Version="1">9653140</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1999 Mar 19;274(12):8335-43</RefSource>
<PMID Version="1">10075741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Differentiation. 2004 Oct;72(8):419-33</RefSource>
<PMID Version="1">15606501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2005 Apr;16(4):1744-55</RefSource>
<PMID Version="1">15689490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2005 May;5(5):341-54</RefSource>
<PMID Version="1">15864276</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Pathol. 2005 Oct;207(2):199-206</RefSource>
<PMID Version="1">16025435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2007 Jan 18;26(3):467-76</RefSource>
<PMID Version="1">16878157</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2007 Mar 1;120(Pt 5):758-71</RefSource>
<PMID Version="1">17284515</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2007 Nov;18(11):4565-78</RefSource>
<PMID Version="1">17804817</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int Rev Cytol. 2007;264:65-163</RefSource>
<PMID Version="1">17964922</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Adh Migr. 2009 Apr-Jun;3(2):148-54</RefSource>
<PMID Version="1">19458482</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2009 Jun 29;185(7):1243-58</RefSource>
<PMID Version="1">19546243</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G774-83</RefSource>
<PMID Version="1">20224006</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Jan 14;286(2):1499-507</RefSource>
<PMID Version="1">21071449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2011 Apr 15;22(8):1121-34</RefSource>
<PMID Version="1">21325624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Prolif. 2011 Aug;44(4):301-10</RefSource>
<PMID Version="1">21702856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Adh Migr. 2011 Jul-Aug;5(4):306-14</RefSource>
<PMID Version="1">21715983</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 2012 Oct;43(10):1745-54</RefSource>
<PMID Version="1">22521077</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(11):e50024</RefSource>
<PMID Version="1">23185521</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1989 Apr 15;49(8):2128-33</RefSource>
<PMID Version="1">2702654</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051187">Desmocollins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051182">Desmogleins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS575287</OtherID>
<OtherID Source="NLM">PMC4061272</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24662833</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.</ArticleTitle>
<Pagination>
<MedlinePgn>4521-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.25</ELocationID>
<Abstract>
<AbstractText>Macro-autophagy is associated with drug resistance in various cancers and can function as an adaptive response to maintain cell survival under metabolic stresses, including androgen deprivation. Androgen deprivation or treatment with androgen receptor (AR) signaling inhibitor (ARSI), Enzalutamide (MDV-3100, ENZA) or bicalutamide induced autophagy in androgen-dependent and in castration-resistant CaP (castration-resistant prostate cancer (CRPC)) cell lines. The autophagic cascade triggered by AR blockage, correlated with the increased light chain 3-II/I ratio and ATG-5 expression. Autophagy was observed in a subpopulation of C4-2B cells that developed insensitivity to ENZA after sustained exposure in culture. Using flow cytometry and clonogenic assays, we showed that inhibiting autophagy with clomipramine (CMI), chloroquine or metformin increased apoptosis and significantly impaired cell viability. This autophagic process was mediated by AMP-dependent protein kinase (AMPK) activation and the suppression of mammalian target of rapamycin (mTOR) through Raptor phosphorylation (Serine 792). Furthermore, small interfering RNA targeting AMPK significantly inhibited autophagy and promoted cell death in CaP cells acutely or chronically exposed to ENZA or androgen deprivation, suggesting that autophagy is an important survival mechanism in CRPC. Lastly, in vivo studies with mice orthotopically implanted with ENZA-resistant cells demonstrated that the combination of ENZA and autophagy modulators, CMI or metformin significantly reduced tumor growth when compared with control groups (P&lt;0.005). In conclusion, autophagy is as an important mechanism of resistance to ARSI in CRPC. Antiandrogen-induced autophagy is mediated through the activation of AMPK pathway and the suppression of mTOR pathway. Blocking autophagy pharmacologically or genetically significantly impairs prostate cancer cell survival in vitro and in vivo, implying the therapeutics potential of autophagy inhibitors in the antiandrogen-resistance setting. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>H G</ForeName>
<Initials>HG</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kung</LastName>
<ForeName>H-J</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>X-B</ForeName>
<Initials>XB</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tilki</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lara</LastName>
<ForeName>P N</ForeName>
<Initials>PN</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo>
<Affiliation>UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>DeVere White</LastName>
<ForeName>R W</ForeName>
<Initials>RW</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>C P</ForeName>
<Initials>CP</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA [2] UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA 165263</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D059002">Androgen Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C540278">MDV 3100</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2010-15-3</RegistryNumber>
<NameOfSubstance UI="D010669">Phenylthiohydantoin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>NUV44L116D</RegistryNumber>
<NameOfSubstance UI="D002997">Clomipramine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2008 Jan;4(1):54-60</RefSource>
<PMID Version="1">17993778</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2010;5(11):e15394</RefSource>
<PMID Version="1">21072212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2008 Apr 25;30(2):214-26</RefSource>
<PMID Version="1">18439900</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2009 May;5(4):567-8</RefSource>
<PMID Version="1">19276647</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2009 Aug;23(8):2741-8</RefSource>
<PMID Version="1">19332642</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Pharmacol. 2007 Jul;151(6):737-48</RefSource>
<PMID Version="1">17471183</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2007 Feb;117(2):326-36</RefSource>
<PMID Version="1">17235397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Intern Med. 2006 Mar 7;144(5):337-43</RefSource>
<PMID Version="1">16520474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2005 Jun;25(12):4977-92</RefSource>
<PMID Version="1">15923616</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2003 Nov 26;115(5):577-90</RefSource>
<PMID Version="1">14651849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2003 May 13;13(10):797-806</RefSource>
<PMID Version="1">12747827</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2003 May 2;278(18):15461-4</RefSource>
<PMID Version="1">12604610</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2010 Jul;6(5):670-1</RefSource>
<PMID Version="1">20559023</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Discov. 2013 Sep;3(9):1030-43</RefSource>
<PMID Version="1">23842682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2013 Aug;12(8):1629-37</RefSource>
<PMID Version="1">23699654</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur Urol. 2013 Aug;64(2):339-40</RefSource>
<PMID Version="1">23830228</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Prostate. 2013 Jul;73(10):1090-102</RefSource>
<PMID Version="1">23532738</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2013 May 23;153(5):1064-79</RefSource>
<PMID Version="1">23706743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BJU Int. 2013 Apr;111(4):672-82</RefSource>
<PMID Version="1">22897391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2013 Jan 15;73(2):483-9</RefSource>
<PMID Version="1">23117885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2012 Sep 27;367(13):1187-97</RefSource>
<PMID Version="1">22894553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Urol. 2012 Oct;188(4):1361-8</RefSource>
<PMID Version="1">22906664</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Autophagy. 2012 Apr;8(4):445-544</RefSource>
<PMID Version="1">22966490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anticancer Res. 2012 May;32(5):1627-37</RefSource>
<PMID Version="1">22593441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2012 Apr 1;72(7):1773-83</RefSource>
<PMID Version="1">22447568</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Dis. 2012;3:e275</RefSource>
<PMID Version="1">22378068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Dis. 2011;2:e199</RefSource>
<PMID Version="1">21881601</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Horm Cancer. 2011 Feb;2(1):38-46</RefSource>
<PMID Version="1">21350583</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Signal. 2011 Sep;23(9):1466-72</RefSource>
<PMID Version="1">21554950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2011 Jun 14;19(6):792-804</RefSource>
<PMID Version="1">21620777</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2011 May 17;19(5):575-86</RefSource>
<PMID Version="1">21575859</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Med Oncol. 2011 Mar;28(1):105-11</RefSource>
<PMID Version="1">20041317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2009 Sep 15;122(Pt 18):3330-9</RefSource>
<PMID Version="1">19706685</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Mar 15;70(6):2465-75</RefSource>
<PMID Version="1">20215500</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2008 Mar 1;68(5):1485-94</RefSource>
<PMID Version="1">18316613</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059002">Androgen Receptor Antagonists</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002738">Chloroquine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002997">Clomipramine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008687">Metformin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010669">Phenylthiohydantoin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064129">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4155805</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043291</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0045</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>74</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The Prostate</Title>
<ISOAbbreviation>Prostate</ISOAbbreviation>
</Journal>
<ArticleTitle>Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1209-21</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/pros.22837</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Honokiol (HNK), derived from the bark of an oriental medicinal plant (Magnolia officinalis), is a promising anticancer agent with preclinical in vitro (PC-3 and LNCaP cells) and in vivo (PC-3 xenografts) efficacy against prostate cancer. However, the mechanisms affecting anticancer response to HNK are not fully understood.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Human (androgen-independent PC-3 and androgen-responsive LNCaP) and murine (Myc-CaP) prostate cancer cells, and PC-3 tumor xenografts were used for various assays. Autophagy was assessed by transmission electron microscopy, immunofluorescence (LC3 puncta), and immunoblotting (LC3BII detection). Cell viability was determined by trypan blue assay. Apoptosis was quantitated by DNA fragmentation detection and Annexin V/propidium iodide assay. Reactive oxygen species (ROS) were detected by electron paramagnetic resonance spectrometry and flow cytometric/microscopic analysis of MitoSOX red fluorescence.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Exposure of PC-3, LNCaP, and Myc-CaP cells to pharmacologic doses of HNK resulted in autophagy induction. The PC-3 tumor xenografts from HNK-treated mice contained higher levels of LC3BII protein compared with control tumors. Cell viability inhibition and apoptosis induction resulting from HNK exposure were significantly augmented by pharmacological inhibition of autophagy using 3-methyladenine as well as RNA interference of autophagy regulator ATG5. HNK-mediated increase in levels of LC3BII protein was partially but markedly diminished in the presence of antioxidants, including N-acetylcysteine, polyethylene glycol-conjugated (PEG)-superoxide dismutase, and PEG-catalase. On the other hand, antioxidants had no impact on HNK-induced apoptosis.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, the present study demonstrates, for the first time, that HNK induces ROS-mediated cytoprotective autophagy in prostate cancer cells.</AbstractText>
<CopyrightInformation>© 2014 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hahm</LastName>
<ForeName>Eun-Ryeong</ForeName>
<Initials>ER</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sakao</LastName>
<ForeName>Kozue</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Shivendra V</ForeName>
<Initials>SV</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA047904</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA047904</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA101753</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA101753-10</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA113363</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA113363-10</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA115498</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA115498-08</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Prostate</MedlineTA>
<NlmUniqueID>8101368</NlmUniqueID>
<ISSNLinking>0270-4137</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017705">Lignans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11513CCO0N</RegistryNumber>
<NameOfSubstance UI="C005499">honokiol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001713">Biphenyl Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019610">Cytoprotection</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017705">Lignans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS598319 [Available on 09/01/15]</OtherID>
<OtherID Source="NLM">PMC4156520 [Available on 09/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">autophagy</Keyword>
<Keyword MajorTopicYN="N">chemoprevention</Keyword>
<Keyword MajorTopicYN="N">honokiol</Keyword>
<Keyword MajorTopicYN="N">prostate cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043756</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0045</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>74</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The Prostate</Title>
<ISOAbbreviation>Prostate</ISOAbbreviation>
</Journal>
<ArticleTitle>Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>1240-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/pros.22841</ELocationID>
<Abstract>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We aimed to evaluate STAT5 expression and cell proliferation change after dihydrotestosterone (DHT) treatment in castration-resistant prostate cancer (CRPC) cells to elucidate the mechanism in relation to different androgen receptor (AR) expression status.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Using DU145, PC3, and LNCaP cells, cell viability assay and Western blot for phosphorylated STAT5 (p-STAT5) were done after DHT treatment at various concentrations. Endogenous levels of nuclear hormone receptor mRNA and protein were identified using real-time RT-PCR and Western blot. We treated the cells with RU486 and then glucocorticoid receptor (GR)-specific small interfering RNA (siRNA), to assess change in DHT-induced STAT5 activation. Immunofluorescence staining of DU145 cells with anti-GR and anti-pSTAT5 Ab before and after DHT treatment was done and visualized.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">DHT treatment enhanced STAT5 phosphorylation and promoted proliferation of all CRPC cells. Endogenous GR was identified strongly in DU145, weakly in PC3 but not in LNCaP cells. AR was identified strongly in LNCaP but not in DU145 cells. RU486 treatment abolished DHT-induced cell proliferation and STAT5 activation in both DU145 and PC3 cells but not in LNCaP cells. Similarly, GR-specific siRNA completely suppressed STAT5 activation. On immunofluorescence, activation of STAT5 and GR translocating into the nucleus after DHT treatment was confirmed. Immunoprecipitation confirmed direct complex formation between the GR and pSTAT5.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In CRPC cells, DHT activated STAT5 enhancing cell proliferation. Activation was induced regardless of presence of AR and in cells devoid of AR, DHT used GR which formed direct complex with p-STAT5.</AbstractText>
<CopyrightInformation>© 2014 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Cheryn</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Yunlim</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Min</LastName>
<ForeName>Gyeong Eun</ForeName>
<Initials>GE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Hanjong</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Prostate</MedlineTA>
<NlmUniqueID>8101368</NlmUniqueID>
<ISSNLinking>0270-4137</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050799">STAT5 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>08J2K08A3Y</RegistryNumber>
<NameOfSubstance UI="D013196">Dihydrotestosterone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013196">Dihydrotestosterone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064129">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011965">Receptors, Glucocorticoid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050799">STAT5 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">STAT5</Keyword>
<Keyword MajorTopicYN="N">androgen receptor</Keyword>
<Keyword MajorTopicYN="N">castration-resistant</Keyword>
<Keyword MajorTopicYN="N">dihydrotestosterone</Keyword>
<Keyword MajorTopicYN="N">glucocorticoid receptor</Keyword>
<Keyword MajorTopicYN="N">prostate neoplasm</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25006128</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1528-0020</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>124</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Blood</Title>
<ISOAbbreviation>Blood</ISOAbbreviation>
</Journal>
<ArticleTitle>A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value.</ArticleTitle>
<Pagination>
<MedlinePgn>1645-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-02-554204</ELocationID>
<Abstract>
<AbstractText>Acute myeloid leukemia (AML) is a group of hematological malignancies with high heterogeneity. There is an increasing need to improve the risk stratification of AML patients, including those with normal cytogenetics, using molecular biomarkers. Here, we report a metabolomics study that identified a distinct glucose metabolism signature with 400 AML patients and 446 healthy controls. The glucose metabolism signature comprises a panel of 6 serum metabolite markers, which demonstrated prognostic value in cytogenetically normal AML patients. We generated a prognosis risk score (PRS) with 6 metabolite markers for each patient using principal component analysis. A low PRS was able to predict patients with poor survival independently of well-established markers. We further compared the gene expression patterns of AML blast cells between low and high PRS groups, which correlated well to the metabolic pathways involving the 6 metabolite markers, with enhanced glycolysis and trichloracetic acid cycle at gene expression level in low PRS group. In vitro results demonstrated enhanced glycolysis contributed to decreased sensitivity to antileukemic agent arabinofuranosyl cytidine (Ara-C), whereas inhibition of glycolysis suppressed AML cell proliferation and potentiated cytotoxicity of Ara-C. Our study provides strong evidence for the use of serum metabolites and metabolic pathways as novel prognostic markers and potential therapeutic targets for AML. </AbstractText>
<CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Wen-Lian</ForeName>
<Initials>WL</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China; Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jing-Han</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Ai-Hua</ForeName>
<Initials>AH</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China; Center for Translational Medicine, Six People's Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Xin</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yi-Huang</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China; Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Tian-Lu</ForeName>
<Initials>TL</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China; Center for Translational Medicine, Six People's Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jun-Min</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mi</LastName>
<ForeName>Jian-Qing</ForeName>
<Initials>JQ</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Yong-Mei</ForeName>
<Initials>YM</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yuan-Fang</ForeName>
<Initials>YF</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yue-Ying</ForeName>
<Initials>YY</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Zhejiang Institute of Hematology, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>He</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Bone Marrow Transplantation Center, First Hospital, Zhejiang University School of Medicine, Hangzhou, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>De-Pei</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>Jiangsu Institute of Hematology, First Hospital, Soochow University School of Medicine, Suzhou, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, First Hospital of China Medical University, Shenyang, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Xiao-Jing</ForeName>
<Initials>XJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, First Hospital of China Medical University, Shenyang, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Jin-Song</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Second Hospital, Dalian Medical University, Dalian, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jian-Yong</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, First Hospital, Nanjing Medical University, Nanjing, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Shuai</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, First Hospital, Nanjing Medical University, Nanjing, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Xiao-Jun</ForeName>
<Initials>XJ</Initials>
<AffiliationInfo>
<Affiliation>Institute of Hematology, Peking University and People's Hospital, Beijing, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Bing-Shun</ForeName>
<Initials>BS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics, SJTU School of Medicine, Shanghai, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Zhu</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China; Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Sai-Juan</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China; Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jia</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University (SJTU) and State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, SJTU School of Medicine, Shanghai, China; Center for Translational Medicine, Six People's Hospital, SJTU School of Medicine, Shanghai, China; University of Hawaii Cancer Center, Honolulu, HI.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Blood</MedlineTA>
<NlmUniqueID>7603509</NlmUniqueID>
<ISSNLinking>0006-4971</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018922">HL-60 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053858">Metabolic Networks and Pathways</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020298">U937 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25103406</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>345</Volume>
<Issue>6201</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins.</ArticleTitle>
<Pagination>
<MedlinePgn>1192-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1256800</ELocationID>
<Abstract>
<AbstractText>An expanded GGGGCC repeat in C9orf72 is the most common genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis. A fundamental question is whether toxicity is driven by the repeat RNA itself and/or by dipeptide repeat proteins generated by repeat-associated, non-ATG translation. To address this question, we developed in vitro and in vivo models to dissect repeat RNA and dipeptide repeat protein toxicity. Expression of pure repeats, but not stop codon-interrupted "RNA-only" repeats in Drosophila caused adult-onset neurodegeneration. Thus, expanded repeats promoted neurodegeneration through dipeptide repeat proteins. Expression of individual dipeptide repeat proteins with a non-GGGGCC RNA sequence revealed that both poly-(glycine-arginine) and poly-(proline-arginine) proteins caused neurodegeneration. These findings are consistent with a dual toxicity mechanism, whereby both arginine-rich proteins and repeat RNA contribute to C9orf72-mediated neurodegeneration. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mizielinska</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grönke</LastName>
<ForeName>Sebastian</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Niccoli</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany. Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London WC1E 6BT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ridler</LastName>
<ForeName>Charlotte E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clayton</LastName>
<ForeName>Emma L</ForeName>
<Initials>EL</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Devoy</LastName>
<ForeName>Anny</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moens</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK. Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London WC1E 6BT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Norona</LastName>
<ForeName>Frances E</ForeName>
<Initials>FE</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Woollacott</LastName>
<ForeName>Ione O C</ForeName>
<Initials>IO</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pietrzyk</LastName>
<ForeName>Julian</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cleverley</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nicoll</LastName>
<ForeName>Andrew J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK. MRC Prion Unit, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pickering-Brown</LastName>
<ForeName>Stuart</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester, Manchester M13 9PT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dols</LastName>
<ForeName>Jacqueline</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cabecinha</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London WC1E 6BT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hendrich</LastName>
<ForeName>Oliver</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fratta</LastName>
<ForeName>Pietro</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK. MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fisher</LastName>
<ForeName>Elizabeth M C</ForeName>
<Initials>EM</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK. MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Partridge</LastName>
<ForeName>Linda</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany. Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London WC1E 6BT, UK. a.isaacs@prion.ucl.ac.uk l.partridge@ucl.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Isaacs</LastName>
<ForeName>Adrian M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK. a.isaacs@prion.ucl.ac.uk l.partridge@ucl.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>G0701441</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Science. 2014 Sep 5;345(6201):1118-9</RefSource>
<PMID Version="1">25190778</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000690">Amyotrophic Lateral Sclerosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042622">DNA Repeat Expansion</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004151">Dipeptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004331">Drosophila melanogaster</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004926">Escherichia coli</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057180">Frontotemporal Dementia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011506">Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24894502</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1367-4811</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Bioinformatics (Oxford, England)</Title>
<ISOAbbreviation>Bioinformatics</ISOAbbreviation>
</Journal>
<ArticleTitle>PePr: a peak-calling prioritization pipeline to identify consistent or differential peaks from replicated ChIP-Seq data.</ArticleTitle>
<Pagination>
<MedlinePgn>2568-75</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/bioinformatics/btu372</ELocationID>
<Abstract>
<AbstractText Label="MOTIVATION" NlmCategory="BACKGROUND">ChIP-Seq is the standard method to identify genome-wide DNA-binding sites for transcription factors (TFs) and histone modifications. There is a growing need to analyze experiments with biological replicates, especially for epigenomic experiments where variation among biological samples can be substantial. However, tools that can perform group comparisons are currently lacking.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We present a peak-calling prioritization pipeline (PePr) for identifying consistent or differential binding sites in ChIP-Seq experiments with biological replicates. PePr models read counts across the genome among biological samples with a negative binomial distribution and uses a local variance estimation method, ranking consistent or differential binding sites more favorably than sites with greater variability. We compared PePr with commonly used and recently proposed approaches on eight TF datasets and show that PePr uniquely identifies consistent regions with enriched read counts, high motif occurrence rate and known characteristics of TF binding based on visual inspection. For histone modification data with broadly enriched regions, PePr identified differential regions that are consistent within groups and outperformed other methods in scaling False Discovery Rate (FDR) analysis.</AbstractText>
<AbstractText Label="AVAILABILITY AND IMPLEMENTATION" NlmCategory="METHODS">http://code.google.com/p/pepr-chip-seq/.</AbstractText>
<CopyrightInformation>© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yanxiao</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Computational Medicine and Bioinformatics, Department of Biostatistics and Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Yu-Hsuan</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Department of Computational Medicine and Bioinformatics, Department of Biostatistics and Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Johnson</LastName>
<ForeName>Timothy D</ForeName>
<Initials>TD</Initials>
<AffiliationInfo>
<Affiliation>Department of Computational Medicine and Bioinformatics, Department of Biostatistics and Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rozek</LastName>
<ForeName>Laura S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Department of Computational Medicine and Bioinformatics, Department of Biostatistics and Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sartor</LastName>
<ForeName>Maureen A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Computational Medicine and Bioinformatics, Department of Biostatistics and Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA Department of Computational Medicine and Bioinformatics, Department of Biostatistics and Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 ES017885</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 ES017885-01</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA097248</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA158286</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA158286-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Bioinformatics</MedlineTA>
<NlmUniqueID>9808944</NlmUniqueID>
<ISSNLinking>1367-4803</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000465">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047369">Chromatin Immunoprecipitation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057890">Epigenomics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023281">Genomics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059372">Nucleotide Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4155259 [Available on 09/15/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25012564</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-5835</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>38</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia research</Title>
<ISOAbbreviation>Leuk. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Establishment and characterization of a rare atypical chronic myeloid leukemia cell line NT-1.</ArticleTitle>
<Pagination>
<MedlinePgn>1111-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.leukres.2014.06.008</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0145-2126(14)00187-8</ELocationID>
<Abstract>
<AbstractText>Human leukemia cell lines are of great value in leukemia research. In this study, we established and described the biological characteristics of a rare atypical chronic myeloid (aCML) leukemia cell line (NT-1). Mononuclear cells were isolated from the bone marrow of a patient with atypical chronic myeloid leukemia (Ph(-)/bcr(-)/abl(-)), and were passaged by liquid culture. Cells were maintained without any cytokines for over 1 year, and named NT-1. This cell line was extensively characterized using morphological assays, flow cytometry, cytogenetic analysis, clonogenic culture, quantitative fluorescent PCR, short tandem repeating sequence PCR (STR-PCR) and array-CGH. Its tumorigenic capacity was also examined in nude mice. The NT-1 cell line had morphological features of chronic myeloid leukemia and major myeloid markers (CD13, CD33, CD11b). Additionally, NT-1 expressed progenitor cells and natural killer cell-related antigens such as CD34, CD117, CD56. Cytogenetic analysis initially demonstrated two abnormalities: 47, xx, +8 and 47, xx, +8 accompanied by t(5;12)(q31;p13) translocation. The one-year passage process did not alter the karyotype. NT-1 cells maintained the same morphology, immunophenotyping and cytogenetic features as primary leukemia cells, which was strongly supported by STR-PCR results. Neither Epstein-Barr virus nor mycoplasma was detected in the NT-1 line. In addition, NT-1 cells showed high tumorigenic capacity in nude mice. NT-1 is a new atypical chronic myeloid leukemia cell line with the +8 and t(5,12) translocation, and exhibits high tumorigenicity in nude mice. This new cell line provides a useful tool for the study of leukemogenesis. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Qian</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Qin-Rong</ForeName>
<Initials>QR</Initials>
<AffiliationInfo>
<Affiliation>The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Sheng-Hua</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ni</LastName>
<ForeName>Xiao-Qing</ForeName>
<Initials>XQ</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Zeng-Hua</ForeName>
<Initials>ZH</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Ya-Ping</ForeName>
<Initials>YP</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China. Electronic address: liuhong6363@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leuk Res</MedlineTA>
<NlmUniqueID>7706787</NlmUniqueID>
<ISSNLinking>0145-2126</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020732">Cytogenetic Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007621">Karyotyping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015464">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D061251">Primary Cell Culture</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Atypical chronic myeloid leukemia</Keyword>
<Keyword MajorTopicYN="N">Cell line</Keyword>
<Keyword MajorTopicYN="N">Translocation</Keyword>
<Keyword MajorTopicYN="N">Tumorigenicity</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25047832</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3675-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00595-14</ELocationID>
<Abstract>
<AbstractText>Cyclin-dependent kinase 7 (CDK7) activates cell cycle CDKs and is a member of the general transcription factor TFIIH. Although there is substantial evidence for an active role of CDK7 in mRNA synthesis and associated processes, the degree of its influence on global and gene-specific transcription in mammalian species is unclear. In the current study, we utilize two novel inhibitors with high specificity for CDK7 to demonstrate a restricted but robust impact of CDK7 on gene transcription in vivo and in in vitro-reconstituted reactions. We distinguish between relative low- and high-dose responses and relate them to distinct molecular mechanisms and altered physiological responses. Low inhibitor doses cause rapid clearance of paused RNA polymerase II (RNAPII) molecules and sufficed to cause genome-wide alterations in gene expression, delays in cell cycle progression at both the G1/S and G2/M checkpoints, and diminished survival of human tumor cells. Higher doses and prolonged inhibition led to strong reductions in RNAPII carboxyl-terminal domain (CTD) phosphorylation, eventual activation of the p53 program, and increased cell death. Together, our data reason for a quantitative contribution of CDK7 to mRNA synthesis, which is critical for cellular homeostasis. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kelso</LastName>
<ForeName>Timothy W R</ForeName>
<Initials>TW</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baumgart</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eickhoff</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Lead Discovery Center GmbH, Dortmund, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Albert</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Antrecht</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lemcke</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klebl</LastName>
<ForeName>Bert</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Lead Discovery Center GmbH, Dortmund, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meisterernst</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cellular and Molecular Biology, Institute of Molecular Tumor Biology, Westfalian Wilhelms University Muenster, Muenster, Germany meistere@uni-muenster.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592924">BS-181</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592925">LDC3140</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592926">LDC4297</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011687">Purines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014227">Triazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C104586">roscovitine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.22</RegistryNumber>
<NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.22</RegistryNumber>
<NameOfSubstance UI="C066067">cyclin-dependent kinase-activating kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance UI="D012319">RNA Polymerase II</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018844">Cyclin-Dependent Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011687">Purines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012319">RNA Polymerase II</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014227">Triazines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187722 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25047839</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.</ArticleTitle>
<Pagination>
<MedlinePgn>3642-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00814-14</ELocationID>
<Abstract>
<AbstractText>One outcome of activation of the phosphatidylinositol 3-kinase (PI3K) pathway is increased aerobic glycolysis, but the upstream signaling events that regulate the PI3K pathway, and thus the Warburg effect, are elusive. Increasing evidence suggests that Plk1, a cell cycle regulator, is also involved in cellular events in addition to mitosis. To test whether Plk1 contributes to activation of the PI3K pathway, and thus aerobic glycolysis, we examined potential targets of Plk1 and identified PTEN as a Plk1 substrate. We hypothesize that Plk1 phosphorylation of PTEN leads to its inactivation, activation of the PI3K pathway, and the Warburg effect. Our data show that overexpression of Plk1 leads to activation of the PI3K pathway and enhanced aerobic glycolysis. In contrast, inhibition of Plk1 causes markedly reduced glucose metabolism in mice. Mechanistically, we show that Plk1 phosphorylation of PTEN and Nedd4-1, an E3 ubiquitin ligase of PTEN, results in PTEN inactivation. Finally, we show that Plk1 phosphorylation of PTEN promotes tumorigenesis in both its phosphatase-dependent and -independent pathways, revealing potentially new drug targets to arrest tumor cell growth. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Zhiguo</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bi</LastName>
<ForeName>Pengpeng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Animal Sciences, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burcham</LastName>
<ForeName>Grant</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Elzey</LastName>
<ForeName>Bennett D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo>
<Affiliation>Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ratliff</LastName>
<ForeName>Timothy</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Konieczny</LastName>
<ForeName>Stephen F</ForeName>
<Initials>SF</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahmad</LastName>
<ForeName>Nihal</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Dermatology, University of Wisconsin, Madison, Wisconsin, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuang</LastName>
<ForeName>Shihuan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Animal Sciences, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Xiaoqi</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA liu8@purdue.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA023168</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA124586</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA157429</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA176748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C518477">BI 2536</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056827">Endosomal Sorting Complexes Required for Transport</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006574">Heterocyclic Compounds, 2-Ring</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011621">Pteridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.137</RegistryNumber>
<NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C090134">polo-like kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C099897">Nedd4 ubiquitin protein ligases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SH1WY3R615</RegistryNumber>
<NameOfSubstance UI="D015739">Nocodazole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2010 Jan 15;16(2):384-9</RefSource>
<PMID Version="1">20068088</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 2010 Mar;138(3):1012-21.e1-5</RefSource>
<PMID Version="1">19962984</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Drug Discov. 2010 Aug;9(8):643-60</RefSource>
<PMID Version="1">20671765</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2010 Sep 1;29(17):2953-65</RefSource>
<PMID Version="1">20664522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18868-73</RefSource>
<PMID Version="1">20921411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19135-6</RefSource>
<PMID Version="1">21041650</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Proteomics. 2011 Jan;10(1):M110.004457</RefSource>
<PMID Version="1">20860994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2011 Jan 21;144(2):187-99</RefSource>
<PMID Version="1">21241890</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4129-34</RefSource>
<PMID Version="1">21325052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2011 Jun;13(6):728-33</RefSource>
<PMID Version="1">21532586</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Commun. 2011;2:395</RefSource>
<PMID Version="1">21772266</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Metab. 2011 Oct 5;14(4):443-51</RefSource>
<PMID Version="1">21982705</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Proteomics. 2011 Nov;10(11):M111.008540</RefSource>
<PMID Version="1">21857030</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2011 Dec;31(23):4844-56</RefSource>
<PMID Version="1">21947279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2011 Dec 9;44(5):721-33</RefSource>
<PMID Version="1">22152476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2012 Jan 9;196(1):29-36</RefSource>
<PMID Version="1">22213801</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 Mar 30;149(1):49-62</RefSource>
<PMID Version="1">22401813</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2012 May;13(5):283-96</RefSource>
<PMID Version="1">22473468</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2012 Jun 15;444(3):457-64</RefSource>
<PMID Version="1">22413754</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2012 Jun 8;287(24):20088-99</RefSource>
<PMID Version="1">22511782</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Proteomics. 2012 Sep;11(9):629-39</RefSource>
<PMID Version="1">22593177</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Res. 2013 Apr;23(4):552-64</RefSource>
<PMID Version="1">23419514</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2014 May 16;289(20):14066-74</RefSource>
<PMID Version="1">24706748</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2000 Jul;20(14):5010-8</RefSource>
<PMID Version="1">10866658</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2000 Oct 13;103(2):253-62</RefSource>
<PMID Version="1">11057898</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2000 Nov;157(5):1623-31</RefSource>
<PMID Version="1">11073822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2001 Jan 12;276(2):993-8</RefSource>
<PMID Version="1">11035045</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2001 Dec 28;276(52):48627-30</RefSource>
<PMID Version="1">11707428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94</RefSource>
<PMID Version="1">12732729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1990 Sep 15;50(18):6075-86</RefSource>
<PMID Version="1">1975513</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 1997 Jun;18(6):1215-23</RefSource>
<PMID Version="1">9214605</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1998 May 29;273(22):13375-8</RefSource>
<PMID Version="1">9593664</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5</RefSource>
<PMID Version="1">10200246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gene Ther. 1999 Jul;6(7):1258-66</RefSource>
<PMID Version="1">10455434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2006 Mar;26(6):2093-108</RefSource>
<PMID Version="1">16507989</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Jan 12;128(1):129-39</RefSource>
<PMID Version="1">17218260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Jan 12;128(1):141-56</RefSource>
<PMID Version="1">17218261</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2007 Feb 20;17(4):304-15</RefSource>
<PMID Version="1">17291761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1919-24</RefSource>
<PMID Version="1">18250300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2008 Mar 7;283(10):6209-21</RefSource>
<PMID Version="1">18171681</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2008 May 2;133(3):403-14</RefSource>
<PMID Version="1">18455982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Ther. 2008 Jun;16(6):1073-80</RefSource>
<PMID Version="1">18414476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2008 Jun 1;68(11):4077-85</RefSource>
<PMID Version="1">18519666</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2008 Jun 26;27(28):3935-43</RefSource>
<PMID Version="1">18297112</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056827">Endosomal Sorting Complexes Required for Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006019">Glycolysis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006574">Heterocyclic Compounds, 2-Ring</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015739">Nocodazole</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051059">PTEN Phosphohydrolase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058539">Phosphatidylinositol 3-Kinase</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011621">Pteridines</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044767">Ubiquitin-Protein Ligases</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187734</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25047840</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1α at chromatin.</ArticleTitle>
<Pagination>
<MedlinePgn>3662-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00205-14</ELocationID>
<Abstract>
<AbstractText>Methylation of histone H3 on lysine 9 or 27 is crucial for heterochromatin formation. Previously considered hallmarks of, respectively, constitutive and facultative heterochromatin, recent evidence has accumulated in favor of coexistence of these two marks and their cooperation in gene silencing maintenance. H3K9me2/3 ensures anchorage at chromatin of heterochromatin protein 1α (HP1α), a main component of heterochromatin. HP1α chromoshadow domain, involved in dimerization and interaction with partners, has additional but still unclear roles in HP1α recruitment to chromatin. Because of previously suggested links between polycomb repressive complex 2 (PRC2), which catalyzes H3K27 methylation, and HP1α, we tested whether PRC2 may regulate HP1α abundance at chromatin. We found that the EZH2 and SUZ12 subunits of PRC2 are required for HP1α stability, as knockdown of either protein led to HP1α degradation. Similar results were obtained upon overexpression of H3K27me2/3 demethylases. We further showed that binding of HP1α/β/γ to H3K9me3 peptides is greatly increased in the presence of H3K27me3, and this is dependent on PRC2. These data fit with recent proteomic studies identifying PRC2 as an indirect H3K9me3 binder in mouse tissues and suggest the existence of a cooperative mechanism of HP1α anchorage at chromatin involving H3 methylation on both K9 and K27 residues. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Boros</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arnoult</LastName>
<ForeName>Nausica</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stroobant</LastName>
<ForeName>Vincent</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Ludwig Institute for Cancer Research, Brussels Branch, and de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Collet</LastName>
<ForeName>Jean-François</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>WELBIO and de Duve Institute, Catholic University of Louvain, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Decottignies</LastName>
<ForeName>Anabelle</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Catholic University of Louvain, Brussels, Belgium anabelle.decottignies@uclouvain.be.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002868">Chromosomal Proteins, Non-Histone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>107283-02-3</RegistryNumber>
<NameOfSubstance UI="C066725">heterochromatin-specific nonhistone chromosomal protein HP-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="D063151">Polycomb Repressive Complex 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.25.1</RegistryNumber>
<NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002868">Chromosomal Proteins, Non-Histone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008745">Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063151">Polycomb Repressive Complex 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046988">Proteasome Endopeptidase Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055550">Protein Stability</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187721 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25071152</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.</ArticleTitle>
<Pagination>
<MedlinePgn>3689-701</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00341-14</ELocationID>
<Abstract>
<AbstractText>Breast cancers are stratified into distinct subtypes, which influence therapeutic responsiveness and patient outcome. Patients with luminal breast cancers are often associated with a better prognosis relative to that with other subtypes. However, subsets of patients with luminal disease remain at increased risk of cancer-related death. A critical process that increases the malignant potential of breast cancers is the epithelial-to-mesenchymal transition (EMT). The p66ShcA adaptor protein stimulates the formation of reactive oxygen species in response to stress stimuli. In this paper, we report a novel role for p66ShcA in inducing an EMT in HER2(+) luminal breast cancers. p66ShcA increases the migratory properties of breast cancer cells and enhances signaling downstream of the Met receptor tyrosine kinase in these tumors. Moreover, Met activation is required for a p66ShcA-induced EMT in luminal breast cancer cells. Finally, elevated p66ShcA levels are associated with the acquisition of an EMT in primary breast cancers spanning all molecular subtypes, including luminal tumors. This is of high clinical relevance, as the luminal and HER2 subtypes together comprise 80% of all newly diagnosed breast cancers. This study identifies p66ShcA as one of the first prognostic biomarkers for the identification of more aggressive tumors with mesenchymal properties, regardless of molecular subtype. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hudson</LastName>
<ForeName>Jesse</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ha</LastName>
<ForeName>Jacqueline R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sabourin</LastName>
<ForeName>Valerie</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Ryuhjin</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>La Selva</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Livingstone</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Podmore</LastName>
<ForeName>Lauren</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Knight</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Forrest</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada Goodman Cancer Research Centre, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Beauchemin</LastName>
<ForeName>Nicole</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada Department of Oncology, McGill University, Montreal, Quebec, Canada Department of Biochemistry, McGill University, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hallett</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada Department of Biochemistry, McGill University, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Morag</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Goodman Cancer Research Centre, Montreal, Quebec, Canada Department of Oncology, McGill University, Montreal, Quebec, Canada Department of Biochemistry, McGill University, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ursini-Siegel</LastName>
<ForeName>Josie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada Department of Oncology, McGill University, Montreal, Quebec, Canada giuseppina.ursini-siegel@mcgill.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C528024">SHC1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055765">Shc Signaling Adaptor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C491743">MET protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D019859">Proto-Oncogene Proteins c-met</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019859">Proto-Oncogene Proteins c-met</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055765">Shc Signaling Adaptor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187732 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25071154</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of UTX in retinoic acid receptor-mediated gene regulation in leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>3765-75</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00839-14</ELocationID>
<Abstract>
<AbstractText>Human UTX, a member of the Jumonji C family of proteins, associates with mixed-lineage leukemia 3/4 complexes. Stimulation with retinoic acid leads to the recruitment of UTX-containing complexes to HOX genes, which results in demethylation of histone H3 lysine 27 and concomitant methylation of histone H3 lysine 4. Here, we show that UTX interacts with the retinoic acid receptor α (RARα) and that this interaction is essential for proper differentiation of leukemic U937 cells in response to retinoic acid. UTX occupies the promoters of several RAR target genes and regulates their transcriptional output by modulating ASH2L complex recruitment. Overexpression of UTX in promyelocytic NB4 cells results in enhanced cellular differentiation upon retinoic acid treatment. Our results show that UTX is important for RAR-mediated transcription and provide insight into the critical role of cross talk between histone H3 lysine 4 methylation and histone H3 lysine 27 demethylation during cellular differentiation. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rocha-Viegas</LastName>
<ForeName>Luciana</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Center for Genomic Regulation, Barcelona, Spain Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Villa</LastName>
<ForeName>Raffaella</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Center for Genomic Regulation, Barcelona, Spain Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gutierrez</LastName>
<ForeName>Arantxa</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Center for Genomic Regulation, Barcelona, Spain Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iriondo</LastName>
<ForeName>Oihana</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Center for Genomic Regulation, Barcelona, Spain Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shiekhattar</LastName>
<ForeName>Ramin</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Di Croce</LastName>
<ForeName>Luciano</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Center for Genomic Regulation, Barcelona, Spain Universitat Pompeu Fabra, Barcelona, Spain Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain luciano.dicroce@crg.eu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485622">ASH2L protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018168">Receptors, Retinoic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C082924">retinoic acid receptor alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5688UTC01R</RegistryNumber>
<NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.11.-</RegistryNumber>
<NameOfSubstance UI="D056466">Histone Demethylases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.11.-</RegistryNumber>
<NameOfSubstance UI="C523998">UTX protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056466">Histone Demethylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007938">Leukemia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018168">Receptors, Retinoic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020298">U937 Cells</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187727 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25000122</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1470-8728</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>463</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The Biochemical journal</Title>
<ISOAbbreviation>Biochem. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Osteopontin O-glycosylation contributes to its phosphorylation and cell-adhesion properties.</ArticleTitle>
<Pagination>
<MedlinePgn>93-102</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1042/BJ20140060</ELocationID>
<Abstract>
<AbstractText>OPN (osteopontin) is a multiphosphorylated extracellular glycoprotein, which has important roles in bone remodelling, inflammation and cancer metastasis. OPN regulates cell spreading and adhesion primarily through its association with several integrins such as αvβ3, and its phosphorylation affects these processes. However, the mechanism by which OPN O-glycosylation affects these processes is not completely understood. In the present study, we demonstrated that OPN O-glycosylation self-regulates its biological activities and also affects its phosphorylation status. We prepared two recombinant OPNs, WT (wild-type)-OPN and mutant OPN (ΔO-OPN), which lacks five O-glycosylation sites at a threonine/proline-rich region. O-glycan defects in OPN increased its phosphorylation level, as observed by dephosphorylation assays. Moreover, compared with WT-OPN, ΔO-OPN exhibited enhanced cell spreading and adhesion activities and decreased associations with β1 integrins. This suggested that defects in O-glycans in OPN altered these activities, and that β1 integrins have a less important role in adhesion to ΔO-OPN. The cell-adhesion activity of dephosphorylated ΔO-OPN was higher than the cell-adhesion activities of ΔO-OPN and dephosphorylated WT-OPN. This suggested that some of the phosphorylation in ΔO-OPN caused by O-glycan defects and O-glycans of OPN suppressed the OPN cell-adhesion activity. Thus functional activities of OPN can be determined by the combined glycosylation and phosphorylation statuses and not by either status alone. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kariya</LastName>
<ForeName>Yoshinobu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kanno</LastName>
<ForeName>Mayumi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsumoto-Morita</LastName>
<ForeName>Kana</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>†Structural Glycobiology Team, Systems Glycobiology Research Group, RIKEN-Max Planck Joint Research Center, RIKEN Global Research Cluster, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Konno</LastName>
<ForeName>Midori</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamaguchi</LastName>
<ForeName>Yoshiki</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>†Structural Glycobiology Team, Systems Glycobiology Research Group, RIKEN-Max Planck Joint Research Center, RIKEN Global Research Cluster, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hashimoto</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>*Department of Biochemistry, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biochem J</MedlineTA>
<NlmUniqueID>2984726R</NlmUniqueID>
<ISSNLinking>0264-6021</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039302">Integrin alphaVbeta3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>106441-73-0</RegistryNumber>
<NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006031">Glycosylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039302">Integrin alphaVbeta3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053495">Osteopontin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25005557</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1470-8728</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>463</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The Biochemical journal</Title>
<ISOAbbreviation>Biochem. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>hnRNP K in PU.1-containing complexes recruited at the CD11b promoter: a distinct role in modulating granulocytic and monocytic differentiation of AML-derived cells.</ArticleTitle>
<Pagination>
<MedlinePgn>115-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1042/BJ20140358</ELocationID>
<Abstract>
<AbstractText>PU.1 is essential for the differentiation of haemopoietic precursors and is strongly implicated in leukaemogenesis, yet the protein interactions that regulate its activity in different myeloid lineages are still largely unknown. In the present study, by combining fluorescent EMSA (electrophoretic mobility-shift assay) with MS, we reveal the presence of hnRNP K (heterogeneous nuclear ribonucleoprotein K) in molecular complexes that PU.1 forms on the CD11b promoter during the agonist-induced maturation of AML (acute myeloid leukaemia)-derived cells along both the granulocytic and the monocytic lineages. Although hnRNP K and PU.1 act synergistically during granulocytic differentiation, hnRNP K seems to have a negative effect on PU.1 activity during monocytic maturation. Since hnRNP K acts as a docking platform, integrating signal transduction pathways to nucleic acid-directed processes, it may assist PU.1 in activating or repressing transcription by recruiting lineage-specific components of the transcription machinery. It is therefore possible that hnRNP K plays a key role in the mechanisms underlying the specific targeting of protein-protein interactions identified as mediators of transcriptional activation or repression and may be responsible for the block of haemopoietic differentiation. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nika</LastName>
<ForeName>Ervin</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>*Section of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brugnoli</LastName>
<ForeName>Federica</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>*Section of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Piazzi</LastName>
<ForeName>Manuela</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>†Cell Signalling Laboratory, Department of Biomedical and Neuromotor Sciences, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lambertini</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>‡Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Via Fossato di Mortara 74, 44121 Ferrara, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grassilli</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>*Section of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bavelloni</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>§SC Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopedic Institute, Via di Barbiano 1/10, 40136 Bologna, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Piva</LastName>
<ForeName>Roberta</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>‡Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Via Fossato di Mortara 74, 44121 Ferrara, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Capitani</LastName>
<ForeName>Silvano</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bertagnolo</LastName>
<ForeName>Valeria</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>*Section of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biochem J</MedlineTA>
<NlmUniqueID>2984726R</NlmUniqueID>
<ISSNLinking>0264-6021</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039481">Antigens, CD11b</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C509295">ITGAM protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C064368">proto-oncogene protein Spi-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>146410-60-8</RegistryNumber>
<NameOfSubstance UI="C072074">HNRNPK protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039481">Antigens, CD11b</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006098">Granulocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012261">Ribonucleoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015534">Trans-Activators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25012820</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1470-8728</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>463</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>The Biochemical journal</Title>
<ISOAbbreviation>Biochem. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>DNA-PKcs-interacting protein KIP binding to TRF2 is required for the maintenance of functional telomeres.</ArticleTitle>
<Pagination>
<MedlinePgn>19-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1042/BJ20131395</ELocationID>
<Abstract>
<AbstractText>Human telomeres associate with shelterin, a six-protein complex that protects chromosome ends from being recognized as sites of DNA damage. The shelterin subunit TRF2 (telomeric repeat-binding factor 2) protects telomeres by facilitating their organization into the protective capping structure. We have reported previously that the DNA-PKcs (DNA-dependent protein kinase catalytic subunit)-interacting protein KIP associates with telomerase through an interaction with hTERT (human telomerase reverse transcriptase). In the present study, we identify KIP as a novel interacting partner of TRF2. KIP is able to interact with both TRF2 and DNA-PKcs at telomeres. Because KIP is required for the association between TRF2 and DNA-PKcs, the interplay of these three proteins may provide a mechanism for the recruitment of DNA-PKcs to telomeres. We also show that KIP binding to TRF2 enhances the telomere-binding activity of TRF2, suggesting that KIP acts as a positive regulator of TRF2 function. Furthermore, depletion of KIP induces DNA-damage response foci at telomeres, thereby leading to induction of growth arrest, cellular senescence and altered cell cycle distribution. Collectively, our findings suggest that KIP, in addition to its association with catalytically active telomerase, plays important roles in the maintenance of functional telomeres and the regulation of telomere-associated DNA-damage response. Thus KIP represents a new pathway for modulating telomerase and telomere function in cancer. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Khadka</LastName>
<ForeName>Prabhat</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>*Department of Integrated Omics for Biomedical Science, Yonsei University, Seoul 120-749, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Ji Hoon</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>*Department of Integrated Omics for Biomedical Science, Yonsei University, Seoul 120-749, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baek</LastName>
<ForeName>Seung Han</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>†Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>Sue Young</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>†Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chung</LastName>
<ForeName>In Kwon</ForeName>
<Initials>IK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biochem J</MedlineTA>
<NlmUniqueID>2984726R</NlmUniqueID>
<ISSNLinking>0264-6021</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C109198">CIB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C504753">TERF2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035341">Telomeric Repeat Binding Protein 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.49</RegistryNumber>
<NameOfSubstance UI="D019098">Telomerase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002135">Calcium-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016922">Cell Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019098">Telomerase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016615">Telomere</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035341">Telomeric Repeat Binding Protein 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23436777</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-7278</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>29</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Environmental toxicology</Title>
<ISOAbbreviation>Environ. Toxicol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of nonpersistent pesticides on estrogen receptor, androgen receptor, and aryl hydrocarbon receptor.</ArticleTitle>
<Pagination>
<MedlinePgn>1201-16</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/tox.21852</ELocationID>
<Abstract>
<AbstractText>Nonpersistent pesticides are considered less harmful for the environment, but their impact as endocrine disruptors has not been fully explored. The pesticide Switch was applied to grape vines, and the maximum residue concentration of its active ingredients was quantified. The transactivation potential of the pesticides Acorit, Frupica, Steward, Reldan, Switch, Cantus, Teldor, and Scala and their active compounds (hexythiazox, mepanipyrim, indoxacarb, chlorpyrifos-methyl, cyprodinil, fludioxonil, boscalid, fenhexamid, and pyrimethanil) were tested on human estrogen receptor α (ERα), androgen receptor (AR) and arylhydrocarbon receptor (AhR) in vitro. Relative binding affinities of the pure pesticide constituents for AR and their effect on human breast cancer and prostate cancer cell lines were evaluated. Residue concentrations of Switch's ingredients were below maximum residue limits. Fludioxonil and fenhexamid were ERα agonists (EC50 -values of 3.7 and 9.0 μM, respectively) and had time-dependent effects on endogenous ERα-target gene expression (cyclin D1, progesterone receptor, and nuclear respiratory factor 1) in MCF-7 human breast cancer cells. Fludioxonil, mepanipyrim, cyprodinil, pyrimethanil, and chlorpyrifos-methyl were AhR-agonists (EC50 s of 0.42, 0.77, 1.4, 4.6, and 5.1 μM, respectively). Weak AR binding was shown for chlorpyrifos-methyl, cyprodinil, fenhexamid, and fludioxonil. Assuming a total uptake which does not take metabolism and clearance rates into account, our in vitro evidence suggests that pesticides could activate pathways affecting hormonal balance, even within permitted limits, thus potentially acting as endocrine disruptors.</AbstractText>
<CopyrightInformation>Copyright © 2013 Wiley Periodicals, Inc., a Wiley company.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Medjakovic</LastName>
<ForeName>Svjetlana</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Christian Doppler Laboratory for Receptor Biotechnology, A-1190 Vienna, Austria; Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, A-1190 Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zoechling</LastName>
<ForeName>Alfred</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gerster</LastName>
<ForeName>Petra</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ivanova</LastName>
<ForeName>Margarita M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Teng</LastName>
<ForeName>Yun</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Klinge</LastName>
<ForeName>Carolyn M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schildberger</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gartner</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jungbauer</LastName>
<ForeName>Alois</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 DK053220</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>02</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Environ Toxicol</MedlineTA>
<NlmUniqueID>100885357</NlmUniqueID>
<ISSNLinking>1520-4081</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052244">Endocrine Disruptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010575">Pesticides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018336">Receptors, Aryl Hydrocarbon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506487">estrogen receptor alpha, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052244">Endocrine Disruptors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047628">Estrogen Receptor alpha</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010575">Pesticides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011944">Receptors, Androgen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018336">Receptors, Aryl Hydrocarbon</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">androgen receptor</Keyword>
<Keyword MajorTopicYN="N">aryl hydrocarbon receptor</Keyword>
<Keyword MajorTopicYN="N">estrogen receptor</Keyword>
<Keyword MajorTopicYN="N">fenhexamid</Keyword>
<Keyword MajorTopicYN="N">fludioxonil</Keyword>
<Keyword MajorTopicYN="N">human cancer cell lines</Keyword>
<Keyword MajorTopicYN="N">pesticides</Keyword>
<Keyword MajorTopicYN="N">wine</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24974217</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1879-355X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>90</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>International journal of radiation oncology, biology, physics</Title>
<ISOAbbreviation>Int. J. Radiat. Oncol. Biol. Phys.</ISOAbbreviation>
</Journal>
<ArticleTitle>Ionizing radiation-inducible miR-27b suppresses leukemia proliferation via targeting cyclin A2.</ArticleTitle>
<Pagination>
<MedlinePgn>53-62</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2014.04.055</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0360-3016(14)00578-1</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Ionizing radiation is a common carcinogen that is important for the development of leukemia. However, the underlying epigenetic mechanisms remain largely unknown. The goal of the study was to explore microRNAome alterations induced by ionizing radiation (IR) in murine thymus, and to determine the role of IR-inducible microRNA (miRNA/miR) in the development of leukemia.</AbstractText>
<AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">We used the well-established C57BL/6 mouse model and miRNA microarray profiling to identify miRNAs that are differentially expressed in murine thymus in response to irradiation. TIB152 human leukemia cell line was used to determine the role of estrogen receptor-α (ERα) in miR-27b transcription. The biological effects of ectopic miR-27b on leukemogenesis were measured by western immunoblotting, cell viability, apoptosis, and cell cycle analyses.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Here, we have shown that IR triggers the differential expression of miR-27b in murine thymus tissue in a dose-, time- and sex-dependent manner. miR-27b was significantly down-regulated in leukemia cell lines CCL119 and TIB152. Interestingly, ERα was overexpressed in those 2 cell lines, and it was inversely correlated with miR-27b expression. Therefore, we used TIB152 as a model system to determine the role of ERα in miR-27b expression and the contribution of miR-27b to leukemogenesis. β-Estradiol caused a rapid and transient reduction in miR-27b expression reversed by either ERα-neutralizing antibody or ERK1/2 inhibitor. Ectopic expression of miR-27b remarkably suppressed TIB152 cell proliferation, at least in part, by inducing S-phase arrest. In addition, it attenuated the expression of cyclin A2, although it had no effect on the levels of PCNA, PPARγ, CDK2, p21, p27, p-p53, and cleaved caspase-3.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data reveal that β-estradiol/ERα signaling may contribute to the down-regulation of miR-27b in acute leukemia cell lines through the ERK1/2 pathway, and that miR-27b may function as a tumor suppressor that inhibits cell proliferation by targeting cyclin A2.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Dongping</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kovalchuk</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Litvinov</LastName>
<ForeName>Dmitry</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kovalchuk</LastName>
<ForeName>Olga</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada. Electronic address: olga.kovalchuk@uleth.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA>
<NlmUniqueID>7603616</NlmUniqueID>
<ISSNLinking>0360-3016</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056751">Cyclin A2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C540674">Mirn27 microRNA, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4TI98Z838E</RegistryNumber>
<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056751">Cyclin A2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004307">Dose-Response Relationship, Radiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004958">Estradiol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007953">Leukemia, Radiation-Induced</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011960">Receptors, Estrogen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059807">S Phase Cell Cycle Checkpoints</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013950">Thymus Gland</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24986743</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1879-355X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>90</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>International journal of radiation oncology, biology, physics</Title>
<ISOAbbreviation>Int. J. Radiat. Oncol. Biol. Phys.</ISOAbbreviation>
</Journal>
<ArticleTitle>Relative biological effectiveness variation along monoenergetic and modulated Bragg peaks of a 62-MeV therapeutic proton beam: a preclinical assessment.</ArticleTitle>
<Pagination>
<MedlinePgn>27-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2014.05.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0360-3016(14)00594-X</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The biological optimization of proton therapy can be achieved only through a detailed evaluation of relative biological effectiveness (RBE) variations along the full range of the Bragg curve. The clinically used RBE value of 1.1 represents a broad average, which disregards the steep rise of linear energy transfer (LET) at the distal end of the spread-out Bragg peak (SOBP). With particular attention to the key endpoint of cell survival, our work presents a comparative investigation of cell killing RBE variations along monoenergetic (pristine) and modulated (SOBP) beams using human normal and radioresistant cells with the aim to investigate the RBE dependence on LET and intrinsic radiosensitvity.</AbstractText>
<AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">Human fibroblasts (AG01522) and glioma (U87) cells were irradiated at 6 depth positions along pristine and modulated 62-MeV proton beams at the INFN-LNS (Catania, Italy). Cell killing RBE variations were measured using standard clonogenic assays and were further validated using Monte Carlo simulations and the local effect model (LEM).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed significant cell killing RBE variations along the proton beam path, particularly in the distal region showing strong dose dependence. Experimental RBE values were in excellent agreement with the LEM predicted values, indicating dose-averaged LET as a suitable predictor of proton biological effectiveness. Data were also used to validate a parameterized RBE model.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The predicted biological dose delivered to a tumor region, based on the variable RBE inferred from the data, varies significantly with respect to the clinically used constant RBE of 1.1. The significant RBE increase at the distal end suggests also a potential to enhance optimization of treatment modalities such as LET painting of hypoxic tumors. The study highlights the limitation of adoption of a constant RBE for proton therapy and suggests approaches for fast implementation of RBE models in treatment planning.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chaudhary</LastName>
<ForeName>Pankaj</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marshall</LastName>
<ForeName>Thomas I</ForeName>
<Initials>TI</Initials>
<AffiliationInfo>
<Affiliation>Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perozziello</LastName>
<ForeName>Francesca M</ForeName>
<Initials>FM</Initials>
<AffiliationInfo>
<Affiliation>Department of Physics, University of Naples Federico II and INFN Naples Section University of Naples, Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Manti</LastName>
<ForeName>Lorenzo</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Physics, University of Naples Federico II and INFN Naples Section University of Naples, Naples, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Currell</LastName>
<ForeName>Frederick J</ForeName>
<Initials>FJ</Initials>
<AffiliationInfo>
<Affiliation>Centre for Plasma Physics, School of Mathematics and Physics, Queen's University Belfast, Belfast, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hanton</LastName>
<ForeName>Fiona</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Centre for Plasma Physics, School of Mathematics and Physics, Queen's University Belfast, Belfast, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McMahon</LastName>
<ForeName>Stephen J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kavanagh</LastName>
<ForeName>Joy N</ForeName>
<Initials>JN</Initials>
<AffiliationInfo>
<Affiliation>Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cirrone</LastName>
<ForeName>Giuseppe Antonio Pablo</ForeName>
<Initials>GA</Initials>
<AffiliationInfo>
<Affiliation>Istituto Nazionale di Fisica Nucleare, LNS, Catania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Romano</LastName>
<ForeName>Francesco</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Istituto Nazionale di Fisica Nucleare, LNS, Catania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Prise</LastName>
<ForeName>Kevin M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. Electronic address: k.prise@qub.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schettino</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK; National Physical Laboratory, Teddington, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>G1100014</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA>
<NlmUniqueID>7603616</NlmUniqueID>
<ISSNLinking>0360-3016</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011522">Protons</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017357">Cyclotrons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018499">Linear Energy Transfer</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D061766">Proton Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011522">Protons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011836">Radiation Tolerance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012062">Relative Biological Effectiveness</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136105</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.</ArticleTitle>
<Pagination>
<MedlinePgn>12889-94</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1323502111</ELocationID>
<Abstract>
<AbstractText>In 2010, a large outbreak of poliomyelitis with unusual 47% lethality occurred in Pointe Noire, Republic of Congo. Vaccine-mediated immunity against the outbreak virus was never investigated. A wild poliovirus 1 (WPV1) isolated from a fatal case (termed PV1-RC2010) showed a previously unknown combination of amino acid exchanges in critical antigenic site 2 (AgS2, VP1 capsid protein positions 221SAAL → 221PADL). These exchanges were also detected in an additional 11 WPV1 strains from fatal cases. PV1-RC2010 escaped neutralization by three different mAbs relevant for AgS2. Virus neutralization was tested in sera from fatal cases, who died before supplementary immunization (n = 24), Gabonese recipients of recent oral polio vaccination (n = 12), routinely vaccinated German medical students (n = 34), and German outpatients tested for antipoliovirus immunity (n = 17) on Vero, human rhabdomyosarcoma, and human epidermoid carcinoma 2 cells. Fatal poliomyelitis cases gave laboratory evidence of previous trivalent vaccination. Neutralizing antibody titers against PV1-RC2010 were significantly lower than those against the vaccine strain Sabin-1, two genetically distinct WPV1s isolated in 1965 and 2010 and two genetically distinct vaccine-derived PV strains. Of German vaccinees tested according to World Health Organization protocols, 15-29% were unprotected according to their neutralization titers (&lt;1:8 serum dilution), even though all were protected against Sabin-1. Phylogenetic analysis of the WPV1 outbreak strains suggested a recent introduction of virus progenitors from Asia with formation of separate Angolan and Congolese lineages. Only the latter carried both critical AgS2 mutations. Antigenetically variant PVs may become relevant during the final phase of poliomyelitis eradication in populations with predominantly vaccine-derived immunity. Sustained vaccination coverage and clinical and environmental surveillance will be necessary.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Drexler</LastName>
<ForeName>Jan Felix</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>Institute of Virology, University of Bonn Medical Centre, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grard</LastName>
<ForeName>Gilda</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Centre International de Recherches Médicales de Franceville, BP 769 Franceville, Gabon;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lukashev</LastName>
<ForeName>Alexander N</ForeName>
<Initials>AN</Initials>
<AffiliationInfo>
<Affiliation>Chumakov Institute of Poliomyelitis and Viral Encephalitides, Moscow 142782, Russia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kozlovskaya</LastName>
<ForeName>Liubov I</ForeName>
<Initials>LI</Initials>
<AffiliationInfo>
<Affiliation>Chumakov Institute of Poliomyelitis and Viral Encephalitides, Moscow 142782, Russia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Böttcher</LastName>
<ForeName>Sindy</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Robert Koch Institute, National Reference Laboratory for Poliomyelitis and Enteroviruses, 13302 Berlin, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uslu</LastName>
<ForeName>Gökhan</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Netherlands Center for Infectious Disease Control, 3720, Bilthoven, The Netherlands;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reimerink</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Netherlands Center for Infectious Disease Control, 3720, Bilthoven, The Netherlands;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gmyl</LastName>
<ForeName>Anatoly P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo>
<Affiliation>Chumakov Institute of Poliomyelitis and Viral Encephalitides, Moscow 142782, Russia; Lomonosov Moscow State University, Moscow 119991, Russia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Taty-Taty</LastName>
<ForeName>Raphaël</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Ministry of Health, Pointe Noire, Republic of Congo; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lekana-Douki</LastName>
<ForeName>Sonia Etenna</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>Centre International de Recherches Médicales de Franceville, BP 769 Franceville, Gabon;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nkoghe</LastName>
<ForeName>Dieudonné</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Centre International de Recherches Médicales de Franceville, BP 769 Franceville, Gabon;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eis-Hübinger</LastName>
<ForeName>Anna M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Institute of Virology, University of Bonn Medical Centre, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Diedrich</LastName>
<ForeName>Sabine</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Robert Koch Institute, National Reference Laboratory for Poliomyelitis and Enteroviruses, 13302 Berlin, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Koopmans</LastName>
<ForeName>Marion</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Netherlands Center for Infectious Disease Control, 3720, Bilthoven, The Netherlands;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Leroy</LastName>
<ForeName>Eric M</ForeName>
<Initials>EM</Initials>
<AffiliationInfo>
<Affiliation>Centre International de Recherches Médicales de Franceville, BP 769 Franceville, Gabon; Institut de Recherche pour le Développement, Unité Mixte de Recherche 224 (Maladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle), Institut de Recherche pour le Développement/Centre National de la Recherche Scientifique/Unité Mixte 1, 34032 Montpellier, France drosten@virology-bonn.de eric.leroy@ird.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Drosten</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Institute of Virology, University of Bonn Medical Centre, 53127 Bonn, Germany; drosten@virology-bonn.de eric.leroy@ird.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GENBANK</DataBankName>
<AccessionNumberList>
<AccessionNumber>JF838278</AccessionNumber>
<AccessionNumber>JF838279</AccessionNumber>
<AccessionNumber>JF838280</AccessionNumber>
<AccessionNumber>JF838281</AccessionNumber>
<AccessionNumber>JF838282</AccessionNumber>
<AccessionNumber>JF838283</AccessionNumber>
<AccessionNumber>JF838284</AccessionNumber>
<AccessionNumber>JF838285</AccessionNumber>
<AccessionNumber>JF838286</AccessionNumber>
<AccessionNumber>JF838287</AccessionNumber>
<AccessionNumber>JF838288</AccessionNumber>
<AccessionNumber>JF838289</AccessionNumber>
<AccessionNumber>JF838290</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057134">Antibodies, Neutralizing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002522">Cercopithecus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D003223">Congo</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058872">Epidemics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016679">Genome, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032541">Mass Vaccination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010802">Phylogeny</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011051">Poliomyelitis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017955">Poliovirus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011055">Poliovirus Vaccine, Oral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012208">Rhabdomyosarcoma</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014709">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014774">Virulence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156724 [Available on 03/02/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25136121</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>35</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.</ArticleTitle>
<Pagination>
<MedlinePgn>12823-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1413933111</ELocationID>
<Abstract>
<AbstractText>Myeloid cells are key regulators of the tumor microenvironment, governing local immune responses. Here we report that tumor-infiltrating myeloid cells and circulating monocytes in patients with glioblastoma multiforme (GBM) express ligands for activating the Natural killer group 2, member D (NKG2D) receptor, which cause down-regulation of NKG2D on natural killer (NK) cells. Tumor-infiltrating NK cells isolated from GBM patients fail to lyse NKG2D ligand-expressing tumor cells. We demonstrate that lactate dehydrogenase (LDH) isoform 5 secreted by glioblastoma cells induces NKG2D ligands on monocytes isolated from healthy individuals. Furthermore, sera from GBM patients contain elevated amounts of LDH, which correlate with expression of NKG2D ligands on their autologous circulating monocytes. NKG2D ligands also are present on circulating monocytes isolated from patients with breast, prostate, and hepatitis C virus-induced hepatocellular carcinomas. Together, these findings reveal a previously unidentified immune evasion strategy whereby tumors produce soluble factors that induce NKG2D ligands on myeloid cells, subverting antitumor immune responses. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Crane</LastName>
<ForeName>Courtney A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo>
<Affiliation>Departments of Neurological Surgery.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Austgen</LastName>
<ForeName>Kathryn</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Pathology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Haberthur</LastName>
<ForeName>Kristen</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Seattle Children's Research Institute, Seattle, WA 98101;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hofmann</LastName>
<ForeName>Carly</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Departments of Neurological Surgery.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moyes</LastName>
<ForeName>Kara White</ForeName>
<Initials>KW</Initials>
<AffiliationInfo>
<Affiliation>Seattle Children's Research Institute, Seattle, WA 98101;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Avanesyan</LastName>
<ForeName>Lia</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Kalmanovitz Liver Immunology Laboratory, California Pacific Medical Center and Research Institute, San Francisco, CA 94115; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fong</LastName>
<ForeName>Lawrence</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Medicine.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Campbell</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Surgery, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cooper</LastName>
<ForeName>Stewart</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Kalmanovitz Liver Immunology Laboratory, California Pacific Medical Center and Research Institute, San Francisco, CA 94115; and Division of Hepatology, California Pacific Medical Center and Sutter Pacific Medical Foundation, San Francisco, CA 94115.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oakes</LastName>
<ForeName>Scott A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>Pathology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parsa</LastName>
<ForeName>Andrew T</ForeName>
<Initials>AT</Initials>
<AffiliationInfo>
<Affiliation>Departments of Neurological Surgery.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lanier</LastName>
<ForeName>Lewis L</ForeName>
<Initials>LL</Initials>
<AffiliationInfo>
<Affiliation>Microbiology, University of California, San Francisco, CA 94143; lewis.lanier@ucsf.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>4R00CA15142</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AI066897</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA097257-06</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA136577</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527085">KLRK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099187">MHC class I-related chain A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C423231">ULBP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.1.1.27</RegistryNumber>
<NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.1.1.27.-</RegistryNumber>
<NameOfSubstance UI="C409670">lactate dehydrogenase 5</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058851">GPI-Linked Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015395">Histocompatibility Antigens Class I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057131">Immune Evasion</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007527">Isoenzymes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007770">L-Lactate Dehydrogenase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022423">Myeloid Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4156766 [Available on 03/02/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">LDH5</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">glioma</Keyword>
<Keyword MajorTopicYN="N">tumor evasion</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25199252</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0001-6209</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>54</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Wei sheng wu xue bao = Acta microbiologica Sinica</Title>
<ISOAbbreviation>Wei Sheng Wu Xue Bao</ISOAbbreviation>
</Journal>
<ArticleTitle>[Isolation and identification of Myxobacteria strain STXZ54 with antitumor activities].</ArticleTitle>
<Pagination>
<MedlinePgn>532-42</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We isolated Myxobacteria strains from soil samples collected from Guangzhou, identified the strain and studied the antitumor activity.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We isolated Myxobacteria strains from soil samples through inactivated E. coli inducing method, identified the strain according to morphological observation, physiological and biochemical characteristics, and the homologous analysis of 16S rRNA sequences of nucleotides. The antitumor spectrum and the corresponding IC50 of the active component separated from the culture was analyzed. Confocal laser scanning microscope was used to examine the growth inhibitory effect of the active component on B16 cells.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We isolated a Myxobacteria strain and identified as Myxococcus macrosporus STXZ54. The active component termed SGF5 showed cytostatic activity against B16, Hela, 4T1, Hep-3B with IC50 values of 10 microg/mL, and HCT-116 cell with IC50 values of 70 microg/mL. Subcellular structure of B16 cells were abnormal observed by confocal laser scanning microscope. Combining the apoptosis and necrosis assay result it is likely that SGF5 can induce apoptosis of B16 cells.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The active component separated from the culture of Myxococcus macrosporus STXZ54 has a significant antitumor activity tested by cytotoxicity assay, which was worth exploiting as potential antitumor drugs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Shaojun</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Rong</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wen</LastName>
<ForeName>Ye</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qin</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Xuezhi</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xia</LastName>
<ForeName>Liqiu</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Wei Sheng Wu Xue Bao</MedlineTA>
<NlmUniqueID>21610860R</NlmUniqueID>
<ISSNLinking>0001-6209</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009231">Myxococcales</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010802">Phylogeny</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D012988">Soil Microbiology</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202044</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4677-83</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The kinase inhibitor sorafenib is the only approved drug which is effective against late-stage hepatocellular carcinoma (HCC). However, the mean survival of patients is still less than one year, making new approaches for tumor treatment essential. Oncogenic signaling through β-catenin is frequently overactivated in HCC and therefore a potential target for a combination therapy with sorafenib.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Two hepatoma cell lines were treated with non-cytotoxic concentrations of sorafenib and different β-catenin inhibitors. The tumor-relevant end-points of proliferation, apoptosis, cell migration, and colony formation were assessed in vitro along with the activity of the Wingless/Int-1(WNT)/β-catenin and mitogen-activated protein kinase pathways.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Combined treatment with sorafenib and β-catenin inhibitors synergized in the inhibition of cell proliferation, migration, colony formation ability, and induction of apoptosis.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In vitro data suggest that the combination of sorafenib and β-catenin inhibition might be a promising approach for HCC treatment.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Muche</LastName>
<ForeName>Sylvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kirschnick</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schwarz</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Braeuning</LastName>
<ForeName>Albert</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany albert.braeuning@uni-tuebingen.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>25X51I8RD4</RegistryNumber>
<NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9ZOQ3TZI87</RegistryNumber>
<NameOfSubstance UI="C471405">sorafenib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009536">Niacinamide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010671">Phenylurea Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
<Keyword MajorTopicYN="N">MAPK signaling</Keyword>
<Keyword MajorTopicYN="N">Wnt signaling</Keyword>
<Keyword MajorTopicYN="N">liver tumor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202045</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4685-92</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although 5-fluorouracil (5-FU)-based combination chemotherapy (i.e. FOLFIRINOX) has demonstrated effectiveness against pancreatic cancer, novel therapeutic strategies must be developed to increase the therapeutic window of these cytotoxic agents. Genistein is a soy-derived isoflavone with pleiotropic biological effects that can enhance the antitumor effect of chemotherapeutic agents.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">To understand how genistein potentiates the antitumor effects of 5-FU, we examined apoptosis and autophagy in MIA PaCa-2 human pancreatic cancer cells and their derived xenografts. Apoptosis was evaluated using DNA fragmentation assays, and western blots of poly(ADP ribose)polymerase and caspase-3. Meanwhile, autophagy was evaluated using western blots of microtubule-associated protein light chain 3 (LC3)-I/II, fluorescent microscopy observation of green fluorescent protein-LC3B puncta formation, and acidic vesicular organelle formation using acridine orange staining. Tumors from animal treatment studies were examined for apoptosis and autophagy using the TdT-mediated dUTP nick-end labeling assay and immunohistochemical staining of LC3B, respectively.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed that genistein increased 5-FU-induced cell death through increased apoptosis, as well as autophagy. The increased autophagy was accompanied by decreased B-cell lymphoma 2 (Bcl2) and increased beclin-1 protein levels. Animal treatment studies supported these observations. The combination of 5-FU and genistein significantly reduced final xenograft tumor volume when compared to 5-FU-alone by inducing apoptosis as well as autophagy.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Genistein can potentiate the antitumor effect of 5-FU by inducing apoptotic as well as autophagic cell death. These results demonstrate the potential of genistein as an adjuvant therapeutic agent against pancreatic cancer.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Rei</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Ya'an</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xinqun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roife</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Ran</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fleming</LastName>
<ForeName>Jason B</ForeName>
<Initials>JB</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A. jbflemin@mdanderson.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 CA009599</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>DH2M523P0H</RegistryNumber>
<NameOfSubstance UI="D019833">Genistein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019833">Genistein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">5-fluorouracil</Keyword>
<Keyword MajorTopicYN="N">Pancreatic ductal adenocarcinoma</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">autophagy</Keyword>
<Keyword MajorTopicYN="N">cell death</Keyword>
<Keyword MajorTopicYN="N">genistein</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202047</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Nanotherapy with hybrid liposomes for colorectal cancer along with apoptosis in vitro and in vivo.</ArticleTitle>
<Pagination>
<MedlinePgn>4701-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">We examined the therapeutic effects of hybrid liposomes (HL) composed of L-α-dimyristylphosphati-dylcholine (DMPC) and polyoxyethylene (25) dodecyl ether (C12(EO)25) on the growth of human colorectal cancer (WiDr) cells in vitro and in vivo.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">HL composed of 95 mol% DMPC and 5 mol% C12(EO)25 were prepared by the sonication method and their therapeutic effects in xenograft mouse models of colorectal cancer liver metastases were examined in vivo.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The inhibitory effects of HL-25 on the growth of WiDr cells along with apoptosis were assessed in vitro. Remarkable inhibitory effects of HL-25 for the liver metastasis of colorectal cancer cells along with apoptosis were revealed on the basis of histological analysis. Prolonged survival was attained for the xenograft mouse model of colorectal cancer after treatment with HL-25 in vivo.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Therapeutic effects of HL-25 without any drugs on the liver metastasis of human colorectal cancer were obtained for the first time in vivo.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ichihara</LastName>
<ForeName>Hideaki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Division of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakagawa</LastName>
<ForeName>Shinichiro</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Immuno-medical Lab, Omote Sando Yoshida Hospital, Kumamoto, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsuoka</LastName>
<ForeName>Yusuke</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Immuno-medical Lab, Omote Sando Yoshida Hospital, Kumamoto, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshida</LastName>
<ForeName>Kenshi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Immuno-medical Lab, Omote Sando Yoshida Hospital, Kumamoto, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsumoto</LastName>
<ForeName>Yoko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Division of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan matumoto@life.sojo-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ueoka</LastName>
<ForeName>Ryuichi</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan Immuno-medical Lab, Omote Sando Yoshida Hospital, Kumamoto, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558492">polyoxyethylene(25)dodecyl ether</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U86ZGC74V5</RegistryNumber>
<NameOfSubstance UI="D004134">Dimyristoylphosphatidylcholine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004134">Dimyristoylphosphatidylcholine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008081">Liposomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050997">Nanomedicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011092">Polyethylene Glycols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hybrid liposome</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">colorectal cancer</Keyword>
<Keyword MajorTopicYN="N">liver metastasis</Keyword>
<Keyword MajorTopicYN="N">nanotherapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202048</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of light irradiation by light emitting diode on colon cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4709-16</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Recent studies have demonstrated the efficacy of irradiation from light emitting diodes (LED) for wound healing, anti-inflammation and anticancer therapies. However, little is known about the effects of visible light in colon cancer cells. The purpose of this study was to evaluate the biological response (including gene expression changes) of human colon cancer cells to different wavelengths of LED irradiation.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Human colon cancer cells (HT29 or HCT116) were seeded onto laboratory dishes that were then put on LED irradiation equipment with a 465 nm-, 525 nm-, or 635 nm-LED. Irradiation at 15 or 30 mW was performed 10 min/day, each day for 5 days. The cell counting kit8 was then used to measure cell viability. Apoptosis and expression of several mRNAs (caspase, MAPK and autophagy pathway) in HT29 cultures irradiated with 465 nm LED were evaluated via AnnexinV/PI and RT-PCR, respectively.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Viability of HT29 and HCT116 cells was lower in 465 nm-LED irradiated cultures than in control cultures, but viability of HT29 cells did not differ between control cultures and 525 nm-LED or 635 nm-LED irradiated cultures. Moreover, the expression of FAS, caspase-3, capase-8, and JUK were significantly higher in 465 nm-LED irradiated cultures than in control cultures, and expression of ERK1/2 and LC3 was lower in blue-irradiated cells.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LED irradiation at 465 nm inhibited the proliferation of HT29 cells and of HCT116 cells. Notably, LED irradiation at 465 nm promoted apoptosis inHT29 cultures via the extrinsic apoptosis pathway and the MAPK pathway.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Matsumoto</LastName>
<ForeName>Noriko</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshikawa</LastName>
<ForeName>Kozo</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan yoshikawa.kozo@tokushima-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shimada</LastName>
<ForeName>Mitsuo</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kurita</LastName>
<ForeName>Nobuhiro</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Hirohiko</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwata</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Higashijima</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chikakiyo</LastName>
<ForeName>Motoya</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishi</LastName>
<ForeName>Masaaki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kashihara</LastName>
<ForeName>Hideya</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takasu</LastName>
<ForeName>Chie</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eto</LastName>
<ForeName>Shohei</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Preventive Environment and Nutrition, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akutagawa</LastName>
<ForeName>Masatake</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Life system, Institute of Technology and Science, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Emoto</LastName>
<ForeName>Takahiro</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Life system, Institute of Technology and Science, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004307">Dose-Response Relationship, Radiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019073">HT29 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D054023">Lasers, Semiconductor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008027">Light</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">HCT116 cells</Keyword>
<Keyword MajorTopicYN="N">HT29</Keyword>
<Keyword MajorTopicYN="N">Light-emitting diode</Keyword>
<Keyword MajorTopicYN="N">colon cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202050</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4723-31</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Activation of the c-JUN N-terminal kinase (JNK) signaling pathway has been associated with poor survival of ovarian cancer patients, but the role(s) and significance of JNK signaling in ovarian cancer cells remain poorly understood. In the present study, we aimed to investigate the role of JNK specifically in ovarian cancer stem cells (CSCs).</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The effect of JNK inhibition on the self-renewal (CSC marker expression, sphere-forming ability) and tumor-initiating capacity was examined in CSCs derived from the A2780 human ovarian cancer cell line. JNK inhibition was achieved either pharmacologically or genetically by use of RNA interference.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Both pharmacological and genetic targeting of JNK resulted in loss of self-renewal and tumor-initiating capacity of A2780 CSCs.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings demonstrate, to our knowledge for the first time, that JNK has a pivotal role in the maintenance of ovarian CSCs.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Seino</LastName>
<ForeName>Manabu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okada</LastName>
<ForeName>Masashi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shibuya</LastName>
<ForeName>Keita</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seino</LastName>
<ForeName>Shizuka</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan Research Institute for Promotion of Medical Sciences, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Shuhei</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan Department of Regional Cancer Network, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ohta</LastName>
<ForeName>Tsuyoshi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kurachi</LastName>
<ForeName>Hirohisa</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kitanaka</LastName>
<ForeName>Chifumi</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan Research Institute for Promotion of Medical Sciences, Yamagata University School of Medicine, Yamagata, Japan ckitanak@med.id.yamagata-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C432165">anthra(1,9-cd)pyrazol-6(2H)-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000873">Anthracenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048031">JNK Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018874">Spheroids, Cellular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
<Keyword MajorTopicYN="N">cancer initiating cells</Keyword>
<Keyword MajorTopicYN="N">tumorigenicity</Keyword>
<Keyword MajorTopicYN="N">xenograft analysis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202053</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of a novel in vivo cancer model using cell sheet engineering.</ArticleTitle>
<Pagination>
<MedlinePgn>4747-54</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">Standard in vivo cancer models entail injecting single cancer cells, but this technique is not always successful. We developed a novel cancer cell sheet by using temperature-responsive polymer poly(N-isopropyl acryl amide)-coated plates, which allow controlled attachment and detachment of living cancer cells via simple temperature changes.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Four human cancer cell lines were used to make cell sheets. The cancer cell sheets were subcutaneously transplanted into nude mice and compared regarding their tumor-forming ability with the conventional cell suspension technique.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Human cancer cell sheets were successfully transplanted into nude mice. The cancer cell sheets resulted in stable engraftment and showed a higher tumor volume determined by total flux with the IVIS® imaging system.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Novel cancer cell sheets are useful tools to make in vivo cancer models in mice for the assessment of anticancer therapeutics.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Ryuji</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aruga</LastName>
<ForeName>Atsushi</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery, Tokyo Women's Medical University, Tokyo, Japan Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan aruga.atsushi@twmu.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kobayashi</LastName>
<ForeName>Hajime</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamato</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Masakazu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018929">Cell Culture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">cell sheet</Keyword>
<Keyword MajorTopicYN="N">mouse model</Keyword>
<Keyword MajorTopicYN="N">tissue engineering</Keyword>
<Keyword MajorTopicYN="N">transplantation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202054</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2.</ArticleTitle>
<Pagination>
<MedlinePgn>4755-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The proliferation in human prostate carcinomas, PC3 and MDA-PCa-2b, was analyzed for cells treated with LLW-3-6 and celecoxib in the presence and absence of sulfasalazine. LLW-3-6 was more potent than celecoxib at mediating a dose-dependent reduction of viable PC3 cells. Co-treatment with a non-lethal dose of sulfasalazine diminished the potency of both drugs in this cell line. The effects of the drugs in MDA-PCa-2b cells were less significant than those observed in the PC3 cells. Localization of COX-2 in LLW-3-6- and CBX-treated PC3 cells is consistent with protein aggregation known for cells responding to stress stimuli. To complement this, an analysis of the theoretical binding interactions of LLW-3-6 was completed to illustrate the potential of LLW-3-6 to bind to COX-2 in a manner similar to that of celecoxib. Studies to further define the mechanism of action for LLW-3-6 are ongoing. </AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yerokun</LastName>
<ForeName>Tokunbo</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, Spelman College, Atlanta, GA, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Winfield</LastName>
<ForeName>Leyte L</ForeName>
<Initials>LL</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry &amp; Biochemistry, Spelman College, Atlanta, GA, U.S.A. lwinfield@spelman.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5P20MD000215-05</GrantID>
<Acronym>MD</Acronym>
<Agency>NIMHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20 MD000215</GrantID>
<Acronym>MD</Acronym>
<Agency>NIMHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052246">Cyclooxygenase 2 Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592933">LLW-3-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>169590-42-5</RegistryNumber>
<NameOfSubstance UI="C105934">celecoxib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Prostate. 2007 Feb 1;67(2):162-71</RefSource>
<PMID Version="1">17075799</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Physiol. 2008 Jun;215(3):593-602</RefSource>
<PMID Version="1">18181196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuropathol Appl Neurobiol. 2008 Jun;34(3):272-83</RefSource>
<PMID Version="1">17971075</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Prev Res (Phila). 2010 Jan;3(1):25-34</RefSource>
<PMID Version="1">20051370</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Glia. 2011 Aug;59(8):1181-9</RefSource>
<PMID Version="1">21192095</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Prev Res (Phila). 2011 Jul;4(7):984-93</RefSource>
<PMID Version="1">21733822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res. 2011;13(6):224</RefSource>
<PMID Version="1">22114931</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet Oncol. 2012 May;13(5):549-58</RefSource>
<PMID Version="1">22452894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biotech Histochem. 2013 Jan;88(1):38-46</RefSource>
<PMID Version="1">23167625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Future Oncol. 2013 Mar;9(3):451-62</RefSource>
<PMID Version="1">23469980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Pharmacokinet. 2000 Mar;38(3):225-42</RefSource>
<PMID Version="1">10749518</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2000 Apr 14;275(15):11397-403</RefSource>
<PMID Version="1">10753955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2000 Dec;113 Pt 23:4139-40</RefSource>
<PMID Version="1">11069756</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Leukemia. 2001 Oct;15(10):1633-40</RefSource>
<PMID Version="1">11587223</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2004 Jun 15;64(12):4309-18</RefSource>
<PMID Version="1">15205346</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 1997 Oct;110 ( Pt 19):2449-59</RefSource>
<PMID Version="1">9410883</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2006 Aug 31;355(9):885-95</RefSource>
<PMID Version="1">16943401</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001562">Benzimidazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052246">Cyclooxygenase 2 Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042541">Intracellular Space</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008968">Molecular Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS634220</OtherID>
<OtherID Source="NLM">PMC4204802</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Benzimidazole</Keyword>
<Keyword MajorTopicYN="N">COX-2</Keyword>
<Keyword MajorTopicYN="N">MDA-PCa 2b</Keyword>
<Keyword MajorTopicYN="N">PC3</Keyword>
<Keyword MajorTopicYN="N">celecoxib</Keyword>
<Keyword MajorTopicYN="N">docking</Keyword>
<Keyword MajorTopicYN="N">focal adhesion</Keyword>
<Keyword MajorTopicYN="N">prostate cancer</Keyword>
<Keyword MajorTopicYN="N">sulfasalazine</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202055</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice.</ArticleTitle>
<Pagination>
<MedlinePgn>4761-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Desmopressin (dDAVP) is a synthetic peptide analog of vasopressin with antidiuretic and hemostatic properties. Recent experimental evidence have suggested that dDAVP can inhibit metastasis formation by agonist action on V2 vasopressin receptors present in both tumor and endothelial cells. We have examined the kinetics of dDAVP effect during metastatic colonization and its potential association with hemostasis.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The experimental metastasis assay was performed by injecting F3II mammary carcinoma cells into the lateral tail vein of syngeneic female BALB/c mice.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinically relevant doses of dDAVP (0.3 to 2 μg/kg intravenously (i.v.)) produced a dose-dependent inhibition in the formation of lung nodules when administered during the first 24 hours after F3II tumor cell injection. The hemostatic agent tranexamic acid (10 mg/kg, i.v.) had no effect on metastasis formation in the same experimental conditions, while the anticoagulant enoxaparin (1 mg/kg, subcutaneously (s.c.)) did not modify the antimetastatic action of dDAVP. In vitro, dDAVP had a strong inhibitory effect on F3II cell colony formation.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">dDAVP interferes with early metastatic disease, and direct association of this effect with hemostatic mechanisms is unlikely.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Garona</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pifano</LastName>
<ForeName>Marina</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scursoni</LastName>
<ForeName>Alejandra M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Pathology Service, Iriarte Hospital of Quilmes, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gomez</LastName>
<ForeName>Daniel E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alonso</LastName>
<ForeName>Daniel F</ForeName>
<Initials>DF</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina dfalonso@unq.edu.ar.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ripoll</LastName>
<ForeName>Giselle V</ForeName>
<Initials>GV</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>ENR1LLB0FP</RegistryNumber>
<NameOfSubstance UI="D003894">Deamino Arginine Vasopressin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003894">Deamino Arginine Vasopressin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Desmopressin</Keyword>
<Keyword MajorTopicYN="N">breast cancer</Keyword>
<Keyword MajorTopicYN="N">hemostasis</Keyword>
<Keyword MajorTopicYN="N">metastasis</Keyword>
<Keyword MajorTopicYN="N">peptide analog</Keyword>
<Keyword MajorTopicYN="N">vasopressin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202056</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine.</ArticleTitle>
<Pagination>
<MedlinePgn>4767-73</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A previously established arsenite-resistant cell line, KAS, is also resistant to a variety of anticancer drugs. In order to understand responsible molecules for the multidrug resistance phenotype of KAS cells, we examined the expressions of ATP-binding cassette (ABC) transporters and found that the ABCB6 and ABCC1/ multidrug resistance protein 1 (ABCC1/MRP1) were increased. ABCC1/MRP1 was not completely responsible for the drug resistance spectrum of KAS cells and several reports have suggested that ABCB6 is related to anticancer drug and metal resistance. We, therefore, established and examined ABCB6-expressing KB cells and ABCB6-knockdown KAS cells. ABCB6 expression enhanced resistance to 5-fluorouracil (5-FU), SN-38 and vincristine (Vcr) but not to arsenite. Conversely, down-regulation of ABCB6 in KAS cells increased the sensitivity of KAS cells to 5-FU, SN-38 and Vcr, but not to arsenite. Our findings suggest that ABCB6 is involved in 5-FU, SN-38 and Vcr resistance. </AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Minami</LastName>
<ForeName>Kentaro</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan Department of Clinical Pharmacy and Pharmacology, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kamijo</LastName>
<ForeName>Youhei</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan Department of Organic and Biological Chemistry, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishizawa</LastName>
<ForeName>Yukihiko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan Department of Clinical Pharmacy and Pharmacology, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tabata</LastName>
<ForeName>Sho</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan Institute for Advanced Biosciences, Keio University, Yamagata, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Horikuchi</LastName>
<ForeName>Fumito</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan Department of Organic and Biological Chemistry, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Masatatsu</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kawahara</LastName>
<ForeName>Kohich</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shinsato</LastName>
<ForeName>Yoshinari</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tachiwada</LastName>
<ForeName>Tokushi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Zhe-Sheng</ForeName>
<Initials>ZS</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy and Allied Health Professions, Department of Pharmaceutical Sciences, St. John's University, Queens, NY, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsujikawa</LastName>
<ForeName>Kazutake</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Graduate School of Pharmaceutical Science, Osaka University, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakagawa</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seki</LastName>
<ForeName>Naohiko</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akiyama</LastName>
<ForeName>Shin-Ichi</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan Clinical Research Center, National Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arima</LastName>
<ForeName>Kazunari</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Organic and Biological Chemistry, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takeda</LastName>
<ForeName>Yasuo</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Pharmacy and Pharmacology, Kagoshima University, Kagoshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Furukawa</LastName>
<ForeName>Tatsuhiko</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Kagoshima University, Kagoshima, Japan furukawa@m3.kufm.kogoshima-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C107991">ABCB6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D027425">Multidrug Resistance-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C421109">multidrug resistance-associated protein 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>57-22-7</RegistryNumber>
<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7673326042</RegistryNumber>
<NameOfSubstance UI="C051890">irinotecan</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>XT3Z54Z28A</RegistryNumber>
<NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018528">ATP-Binding Cassette Transporters</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002166">Camptothecin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007624">KB Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D027425">Multidrug Resistance-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ABC transporters</Keyword>
<Keyword MajorTopicYN="N">ABCB6</Keyword>
<Keyword MajorTopicYN="N">anticancer agents</Keyword>
<Keyword MajorTopicYN="N">arsenite</Keyword>
<Keyword MajorTopicYN="N">drug resistance</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202059</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Branched chain amino acid suppressed insulin-initiated proliferation of human cancer cells through induction of autophagy.</ArticleTitle>
<Pagination>
<MedlinePgn>4789-96</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Branched chain amino acid (BCAA) dietary supplementation inhibits activation of the insulin-like growth factor (IGF)/IGF-I receptor (IGF-IR) axis in diabetic animal models. However, the in vitro effect of BCAA on human cancer cell lines under hyper-insulinemic conditions remains unclear.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Colon (HCT-116) and hepatic (HepG2) tumor cells were treated with varying concentrations of BCAA with or without fluorouracil (5-FU). The effect of BCAA on insulin-initiated proliferation was determined. Gene and protein expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting, respectively.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">BCAA supplementation had no significant effect on cell proliferation and did not show significant synergistic or antagonistic effects with 5-FU. However, BCAA significantly decreased insulin-initiated proliferation of human colon and hepatic cancer cell lines in vitro. BCAA supplementation caused a marked decrease in activated IGF-IR expression and significantly enhanced both mRNA and protein expression of LC3-II and BECN1 (BECLIN-1).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BCAA could be a useful chemopreventive modality for cancer in hyperinsulinemic conditions.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wubetu</LastName>
<ForeName>Gizachew Yismaw</ForeName>
<Initials>GY</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Utsunomiya</LastName>
<ForeName>Tohru</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ishikawa</LastName>
<ForeName>Daichi</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ikemoto</LastName>
<ForeName>Tetsuya</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamada</LastName>
<ForeName>Shinichiro</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morine</LastName>
<ForeName>Yuji</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwahashi</LastName>
<ForeName>Shuichi</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saito</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arakawa</LastName>
<ForeName>Yusuke</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Imura</LastName>
<ForeName>Satoru</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Arimochi</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology and Parasitology, The University of Tokushima, Tokushima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shimada</LastName>
<ForeName>Mitsuo</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Tokushima, Tokushima, Japan mitsuo.shimada@tokushima-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000597">Amino Acids, Branched-Chain</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000597">Amino Acids, Branched-Chain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019587">Dietary Supplements</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045325">HCT116 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056945">Hep G2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017526">Receptor, IGF Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Autophagy</Keyword>
<Keyword MajorTopicYN="N">BCAA</Keyword>
<Keyword MajorTopicYN="N">colorectal cancer</Keyword>
<Keyword MajorTopicYN="N">insulin</Keyword>
<Keyword MajorTopicYN="N">liver cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202060</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cucurbitacin-D-induced CDK1 mRNA up-regulation causes proliferation arrest of a non-small cell lung carcinoma cell line (NSCLC-N6).</ArticleTitle>
<Pagination>
<MedlinePgn>4797-806</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Despite progress in chemotherapeutic agents, non-small cell lung cancers (NSCLC) still have a poor survival rate. Thus, development of new therapeutic strategies, specifically against cancer cells is still required. For this purpose, we treated the non-small cell lung cancer cell line NSCLC-N6 with the natural product cucurbitacin D (CucD) - extracted from the plant Ecballium elaterium in order first to assess its in vitro cytotoxicity, but also to study the genetic changes that it could bring out. CucD has shown a blocking in the G1 phase of the cell cycle in NSCLC-N6 cells prior to apoptotic cell death. The reverse transcriptase-polymerase chain reaction-differential display (RT-PCR-DD) technique was also applied on treated cells to elucidate the genetic mechanisms involved. We revealed an overexpression of Cyclin-dependent kinase 1 (CDK1) mRNA after treatment and, with the use of antisense oligonucleotides, an effective role in the proliferation arrest of NSCLC-N6 cells. The present study provides new insights about the mechanisms of proliferation arrest in tumor cells and open new ways of treatment to target tumor growth. </AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jacquot</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Equipe IICIMed EA 1155, Laboratoire CPCM, Faculté de Pharmacie, Université de Nantes, Nantes, France Catherine.jacquot@univ-nantes.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rousseau</LastName>
<ForeName>Benedicte</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Equipe IICIMed EA 1155, Laboratoire CPCM, Faculté de Pharmacie, Université de Nantes, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carbonnelle</LastName>
<ForeName>Delphine</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Equipe IICIMed EA 1155, Laboratoire CPCM, Faculté de Pharmacie, Université de Nantes, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chinou</LastName>
<ForeName>Ioanna</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Division of Pharmacognosy and Chemistry of Natural Products, University of Athens, Athens, Greece.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malleter</LastName>
<ForeName>Marine</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Equipe IICIMed EA 1155, Laboratoire CPCM, Faculté de Pharmacie, Université de Nantes, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tomasoni</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Equipe IICIMed EA 1155, Laboratoire CPCM, Faculté de Pharmacie, Université de Nantes, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roussakis</LastName>
<ForeName>Christos</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Equipe IICIMed EA 1155, Laboratoire CPCM, Faculté de Pharmacie, Université de Nantes, Nantes, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3877-86-9</RegistryNumber>
<NameOfSubstance UI="C038105">cucurbitacin D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.22</RegistryNumber>
<NameOfSubstance UI="D016203">CDC2 Protein Kinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016203">CDC2 Protein Kinase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CDK1</Keyword>
<Keyword MajorTopicYN="N">Cucurbitacin D</Keyword>
<Keyword MajorTopicYN="N">Ecbalium elaterium</Keyword>
<Keyword MajorTopicYN="N">G1 cell cycle arrest</Keyword>
<Keyword MajorTopicYN="N">NSCLC-N6</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">gene expression</Keyword>
<Keyword MajorTopicYN="N">lung cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202061</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4807-11</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Active hexose-correlated compound (AHCC) is an extract of basidiomycete mushroom. It has been used as health food due to its efficacy of enhancing antitumor effects and reducing adverse effects of chemotherapy. Our previous research showed that AHCC down-regulated heat-shock protein (HSP)-27 and exhibited cytotoxic effects against gemcitabine-resistant pancreatic cancer cells. Sex-determining region Y-box 2 (SOX2) is reported to be up-regulated in other kinds of cancer cells and involved in carcinogenesis and malignancy. The aim of this study was to investigate the effects of AHCC on protein expression of SOX2 in the gemcitabine-resistant pancreatic cancer cell line KLM1-R.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">AHCC was applied to KLM1-R cells and expression of SOX2 was analyzed by western blotting.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">AHCC down-regulated SOX2 in KLM1-R cells. Nanog and Oct4, co-workers of SOX2 in maintaining pluripotency, did not exhibit any significant change in protein expression.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We showed the potential of AHCC to be a candidate for combinatorial therapy in anticancer drug regimens. This result suggests that the target of AHCC in expressing therapeutic efficacy was not the pluripotent cells such as cancer stem cells (CSCs) but SOX2-specific.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nawata</LastName>
<ForeName>Junya</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuramitsu</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan climates@yamaguchi-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yufeng</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kitagawa</LastName>
<ForeName>Takao</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tokuda</LastName>
<ForeName>Kazuhiro</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baron</LastName>
<ForeName>Byron</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akada</LastName>
<ForeName>Junko</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suenaga</LastName>
<ForeName>Shigeyuki</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan Department of Hepatology and Gastroenterology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kaino</LastName>
<ForeName>Seiji</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatology and Gastroenterology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maehara</LastName>
<ForeName>Shin-Ichiro</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maehara</LastName>
<ForeName>Yoshihiko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sakaida</LastName>
<ForeName>Isao</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatology and Gastroenterology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakamura</LastName>
<ForeName>Kazuyuki</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan Centre of Clinical Laboratories in Tokuyama Medical Association Hospital, Shunan-shi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C499366">Active Hexose Correlated Compound</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527782">SOX2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055748">SOXB1 Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011134">Polysaccharides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055748">SOXB1 Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">AHCC</Keyword>
<Keyword MajorTopicYN="N">SOX2</Keyword>
<Keyword MajorTopicYN="N">gemcitabine</Keyword>
<Keyword MajorTopicYN="N">heat-shock protein-27</Keyword>
<Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202063</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Nogo-B receptor expression correlates negatively with malignancy grade and ki-67 antigen expression in invasive ductal breast carcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>4819-28</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nogo-B receptor (NgBR) has been shown to be involved in endothelial cell chemotaxis and morphogenesis. However, few studies analyzing its expression in cancer cells have been performed.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We examined NgBR expression in 233 patients with invasive ductal breast carcinoma (IDC) and corresponding non-malignant breast tissues (NMBT) on mRNA (real-time polymerase chain reaction) and protein levels (immunohistochemistry; IHC and western-blot analysis). NgBR expression was found also analyzed in breast cancer cell lines of varying invasiveness.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">NgBR expression was increased in IDC compared to NMBT on the mRNA (p=0.0007) and protein level (p=0.018). NgBR expression decreased significantly with IDC malignancy grade and correlated negatively with the Ki-67 antigen expression (r=-0.18; p=0.0005). High NgBR mRNA expression was associated with estrogen receptor negativity (p=0.0023) and the triple-negative phenotype of the tumors (p=0.0129).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NgBR may be involved in IDC development, however, its role in its progression requires further research.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pula</LastName>
<ForeName>Bartosz</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Histology and Embryology, Medical University, Wroclaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Olbromski</LastName>
<ForeName>Mateusz</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Histology and Embryology, Medical University, Wroclaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Owczarek</LastName>
<ForeName>Tomasz</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Environmental and Life Sciences, Wroclaw, Poland Laboratory of Glycobiology and Cell Interactions, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ambicka</LastName>
<ForeName>Aleksandra</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Tumour Pathology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Witkiewicz</LastName>
<ForeName>Wojciech</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Research and Development Center, Regional Specialist Hospital, Wroclaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ugorski</LastName>
<ForeName>Maciej</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Environmental and Life Sciences, Wroclaw, Poland Laboratory of Glycobiology and Cell Interactions, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rys</LastName>
<ForeName>Janusz</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Tumour Pathology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zabel</LastName>
<ForeName>Maciej</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Histology and Embryology, Medical University, Wroclaw, Poland Department of Histology and Embryology, Medical University, Poznan, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dziegiel</LastName>
<ForeName>Piotr</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Histology and Embryology, Medical University, Wroclaw, Poland Department of Physiotherapy, University School of Physical Education, Wroclaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Podhorska-Okolow</LastName>
<ForeName>Marzena</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Histology and Embryology, Medical University, Wroclaw, Poland marzenna.podhorska-okolow@umed.wroc.pl.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C512614">NUS1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018270">Carcinoma, Ductal, Breast</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002461">Cell Line, Transformed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019394">Ki-67 Antigen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060787">Neoplasm Grading</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">Ki-67 antigen</Keyword>
<Keyword MajorTopicYN="N">NgBR</Keyword>
<Keyword MajorTopicYN="N">Nogo-B receptor</Keyword>
<Keyword MajorTopicYN="N">immunohistochemistry</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202064</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hsp70 inhibition potentiates radicicol-induced cell death in anaplastic thyroid carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4829-37</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The aim of the present study was to evaluate the effect of radicicol, an inhibitor of heat shock protein (hsp) 90, alone or in combination with hsp70 inhibition on survival of anaplastic thyroid carcinoma (ATC) cells.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Antitumor activity of radicicol-alone or in combination with the hsp70 inhibitor VER155008 was investigated in 8505C and CAL62 cells.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Radicicol decreased cell viability and Akt protein levels, and increased the percentage of dead cells and hsp70 protein levels. In PIK3CA plasmid-transfected cells, compared to cells treated with radicicol-alone, cell viability increased and cellular death decreased. In cells treated with both radicicol and VER155008, compared to cells treated with radicicol-alone, cell viability further decreased and the percentage of dead cells further increased, with a parallel decrease of the protein levels of heat shock cognate 70, Akt and survivin.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that radicicol induces cell death mediated through PI3K/Akt signaling with modulation of hsp90 client proteins and hsp70 inhibition enhances radicicol-induced cell death with suppression of survivin in ATC cells.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Si Hyoung</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Jun Goo</ForeName>
<Initials>JG</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chul Sik</ForeName>
<Initials>CS</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ihm</LastName>
<ForeName>Sung-Hee</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Moon Gi</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoo</LastName>
<ForeName>Hyung Joon</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Seong Jin</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea leesj@hallym.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011684">Purine Nucleosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C550733">VER 155008</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>12772-57-5</RegistryNumber>
<NameOfSubstance UI="C035359">monorden</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018840">HSP70 Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018942">Macrolides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011684">Purine Nucleosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D065646">Thyroid Carcinoma, Anaplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Akt</Keyword>
<Keyword MajorTopicYN="N">Anaplastic thyroid carcinoma</Keyword>
<Keyword MajorTopicYN="N">hsp70</Keyword>
<Keyword MajorTopicYN="N">hsp90</Keyword>
<Keyword MajorTopicYN="N">radicicol</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202065</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Human adipose tissue-derived mesenchymal stem cells inhibit T-cell lymphoma growth in vitro and in vivo.</ArticleTitle>
<Pagination>
<MedlinePgn>4839-47</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Human mesenchymal stem cells (hMSCs) are thought to be one of the most reliable stem cell sources for a variety of cell therapies. This study investigated the anti-tumor effect of human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) on EL4 murine T-cell lymphoma in vitro and in vivo.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The growth-inhibitory effect of hAT-MSCs on EL4 tumor cells was evaluated using a WST-1 cell proliferation assay. Cell-cycle arrest and apoptosis were investigated by flow cytometry and western blot. To evaluate an anti-tumor effect of hAT-MSCs on T-cell lymphoma in vivo, CM-DiI-labeled hAT-MSCs were circumtumorally injected in tumor-bearing nude mice, and tumor size was measured.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">hAT-MSCs inhibited T-cell lymphoma growth by altering cell-cycle progression and inducing apoptosis in vitro. hAT-MSCs inhibited tumor growth in tumor-bearing nude mice and prolonged survival time. Immunofluorescence analysis showed that hAT-MSCs migrated to tumor sites.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">hAT-MSCs suppress the growth of T-cell lymphoma, suggesting a therapeutic option for T-cell lymphoma.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Jin-Ok</ForeName>
<Initials>JO</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chae</LastName>
<ForeName>Ji-Sang</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Coh</LastName>
<ForeName>Ye-Rin</ForeName>
<Initials>YR</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>Woo-Sung</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Hee-Woo</ForeName>
<Initials>HW</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Il-Seob</ForeName>
<Initials>IS</Initials>
<AffiliationInfo>
<Affiliation>Stem Cell Research Center, K-STEMCELL Co., Ltd, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Sung-Keun</ForeName>
<Initials>SK</Initials>
<AffiliationInfo>
<Affiliation>Stem Cell Research Center, K-STEMCELL Co., Ltd, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Youn</LastName>
<ForeName>Hwa-Young</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea hyyoun@snu.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000273">Adipose Tissue</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018920">Coculture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016399">Lymphoma, T-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045164">Mesenchymal Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059630">Mesenchymal Stromal Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Mesenchymal stem cell</Keyword>
<Keyword MajorTopicYN="N">T-cell lymphoma</Keyword>
<Keyword MajorTopicYN="N">cytotherapy</Keyword>
<Keyword MajorTopicYN="N">growth inhibition</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202067</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4857-68</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The aim of the present study was to elucidate whether tunicamycin (TM) induces paraptosis as a cell death subroutine in anaplastic thyroid carcinoma (ATC) cells.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">8505C, CAL62 and FRO cells were used. After treatment of TM, cell survival and morphology were investigated. The effect of the BRAF(V600E) inhibitor PLX4032 in combination with TM was evaluated.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In FRO cells, TM induced paraptosis characteristic of cytoplasmic vacuolation and endoplasmic reticulum (ER) swelling, which was not associated with caspase activation and ER stress. TM-induced paraptosis was ameliorated by pre-treatment with the translation inhibitor cycloheximide, while it was accelerated by pre-treatment with the proteasome inhibitor MG132. PLX4032 augmented TM-induced paraptosis.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TM induces paraptosis relevant to de novo protein synthesis and proteasomal activity, and inhibition of BRAF(V600E) potentiates TM-induced paraptosis in FRO cells harboring BRAF(V600E).</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Si Hyoung</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Hae-Young</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>Ilsong Institute of Life Science, Gyeonggi-Do, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Yong-Sun</ForeName>
<Initials>YS</Initials>
<AffiliationInfo>
<Affiliation>Ilsong Institute of Life Science, Gyeonggi-Do, Republic of Korea Department of Microbiology, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Jun Goo</ForeName>
<Initials>JG</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chul Sik</ForeName>
<Initials>CS</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ihm</LastName>
<ForeName>Sung-Hee</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Moon Gi</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoo</LastName>
<ForeName>Hyung Joon</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Seong Jin</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea leesj@hallym.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551177">PLX4032</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11089-65-9</RegistryNumber>
<NameOfSubstance UI="D014415">Tunicamycin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.25.1</RegistryNumber>
<NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020169">Caspases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059865">Endoplasmic Reticulum Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046988">Proteasome Endopeptidase Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014176">Protein Biosynthesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D065646">Thyroid Carcinoma, Anaplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014415">Tunicamycin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Anaplastic thyroid carcinoma</Keyword>
<Keyword MajorTopicYN="N">BRAF</Keyword>
<Keyword MajorTopicYN="N">paraptosis</Keyword>
<Keyword MajorTopicYN="N">tunicamycin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202069</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Quantitative structure-cytotoxicity relationship of piperic acid amides.</ArticleTitle>
<Pagination>
<MedlinePgn>4877-84</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A total of 12 piperic acid amides, including piperine, were subjected to quantitative structure-activity relationship (QSAR) analysis, based on their cytotoxicity, tumor selectivity and anti-HIV activity, in order to find new biological activities.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Cytotoxicity against four human oral squamous cell carcinoma (OSCC) cell lines and three human oral normal cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Tumor selectivity was evaluated by the ratio of the mean 50% cytotoxic concentration (CC50) against normal oral cells to that against OSCC cell lines. Anti-HIV activity was evaluated by the ratio of the CC50 to 50% HIV infection-cytoprotective concentration (EC50). Physicochemical, structural, and quantum-chemical parameters were calculated based on the conformations optimized by LowModeMD method followed by density functional theory method.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">All compounds showed low-to-moderate tumor selectivity, but no anti-HIV activity. N-Piperoyldopamine ( 8: ) which has a catechol moiety, showed the highest tumor selectivity, possibly due to its unique molecular shape and electrostatic interaction, especially its largest partial equalization of orbital electronegativities and vsurf descriptors.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study suggests that molecular shape and ability for electrostatic interaction are useful parameters for estimating the tumor selectivity of piperic acid amides.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shimada</LastName>
<ForeName>Chiyako</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Division of Pharmacology, Meikai University School of Dentistry, Sakado, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uesawa</LastName>
<ForeName>Yoshihiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Pharmaceutics, Meiji Pharmaceutical University, Noshio, Kiyose, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ishihara</LastName>
<ForeName>Mariko</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Basic Chemistry, Meikai University School of Dentistry, Sakado, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kagaya</LastName>
<ForeName>Hajime</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Pharmaceutics, Meiji Pharmaceutical University, Noshio, Kiyose, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kanamoto</LastName>
<ForeName>Taisei</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>St. Marianna University School of Medicine, Kanagawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Terakubo</LastName>
<ForeName>Shigemi</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>St. Marianna University School of Medicine, Kanagawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakashima</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>St. Marianna University School of Medicine, Kanagawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takao</LastName>
<ForeName>Koichi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miyashiro</LastName>
<ForeName>Takaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sugita</LastName>
<ForeName>Yoshiaki</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sakagami</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Division of Pharmacology, Meikai University School of Dentistry, Sakado, Saitama, Japan sakagami@dent.meikai.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000577">Amides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005231">Fatty Acids, Unsaturated</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5285-18-7</RegistryNumber>
<NameOfSubstance UI="C017637">piperic acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000577">Amides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019380">Anti-HIV Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005231">Fatty Acids, Unsaturated</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008826">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D021281">Quantitative Structure-Activity Relationship</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Piperic acid amides</Keyword>
<Keyword MajorTopicYN="N">QSAR analysis</Keyword>
<Keyword MajorTopicYN="N">anti-HIV activity</Keyword>
<Keyword MajorTopicYN="N">cytotoxicity</Keyword>
<Keyword MajorTopicYN="N">tumor selectivity</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202070</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.</ArticleTitle>
<Pagination>
<MedlinePgn>4885-92</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Forodesine inhibits purine nucleoside phosphorylase, resulting in an accumulation of intracellular dGTP and consequently cell death. 9-β-D-Arabinofuranosylguanine (ara-G) is an active compound of nelarabine that is intracellularly phosphorylated to a triphosphate form, which inhibits DNA synthesis. Both agents show cytotoxicity toward T-cell malignancies. In the present study, we investigated the cytotoxicity of forodesine in vitro using ara-G-resistant leukemia cells.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">T-Lymphoblastic leukemia cell line CCRF-CEM and ara-G-resistant CEM variant cell line CEM/ara-G that we had previously established were used.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A growth-inhibition assay demonstrated that CEM cells were insensitive to single-agent forodesine treatment. The cells were also insensitive to deoxyguanosine at a maximal concentration of 10 μM. CEM/ara-G cells were 80-fold more resistant to ara-G than were CEM cells, and the mode of sensitivity to forodesine and deoxyguanosine was similar to that of CEM cells. In the presence of 10 μM deoxyguanosine, forodesine effectively inhibited the growth of CEM cells but not that of CEM/ara-G cells. Flow cytometric analyses showed that combination of forodesine and deoxyguanosine induced apoptosis of CEM cells but not of CEM/ara-G cells. The addition of ara-G did not augment the cytotoxicity of the forodesine/deoxyguanosine combination towards CEM cells or CEM/ara-G cells. The combination index revealed antagonism between forodesine and ara-G. The intracellular production of ara-G triphosphate was reduced in the presence of forodesine.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nelarabine-resistant CEM/ara-G cells are insensitive to forodesine.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yamauchi</LastName>
<ForeName>Takahiro</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Matsuoka, Fukui, Japan tyamauch@u-fukui.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uzui</LastName>
<ForeName>Kanako</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Matsuoka, Fukui, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishi</LastName>
<ForeName>Rie</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Matsuoka, Fukui, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tasaki</LastName>
<ForeName>Toshiki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Matsuoka, Fukui, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ueda</LastName>
<ForeName>Takanori</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Matsuoka, Fukui, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001087">Arabinonucleosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011684">Purine Nucleosides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>426X066ELK</RegistryNumber>
<NameOfSubstance UI="C113101">forodesine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>60158CV180</RegistryNumber>
<NameOfSubstance UI="C104457">nelarabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.1</RegistryNumber>
<NameOfSubstance UI="D011683">Purine-Nucleoside Phosphorylase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001087">Arabinonucleosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018432">Drug Resistance, Multiple</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018922">HL-60 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016393">Lymphoma, B-Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054218">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011684">Purine Nucleosides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011683">Purine-Nucleoside Phosphorylase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011744">Pyrimidinones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Forodesine</Keyword>
<Keyword MajorTopicYN="N">ara-G</Keyword>
<Keyword MajorTopicYN="N">ara-GTP</Keyword>
<Keyword MajorTopicYN="N">deoxyguanosine</Keyword>
<Keyword MajorTopicYN="N">leukemia</Keyword>
<Keyword MajorTopicYN="N">nelarabine</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202071</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.</ArticleTitle>
<Pagination>
<MedlinePgn>4893-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>No targeted-therapy has been established for triple-negative breast cancer accompanied by mutations in breast cancer susceptibility gene1 (BRCA1) mutation. In the present study, using BRCA1 wild-type cells (MDA-MB-231) and BRCA1-mutated cells (MDA-MB-436), we investigated miRNA expression and apoptosis on day 1 after addition of gemcitabine-alone and in combination with poly ADP-ribose polymerase-1 (PARP1) inhibitor. After drug treatment, there were significantly fewer apoptotic BRCA1 wild-type cells than BRCA1-mutated cells. Expression of miRNA-26a, -29b, -100, and -148a increased in BRCA1 wild-type cells exposed to gemcitabine-alone and in combination with the PARP1 inhibitor. The addition of PARP1 inhibitor reduced miR-206 expression in BRCA1 wild-type cells but increased it in BRCA1-mutated cells. It was suggested that miR-206 serves as a target molecule of PARP1 inhibitor combination therapy for BRCA1 wild-type triple-negative breast cancer cells. </AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sasaki</LastName>
<ForeName>Akiko</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, School of Medicine, Showa University, Shinagawa-ku, Tokyo, Japan sakiko@med.showa-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsunoda</LastName>
<ForeName>Yuko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Kameda Medical Center, Breast Center, Kamogawa City, Chiba, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsuji</LastName>
<ForeName>Mayumi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, School of Medicine, Showa University, Shinagawa-ku, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Udaka</LastName>
<ForeName>Yuko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, School of Medicine, Showa University, Shinagawa-ku, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oyamada</LastName>
<ForeName>Hideto</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, School of Medicine, Showa University, Shinagawa-ku, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsuchiya</LastName>
<ForeName>Hiromichi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, School of Medicine, Showa University, Shinagawa-ku, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oguchi</LastName>
<ForeName>Katsuji</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, School of Medicine, Showa University, Shinagawa-ku, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C546087">MIRN206 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0W860991D6</RegistryNumber>
<NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B76N6SBZ8R</RegistryNumber>
<NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019313">BRCA1 Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011065">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064726">Triple Negative Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BRCA1</Keyword>
<Keyword MajorTopicYN="N">PARP1</Keyword>
<Keyword MajorTopicYN="N">TNBC</Keyword>
<Keyword MajorTopicYN="N">breast cancer cells</Keyword>
<Keyword MajorTopicYN="N">miRNA</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202072</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro.</ArticleTitle>
<Pagination>
<MedlinePgn>4899-907</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The goal of the present study was to evaluate if the multiple tyrosine kinase inhibitor (TKI) TKI258 has any treatment value for infant/childhood acute lymphoblatic leukemia (ALL), especially those ALLs bearing the mixed lineage leukemia (MLL) genes.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Cell proliferation was measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; cell apoptosis and cell-cycle distribution with flow cytometry. Gene expression at the protein level was determined by western blotting.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">These ALL cells were extremely sensitive to TKI258 treatment with a concentration for 50% inhibition of cell proliferation (IC50) values in the nanomolar range in vitro. By combination with mTOR inhibitor RAD001, a synergistic effect on cell death and cell proliferation was observed in these cells.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TKI258 may become a potent therapeutic agent, either alone or in combination with RAD001, for treatment of ALL, especially the entity with MLL genes.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eucker</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany jan.eucker@charite.de hongyu.liu@charite.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zang</LastName>
<ForeName>Chuanbing</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Yongan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Central Research Laboratory, Taiyuan Central Hospital, Taiyuan, P.R. China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xinhua</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Central Research Laboratory, Taiyuan Central Hospital, Taiyuan, P.R. China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Habbel</LastName>
<ForeName>Piet</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schulz</LastName>
<ForeName>Carsten-Oliver</ForeName>
<Initials>CO</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scholz</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Hongyu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany jan.eucker@charite.de hongyu.liu@charite.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C500007">4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497422">MLL protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>149025-06-9</RegistryNumber>
<NameOfSubstance UI="D051788">Myeloid-Lymphoid Leukemia Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9HW64Q8G6G</RegistryNumber>
<NameOfSubstance UI="C107135">everolimus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001562">Benzimidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051788">Myeloid-Lymphoid Leukemia Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011505">Protein-Tyrosine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015363">Quinolones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014178">Translocation, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">IC50 (concentration for 50% inhibition of cell proliferation)</Keyword>
<Keyword MajorTopicYN="N">Infant and childhood ALL</Keyword>
<Keyword MajorTopicYN="N">cell apoptosis</Keyword>
<Keyword MajorTopicYN="N">cell proliferation</Keyword>
<Keyword MajorTopicYN="N">mTOR inhibitor RAD001</Keyword>
<Keyword MajorTopicYN="N">multi-tyrosine kinase inhibitor TKI258</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202073</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.</ArticleTitle>
<Pagination>
<MedlinePgn>4909-14</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">BCR-ABL-positive (BCR-ABL(+)) leukemia is very difficult to treat although much improvement has been achieved due to the clinical application of imatinib and the second-generation tyrosine kinase inhibitors (TKIs). This study aimed to evaluate for the first time the treatment value of the multiple tyrosine kinase inhibitor TKI258 in BCR-ABL(+) leukemia.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Proliferation of different BCR-ABL(+) leukemic cells was measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; cell apoptosis with Annexin V/propidium iodide (PI) and flow cytometry. Gene expression at the protein level was determined by western blotting.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">This drug showed treatment efficacy in naïve and imatinib-resistant BCR-ABL(+) leukemia cells, particularly in cells harboring T315I-mutated BCR-ABL, for which no effective inhibitor is available to date. By combination with the mTOR inhibitor RAD001, a synergistic effect on cell proliferation was observed in these cell lines.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TKI258 may become a potent therapeutic agent, either alone or in combination with RAD001, for treatment of BCR-ABL(+) leukemia.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eucker</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany jan.eucker@charite.de hongyu.liu@charite.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zang</LastName>
<ForeName>Chuanbing</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Yongan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Central Research Laboratory, Taiyuan Central Hospital, Taiyuan, P.R. China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xinhua</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Central Research Laboratory, Taiyuan Central Hospital, Taiyuan, P.R. China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Habbel</LastName>
<ForeName>Piet</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Neumann</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scholz</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Hongyu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, Charité-University Medicine, Berlin, Germany jan.eucker@charite.de hongyu.liu@charite.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C500007">4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9HW64Q8G6G</RegistryNumber>
<NameOfSubstance UI="C107135">everolimus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D016044">Fusion Proteins, bcr-abl</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001562">Benzimidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016044">Fusion Proteins, bcr-abl</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007938">Leukemia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015363">Quinolones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BCR-ABL+ leukemia</Keyword>
<Keyword MajorTopicYN="N">cell apoptosis</Keyword>
<Keyword MajorTopicYN="N">cell proliferation</Keyword>
<Keyword MajorTopicYN="N">mTOR inhibitor RAD001</Keyword>
<Keyword MajorTopicYN="N">multi-tyrosine kinase inhibitor TKI258</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202074</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>HSP27 knockdown produces synergistic induction of apoptosis by HSP90 and kinase inhibitors in glioblastoma multiforme.</ArticleTitle>
<Pagination>
<MedlinePgn>4915-27</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The heat-shock proteins HSP27 and HSP90 perpetuate the malignant nature of glioblastoma multiforme (GBM) and offer promise as targets for novel cancer therapeutics. The present study sought to define synergistic antitumor benefits of concurrent HSP27-knockdown and the HSP90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) or, comparatively, the non-selective kinase inhibitor, staurosporine, in GBM cells.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Dose-response relations were determined for 17-AAG and staurosporine in three GBM cell lines. HSP27-targeted siRNA was administered alone or in combination with subtherapeutic concentrations of each drug and cells were evaluated for viability, proliferation and apoptosis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Adjuvant HSP27 knockdown with 17-AAG or staurosporine produced marked and synergistic decrease in GBM cell viability and proliferation, with robust elevation of apoptotic fractions and caspase-3 activation.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">HSP27 knockdown confers potent chemosensitization of GBM cells. These novel data support the development of HSP-targeting strategies and, specifically, anti-HSP27 agents for the treatment of GBM.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Belkacemi</LastName>
<ForeName>Louiza</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hebb</LastName>
<ForeName>Matthew O</ForeName>
<Initials>MO</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada mhebb@uwo.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016227">Benzoquinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055551">HSP27 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047029">Lactams, Macrocyclic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4GY0AVT3L4</RegistryNumber>
<NameOfSubstance UI="C112765">tanespimycin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016227">Benzoquinones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055551">HSP27 Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018841">HSP90 Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047029">Lactams, Macrocyclic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">HSP27</Keyword>
<Keyword MajorTopicYN="N">gene therapy</Keyword>
<Keyword MajorTopicYN="N">glioblastoma</Keyword>
<Keyword MajorTopicYN="N">molecular chaperones</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202075</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.</ArticleTitle>
<Pagination>
<MedlinePgn>4929-37</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world. While the incidence of HNSCC associated with tobacco and alcohol abuse is falling, the incidence of HNSCC associated with human papilloma virus (HPV) is rising. Proliferation, cell migration and formation of metastases are dependent on interactions between the tumor cells, tumor stromal cells and the extracellular matrix (ECM). Degradation of the ECM is a crucial step in the process of local tumor infiltration and formation of locoregional and distant metastases. Matrix metalloproteinases (MMPs) are a family of enzymes that are able to degrade the ECM. Locally advanced HNSCC with cervical node metastases are treated with docetaxel in induction chemotherapy (ICT) combined with platinum-based chemotherapy and 5-fluorouracil (5-FU) as standard clinical anti-neoplastic regimens. This study evaluated the expression of MMP-14 and MMP-2 in HPV-positive (CERV196) and HPV-negative squamous cell carcinoma (HNSCC 11A and 14C) and the alteration of expression levels after exposure to either docetaxel or 5-FU.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Tumor cells were exposed to 5-FU or docetaxel in concentrations of 1.0 and 5.0 μmol/ml. MMP-protein expression was evaluated by enzyme-linked immunosorbent assay (ELISA) after 2, 3, 5, 8 and 10 days of incubation.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Docetaxel exposure significantly decreased MMP-14 expression in HNSCC 11A and especially 14C but not in CERV196 apart from an apoptotic process. 5-FU had no significant effect on MMP-14 expression independent of the HPV-status. Significant alterations of MMP-2 could be detected in HNSCC 11A only.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although neither of the applied drugs were selective inhibitors of MMP-expression, surprisingly docetaxel significantly decreased MMP-14 in HNSCC 14C and 11A in this study. Interestingly, HPV-positive CERV196 was not sensitive to decreased MMP-14 or -2 expression following incubation with 5-FU or docetaxel.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Aderhold</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany christoph.aderhold@umm.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Umbreit</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Faber</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Birk</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sommer</LastName>
<ForeName>Jörg Ulrich</ForeName>
<Initials>JU</Initials>
<AffiliationInfo>
<Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hörmann</LastName>
<ForeName>Karl</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schultz</LastName>
<ForeName>Johannes David</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>15H5577CQD</RegistryNumber>
<NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.24</RegistryNumber>
<NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.80</RegistryNumber>
<NameOfSubstance UI="D053511">Matrix Metalloproteinase 14</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C535575">Carcinoma, squamous cell of head and neck</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053511">Matrix Metalloproteinase 14</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020778">Matrix Metalloproteinase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043823">Taxoids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">MMP-14</Keyword>
<Keyword MajorTopicYN="N">MMP-2</Keyword>
<Keyword MajorTopicYN="N">docetaxel</Keyword>
<Keyword MajorTopicYN="N">fluorouracil</Keyword>
<Keyword MajorTopicYN="N">head and neck squamous cell carcinoma</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202076</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Microarray analysis of gene expression in lung cancer cell lines treated by fractionated irradiation.</ArticleTitle>
<Pagination>
<MedlinePgn>4939-48</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To identify differentially expressed genes between parent and radioresistant lung cancer cell lines established by fractionated irradiation.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Lung cancer cell lines (A549, NCI-H1650) were irradiated with several fractionation schemes. Clonogenic assays were used to identify radioresistant cell lines. We compared the gene expression profiles on a cDNA microarray.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Four established cell (A549-2G, A549-5G, H1650-2G and H1650-5G) were shown to be radioresistant (p≤0.05). Seventy-two genes were commonly altered in A549-G and 655 genes in H1650-G, compared to their parental cells. Genes in the wingless-type MMTV integration site family (WNT) signaling pathway were the ones most frequently altered in both A549-G and H1650-G cells. Those involved in inflammation; integrin, platelet-derived growth factor (PDGF), interleukin, transforming growth factor-beta (TGFB), epidermal growth factor receptor (EGFR) signaling, were commonly altered in radioresistant H1650 sublines.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The major gene expression changes during irradiation are related to WNT signaling pathway.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Sung-Ja</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Chan</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Chonnam National University Medical School, Gwangju, Republic of Korea cchoi@chonnam.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Yoo-Duk</ForeName>
<Initials>YD</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Young-Chul</ForeName>
<Initials>YC</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Kyu-Sik</ForeName>
<Initials>KS</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>In-Jae</ForeName>
<Initials>IJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ban</LastName>
<ForeName>Hee-Jung</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoon</LastName>
<ForeName>Mee-Sun</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>Taek-Keun</ForeName>
<Initials>TK</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jeong</LastName>
<ForeName>Jae-Uk</ForeName>
<Initials>JU</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Joo-Young</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chung</LastName>
<ForeName>Woong-Ki</ForeName>
<Initials>WK</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016000">Cluster Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019583">Dose Fractionation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004307">Dose-Response Relationship, Radiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011836">Radiation Tolerance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
<Keyword MajorTopicYN="N">cDNA miroarrays</Keyword>
<Keyword MajorTopicYN="N">fractionated irradiation</Keyword>
<Keyword MajorTopicYN="N">radioresistance</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202081</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1791-7530</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Anticancer research</Title>
<ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Equol induces mitochondria-mediated apoptosis of human cervical cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4985-92</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The present study aimed to investigate anticancer properties of equol and demonstrate its underlying mechanisms of action in human cervical cancer HeLa cells.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Inhibition of cell viability was examined by 3-(4,5-dimethylthiazoly-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was evaluated by observation of apoptotic cell morphology, and an increase of annexin-V(+) cells. Western blotting was used to examine apoptosis-related proteins. Flow cytometry was used to measure mitochondrial membrane potential (MMP) and reactive oxygen species (ROS).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Equol treatment inhibited HeLa cell proliferation in dose- and time-dependent manner. Equol-induced apoptotic cell death was accompanied by the activation of caspases, and alteration of MMP and mitochondrial membrane proteins; equol also rapidly triggered ROS production. Pre-treatment with N-acetylcysteine blocked loss of MMP, caused increase of Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, caspase-8 activation, and apoptosis induced by equol.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Equol is a potential anticancer agent against HeLa, with possible mechanisms involved in ROS generation and mitochondrial membrane alteration.</AbstractText>
<CopyrightInformation>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Eun Young</ForeName>
<Initials>EY</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Jin Young</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Young-Ja</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>An Keun</ForeName>
<Initials>AK</Initials>
<AffiliationInfo>
<Affiliation>College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea akkim@sookmyung.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Greece</Country>
<MedlineTA>Anticancer Res</MedlineTA>
<NlmUniqueID>8102988</NlmUniqueID>
<ISSNLinking>0250-7005</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>531-95-3</RegistryNumber>
<NameOfSubstance UI="D060754">Equol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020169">Caspases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060754">Equol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002583">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Equol</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">caspase</Keyword>
<Keyword MajorTopicYN="N">cervical cancer cells</Keyword>
<Keyword MajorTopicYN="N">mitochondria</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25186190</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6750</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC biotechnology</Title>
<ISOAbbreviation>BMC Biotechnol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Identification of an antibody fragment specific for androgen-dependent prostate cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>81</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6750-14-81</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prostate cancer is the most-diagnosed non-skin cancer among males in the US, and the second leading cause of cancer-related death. Current methods of treatment and diagnosis are not specific for the disease. This work identified an antibody fragment that binds selectively to a molecule on the surface of androgen-dependent prostate cancer cells but not benign prostatic cells.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Antibody fragment identification was achieved using a library screening and enrichment strategy. A library of 109 yeast-displayed human non-immune antibody fragments was enriched for those that bind to androgen-dependent prostate cancer cells, but not to benign prostatic cells or purified prostate-specific membrane antigen (PSMA). Seven rounds of panning and fluorescence-activated cell sorting (FACS) screening yielded one antibody fragment identified from the enriched library. This molecule, termed HiR7.8, has a low-nanomolar equilibrium dissociation constant (Kd) and high specificity for androgen-dependent prostate cancer cells.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Antibody fragment screening from a yeast-displayed library has yielded one molecule with high affinity and specificity. With further pre-clinical development, it is hoped that the antibody fragment identified using this screening strategy will be useful in the specific detection of prostate cancer and in targeted delivery of therapeutic agents for increased efficacy and reduced side effects.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Williams</LastName>
<ForeName>Ryan M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hajiran</LastName>
<ForeName>Cyrus J</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nayeem</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sooter</LastName>
<ForeName>Letha J</ForeName>
<Initials>LJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Basic Pharmaceutical Sciences, West Virginia University, 1 Medical Center Drive, PO Box 9530, Morgantown, WV 26506, USA. lsooter@hsc.wvu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P20 RR016440</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RR020866</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RR032138</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Biotechnol</MedlineTA>
<NlmUniqueID>101088663</NlmUniqueID>
<ISSNLinking>1472-6750</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007128">Immunoglobulin Fragments</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Drug Discov. 2006 Feb;5(2):147-59</RefSource>
<PMID Version="1">16424916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33</RefSource>
<PMID Version="1">16912265</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2006 Dec 8;244(2):274-88</RefSource>
<PMID Version="1">16500022</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Immunol. 2006;7:24</RefSource>
<PMID Version="1">17014727</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2006 Dec 29;281(52):40135-43</RefSource>
<PMID Version="1">17068330</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Apr 15;109(8):3393-9</RefSource>
<PMID Version="1">17164345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biotechnol Bioeng. 2007 Sep 1;98(1):39-47</RefSource>
<PMID Version="1">17657772</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2007 Sep 21;282(38):27659-65</RefSource>
<PMID Version="1">17644522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2007 Oct 1;67(19):9507-17</RefSource>
<PMID Version="1">17909061</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>World J Gastroenterol. 2005 Jul 14;11(26):3985-9</RefSource>
<PMID Version="1">15996020</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 2005 Sep;304(1-2):30-42</RefSource>
<PMID Version="1">16099466</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Chin Med J (Engl). 2011 Nov;124(22):3806-9</RefSource>
<PMID Version="1">22340245</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Transl Med. 2012 Mar 28;4(127):127rv3</RefSource>
<PMID Version="1">22461644</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 1999 Nov 17;91(22):1950-6</RefSource>
<PMID Version="1">10564679</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Treat Rev. 2000 Aug;26(4):287-90</RefSource>
<PMID Version="1">10913383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunol Today. 2000 Aug;21(8):397-402</RefSource>
<PMID Version="1">10916143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10701-5</RefSource>
<PMID Version="1">10984501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2000 Nov 1;60(21):6134-41</RefSource>
<PMID Version="1">11085537</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2001;19(1):24-36</RefSource>
<PMID Version="1">11209088</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Oncol. 2001 Nov;13(6):522-7</RefSource>
<PMID Version="1">11673694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Oncol. 2001 Aug;28(4 Suppl 15):3-7</RefSource>
<PMID Version="1">11685722</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2001 Oct;1(1):34-45</RefSource>
<PMID Version="1">11900250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2002 Jun;23(6):967-75</RefSource>
<PMID Version="1">12082018</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Genet Cytogenet. 2002 Dec;139(2):115-25</RefSource>
<PMID Version="1">12550771</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Biotechnol. 2003 Feb;21(2):163-70</RefSource>
<PMID Version="1">12536217</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 2003 Mar 1;274(1-2):185-97</RefSource>
<PMID Version="1">12609544</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 2004 Mar;35(3):290-7</RefSource>
<PMID Version="1">15017584</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2004 Aug 1;64(15):5311-21</RefSource>
<PMID Version="1">15289337</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 1978 Mar 15;21(3):274-81</RefSource>
<PMID Version="1">631930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest Urol. 1979 Jul;17(1):16-23</RefSource>
<PMID Version="1">447482</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1983 Apr;43(4):1809-18</RefSource>
<PMID Version="1">6831420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 1986 May;17(5):501-13</RefSource>
<PMID Version="1">2422108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1989 Dec 8;246(4935):1275-81</RefSource>
<PMID Version="1">2531466</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 1993 Feb 1;71(3 Suppl):1098-109</RefSource>
<PMID Version="1">7679039</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1993 Mar 1;53(5):1037-42</RefSource>
<PMID Version="1">8094996</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24</RefSource>
<PMID Version="1">7535634</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Dec 20;450(7173):1235-9</RefSource>
<PMID Version="1">18097410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 1995 Nov 23;333(21):1401-5</RefSource>
<PMID Version="1">7477122</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Biol. 1996 Jan 12;255(1):28-43</RefSource>
<PMID Version="1">8568873</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Bacteriol. 1996 Mar;178(5):1341-6</RefSource>
<PMID Version="1">8631711</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 1997 Feb 28;201(2):223-31</RefSource>
<PMID Version="1">9050944</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Biotechnol. 1997 Jun;15(6):553-7</RefSource>
<PMID Version="1">9181578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Chem Soc. 2008 Jul 16;130(28):9137-43</RefSource>
<PMID Version="1">18558676</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2009 Mar 26;360(13):1351-4</RefSource>
<PMID Version="1">19297564</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Nucl Med. 2009 Apr;50(4):606-11</RefSource>
<PMID Version="1">19289418</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Chem Biol. 2009 Jun;13(3):235-44</RefSource>
<PMID Version="1">19414278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Med. 2009;60:139-51</RefSource>
<PMID Version="1">18947298</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncol Rep. 2009 Dec;22(6):1451-8</RefSource>
<PMID Version="1">19885599</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Front Biosci (Schol Ed). 2010;2:677-84</RefSource>
<PMID Version="1">20036976</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2010 Feb;28(2):344-56</RefSource>
<PMID Version="1">20020426</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Drug Deliv Rev. 2010 Mar 8;62(3):284-304</RefSource>
<PMID Version="1">19909778</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Nucl Med. 2010 Mar;51(3):427-32</RefSource>
<PMID Version="1">20150269</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Soc Trans. 1997 May;25(2):715-7</RefSource>
<PMID Version="1">9191189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 1997 Jun;18(6):1215-23</RefSource>
<PMID Version="1">9214605</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1998 Feb 1;58(3):485-90</RefSource>
<PMID Version="1">9458094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1998 Mar 1;58(5):991-6</RefSource>
<PMID Version="1">9500461</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2902-7</RefSource>
<PMID Version="1">9501188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Cancer. 1998 Jul;78(2):181-8</RefSource>
<PMID Version="1">9683291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1998 Aug 15;58(16):3732-5</RefSource>
<PMID Version="1">9721886</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 1997 Jan;3(1):81-5</RefSource>
<PMID Version="1">9815541</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS J. 2010 May;277(10):2291-303</RefSource>
<PMID Version="1">20423457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Appl Microbiol Biotechnol. 2010 Dec;88(6):1385-91</RefSource>
<PMID Version="1">20878322</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Jan 15;71(2):484-95</RefSource>
<PMID Version="1">21224349</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2011 Jun;121(6):2383-90</RefSource>
<PMID Version="1">21555850</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Intern Med. 2011 Dec 6;155(11):762-71</RefSource>
<PMID Version="1">21984740</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Electrophoresis. 2012 Mar;33(5):866-9</RefSource>
<PMID Version="1">22522541</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Intern Med. 2012 Apr 23;172(8):668-70</RefSource>
<PMID Version="1">22529237</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Intern Med. 2012 Jul 17;157(2):120-34</RefSource>
<PMID Version="1">22801674</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29</RefSource>
<PMID Version="1">24399786</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Q J Nucl Med. 1998 Dec;42(4):225-41</RefSource>
<PMID Version="1">9973838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Oncol. 1999 Jun;14(6):1185-95</RefSource>
<PMID Version="1">10339677</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 2005 Jan;296(1-2):159-70</RefSource>
<PMID Version="1">15680160</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>CA Cancer J Clin. 2005 Sep-Oct;55(5):300-18; quiz 323-5</RefSource>
<PMID Version="1">16166075</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000915">Antibody Affinity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D000918">Antibody Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007128">Immunoglobulin Fragments</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4158339</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24814201</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-8673</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>191</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of surgical research</Title>
<ISOAbbreviation>J. Surg. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>379-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jss.2014.04.016</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0022-4804(14)00370-9</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although papillary thyroid carcinoma (PTC) has favorable prognosis, it is prone to cervical lymph node metastasis. Chemokine receptors play a role in metastasis of tumor cells, and accumulating evidence suggests an important role for the chemokine receptor CXCR7 in cancer development. We previously demonstrated high expression of CXCR7 protein in PTC tissue. In this study, we further evaluated the role of CXCR7 in PTC.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The expression of CXCR7 messenger RNA and protein in 79 cases of PTC and peritumoral tissues was detected by real-time quantitative polymerase chain reaction and Western blot. The association between CXCR7 expression and clinicopathologic characteristics in PTC was analyzed. Stable CXCR7 overexpression and knockdown PTC cells were constructed and used to examine proliferation, cell cycle, apoptosis and invasion of PTC cells by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, propidium iodide staining, 7-amino-actinomycin D staining, and invasion assay. We examined cell cycle regulatory protein levels by Western blot.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">CXCR7 messenger RNA and protein levels were markedly increased in PTC and correlated with tumor progression. CXCR7 could regulate proliferation, cell cycle, apoptosis, invasion, and the expression of cell cycle regulatory proteins involved in the S-G2 phase transition. Knockdown of CXCR7 in PTC cells suppressed cell proliferation and invasion, decreased expression of cyclin A, CDK2 and PCNA, increased expression of p21 and p57, induced S phase arrest, and promoted apoptosis.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CXCR7 plays an important role in regulating growth and metastasis ability of PTC cell and provides a potential target for therapeutic interventions in PTC.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Zhen</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Affiliated Shengjing Hospital, China Medical University, Shenyang, China. Electronic address: liuz@sj-hospital.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Lei</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Teng</LastName>
<ForeName>Xuyong</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Affiliated Shengjing Hospital, China Medical University, Shenyang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hengwei</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Affiliated Shengjing Hospital, China Medical University, Shenyang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guan</LastName>
<ForeName>Haixia</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Endocrinology, First Affiliated Hospital, China Medical University, Shenyang, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Surg Res</MedlineTA>
<NlmUniqueID>0376340</NlmUniqueID>
<ISSNLinking>0022-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C501896">CXCR7 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054387">Receptors, CXCR</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C536915">Thyroid cancer, papillary</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002277">Carcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054377">Chemokine CXCL12</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054387">Receptors, CXCR</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CXCR7</Keyword>
<Keyword MajorTopicYN="N">Chemokine receptor</Keyword>
<Keyword MajorTopicYN="N">Invasion</Keyword>
<Keyword MajorTopicYN="N">Proliferation</Keyword>
<Keyword MajorTopicYN="N">Thyroid neoplasms</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24996256</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-8673</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>191</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of surgical research</Title>
<ISOAbbreviation>J. Surg. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest.</ArticleTitle>
<Pagination>
<MedlinePgn>280-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jss.2014.05.083</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0022-4804(14)00546-0</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hepatocellular carcinoma (HCC) is commonly diagnosed at an advanced stage and has limited effective treatment options. The aberrant regulation of the phosphoinositide 3-kinase/Akt pathway in HCC makes it an attractive therapeutic target. The effect of MK2206, a novel, allosteric Akt inhibitor, on HCC cells is not yet fully understood. We hypothesized that inhibition of Akt by MK2206 would impact cellular viability.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Human Huh7, Hep3B, and HepG2 cell lines were treated with 0-2 μM of MK2206 for 96 h. Cell viability was determined by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Western blot analysis was used to examine the expression level of various protein markers to assess the mechanism of drug action and proliferation inhibition.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed a reduction in cellular viability by ≥55% for all cell lines (control versus 2 μM MK2206; P &lt;0.001). Western blot analysis revealed reduction in the level of phosphorylated AKT-Ser473 with no change in AKT-thr308 expression confirming the specificity of MK2206. There was an observed reduction in caspase-9 and survivin. Importantly, there were increases in p21 and p27 along with decreased cyclinD1 expression after treatment.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates the anti-tumor activity of MK2206 in HCC cells. The observed reduction in survivin and pro-caspase 9 suggests that MK2206 induces apoptosis. However, HCC proliferation is also halted via induction of cell cycle arrest as indicated by the increase in p21 and p27 expression and decrease in cyclinD1. Importantly, the concentration needed to achieve growth inhibition in HCC is lower than that needed for other cancer types.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wilson</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Division of Surgical Oncology, Department of Surgery, Translational and Biomedical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kunnimalaiyaan</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Surgical Oncology, Department of Surgery, Translational and Biomedical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gamblin</LastName>
<ForeName>T C</ForeName>
<Initials>TC</Initials>
<AffiliationInfo>
<Affiliation>Division of Surgical Oncology, Department of Surgery, Translational and Biomedical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: tcgamblin@mcw.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kunnimalaiyaan</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Surgical Oncology, Department of Surgery, Translational and Biomedical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: mkunnima@mcw.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Surg Res</MedlineTA>
<NlmUniqueID>0376340</NlmUniqueID>
<ISSNLinking>0022-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C548887">MK 2206</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006575">Heterocyclic Compounds, 3-Ring</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Cell cycle arrest</Keyword>
<Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
<Keyword MajorTopicYN="N">MK2206</Keyword>
<Keyword MajorTopicYN="N">PI3K/Akt/mTOR</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031336</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules.</ArticleTitle>
<Pagination>
<MedlinePgn>11229-39</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00727-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Mammalian cells produce many proteins, such as IFITM3, ISG15, MxA, and viperin, that inhibit influenza A virus (IAV) infection. Here, we show that a new class of host protein, histone deacetylase 6 (HDAC6), inhibits IAV infection. We found that HDAC6-overexpressing cells release about 3-fold less IAV progeny, whereas HDAC6-depleted cells release about 6-fold more IAV progeny. The deacetylase activity of HDAC6 played a role in its anti-IAV function as tubacin, a specific small-molecule inhibitor of HDAC6, increased the release of IAV progeny in a dose-dependent manner. Further, as visualized by electron microscopy, tubacin-treated cells showed an increase in IAV budding at the plasma membrane, the site of IAV assembly. Tubacin is a domain-specific inhibitor and binds to one of the two HDAC6 catalytic domains possessing tubulin deacetylase activity. This indicated the potential involvement of acetylated microtubules in the trafficking of viral components to the plasma membrane. Indeed, as quantified by flow cytometry, there was about a 2.0- to 2.5-fold increase and about a 2.0-fold decrease in the amount of viral envelope protein hemagglutinin present on the plasma membrane of tubacin-treated/HDAC6-depleted and HDAC6-overexpressing cells, respectively. In addition, the viral ribonucleoprotein complex was colocalized with acetylated microtubule filaments, and viral nucleoprotein coimmunoprecipitated with acetylated tubulin. Together, our findings indicate that HDAC6 is an anti-IAV host factor and exerts its anti-IAV function by negatively regulating the trafficking of viral components to the host cell plasma membrane via its substrate, acetylated microtubules.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Host cells produce many proteins that have the natural ability to restrict influenza virus infection. Here, we discovered that another host protein, histone deacetylase 6 (HDAC6), inhibits influenza virus infection. We demonstrate that HDAC6 exerts its anti-influenza virus function by negatively regulating the trafficking of viral components to the site of influenza virus assembly via its substrate, acetylated microtubules. HDAC6 is a multisubstrate enzyme and regulates multiple cellular pathways, including the ones leading to various cancers, neurodegenerative diseases, and inflammatory disorders. Therefore, several drugs targeting HDAC6 are under clinical development for the treatment of a wide range of diseases. Influenza virus continues to be a major global public health problem due to regular emergence of drug-resistant and novel influenza virus strains in humans. As an alternative antiviral strategy, HDAC6 modulators could be employed to stimulate the anti-influenza virus potential of endogenous HDAC6 to inhibit influenza virus infection.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Husain</LastName>
<ForeName>Matloob</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand matloob.husain@otago.ac.nz.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cheung</LastName>
<ForeName>Chen-Yi</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000813">Anilides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C474316">tubacin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="C433811">HDAC6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000107">Acetylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000813">Anilides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056572">Histone Deacetylase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006877">Hydroxamic Acids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053118">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061985">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008870">Microtubules</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012261">Ribonucleoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014771">Virion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057074">Virus Release</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178787 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031339</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.</ArticleTitle>
<Pagination>
<MedlinePgn>11166-77</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01785-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">The EBNA1 protein of Epstein-Barr virus (EBV) plays multiple roles in EBV latent infection, including altering cellular pathways relevant for cancer. Here we used microRNA (miRNA) cloning coupled with high-throughput sequencing to identify the effects of EBNA1 on cellular miRNAs in two nasopharyngeal carcinoma cell lines. EBNA1 affected a small percentage of cellular miRNAs in both cell lines, in particular, upregulating multiple let-7 family miRNAs, including let-7a. The effects of EBNA1 on let-7a were verified by demonstrating that EBNA1 silencing in multiple EBV-positive carcinomas downregulated let-7a. Accordingly, the let-7a target, Dicer, was found to be partially downregulated by EBNA1 expression (at the mRNA and protein levels) and upregulated by EBNA1 silencing in EBV-positive cells. Reporter assays based on the Dicer 3' untranslated region with and without let-7a target sites indicated that the effects of EBNA1 on Dicer were mediated by let-7a. EBNA1 was also found to induce the expression of let-7a primary RNAs in a manner dependent on the EBNA1 transcriptional activation region, suggesting that EBNA1 induces let-7a by transactivating the expression of its primary transcripts. Consistent with previous reports that Dicer promotes EBV reactivation, we found that a let-7a mimic inhibited EBV reactivation to the lytic cycle, while a let-7 sponge increased reactivation. The results provide a mechanism by which EBNA1 could promote EBV latency by inducing let-7 miRNAs.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The EBNA1 protein of Epstein-Barr virus (EBV) contributes in multiple ways to the latent mode of EBV infection that leads to lifelong infection. In this study, we identify a mechanism by which EBNA1 helps to maintain EBV infection in a latent state. This involves induction of a family of microRNAs (let-7 miRNAs) that in turn decreases the level of the cellular protein Dicer. We demonstrate that let-7 miRNAs inhibit the reactivation of latent EBV, providing an explanation for our previous observation that EBNA1 promotes latency. In addition, since decreased levels of Dicer have been associated with metastatic potential, EBNA1 may increase metastases by downregulating Dicer.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mansouri</LastName>
<ForeName>Sheila</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Qun</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Banting and Best Department of Medical Research and Donnelly Centre, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blencowe</LastName>
<ForeName>Benjamin J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada Banting and Best Department of Medical Research and Donnelly Centre, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Claycomb</LastName>
<ForeName>Julie M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Frappier</LastName>
<ForeName>Lori</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Canada lori.frappier@utoronto.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>12477</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C417029">EBV-encoded nuclear antigen 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019309">Epstein-Barr Virus Nuclear Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C487931">mirnlet7 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.13.12.-</RegistryNumber>
<NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="C408087">DICER1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.26.3</RegistryNumber>
<NameOfSubstance UI="D043244">Ribonuclease III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019309">Epstein-Barr Virus Nuclear Antigens</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017930">Genes, Reporter</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004854">Herpesvirus 4, Human</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008156">Luciferases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043244">Ribonuclease III</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017735">Virus Latency</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178782 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031343</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Phosphorylation of hepatitis C virus RNA polymerases ser29 and ser42 by protein kinase C-related kinase 2 regulates viral RNA replication.</ArticleTitle>
<Pagination>
<MedlinePgn>11240-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01826-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Hepatitis C virus (HCV) nonstructural protein 5B (NS5B), an RNA-dependent RNA polymerase (RdRp), is the key enzyme for HCV RNA replication. We previously showed that HCV RdRp is phosphorylated by protein kinase C-related kinase 2 (PRK2). In the present study, we used biochemical and reverse-genetics approaches to demonstrate that HCV NS5B phosphorylation is crucial for viral RNA replication in cell culture. Two-dimensional phosphoamino acid analysis revealed that PRK2 phosphorylates NS5B exclusively at its serine residues in vitro and in vivo. Using in vitro kinase assays and mass spectrometry, we identified two phosphorylation sites, Ser29 and Ser42, in the Δ1 finger loop region that interacts with the thumb subdomain of NS5B. Colony-forming assays using drug-selectable HCV subgenomic RNA replicons revealed that preventing phosphorylation by Ala substitution at either Ser29 or Ser42 impairs HCV RNA replication. Furthermore, reverse-genetics studies using HCV infectious clones encoding phosphorylation-defective NS5B confirmed the crucial role of these PRK2 phosphorylation sites in viral RNA replication. Molecular-modeling studies predicted that the phosphorylation of NS5B stabilizes the interactions between its Δ1 loop and thumb subdomain, which are required for the formation of the closed conformation of NS5B known to be important for de novo RNA synthesis. Collectively, our results provide evidence that HCV NS5B phosphorylation has a positive regulatory role in HCV RNA replication.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">While the role of RNA-dependent RNA polymerases (RdRps) in viral RNA replication is clear, little is known about their functional regulation by phosphorylation. In this study, we addressed several important questions about the function and structure of phosphorylated hepatitis C virus (HCV) nonstructural protein 5B (NS5B). Reverse-genetics studies with HCV replicons encoding phosphorylation-defective NS5B mutants and analysis of their RdRp activities revealed previously unidentified NS5B protein features related to HCV replication and NS5B phosphorylation. These attributes most likely reflect potential structural changes induced by phosphorylation in the Δ1 finger loop region of NS5B with two identified phosphate acceptor sites, Ser29 and Ser42, which may transiently affect the closed conformation of NS5B. Elucidating the effects of dynamic changes in NS5B phosphorylation status during viral replication and their impacts on RNA synthesis will improve our understanding of the molecular mechanisms of NS5B phosphorylation-mediated regulation of HCV replication.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Song-Hee</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Seong-Jun</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Eun-Jung</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Tae-Eun</ForeName>
<Initials>TE</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moon</LastName>
<ForeName>Jae-Su</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Geon-Woo</ForeName>
<Initials>GW</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Seung-Hoon</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Kun</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Mass Spectrometry Research, Korea Basic Science Institute, Ochang, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoo</LastName>
<ForeName>Jong Shin</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Division of Mass Spectrometry Research, Korea Basic Science Institute, Ochang, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Son</LastName>
<ForeName>Woo Sung</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacy, CHA University, Pocheon-si, Gyeonggi-do, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rhee</LastName>
<ForeName>Jin-Kyu</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>Western Seoul Center of Korea Basic Science Institute, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Seung Hyun</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Department of Oral Microbiology and Immunology, DRI, and BK21 Program, School of Dentistry, Seoul National University, Seoul, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>Jong-Won</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea jwoh@yonsei.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>PDB</DataBankName>
<AccessionNumberList>
<AccessionNumber>1GX5</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>452VLY9402</RegistryNumber>
<NameOfSubstance UI="D012694">Serine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.48</RegistryNumber>
<NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016174">Hepacivirus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011493">Protein Kinase C</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017433">Protein Structure, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012324">RNA Replicase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012694">Serine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017361">Viral Nonstructural Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178806 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031344</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Annexin V incorporated into influenza virus particles inhibits gamma interferon signaling and promotes viral replication.</ArticleTitle>
<Pagination>
<MedlinePgn>11215-28</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01405-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">During the budding process, influenza A viruses (IAVs) incorporate multiple host cell membrane proteins. However, for most of them, their significance in viral morphogenesis and infectivity remains unknown. We demonstrate here that the expression of annexin V (A5) is upregulated at the cell surface upon IAV infection and that a substantial proportion of the protein is present in lipid rafts, the site of virus budding. Western blotting and immunogold analysis of highly purified IAV particles showed the presence of A5 in the virion. Significantly, gamma interferon (IFN-γ)-induced Stat phosphorylation and IFN-γ-induced 10-kDa protein (IP-10) production in macrophage-derived THP-1 cells was inhibited by purified IAV particles. Disruption of the IFN-γ signaling pathway was A5 dependent since downregulation of its expression or its blockage reversed the inhibition and resulted in decreased viral replication in vitro. The functional significance of these results was also observed in vivo. Thus, IAVs can subvert the IFN-γ antiviral immune response by incorporating A5 into their envelope during the budding process.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Many enveloped viruses, including influenza A viruses, bud from the plasma membrane of their host cells and incorporate cellular surface proteins into viral particles. However, for the vast majority of these proteins, only the observation of their incorporation has been reported. We demonstrate here that the host protein annexin V is specifically incorporated into influenza virus particles during the budding process. Importantly, we showed that packaged annexin V counteracted the antiviral activity of gamma interferon in vitro and in vivo. Thus, these results showed that annexin V incorporated in the viral envelope of influenza viruses allow viral escape from immune surveillance. Understanding the role of host incorporated protein into virions may reveal how enveloped RNA viruses hijack the host cell machinery for their own purposes.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Berri</LastName>
<ForeName>Fatma</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Haffar</LastName>
<ForeName>Ghina</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lê</LastName>
<ForeName>Vuong Ba</ForeName>
<Initials>VB</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sadewasser</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paki</LastName>
<ForeName>Katharina</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lina</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wolff</LastName>
<ForeName>Thorsten</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Riteau</LastName>
<ForeName>Béatrice</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>VirPath, EMR4610 Virologie et Pathologie Humaine, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France INRA, Tours, France beatrice.riteau@laposte.net.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017304">Annexin A5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C114753">CXCL10 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017304">Annexin A5</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054357">Chemokine CXCL10</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009980">Influenza A virus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061985">Madin Darby Canine Kidney Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021962">Membrane Microdomains</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050791">STAT Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014771">Virion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057074">Virus Release</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178827 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031347</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Seed sequence-matched controls reveal limitations of small interfering RNA knockdown in functional and structural studies of hepatitis C virus NS5A-MOBKL1B interaction.</ArticleTitle>
<Pagination>
<MedlinePgn>11022-33</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01582-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Hepatitis C virus (HCV) is a widespread human pathogen causing liver cirrhosis and cancer. Similar to the case for other viruses, HCV depends on host and viral factors to complete its life cycle. We used proteomic and yeast two-hybrid approaches to elucidate host factors involved in HCV nonstructural protein NS5A function and found that MOBKL1B interacts with NS5A. Initial experiments with small interfering RNA (siRNA) knockdown suggesting a role in HCV replication led us to examine the interaction using biochemical and structural approaches. As revealed by a cocrystal structure of a core MOBKL1B-NS5A peptide complex at 1.95 Å, NS5A binds to a hydrophobic patch on the MOBKL1B surface. Biosensor binding assays identified a highly conserved, 18-amino-acid binding site in domain II of NS5A, which encompasses residues implicated in cyclophilin A (CypA)-dependent HCV RNA replication. However, a CypA-independent HCV variant had reduced replication in MOBKL1B knockdown cells, even though its NS5A does not interact with MOBKL1B. These discordant results prompted more extensive studies of MOBKL1B gene knockdowns, which included additional siRNAs and specifically matched seed sequence siRNA controls. We found that reduced virus replication after treating cells with MOBKL1B siRNA was actually due to off-target inhibition, which indicated that the initial finding of virus replication dependence on the MOBKL1B-NS5A interaction was incorrect. Ultimately, using several approaches, we found no relationship of the MOBKL1B-NS5A interaction to virus replication. These findings collectively serve as a reminder to investigators and scientific reviewers of the pervasive impact of siRNA off-target effects on interpretation of biological data.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Our study illustrates an underappreciated shortcoming of siRNA gene knockdown technology. We initially identified a cellular protein, MOBKL1B, as a binding partner with the NS5A protein of hepatitis C virus (HCV). MOBKL1B siRNA, but not irrelevant RNA, treatment was associated with both reduced virus replication and the absence of MOBKL1B. Believing that HCV replication depended on the MOBKL1B-NS5A interaction, we carried out structural and biochemical analyses. Unexpectedly, an HCV variant lacking the MOBKL1B-NS5A interaction could not replicate after cells were treated with MOBKL1B siRNA. By repeating the MOBKL1B siRNA knockdowns and including seed sequence-matched siRNA instead of irrelevant siRNA as a control, we found that the MOBKL1B siRNAs utilized had off-target inhibitory effects on virus replication. Collectively, our results suggest that stricter controls must be utilized in all RNA interference (RNAi)-mediated gene knockdown experiments to ensure sound conclusions and a reliable scientific knowledge database.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chung</LastName>
<ForeName>Hyo-Young</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gu</LastName>
<ForeName>Meigang</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Buehler</LastName>
<ForeName>Eugen</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>MacDonald</LastName>
<ForeName>Margaret R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rice</LastName>
<ForeName>Charles M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA ricec@mail.rockefeller.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01CA057973</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C496256">MOB1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016477">Artifacts</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016174">Hepacivirus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062105">Molecular Docking Simulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054730">Protein Interaction Domains and Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025941">Protein Interaction Mapping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017361">Viral Nonstructural Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178819 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25031355</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A virulent bioluminescent and fluorescent dual-reporter Marek's disease virus unveils an alternative spreading pathway in addition to cell-to-cell contact.</ArticleTitle>
<Pagination>
<MedlinePgn>11617-23</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01482-14</ELocationID>
<Abstract>
<AbstractText>Marek's disease virus (MDV) is a growing threat for the poultry industry. Unfortunately, despite successful vaccination against the disease, MDV remains in circulation within vaccinated flocks, leading to the selection of increasingly virulent pathotypes. Detailed knowledge of the virus biology and the host-virus interaction is required to improve the vaccine efficiency. In the present study, I engineered an original, dual-reporter MDV to track and quantify virus replication in vitro and in vivo. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Harmache</LastName>
<ForeName>Abdallah</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institut National de la Recherche Agronomique (INRA), Centre Val de Loire, Nouzilly, France Université François Rabelais, UMR1282 Infectiologie et Santé Publique, Tours, France abdallah.harmache@tours.inra.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-22-9</RegistryNumber>
<NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.13.12.-</RegistryNumber>
<NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002645">Chickens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017930">Genes, Reporter</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016679">Genome, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049452">Green Fluorescent Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008381">Herpesvirus 2, Gallid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008156">Luciferases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008163">Luminescent Measurements</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008380">Marek Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008856">Microscopy, Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016865">Reassortant Viruses</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013552">Swine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052700">Teschovirus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014774">Virulence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178790 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25056895</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Characterization of the mode of action of a potent dengue virus capsid inhibitor.</ArticleTitle>
<Pagination>
<MedlinePgn>11540-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01745-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Dengue viruses (DV) represent a significant global health burden, with up to 400 million infections every year and around 500,000 infected individuals developing life-threatening disease. In spite of attempts to develop vaccine candidates and antiviral drugs, there is a lack of approved therapeutics for the treatment of DV infection. We have previously reported the identification of ST-148, a small-molecule inhibitor exhibiting broad and potent antiviral activity against DV in vitro and in vivo (C. M. Byrd et al., Antimicrob. Agents Chemother. 57:15-25, 2013, doi:10 .1128/AAC.01429-12). In the present study, we investigated the mode of action of this promising compound by using a combination of biochemical, virological, and imaging-based techniques. We confirmed that ST-148 targets the capsid protein and obtained evidence of bimodal antiviral activity affecting both assembly/release and entry of infectious DV particles. Importantly, by using a robust bioluminescence resonance energy transfer-based assay, we observed an ST-148-dependent increase of capsid self-interaction. These results were corroborated by molecular modeling studies that also revealed a plausible model for compound binding to capsid protein and inhibition by a distinct resistance mutation. These results suggest that ST-148-enhanced capsid protein self-interaction perturbs assembly and disassembly of DV nucleocapsids, probably by inducing structural rigidity. Thus, as previously reported for other enveloped viruses, stabilization of capsid protein structure is an attractive therapeutic concept that also is applicable to flaviviruses.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Dengue viruses are arthropod-borne viruses representing a significant global health burden. They infect up to 400 million people and are endemic to subtropical and tropical areas of the world. Currently, there are neither vaccines nor approved therapeutics for the prophylaxis or treatment of DV infections, respectively. This study reports the characterization of the mode of action of ST-148, a small-molecule capsid inhibitor with potent antiviral activity against all DV serotypes. Our results demonstrate that ST-148 stabilizes capsid protein self-interaction, thereby likely perturbing assembly and disassembly of viral nucleocapsids by inducing structural rigidity. This, in turn, might interfere with the release of viral RNA from incoming nucleocapsids (uncoating) as well as assembly of progeny virus particles. As previously reported for other enveloped viruses, we propose the capsid as a novel tractable target for flavivirus inhibitors.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Scaturro</LastName>
<ForeName>Pietro</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Trist</LastName>
<ForeName>Iuni Margaret Laura</ForeName>
<Initials>IM</Initials>
<AffiliationInfo>
<Affiliation>School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paul</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Anil</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Acosta</LastName>
<ForeName>Eliana G</ForeName>
<Initials>EG</Initials>
<AffiliationInfo>
<Affiliation>Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Byrd</LastName>
<ForeName>Chelsea M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>SIGA Technologies, Inc., Corvallis, Oregon, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jordan</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>SIGA Technologies, Inc., Corvallis, Oregon, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brancale</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bartenschlager</LastName>
<ForeName>Ralf</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany German Center for Infection Research, Heidelberg, Germany ralf.bartenschlager@med.uni-heidelberg.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>PDB</DataBankName>
<AccessionNumberList>
<AccessionNumber>1R6R</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C581551">ST-148</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013830">Thiadiazoles</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002213">Capsid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D036022">Capsid Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002522">Cercopithecus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006224">Cricetinae</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018360">Crystallography, X-Ray</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003716">Dengue Virus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006575">Heterocyclic Compounds, 3-Ring</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062105">Molecular Docking Simulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016415">Sequence Alignment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013830">Thiadiazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014709">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014771">Virion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019065">Virus Assembly</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053586">Virus Internalization</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057074">Virus Release</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178822 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25078688</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Murine gammaherpesvirus 68 reactivation from B cells requires IRF4 but not XBP-1.</ArticleTitle>
<Pagination>
<MedlinePgn>11600-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01876-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Gammaherpesviruses display tropism for B cells and, like all known herpesviruses, exhibit distinct lytic and latent life cycles. One well-established observation among members of the gammaherpesvirus family is the link between viral reactivation from latently infected B cells and plasma cell differentiation. Importantly, a number of studies have identified a potential role for a CREB/ATF family member, X-box binding protein 1 (XBP-1), in trans-activating the immediate early BZLF-1 or BRLF1/gene 50 promoters of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), respectively. XBP-1 is required for the unfolded protein response and has been identified as a critical transcription factor in plasma cells. Here, we demonstrate that XBP-1 is capable of trans-activating the murine gammaherpesvirus 68 (MHV68) RTA promoter in vitro, consistent with previous observations for EBV and KSHV. However, we show that in vivo there does not appear to be a requirement for XBP-1 expression in B cells for virus reactivation. The MHV68 M2 gene product under some experimental conditions plays an important role in virus reactivation from B cells. M2 has been shown to drive B cell differentiation to plasma cells, as well as interleukin-10 (IL-10) production, both of which are dependent on M2 induction of interferon regulatory factor 4 (IRF4) expression. IRF4 is required for plasma cell differentiation, and consistent with a role for plasma cells in MHV68 reactivation from B cells, we show that IRF4 expression in B cells is required for efficient reactivation of MHV68 from splenocytes. Thus, the latter analyses are consistent with previous studies linking plasma cell differentiation to MHV68 reactivation from B cells. The apparent independence of MHV68 reactivation from XBP-1 expression in plasma cells may reflect redundancy among CREB/ATF family members or the involvement of other plasma cell-specific transcription factors. Regardless, these findings underscore the importance of in vivo studies in assessing the relevance of observations made in tissue culture models.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">All known herpesviruses establish a chronic infection of their respective host, persisting for the life of the individual. A critical feature of these viruses is their ability to reactivate from a quiescent form of infection (latency) and generate progeny virus. In the case of gammaherpesviruses, which are associated with the development of lymphoproliferative disorders, including lymphomas, reactivation from latently infected B lymphocytes occurs upon terminal differentiation of these cells to plasma cells-the cell type that produces antibodies. A number of studies have linked a plasma cell transcription factor, XBP-1, to the induction of gammaherpesvirus reactivation, and we show here that indeed in tissue culture models this cellular transcription factor can trigger expression of the murine gammaherpesvirus gene involved in driving virus reactivation. However, surprisingly, when we examined the role of XBP-1 in the setting of infection of mice-using mice that lack a functional XBP-1 gene in B cells-we failed to observe a role for XBP-1 in virus reactivation. However, we show that another cellular factor essential for plasma cell differentiation, IRF4, is critical for virus reactivation. Thus, these studies point out the importance of studies in animal models to validate findings from studies carried out in cell lines passaged in vitro.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Matar</LastName>
<ForeName>Caline G</ForeName>
<Initials>CG</Initials>
<AffiliationInfo>
<Affiliation>Microbiology and Molecular Genetics Graduate Program, Emory University, Atlanta, Georgia, USA Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rangaswamy</LastName>
<ForeName>Udaya Shankari</ForeName>
<Initials>US</Initials>
<AffiliationInfo>
<Affiliation>Microbiology and Molecular Genetics Graduate Program, Emory University, Atlanta, Georgia, USA Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wakeman</LastName>
<ForeName>Brian S</ForeName>
<Initials>BS</Initials>
<AffiliationInfo>
<Affiliation>Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, Georgia, USA Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwakoshi</LastName>
<ForeName>Neal</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Division of Transplantation, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Speck</LastName>
<ForeName>Samuel H</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, Georgia, USA Emory Vaccine Center, Emory University, Atlanta, Georgia, USA sspeck@emory.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577263">M2 protein, murine gammaherpesvirus 68</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C094531">interferon regulatory factor-4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C056311">regulatory factor X transcription factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006566">Herpesviridae Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050835">Interferon Regulatory Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010950">Plasma Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018144">Rhadinovirus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013154">Spleen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014764">Viral Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014775">Virus Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017735">Virus Latency</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178818 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25078689</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>88</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>AUF1 p45 promotes West Nile virus replication by an RNA chaperone activity that supports cyclization of the viral genome.</ArticleTitle>
<Pagination>
<MedlinePgn>11586-99</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01283-14</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">A central aspect of current virology is to define the function of cellular proteins (host factors) that support the viral multiplication process. This study aimed at characterizing cellular proteins that assist the RNA replication process of the prevalent human pathogen West Nile virus (WNV). Using in vitro and cell-based approaches, we defined the p45 isoform of AU-rich element RNA-binding protein 1 (AUF1) as a host factor that enables efficient WNV replication. It was demonstrated that AUF1 p45 has an RNA chaperone activity, which aids the structural rearrangement and cyclization of the WNV RNA that is required by the viral replicase to initiate RNA replication. The obtained data suggest the RNA chaperone activity of AUF1 p45 is an important determinant of the WNV life cycle.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">In this study, we identified a cellular protein, AUF1 (also known as heterogeneous ribonucleoprotein D [hnRNPD]), acting as a helper (host factor) of the multiplication process of the important human pathogen West Nile virus. Several different variants of AUF1 exist in the cell, and one variant, AUF1 p45, was shown to support viral replication most significantly. Interestingly, we obtained a set of experimental data indicating that a main function of AUF1 p45 is to modify and thus prepare the West Nile virus genome in such a way that the viral enzyme that generates progeny genomes is empowered to do this considerably more efficiently than in the absence of the host factor. The capability of AUF1 p45 to rearrange the West Nile virus genome was thus identified to be an important aspect of a West Nile virus infection.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Friedrich</LastName>
<ForeName>Susann</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry and Biotechnology (NFI), Martin Luther University Halle-Wittenberg, Halle, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schmidt</LastName>
<ForeName>Tobias</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry and Biotechnology (NFI), Martin Luther University Halle-Wittenberg, Halle, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Geissler</LastName>
<ForeName>René</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry and Biotechnology (NFI), Martin Luther University Halle-Wittenberg, Halle, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lilie</LastName>
<ForeName>Hauke</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry and Biotechnology (NFI), Martin Luther University Halle-Wittenberg, Halle, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chabierski</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Vaccine Technologies Unit, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ulbert</LastName>
<ForeName>Sebastian</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Vaccine Technologies Unit, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liebert</LastName>
<ForeName>Uwe G</ForeName>
<Initials>UG</Initials>
<AffiliationInfo>
<Affiliation>Institute of Virology, Leipzig University, Leipzig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Golbik</LastName>
<ForeName>Ralph P</ForeName>
<Initials>RP</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry and Biotechnology (NFI), Martin Luther University Halle-Wittenberg, Halle, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Behrens</LastName>
<ForeName>Sven-Erik</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry and Biotechnology (NFI), Martin Luther University Halle-Wittenberg, Halle, Germany sven.behrens@biochemtech.uni-halle.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034502">Heterogeneous-Nuclear Ribonucleoprotein D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C019551">RNA, circular</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C084508">hnRNP D0</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>63231-63-0</RegistryNumber>
<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D016679">Genome, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034502">Heterogeneous-Nuclear Ribonucleoprotein D</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018832">Molecular Chaperones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020033">Protein Isoforms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012313">RNA</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012367">RNA, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014902">West Nile virus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4178777 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25069723</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-0111</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>86</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular pharmacology</Title>
<ISOAbbreviation>Mol. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A axis during oxidative stress.</ArticleTitle>
<Pagination>
<MedlinePgn>450-62</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1124/mol.114.094318</ELocationID>
<Abstract>
<AbstractText>We investigated the regulation of mitochondrial poly(ADP-ribose) polymerase 1 (PARP1) by the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) system during oxidative stress in U937 monocytes. Oxidative stress induced an early (10 minutes) mitochondrial DNA damage, and concomitant activation of PARP1 in the mitochondria. These early events were followed by a progressive mitochondrial oxidant production and nuclear PARP1 activation (by 6 hours). These processes led to a functional impairment of mitochondria, culminating in cell death of mixed (necrotic/apoptotic) type. β-Adrenoceptor blockade with propranolol or inhibition of its downstream cAMP/PKA signaling attenuated, while β-adrenoceptor agonists and cAMP/PKA activators enhanced, the oxidant-mediated PARP1 activation. In the presence of cAMP, recombinant PKA directly phosphorylated recombinant PARP1 on serines 465 (in the automodification domain) and 782 and 785 (both in the catalytic domain). Inhibition of the β-adrenergic receptor/cAMP/PKA axis protected against the oxidant-mediated cell injury. Propranolol also suppressed PARP1 activation in peripheral blood leukocytes during bacterial lipopolysaccharide (LPS)-induced systemic inflammation in mice. We conclude that the activation of mitochondrial PARP1 is an early, active participant in oxidant-induced cell death, which is under the control of β-adrenoceptor/cAMP/PKA axis through the regulation of PARP1 activity by PARP1 phosphorylation. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Brunyanszki</LastName>
<ForeName>Attila</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Olah</LastName>
<ForeName>Gabor</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Coletta</LastName>
<ForeName>Ciro</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Szczesny</LastName>
<ForeName>Bartosz</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Szabo</LastName>
<ForeName>Csaba</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas szabocsaba@aol.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>GM060338</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Pharmacol</MedlineTA>
<NlmUniqueID>0035623</NlmUniqueID>
<ISSNLinking>0026-895X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011943">Receptors, Adrenergic, beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9Y8NXQ24VQ</RegistryNumber>
<NameOfSubstance UI="D011433">Propranolol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.11</RegistryNumber>
<NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000319">Adrenergic beta-Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017868">Cyclic AMP-Dependent Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004272">DNA, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007962">Leukocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024101">Mitochondrial Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018384">Oxidative Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011065">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011433">Propranolol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011943">Receptors, Adrenergic, beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4164979 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24596136</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Anticancer effects of baicalein on hepatocellular carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1342-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ptr.5135</ELocationID>
<Abstract>
<AbstractText>The therapeutic potential of baicalein against hepatoma cells was evaluated in vitro and in vivo. In cell viability assays, baicalein showed significant cytotoxicity against the hepatocellular carcinoma cell lines H22, Bel-7404, and Hep G2 and moderate cytotoxicity against immortalized human hepatocytes. Baicalein induced G0/G1-phase arrest in hepatocellular carcinoma cells, inhibited AKT, and promoted the degradation of β-catenin and cyclin D1 without activation of GSK-3β. Furthermore, baicalein significantly inhibited H22 xenograft tumor growth without causing obvious adverse effects on weight or liver and spleen weight indexes in ICR mice. Immunohistochemical analysis showed that the inhibition of tumor growth in baicalein-treated mice was associated with decreased AKT, β-catenin, and cyclin D1 expression ex vivo. Our data indicate that baicalein might regulate cyclin D1 transcription via a β-catenin-dependent mechanism, leading to cell cycle arrest at G0/G1 phase and impaired cancer cell proliferation. These results suggest that baicalein is a potential candidate for the treatment of hepatocellular carcinoma.</AbstractText>
<CopyrightInformation>Copyright © 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Yi-Hu</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Li-Hui</ForeName>
<Initials>LH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grahn</LastName>
<ForeName>Tan Hooi Min</ForeName>
<Initials>TH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ye</LastName>
<ForeName>Ai-Fang</ForeName>
<Initials>AF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Yan-Rong</ForeName>
<Initials>YR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Qi-Yu</ForeName>
<Initials>QY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530104">CCND1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495270">CTNNB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044950">Flavanones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>49QAH60606</RegistryNumber>
<NameOfSubstance UI="C006680">baicalein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C448280">glycogen synthase kinase 3 beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.26</RegistryNumber>
<NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044950">Flavanones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038362">Glycogen Synthase Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008813">Mice, Inbred ICR</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">baicalein</Keyword>
<Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword>
<Keyword MajorTopicYN="N">β-catenin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24633846</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>In vitro antitumoral activity of compounds isolated from Artemisia gorgonum Webb.</ArticleTitle>
<Pagination>
<MedlinePgn>1329-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ptr.5133</ELocationID>
<Abstract>
<AbstractText>Artemisia gorgonum (Asteraceae) is an endemic plant to the Cape Verde islands and plays an important role in traditional medicine. The chloroform extract of the plant aerial parts afforded six sesquiterpene lactones, two methoxylated flavonoids, two lignans, and one tetracyclic triterpene, which were isolated by chromatographic methods and their structure established by physical and spectroscopic techniques. The cytotoxic activity of the three major constituents, namely, arborescin, artemetin, and sesamin, was evaluated on neuroblastoma (SH-SY5Y), hepatocarcinoma (HepG2), and nontumoral bone marrow stromal (S17) cell lines. The application of different concentrations of the compounds significantly decreased tumor cells viability at different extents, especially at the highest concentrations tested. Arborescin is the most promising compound as it was able to reduce tumoral cell viability with an IC50 significantly lower (229-233 μM; p &lt; 0.01) than that of S17 cells (445 μM). Arborescin and artemetin were less toxic to nontumoral cells than the antitumoral drug tested, etoposide. Our results indicate that arborescin has a significant cytotoxic activity in vitro, more pronounced on the cancer cell lines, confirming A. gorgonum as a source of potential antitumoral molecules.</AbstractText>
<CopyrightInformation>Copyright © 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Martins</LastName>
<ForeName>Alice</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Departamento/Centro de Química e Bioquímica Faculdade de Ciências, Universidade de Lisboa, 1749-016, Lisboa, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mignon</LastName>
<ForeName>Rukmini</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bastos</LastName>
<ForeName>Marina</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Batista</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neng</LastName>
<ForeName>Nuno R</ForeName>
<Initials>NR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nogueira</LastName>
<ForeName>José M F</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vizetto-Duarte</LastName>
<ForeName>Catarina</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Custódio</LastName>
<ForeName>Luísa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Varela</LastName>
<ForeName>João</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rauter</LastName>
<ForeName>Amélia P</ForeName>
<Initials>AP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004149">Dioxoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017705">Lignans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045789">Sesquiterpenes, Guaiane</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592744">arborescin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>73KMT7R64H</RegistryNumber>
<NameOfSubstance UI="C054132">artemetin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>S7946O4P76</RegistryNumber>
<NameOfSubstance UI="C054125">sesamin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019306">Artemisia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004149">Dioxoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005419">Flavonoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017705">Lignans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035261">Plant Components, Aerial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045789">Sesquiterpenes, Guaiane</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Artemisia gorgonum</Keyword>
<Keyword MajorTopicYN="N">antitumor activity</Keyword>
<Keyword MajorTopicYN="N">arborescin</Keyword>
<Keyword MajorTopicYN="N">artemetin</Keyword>
<Keyword MajorTopicYN="N">sesamin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24638915</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Anti-metastatic effect of supercritical extracts from the Citrus hassaku pericarp via inhibition of C-X-C chemokine receptor type 4 (CXCR4) and matrix metalloproteinase-9 (MMP-9).</ArticleTitle>
<Pagination>
<MedlinePgn>1374-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ptr.5140</ELocationID>
<Abstract>
<AbstractText>The fruit of hassaku (Citrus hassaku Hort. ex Tanaka) is locally known as phalsak in Korea. Recently, the fruit extract has been known to exhibit in vivo preventive effects against UVB-induced pigmentation, antiallergic activity, and enhancement of blood fluidity. However, the exact mechanisms of how supercritical extracts of phalsak peel (SEPS) inhibits tumor metastasis and invasion are still not fully understood. We found that SEPS could downregulate the constitutive expression of both CXCR4 and HER2 in human breast cancer MDA-MB-231 cells as compared with other cells. SEPS also suppressed matrix metalloproteinase-9 (MMP-9) expression and its enzymatic activity under non-cytotoxic concentrations. Neither proteasome inhibition nor lysosomal stabilization had any effect on the SEPS-induced decrease in CXCR4 expression. A detailed study of the underlying molecular mechanisms revealed that the regulation of the downregulation of CXCR4 was at the transcriptional level, as indicated by downregulation of mRNA expression, suppression of NF-κB activity, and inhibition of chromatin immunoprecipitation activity. Suppression of CXCR4 expression by SEPS correlated with the inhibition of CXCL12-stimulated invasion of MDA-MB-231 cells. Overall, our results indicate, for the first time, that SEPS can suppress CXCR4 and MMP-9 expressions through blockade of NF-κB activation and thus has the potential to suppress metastasis of breast cancer.</AbstractText>
<CopyrightInformation>Copyright © 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chulwon</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine and Institute of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul, 130-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Dongmin</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>Dongwoo</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chung</LastName>
<ForeName>Won-Seok</ForeName>
<Initials>WS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Kyoo Seok</ForeName>
<Initials>KS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hoon</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Seung-Hoon</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shim</LastName>
<ForeName>Bum Sang</ForeName>
<Initials>BS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Somi K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Kwang Seok</ForeName>
<Initials>KS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C498143">RELA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051996">Transcription Factor RelA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.35</RegistryNumber>
<NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.35</RegistryNumber>
<NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002957">Citrus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005638">Fruit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020780">Matrix Metalloproteinase 9</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019718">Receptors, CXCR4</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051996">Transcription Factor RelA</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CXCR4</Keyword>
<Keyword MajorTopicYN="N">Citrus hassaku Hort. ex Tanaka</Keyword>
<Keyword MajorTopicYN="N">MMP-9</Keyword>
<Keyword MajorTopicYN="N">NF-κB</Keyword>
<Keyword MajorTopicYN="N">metastasis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25058043</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1879-3185</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>324</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology</Title>
<ISOAbbreviation>Toxicology</ISOAbbreviation>
</Journal>
<ArticleTitle>Mitochondrial proteomic analysis reveals the molecular mechanisms underlying reproductive toxicity of zearalenone in MLTC-1 cells.</ArticleTitle>
<Pagination>
<MedlinePgn>55-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tox.2014.07.007</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0300-483X(14)00140-1</ELocationID>
<Abstract>
<AbstractText>Zearalenone (ZEA), a Fusarium mycotoxin that contaminates cereal crops worldwide, has been shown to affect the male reproductive system and trigger reactive oxygen species (ROS) generation. However, the mechanisms of its toxicity have not been fully understood. Because mitochondrion is a key organelle involved in producing ROS and generating metabolic intermediates for biosynthesis, an iTRAQ-based mitoproteomics approach was employed to identify the molecular mechanism of zearalenone toxicity using mitochondria of mouse Leydig tumor cells (MLTC-1). A total of 2014 nonredundant proteins were identified, among which 1401 proteins (69.56%) were overlapped. There were 52 differentially expressed proteins in response to ZEA, and they were primarily involved in energy metabolism, molecular transport and endocrine-related functions. Consistent with mitochondrial proteomic analysis, the ATP and intracellular Ca(2+) levels increased after ZEA treatment. The results suggest that lipid metabolism changed significantly after low-dose ZEA exposure, resulting in two alterations. One is the increase in energy production through promoted fatty acid uptake and β-oxidation, along with excessive oxidative stress; the other is an inhibition of steroidogenesis and esterification, possibly resulting in reduced hormone secretion. A hypothetical model of ZEA-induced mitochondrial damage is proposed to provide a framework for the mechanism of ZEA toxicity. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yuzhe</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Boyang</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Kunlun</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Xiaoyun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>YunBo</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Rui</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Haoshu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Animal Physiology, College of Biological Sciences, China Agricultural University, Beijing, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Xiao Li</ForeName>
<Initials>XL</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Wentao</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Food Safety and Molecular Biology, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People's Republic of China. Electronic address: xuwentao@cau.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Toxicology</MedlineTA>
<NlmUniqueID>0361055</NlmUniqueID>
<ISSNLinking>0300-483X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3XMK78S47O</RegistryNumber>
<NameOfSubstance UI="D013739">Testosterone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5W827M159J</RegistryNumber>
<NameOfSubstance UI="D015025">Zearalenone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8L70Q75FXE</RegistryNumber>
<NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000255">Adenosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002851">Chromatography, High Pressure Liquid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030562">Databases, Protein</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004734">Energy Metabolism</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007984">Leydig Cell Tumor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024101">Mitochondrial Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040901">Proteomics</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012098">Reproduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053719">Tandem Mass Spectrometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013739">Testosterone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015025">Zearalenone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Endocrine disorder</Keyword>
<Keyword MajorTopicYN="N">Fatty acid oxidation</Keyword>
<Keyword MajorTopicYN="N">Lipid metabolism</Keyword>
<Keyword MajorTopicYN="N">Mitoproteomics</Keyword>
<Keyword MajorTopicYN="N">Mouse Leydig tumor cells</Keyword>
<Keyword MajorTopicYN="N">Reproductive toxicity</Keyword>
<Keyword MajorTopicYN="N">Zearalenone</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25204152</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[GC-MS analysis and cytotoxic activity of the supercritical extracts from roots and stems of Zanthoxylum nitidum].</ArticleTitle>
<Pagination>
<MedlinePgn>710-4</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The volatile components of roots and stems of Zanthoxylum nitidum were investigated by supercritical fluid carbon dioxide extraction (SFE-CO2) and gas chromatography-mass spectrometry(GC-MS). Thirty-one and fifty-one compounds were identified in the supercritical extracts from roots and stems of Z. nitidum, respectively, and total twenty-seven compounds were the common constituents. Among them, the major constituents in root and stem supercritical extracts were spathulenol (18.49 and 26.18%), n-hexadecanoic acid (14.24% and 12.79%), ar-tumerone (6.95% and 8.88%), oleic acid (8.39% and 5.71%) and hexanoic acid (4.39% and 7.78%). The in-vitro MTT assay showed that the volatile components of roots and stems of Z. nitidum did not exhibited any cytotoxic activity against human cancer Huh-7 and normal IEC-6 cells. These results indicated the same nature of the volatile constituents in the root and stem of Z. nitidum. This investigation may provide further evidence for expansion of medicinal parts of Z. nitidum.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Zi-Ning</ForeName>
<Initials>ZN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jia-Wei</ForeName>
<Initials>JW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Wu-Guo</ForeName>
<Initials>WG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sima</LastName>
<ForeName>Zhen-Hua</ForeName>
<Initials>ZH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Wei-Wen</ForeName>
<Initials>WW</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025924">Chromatography, Supercritical Fluid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008401">Gas Chromatography-Mass Spectrometry</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018517">Plant Roots</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018547">Plant Stems</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032106">Zanthoxylum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25204183</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Study on anti-tumor and anti-metastasis mechanism of alcohol extracts from pharbitidis semen against Lewis lung cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>879-84</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effect of alcohol extracts from Pharbitidis Semen on the proliferation and metastasis of Lewis lung cancer, and study its anti-tumor mechanism.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">In vitro, MTT assay and scratch assay were adopted to detect the effect of alcohol extracts from Pharbitidis Semen on the proliferation and metastasis of Lewis lung cancer cells. The cell autophagy was detected by the acridine orange staining. The gap-junction intercellular communication (GJIC) was investigated by the fluorescent yellow transfer. The expression of aquaporin 1 (AQP1) was analyzed by the Western blotting. In vivo, the subcutaneous implant model and the experimental pulmonary metastasis model of Lewis lung cancer in mice were established to evaluate the anti-tumor and anti-metastasis effects of alcohol extract from Pharbitidis Semen. The serum carcinoembryonic antigen (CEA) and beta2 microglobulin (beta2-MG) of mice bearing Lewis lung cancer were detected by the electrochemiluminesence immunoassay. The expressions of lung AQP1 and Connexin 43 (Cx43) were examined by the immunohistochemical method.</AbstractText>
<AbstractText Label="RESULT" NlmCategory="RESULTS">In vitro, alcohol extracts from Pharbitidis Semen inhibited the cell proliferation in a dose-dependent matter, significantly prevented the cell migration, down-regulated AQP1 proteins of cells, promoted GJIC, and decreased the serum-free autophagy of tumor cells. In vivo, compared with untreated model mice, alcohol extracts from Pharbitidis Semen inhibited the tumor growth in a dose-dependent matter, prevented the tumor metastasis and prolonged the life span of mice bearing Lewis lung cancer, while decreasing serum CEA and beta2-MG of mice bearing Lewis lung cancer, enhancing the immumohistochemical staining intensity of Cx43 and weakening aquaporins AQP1 positive intensity.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Alcohol extracts from Pharbitidis Semen could prevent the proliferation and metastasis in Lewis lung cancer cells. Its mechanism may be related to the promotion of GJIC and the down-regulation of AQP1.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jia-Huan</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Du</LastName>
<ForeName>Gang-Jun</ForeName>
<Initials>GJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Wei-Jie</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Ying-Hui</ForeName>
<Initials>YH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Bei</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018031">Connexin 43</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>146410-94-8</RegistryNumber>
<NameOfSubstance UI="D051398">Aquaporin 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051398">Aquaporin 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018827">Carcinoma, Lewis Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018031">Connexin 43</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D027741">Ipomoea</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012639">Seeds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25186638</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Tanshinone IIA pretreatment protects free flaps against hypoxic injury by upregulating stem cell-related biomarkers in epithelial skin cells.</ArticleTitle>
<Pagination>
<MedlinePgn>331</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-331</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Partial or total flap necrosis after flap transplantation is sometimes encountered in reconstructive surgery, often as a result of a period of hypoxia that exceeds the tolerance of the flap tissue. The purpose of this study was to determine whether Tanshinone IIA (TSA) pretreatment can protect flap tissue against hypoxic injury and improve its viability.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Primary epithelial cells isolated from the dorsal skin of mice were pretreated with TSA for 2 weeks. Cell Counting Kit-8 and Trypan Blue assays were carried out to examine the proliferation of TSA-pretreated cells after exposure to cobalt chloride. Polymerase chain reaction and western blot analysis were used to assess the expression of β-catenin, vascular endothelial growth factor (VEGF), sex determining region Y-box 2 (SOX2), OCT4 (also known as POU domain class 5 transcription factor 1), Nanog, and glycogen synthase kinase-3 beta (GSK-3β) in TSA-treated cells. In other experiments, after mice were pretreated with TSA for 2 weeks, a reproducible ischemic flap model was implemented, and the area of surviving tissue in the transplanted flaps was measured. Immunohistochemistry was conducted to examine Wnt signaling as well as stem cell- and angiogenesis-related biomarkers in epithelial tissue in vivo.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Epidermal cells, pretreated with TSA, showed enhanced resistance to hypoxia. Activation of the Wnt signaling pathway in TSA-pretreated cells was characterized by the upregulation of β-catenin and the downregulation of GSK-3β. The expression of SOX2, Nanog, and OCT4 were also higher in TSA-pretreated epithelial cells than in control cells. In the reproducible ischemic flap model, pretreatment with TSA enhanced resistance to hypoxia and increased the area of surviving tissue in transplanted flaps. The expression of Wnt signaling pathway components, stem-cell related biomarkers, and VEGF and CD34, which are involved in the regeneration of blood vessels, was also upregulated in TSA-pretreated flap tissue.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TSA pretreatment protects free flaps against hypoxic injury and increases the area of surviving tissue by activating Wnt signaling and upregulating stem cell-related biomarkers.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Zihan</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Lijun</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Yaowen</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Yadong</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qin</LastName>
<ForeName>Gaoping</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mu</LastName>
<ForeName>Shengzhi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Ronghui</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Benfeng</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Wenjie</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Zhenxin</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Burns and Plastic Surgery, Shaanxi Provincial People's Hospital, 256 West Youyi Road, Xi'an 710068, China. zzsxa2006@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045784">Diterpenes, Abietane</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>568-73-0</RegistryNumber>
<NameOfSubstance UI="C021751">tanshinone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C448280">glycogen synthase kinase 3 beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.26</RegistryNumber>
<NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Mutat Res. 1999 Dec 17;431(2):351-9</RefSource>
<PMID Version="1">10636000</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Aviat Space Environ Med. 2000 Feb;71(2):119-24</RefSource>
<PMID Version="1">10685584</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2002 Jan;109(1):45-52</RefSource>
<PMID Version="1">11786790</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2002 Oct;119(4):888-99</RefSource>
<PMID Version="1">12406335</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2003 May 22;423(6938):448-52</RefSource>
<PMID Version="1">12717451</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11830-5</RefSource>
<PMID Version="1">12913119</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2004 Jul;114(1):74-82</RefSource>
<PMID Version="1">15220572</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 1974 Aug;63(2):187-93</RefSource>
<PMID Version="1">4602091</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2006 Oct 6;127(1):171-83</RefSource>
<PMID Version="1">17018284</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Plast Reconstr Aesthet Surg. 2007;60(3):272-8</RefSource>
<PMID Version="1">17293285</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Mar 8;446(7132):185-9</RefSource>
<PMID Version="1">17330052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Vascul Pharmacol. 2007 Jun;46(6):427-38</RefSource>
<PMID Version="1">17337361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 May 17;447(7142):316-20</RefSource>
<PMID Version="1">17507982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2007 Jun 20;25(18):2586-93</RefSource>
<PMID Version="1">17577038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Pharmacol. 2007 Jul 30;568(1-3):213-21</RefSource>
<PMID Version="1">17537428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Nov 30;131(5):861-72</RefSource>
<PMID Version="1">18035408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2007 Dec 21;318(5858):1917-20</RefSource>
<PMID Version="1">18029452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2008 Jan 18;319(5861):323-7</RefSource>
<PMID Version="1">18063757</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2008 Mar;121(3):860-77</RefSource>
<PMID Version="1">18317135</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Biochem Sci. 2008 Dec;33(12):583-91</RefSource>
<PMID Version="1">18848452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Microsurgery. 2009;29(1):72-9</RefSource>
<PMID Version="1">18946882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Jul 9;114(2):371-9</RefSource>
<PMID Version="1">19417213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17061-6</RefSource>
<PMID Version="1">19805089</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pharm Biol. 2010 May;48(5):484-7</RefSource>
<PMID Version="1">20645787</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 2010 Sep;139(3):718-22</RefSource>
<PMID Version="1">20659460</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tohoku J Exp Med. 2010 Oct;222(2):131-40</RefSource>
<PMID Version="1">20944441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Plast Reconstr Aesthet Surg. 2010 Dec;63(12):2152-9</RefSource>
<PMID Version="1">20359971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phytomedicine. 2010 Dec 15;18(1):58-64</RefSource>
<PMID Version="1">20638255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2011 Jan;127 Suppl 1:131S-141S</RefSource>
<PMID Version="1">21200283</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Orthop. 2011 Apr;82(2):125-30</RefSource>
<PMID Version="1">21438671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15858-63</RefSource>
<PMID Version="1">21911394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Atherosclerosis. 2012 Jan;220(1):3-10</RefSource>
<PMID Version="1">21774934</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(6):e40165</RefSource>
<PMID Version="1">22768247</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Jul 5;487(7405):57-63</RefSource>
<PMID Version="1">22722858</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Transl Res. 2012 Aug;160(2):114-24</RefSource>
<PMID Version="1">22677363</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cold Spring Harb Perspect Biol. 2012 Aug;4(8):a008078</RefSource>
<PMID Version="1">22723493</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cell Rev. 2012 Sep;8(3):854-62</RefSource>
<PMID Version="1">22529016</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Brain Res. 2012 Dec 7;1488:81-91</RefSource>
<PMID Version="1">23063715</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Fitoterapia. 2012 Dec;83(8):1666-74</RefSource>
<PMID Version="1">23022532</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Expert Opin Ther Pat. 2013 Feb;23(2):149-53</RefSource>
<PMID Version="1">23231009</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Physiol Biochem. 2012;30(4):843-52</RefSource>
<PMID Version="1">22890296</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 2013 May 15;319(9):1317-23</RefSource>
<PMID Version="1">23291327</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000860">Anoxia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045784">Diterpenes, Abietane</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058752">Free Tissue Flaps</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038362">Glycogen Synthase Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016038">Skin Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4162953</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25010864</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.</ArticleTitle>
<Pagination>
<MedlinePgn>1150-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.386</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chemotherapy response in ovarian cancer patients is frequently compromised by drug resistance, possibly due to altered drug metabolism. Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but variably expressed in ovarian tumours. We have created novel ovarian tumour cell line models to investigate the extent to which differential GSTP1 expression influences chemosensitivity.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Glutathione S-transferase P1 was stably deleted in A2780 and expression significantly reduced in cisplatin-resistant A2780DPP cells using Mission shRNA constructs, and MTT assays used to compare chemosensitivity to chemotherapy drugs used to treat ovarian cancer. Differentially expressed genes in GSTP1 knockdown cells were identified by Illumina HT-12 expression arrays and qRT-PCR analysis, and altered pathways predicted by MetaCore (GeneGo) analysis. Cell cycle changes were assessed by FACS analysis of PI-labelled cells and invasion and migration compared in quantitative Boyden chamber-based assays.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Glutathione S-transferase P1 knockdown selectively influenced cisplatin and carboplatin chemosensitivity (2.3- and 4.83-fold change in IC50, respectively). Cell cycle progression was unaffected, but cell invasion and migration was significantly reduced. We identified several novel GSTP1 target genes and candidate platinum chemotherapy response biomarkers.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Glutathione S-transferase P1 has an important role in cisplatin and carboplatin metabolism in ovarian cancer cells. Inter-tumour differences in GSTP1 expression may therefore influence response to platinum-based chemotherapy in ovarian cancer patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sawers</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Research, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferguson</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Dundee Cancer Centre, NHS Tayside, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ihrig</LastName>
<ForeName>B R</ForeName>
<Initials>BR</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Research, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Young</LastName>
<ForeName>H C</ForeName>
<Initials>HC</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Research, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chakravarty</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Bioinformatics and Biostatistics Service, Cancer Research UK, 44 Lincolns Inn Fields, London WC2A 3PX, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wolf</LastName>
<ForeName>C R</ForeName>
<Initials>CR</Initials>
<AffiliationInfo>
<Affiliation>1] Division of Cancer Research, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK [2] Cancer Research UK Molecular Pharmacology Unit, Division of Cancer Research, Medical Research Institute, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Research, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>BG3F62OND5</RegistryNumber>
<NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.5.1.18</RegistryNumber>
<NameOfSubstance UI="D051549">Glutathione S-Transferase pi</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016190">Carboplatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051549">Glutathione S-Transferase pi</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25010867</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1).</ArticleTitle>
<Pagination>
<MedlinePgn>1188-200</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.382</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nin one binding protein (NOB1) was identified as a potential oncogene in human glioma and miR-646 plays an important role in human growth and development. However, the underlying molecular mechanisms of NOB1 in tumorigenicity and its correlation with miR-646 in renal cell carcinoma (RCC) have not been investigated.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We performed bioinformatic analysis to explore miRNA targeting NOB1. The expression of NOB1 and miR-646 from 100 cases of clear cell RCC (ccRCC) and 30 cases of adjacent non-tumour tissues were detected by quantitative real-time PCR. The expression of miR-646 was correlated with NOB1 expression, tumour features and patient metastasis-free survival. The effect of overexpression of mir-646 on renal cancer cell proliferation was detected by colony formation in soft agar. Using a xenograft tumour model, we observed the in vivo tumorigenesis effect of miR-646 and NOB1.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">miR-646 negatively regulated NOB1 and inhibited the proliferation and migration of renal cancer cells. There was a significant upregulation of NOB1 in ccRCC and it was further increased in metastatic cases, while miR-646 was downregulated in tumour tissues and further decreased in metastatic ccRCC. Additionally, expression of miR-646 was inversely correlated with the expression of NOB1. The downregulation of miR-646 also indicated a higher probability of developing metastasis. Most importantly, miR-646 expression was an independent predictor of ccRCC metastasis by the univariate analysis and binary logistic regression model (both P&lt;0.05). Colony formation in soft agar and xenograft tumour model suggested that miR-646 and NOB1 are required for tumorigenesis in vitro and in vivo. Furthermore, suppression of NOB1 increased the phosphorylation of several proteins in MAPK pathway.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Downregulated miR-646 in ccRCC was associated with tumour metastasis through MAPK pathway by targeting NOB1. miR-646 and NOB1 may play an important role in the development of ccRCC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Nephrology, Nanjing University Affiliated Drum Tower Hospital, Nanjing, Jiangsu 210093, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Y-F</ForeName>
<Initials>YF</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Y-F</ForeName>
<Initials>YF</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32603, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Che</LastName>
<ForeName>J-P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>G-C</ForeName>
<Initials>GC</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yao</LastName>
<ForeName>X-D</ForeName>
<Initials>XD</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>J-H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592812">MIRN646 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506664">NOB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016601">RNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014410">Tumor Stem Cell Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25025965</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation.</ArticleTitle>
<Pagination>
<MedlinePgn>1139-49</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.385</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite its promise as a highly useful therapy for pancreatic cancer (PC), the addition of external beam radiation therapy to PC treatment has shown varying success in clinical trials. Understanding PC radioresistance and discovery of methods to sensitise PC to radiation will increase patient survival and improve quality of life. In this study, we identified PC radioresistance-associated pathways using global, unbiased techniques.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Radioresistant cells were generated by sequential irradiation and recovery, and global genome cDNA microarray analysis was performed to identify differentially expressed genes in radiosensitive and radioresistant cells. Ingenuity pathway analysis was performed to discover cellular pathways and functions associated with differential radioresponse and identify potential small-molecule inhibitors for radiosensitisation. The expression of FDPS, one of the most differentially expressed genes, was determined in human PC tissues by IHC and the impact of its pharmacological inhibition with zoledronic acid (ZOL, Zometa) on radiosensitivity was determined by colony-forming assays. The radiosensitising effect of Zol in vivo was determined using allograft transplantation mouse model.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Microarray analysis indicated that 11 genes (FDPS, ACAT2, AG2, CLDN7, DHCR7, ELFN2, FASN, SC4MOL, SIX6, SLC12A2, and SQLE) were consistently associated with radioresistance in the cell lines, a majority of which are involved in cholesterol biosynthesis. We demonstrated that knockdown of farnesyl diphosphate synthase (FDPS), a branchpoint enzyme of the cholesterol synthesis pathway, radiosensitised PC cells. FDPS was significantly overexpressed in human PC tumour tissues compared with healthy pancreas samples. Also, pharmacologic inhibition of FDPS by ZOL radiosensitised PC cell lines, with a radiation enhancement ratio between 1.26 and 1.5. Further, ZOL treatment resulted in radiosensitisation of PC tumours in an allograft mouse model.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Unbiased pathway analysis of radioresistance allowed for the discovery of novel pathways associated with resistance to ionising radiation in PC. Specifically, our analysis indicates the importance of the cholesterol synthesis pathway in PC radioresistance. Further, a novel radiosensitiser, ZOL, showed promising results and warrants further study into the universality of these findings in PC, as well as the true potential of this drug as a clinical radiosensitiser.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Souchek</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Fred &amp; Pamela Buffet Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baine</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Fred &amp; Pamela Buffet Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rachagani</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kaur</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lester</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lazenby</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Johansson</LastName>
<ForeName>S L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jain</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>1] Fred &amp; Pamela Buffet Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA [2] Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Batra</LastName>
<ForeName>S K</ForeName>
<Initials>SK</Initials>
<AffiliationInfo>
<Affiliation>1] Fred &amp; Pamela Buffet Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA [2] Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P50 CA127297</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54CA163120</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UO1 CA111294</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011838">Radiation-Sensitizing Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6XC1PAD3KF</RegistryNumber>
<NameOfSubstance UI="C088658">zoledronic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>97C5T2UQ7J</RegistryNumber>
<NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.5.1.10</RegistryNumber>
<NameOfSubstance UI="D051228">Geranyltranstransferase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002784">Cholesterol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018076">DNA, Complementary</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004164">Diphosphonates</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051228">Geranyltranstransferase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011836">Radiation Tolerance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011838">Radiation-Sensitizing Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25072257</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1180-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.427</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The oncoprotein-18/stathmin 1 (STMN1), involved in cell progression and migration, is associated with clinical outcome in breast cancer. Here we aim to investigate its clinical significance in urinary bladder cancer and its possibilities as a therapeutic target.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Immunohistochemical analyses of STMN1 protein expression were performed in three patient cohorts: cohort I (n=115 Ta, n=115 T1, n=112 T2-4 stages), cohort II, based on randomised controlled trials (n=239 T1-T4), and cohort III of primary tumour/matched metastasis (n=90 T1-T4). The effects of STMN1 on cell proliferation and migration were evaluated in the urinary bladder cancer cell line, T24, by inhibiting STMN1-cellular expression using siRNA.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In cohort I, high STMN1 expression correlated to shorter disease-specific survival hazard ratio (HR)=2.04 (95% confidence interval (CI) 1.13-3.68; P=0.02), elevated p53- (P&lt;0.001) and Ki67-protein levels (P&lt;0.001). The survival result was validated in cohort II: HR=1.76 (95% CI 1.04-2.99; P=0.03). In the metastatic bladder cancer material, 70% of the patients were STMN1-positive in both the primary tumour and matched metastases. In vitro, the growth and migration of the T24 cells were significantly reduced (P&lt;0.01, P&lt;0.0001, respectively), when transfecting the cells with STMN1-siRNA.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">STMN1 protein expression has prognostic significance but is primarily a potential treatment target in urinary bladder cancer.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hemdan</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala 751 85, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lindén</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala 751 85, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lind</LastName>
<ForeName>S B</ForeName>
<Initials>SB</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden [2] Department of Chemistry-BMC, Science for Life Laboratory, Uppsala University, Uppsala 751 24, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Namuduri</LastName>
<ForeName>A V</ForeName>
<Initials>AV</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala 751 85, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sjöstedt</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Ståhl</LastName>
<ForeName>T D</ForeName>
<Initials>TD</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology-Pathology, Karolinska Institute, Stockholm 171 76, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Asplund</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malmström</LastName>
<ForeName>P-U</ForeName>
<Initials>PU</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala 751 85, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Segersten</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala 751 85, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493995">STMN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050777">Stathmin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002295">Carcinoma, Transitional Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019394">Ki-67 Antigen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050777">Stathmin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046888">Tissue Array Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001749">Urinary Bladder Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093491</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1168-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.421</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple lines of evidence support that the Hedgehog (Hh) signalling has a role in the maintenance and progression of different human cancers. Therefore, inhibition of the Hh pathway represents a valid anticancer therapeutic approach for renal cell carcinoma (RCC) patients. NVP-LDE225 is a Smoothened (Smo) antagonist that induces dose-related inhibition of Hh and Smo-dependent tumour growth.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We assayed the effects of NVP-LDE225 alone or in combination with everolimus or sunitinib on the growth and invasion of human RCC models both in vitro and in vivo. To this aim, we used a panel of human RCC models, comprising cells with acquired resistance to sunitinib - a multiple tyrosine kinase inhibitor approved as a first-line treatment for RCC.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">NVP-LDE225 cooperated with either everolimus or sunitinib to inhibit proliferation, migration, and invasion of RCC cells even in sunitinib-resistant (SuR) cells. Some major transducers involved in tumour cell motility, including paxillin, were also efficiently inhibited by the combination therapy, as demonstrated by western blot and confocal microscopy assays. Moreover, these combined treatments inhibited tumour growth and increased animal survival in nude mice xenografted with SuR RCC cells. Finally, lung micrometastasis formation was reduced when mice were treated with NVP-LDE225 plus everolimus or sunitinib, as evidenced by artificial metastatic assays.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hedgehog inhibition by NVP-LDE225 plus sunitinib or everolimus bolsters antitumour activity by interfering with tumour growth and metastatic spread, even in SuR cells. Thus, this new evidence puts forward a new promising therapeutic approach for RCC patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>D'Amato</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rosa</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marciano</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>D'Amato</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Formisano</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nappi</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raimondo</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Di Mauro</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Servetto</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fulciniti</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Anatomia Patologica e Citopatologia, Istituto Nazionale Tumori 'Fondazione G. Pascale', IRCCS, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cipolletta</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Anatomia Patologica e Citopatologia, Istituto Nazionale Tumori 'Fondazione G. Pascale', IRCCS, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bianco</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Radioterapia, Istituto Nazionale Tumori 'Fondazione G. Pascale', IRCCS, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ciardiello</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', II Universitá degli Studi di Napoli, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Veneziani</LastName>
<ForeName>B M</ForeName>
<Initials>BM</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>De Placido</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bianco</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cattedra di Oncologia Medica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C400551">GLI1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C082593">GLI2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051741">Kruppel-Like Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C561435">LDE225</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051419">Paxillin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491023">SMO protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C473478">sunitinib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9HW64Q8G6G</RegistryNumber>
<NameOfSubstance UI="C107135">everolimus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008841">Actin Cytoskeleton</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000199">Actins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001713">Biphenyl Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053823">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051741">Kruppel-Like Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061206">Neoplasm Micrometastasis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051419">Paxillin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011758">Pyrroles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25175806</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Drugging MYCN through an allosteric transition in Aurora kinase A.</ArticleTitle>
<Pagination>
<MedlinePgn>414-27</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00305-5</ELocationID>
<Abstract>
<AbstractText>MYC proteins are major drivers of cancer yet are considered undruggable because their DNA binding domains are composed of two extended alpha helices with no apparent surfaces for small-molecule binding. Proteolytic degradation of MYCN protein is regulated in part by a kinase-independent function of Aurora A. We describe a class of inhibitors that disrupts the native conformation of Aurora A and drives the degradation of MYCN protein across MYCN-driven cancers. Comparison of cocrystal structures with structure-activity relationships across multiple inhibitors and chemotypes, coupled with mechanistic studies and biochemical assays, delineates an Aurora A conformation-specific effect on proteolytic degradation of MYCN, rather than simple nanomolar-level inhibition of Aurora A kinase activity. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gustafson</LastName>
<ForeName>William Clay</ForeName>
<Initials>WC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meyerowitz</LastName>
<ForeName>Justin Gabriel</ForeName>
<Initials>JG</Initials>
<AffiliationInfo>
<Affiliation>Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nekritz</LastName>
<ForeName>Erin A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Justin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Benes</LastName>
<ForeName>Cyril</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02114, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Charron</LastName>
<ForeName>Elise</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simonds</LastName>
<ForeName>Erin F</ForeName>
<Initials>EF</Initials>
<AffiliationInfo>
<Affiliation>Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seeger</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology/Oncology, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Mailstop #57, Los Angeles, CA 90027, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matthay</LastName>
<ForeName>Katherine K</ForeName>
<Initials>KK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hertz</LastName>
<ForeName>Nicholas T</ForeName>
<Initials>NT</Initials>
<AffiliationInfo>
<Affiliation>Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eilers</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074 Würzburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shokat</LastName>
<ForeName>Kevan M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weiss</LastName>
<ForeName>William A</ForeName>
<Initials>WA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: waweiss@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>PDB</DataBankName>
<AccessionNumberList>
<AccessionNumber>4J8M</AccessionNumber>
<AccessionNumber>4J8N</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1U54HG006097-01</GrantID>
<Acronym>HG</Acronym>
<Agency>NHGRI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F30 CA174154</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F30CA174154</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08 NS079485</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08NS079485</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>L40 CA153057</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 CA081403</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01CA081403</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30CA82103</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA102321</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA148699</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA159859</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA102321</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA148699</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA159859</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM064337</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592902">CD532 compound</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C459801">MYCN protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C576917">AURKA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D064096">Aurora Kinase A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000494">Allosteric Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019540">Area Under Curve</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064096">Aurora Kinase A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020134">Catalytic Domain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018360">Crystallography, X-Ray</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009447">Neuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015513">Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010671">Phenylurea Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017433">Protein Structure, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059748">Proteolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059807">S Phase Cell Cycle Checkpoints</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS616550 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4160413 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203321</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>344-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.009</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00300-6</ELocationID>
<Abstract>
<AbstractText>In a genome-wide survey on somatic copy-number alterations (SCNAs) of long noncoding RNA (lncRNA) in 2,394 tumor specimens from 12 cancer types, we found that about 21.8% of lncRNA genes were located in regions with focal SCNAs. By integrating bioinformatics analyses of lncRNA SCNAs and expression with functional screening assays, we identified an oncogene, focally amplified lncRNA on chromosome 1 (FAL1), whose copy number and expression are correlated with outcomes in ovarian cancer. FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a number of genes including CDKN1A. The oncogenic activity of FAL1 is partially attributable to its repression of p21. FAL1-specific siRNAs significantly inhibit tumor growth in vivo.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Xiaowen</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Yi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Dongmei</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; State Key Laboratory of Biotherapy, West China Medical School, Sichuan University, Chengdu 610041, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Sihai D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo>
<Affiliation>Department of Statistics, University of Illinois at Urbana-Champaign, Champaign, IL 61820, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Zhongyi</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Greshock</LastName>
<ForeName>Joel</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Youyou</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, West China Medical School, Sichuan University, Chengdu 610041, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Xiaomin</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Stem Biology and Tissue Engineering, Department of Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Li-Ping</ForeName>
<Initials>LP</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jean</LastName>
<ForeName>Stephanie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Chunsheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Qihong</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Wistar Institute, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Katsaros</LastName>
<ForeName>Dionyssios</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, University of Turin, Turin 10124, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Montone</LastName>
<ForeName>Kathleen T</ForeName>
<Initials>KT</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tanyi</LastName>
<ForeName>Janos L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Yiling</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, MD Anderson Cancer Center, Houston, TX 7705, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boyd</LastName>
<ForeName>Jeff</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Cancer Genome Institute, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nathanson</LastName>
<ForeName>Katherine L</ForeName>
<Initials>KL</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Hongzhe</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mills</LastName>
<ForeName>Gordon B</ForeName>
<Initials>GB</Initials>
<AffiliationInfo>
<Affiliation>Department of Systems Biology, MD Anderson Cancer Center, Houston, TX 7705, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Lin</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Research on Reproduction &amp; Women's Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: linzhang@mail.med.upenn.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K12 HD000849</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K12HD000849</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 CA099031</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01CA099031</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA083638</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA083639</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA098258</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50CA083638</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50CA083639</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50CA098258</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA127334</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA142776</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA148759</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA127334</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA142776</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA148759</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U24 CA143883</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U24CA143883</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C069077">BMI1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D063150">Polycomb Repressive Complex 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Cancer Cell. 2014 Sep 8;26(3):303-4</RefSource>
<PMID Version="1">25203317</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016922">Cell Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023281">Genomics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009375">Neoplasms, Glandular and Epithelial</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009857">Oncogenes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063150">Polycomb Repressive Complex 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055550">Protein Stability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D062085">RNA, Long Noncoding</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS616127 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4159613 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203322</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis.</ArticleTitle>
<Pagination>
<MedlinePgn>358-73</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.022</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00310-9</ELocationID>
<Abstract>
<AbstractText>Metastatic dissemination is often initiated by the reactivation of an embryonic development program referred to as epithelial-mesenchymal transition (EMT). The transcription factor SNAIL promotes EMT and elicits associated pathological characteristics such as invasion, metastasis, and stemness. To better understand the posttranslational regulation of SNAIL, we performed a luciferase-based, genome-wide E3 ligase siRNA library screen and identified SCF-FBXO11 as an important E3 that targets SNAIL for ubiquitylation and degradation. Furthermore, we discovered that SNAIL degradation by FBXO11 is dependent on Ser-11 phosphorylation of SNAIL by protein kinase D1 (PKD1). FBXO11 blocks SNAIL-induced EMT, tumor initiation, and metastasis in multiple breast cancer models. These findings establish the PKD1-FBXO11-SNAIL axis as a mechanism of posttranslational regulation of EMT and cancer metastasis. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Hanqiu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Minhong</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA; Department of Cell Biology and Program of Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zha</LastName>
<ForeName>Yin-Lian</ForeName>
<Initials>YL</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Wenyang</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blanco</LastName>
<ForeName>Mario Andres</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, Harvard Medical School and Division of Newborn Medicine, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ren</LastName>
<ForeName>Guangwen</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Tianhua</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology and Program of Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Storz</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Mayo Clinic, Griffin Building, Room 306, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Hui-Yun</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Yibin</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA; Genomic Instability and Tumor Progression Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA. Electronic address: ykang@princeton.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE50889</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA140182</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>GM086435</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA134519</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA141062</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA134519</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA141062</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044783">F-Box Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050396">TRPP Cation Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C087882">polycystic kidney disease 1 protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C086988">snail family transcription factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.-</RegistryNumber>
<NameOfSubstance UI="D011484">Protein-Arginine N-Methyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.23</RegistryNumber>
<NameOfSubstance UI="C457579">FBXO11 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044843">SKP Cullin F-Box Protein Ligases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044783">F-Box Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011484">Protein-Arginine N-Methyltransferases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059748">Proteolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044843">SKP Cullin F-Box Protein Ligases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050396">TRPP Cation Channels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D054875">Ubiquitination</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS618764 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4159622 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203323</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression.</ArticleTitle>
<Pagination>
<MedlinePgn>374-89</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00301-8</ELocationID>
<Abstract>
<AbstractText>Splicing dysregulation is one of the molecular hallmarks of cancer. However, the underlying molecular mechanisms remain poorly defined. Here we report that the splicing factor RBM4 suppresses proliferation and migration of various cancer cells by specifically controlling cancer-related splicing. Particularly, RBM4 regulates Bcl-x splicing to induce apoptosis, and coexpression of Bcl-xL partially reverses the RBM4-mediated tumor suppression. Moreover, RBM4 antagonizes an oncogenic splicing factor, SRSF1, to inhibit mTOR activation. Strikingly, RBM4 expression is decreased dramatically in cancer patients, and the RBM4 level correlates positively with improved survival. In addition to providing mechanistic insights of cancer-related splicing dysregulation, this study establishes RBM4 as a tumor suppressor with therapeutic potential and clinical values as a prognostic factor. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute of Cancer Stem Cell, Second Affiliated Hospital, Cancer Center, Dalian Medical University, Dalian 116044, China; Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: yangwang@dlmedu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, First Affiliated Hospital. Dalian Medical University, Dalian 116001, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qian</LastName>
<ForeName>Haili</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Molecular Oncology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsai</LastName>
<ForeName>Yihsuan S</ForeName>
<Initials>YS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shao</LastName>
<ForeName>Shujuan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Key Laboratory of Proteomics of Liaoning Province, Dalian Medical University, Dalian 116044, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Quentin</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Institute of Cancer Stem Cell, Second Affiliated Hospital, Cancer Center, Dalian Medical University, Dalian 116044, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dominguez</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Zefeng</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: zefeng@med.unc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE58594</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA158283</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-CA158283</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C473692">RBM4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051020">bcl-X Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>170974-22-8</RegistryNumber>
<NameOfSubstance UI="C095829">serine-arginine-rich splicing proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017398">Alternative Splicing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016601">RNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051020">bcl-X Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS616128 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4159621 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203324</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-3686</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Cancer cell</Title>
<ISOAbbreviation>Cancer Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Notch activation as a driver of osteogenic sarcoma.</ArticleTitle>
<Pagination>
<MedlinePgn>390-401</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2014.07.023</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1535-6108(14)00311-0</ELocationID>
<Abstract>
<AbstractText>Osteogenic sarcoma (OS) is a deadly skeletal malignancy whose cause is unknown. We report here a mouse model of OS based on conditional expression of the intracellular domain of Notch1 (NICD). Expression of the NICD in immature osteoblasts was sufficient to drive the formation of bone tumors, including OS, with complete penetrance. These tumors display features of human OS; namely, histopathology, cytogenetic complexity, and metastatic potential. We show that Notch activation combined with loss of p53 synergistically accelerates OS development in mice, although p53-driven OS is not Rbpj dependent, which demonstrates a dual dominance of the Notch oncogene and p53 mutation in the development of OS. Using this model, we also reveal the osteoblasts as the potential sources of OS. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tao</LastName>
<ForeName>Jianning</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Ming-Ming</ForeName>
<Initials>MM</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Lichun</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Salvo</LastName>
<ForeName>Jason S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zeng</LastName>
<ForeName>Huan-Chang</ForeName>
<Initials>HC</Initials>
<AffiliationInfo>
<Affiliation>Program in Developmental Biology, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dawson</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bertin</LastName>
<ForeName>Terry K</ForeName>
<Initials>TK</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rao</LastName>
<ForeName>Pulivarthi H</ForeName>
<Initials>PH</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Rui</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Donehower</LastName>
<ForeName>Lawrence A</ForeName>
<Initials>LA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gannon</LastName>
<ForeName>Francis</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Brendan H</ForeName>
<Initials>BH</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA; Program in Developmental Biology, Baylor College of Medicine, One Baylor Plaza, R815, Houston, TX 77030, USA; Howard Hughes Medical Institute, Houston, TX 77030, USA. Electronic address: blee@bcm.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>SRA</DataBankName>
<AccessionNumberList>
<AccessionNumber>SRP036832</AccessionNumber>
<AccessionNumber>SRP036865</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>AI036211</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>AR061565</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DE016990</GrantID>
<Acronym>DE</Acronym>
<Agency>NIDCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HD022657</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>HD024064</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 HD022657</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 HD070394</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA125123</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA125123</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 HD024064</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R03 AR061565</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RR024574</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Cell</MedlineTA>
<NlmUniqueID>101130617</NlmUniqueID>
<ISSNLinking>1535-6108</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497762">Notch1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001859">Bone Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057507">Mice, 129 Strain</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010006">Osteoblasts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012516">Osteosarcoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051881">Receptor, Notch1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS618765 [Available on 09/08/15]</OtherID>
<OtherID Source="NLM">PMC4159617 [Available on 09/08/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203208</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-1551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Developmental cell</Title>
<ISOAbbreviation>Dev. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination.</ArticleTitle>
<Pagination>
<MedlinePgn>553-68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.devcel.2014.08.006</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1534-5807(14)00516-4</ELocationID>
<Abstract>
<AbstractText>The role of endocytic proteins and the molecular mechanisms underlying epithelial cell cohesion and tumor dissemination are not well understood. Here, we report that the endocytic F-BAR-containing CDC42-interacting protein 4 (CIP4) is required for ERBB2- and TGF-β1-induced cell scattering, breast cancer (BC) cell motility and invasion into 3D matrices, and conversion from ductal breast carcinoma in situ to invasive carcinoma in mouse xenograft models. CIP4 promotes the formation of an E-cadherin-CIP4-SRC complex that controls SRC activation, E-cadherin endocytosis, and localized phosphorylation of the myosin light chain kinase, thereby impinging on the actomyosin contractility required to generate tangential forces to break cell-cell junctions. CIP4 is upregulated in ERBB2-positive human BC, correlates with increased distant metastasis, and is an independent predictor of poor disease outcome in subsets of BC patients. Thus, it critically controls cell-cell cohesion and is required for the acquisition of an invasive phenotype in breast tumors.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rolland</LastName>
<ForeName>Yannève</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marighetti</LastName>
<ForeName>Paola</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malinverno</LastName>
<ForeName>Chiara</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Confalonieri</LastName>
<ForeName>Stefano</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Dipartimento di Oncologia Sperimentale, Istituto Europeo di Oncologia, 20141 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luise</LastName>
<ForeName>Chiara</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Dipartimento di Oncologia Sperimentale, Istituto Europeo di Oncologia, 20141 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ducano</LastName>
<ForeName>Nadia</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Scienze Oncologiche, Università degli Studi di Torino, Istituto per la Ricerca e la Cura del Cancro, Strada Provinciale 142 10060 Candiolo, Turin, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Palamidessi</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bisi</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kajiho</LastName>
<ForeName>Hiroaki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Troglio</LastName>
<ForeName>Flavia</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Dipartimento di Oncologia Sperimentale, Istituto Europeo di Oncologia, 20141 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shcherbakova</LastName>
<ForeName>Olga G</ForeName>
<Initials>OG</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dunn</LastName>
<ForeName>Alexander R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oldani</LastName>
<ForeName>Amanda</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lanzetti</LastName>
<ForeName>Letizia</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Scienze Oncologiche, Università degli Studi di Torino, Istituto per la Ricerca e la Cura del Cancro, Strada Provinciale 142 10060 Candiolo, Turin, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Di Fiore</LastName>
<ForeName>Pier Paolo</ForeName>
<Initials>PP</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Dipartimento di Oncologia Sperimentale, Istituto Europeo di Oncologia, 20141 Milan, Italy; Dipartimento di Scienze della Salute, San Paolo, Università degli Studi di Milano, 20122 Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Disanza</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Electronic address: andrea.disanza@ifom.eu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scita</LastName>
<ForeName>Giorgio</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Dipartimento di Scienze della Salute, San Paolo, Università degli Studi di Milano, 20122 Milan, Italy. Electronic address: giorgio.scita@ifom.eu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Cell</MedlineTA>
<NlmUniqueID>101120028</NlmUniqueID>
<ISSNLinking>1534-5807</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508960">TGFB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C406285">TRIP10 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508961">Tgfb1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485787">Trip10 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9013-26-7</RegistryNumber>
<NameOfSubstance UI="D000205">Actomyosin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C524056">Erbb2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000205">Actomyosin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015820">Cadherins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018270">Carcinoma, Ductal, Breast</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002285">Carcinoma, Intraductal, Noninfiltrating</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004705">Endocytosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008869">Microtubule-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053773">Transforming Growth Factor beta1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064726">Triple Negative Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25203209</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1878-1551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>8</Day>
</PubDate>
</JournalIssue>
<Title>Developmental cell</Title>
<ISOAbbreviation>Dev. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Ena/VASP proteins cooperate with the WAVE complex to regulate the actin cytoskeleton.</ArticleTitle>
<Pagination>
<MedlinePgn>569-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.devcel.2014.08.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1534-5807(14)00493-6</ELocationID>
<Abstract>
<AbstractText>Ena/VASP proteins and the WAVE regulatory complex (WRC) regulate cell motility by virtue of their ability to independently promote actin polymerization. We demonstrate that Ena/VASP and the WRC control actin polymerization in a cooperative manner through the interaction of the Ena/VASP EVH1 domain with an extended proline rich motif in Abi. This interaction increases cell migration and enables VASP to cooperatively enhance WRC stimulation of Arp2/3 complex-mediated actin assembly in vitro in the presence of Rac. Loss of this interaction in Drosophila macrophages results in defects in lamellipodia formation, cell spreading, and redistribution of Ena to the tips of filopodia-like extensions. Rescue experiments of abi mutants also reveals a physiological requirement for the Abi:Ena interaction in photoreceptor axon targeting and oogenesis. Our data demonstrate that the activities of Ena/VASP and the WRC are intimately linked to ensure optimal control of actin polymerization during cell migration and development.</AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Xing Judy</ForeName>
<Initials>XJ</Initials>
<AffiliationInfo>
<Affiliation>Cell Motility Laboratory, London Research Institute, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Squarr</LastName>
<ForeName>Anna Julia</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo>
<Affiliation>Institute of Neurobiology, University of Muenster, Badestrasse 9, 48149 Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stephan</LastName>
<ForeName>Raiko</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institute of Neurobiology, University of Muenster, Badestrasse 9, 48149 Muenster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Baoyu</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute and Department of Biophysics, UT Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Higgins</LastName>
<ForeName>Theresa E</ForeName>
<Initials>TE</Initials>
<AffiliationInfo>
<Affiliation>Cell Motility Laboratory, London Research Institute, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barry</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Cell Motility Laboratory, London Research Institute, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martin</LastName>
<ForeName>Morag C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Cell Motility Laboratory, London Research Institute, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rosen</LastName>
<ForeName>Michael K</ForeName>
<Initials>MK</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute and Department of Biophysics, UT Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bogdan</LastName>
<ForeName>Sven</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Institute of Neurobiology, University of Muenster, Badestrasse 9, 48149 Muenster, Germany. Electronic address: sbogdan@uni-muenster.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Way</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Cell Motility Laboratory, London Research Institute, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3LY, UK. Electronic address: michael.way@cancer.org.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01-GM56322</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dev Cell</MedlineTA>
<NlmUniqueID>101120028</NlmUniqueID>
<ISSNLinking>1534-5807</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C092744">ENA/VASP proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051300">Wiskott-Aldrich Syndrome Protein Family</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9DLQ4CIU6V</RegistryNumber>
<NameOfSubstance UI="D011392">Proline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2012 Feb 1;441(3):889-99</RefSource>
<PMID Version="1">22014333</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Methods Enzymol. 2014;540:55-72</RefSource>
<PMID Version="1">24630101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2005 Oct;7(10):977-84</RefSource>
<PMID Version="1">16155589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2006 Feb 27;172(5):771-82</RefSource>
<PMID Version="1">16505170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2006 May 9;16(9):845-53</RefSource>
<PMID Version="1">16563765</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phys Rev Lett. 2006 Jul 21;97(3):038102</RefSource>
<PMID Version="1">16907546</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Differ. 2006 Oct;13(10):1651-62</RefSource>
<PMID Version="1">16439990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2006 Nov 27;580(27):6464-70</RefSource>
<PMID Version="1">17101133</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2007 Mar 16;282(11):8446-53</RefSource>
<PMID Version="1">17229736</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 2007 May 15;305(2):470-82</RefSource>
<PMID Version="1">17383630</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2007 Dec 28;28(6):1071-82</RefSource>
<PMID Version="1">18158903</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2008 Apr 11;283(15):9814-9</RefSource>
<PMID Version="1">18283104</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2008 Nov 7;32(3):426-38</RefSource>
<PMID Version="1">18995840</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2008 Nov 19;27(22):2943-54</RefSource>
<PMID Version="1">18923426</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2009 Mar 5;458(7234):87-91</RefSource>
<PMID Version="1">19262673</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2000 Jun 23;101(7):717-28</RefSource>
<PMID Version="1">10892743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2000 Jul 21;275(29):22503-11</RefSource>
<PMID Version="1">10801818</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2000 Sep 15;19(18):4903-14</RefSource>
<PMID Version="1">10990454</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2002 Feb 18;156(4):677-87</RefSource>
<PMID Version="1">11854308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2002 Feb 18;156(4):689-701</RefSource>
<PMID Version="1">11854309</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2002 May 17;109(4):509-21</RefSource>
<PMID Version="1">12086607</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2003 Mar 1;116(Pt 5):897-906</RefSource>
<PMID Version="1">12571287</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2003 Apr 14;161(1):33-9</RefSource>
<PMID Version="1">12695497</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2003 Jun 13;278(24):21685-92</RefSource>
<PMID Version="1">12672821</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2003 Sep 15;162(6):1079-88</RefSource>
<PMID Version="1">12975351</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Biol. 2003 Oct 28;13(21):1867-75</RefSource>
<PMID Version="1">14588242</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2004 Feb 25;23(4):749-59</RefSource>
<PMID Version="1">14765121</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol. 2003;2(4):27</RefSource>
<PMID Version="1">14527345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2004 Oct;7(4):571-83</RefSource>
<PMID Version="1">15469845</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2004 Oct;7(4):585-95</RefSource>
<PMID Version="1">15469846</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 1989 Jul 14;58(1):103-13</RefSource>
<PMID Version="1">2502313</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 1995 Mar 1;9(5):521-33</RefSource>
<PMID Version="1">7535279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 1995 Nov 1;9(21):2569-82</RefSource>
<PMID Version="1">7590236</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 1997 Sep 1;16(17):5433-44</RefSource>
<PMID Version="1">9312002</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 1998 Jan;18(1):152-60</RefSource>
<PMID Version="1">9418863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mech Dev. 1998 Nov;78(1-2):113-8</RefSource>
<PMID Version="1">9858703</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuron. 1999 Feb;22(2):301-12</RefSource>
<PMID Version="1">10069336</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3739-44</RefSource>
<PMID Version="1">10097107</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2005 Jan 17;579(2):455-63</RefSource>
<PMID Version="1">15642358</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Front Biosci (Landmark Ed). 2009;14:833-46</RefSource>
<PMID Version="1">19273103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Struct Mol Biol. 2009 May;16(5):561-3</RefSource>
<PMID Version="1">19363480</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2009 Jun 15;122(Pt 12):1947-53</RefSource>
<PMID Version="1">19494122</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Biol. 2009 Sep 1;333(1):90-107</RefSource>
<PMID Version="1">19576200</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2009 Sep;136(18):3099-107</RefSource>
<PMID Version="1">19675132</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):843-50</RefSource>
<PMID Version="1">20110575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Biochem. 2010;79:707-35</RefSource>
<PMID Version="1">20533885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2010 Nov 1;191(3):571-84</RefSource>
<PMID Version="1">21041447</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2011 Feb 2;30(3):456-67</RefSource>
<PMID Version="1">21217643</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Apr 1;286(13):11543-54</RefSource>
<PMID Version="1">21278383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2011 Sep 15;438(3):535-43</RefSource>
<PMID Version="1">21749319</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2011 Nov;22(21):4079-92</RefSource>
<PMID Version="1">21900504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Dev Cell. 2012 Jan 17;22(1):12-23</RefSource>
<PMID Version="1">22264728</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(5):e37035</RefSource>
<PMID Version="1">22606326</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cell Biol. 2012 Nov-Dec;91(11-12):861-8</RefSource>
<PMID Version="1">22555291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Fly (Austin). 2012 Oct-Dec;6(4):213-27</RefSource>
<PMID Version="1">22940759</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Microsc. 2013 Sep;251(3):224-31</RefSource>
<PMID Version="1">23410210</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Cell Biol. 2013 Oct;25(5):565-73</RefSource>
<PMID Version="1">23639310</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eukaryot Cell. 2013 Nov;12(11):1509-16</RefSource>
<PMID Version="1">24036345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cell Biol. 2013 Oct-Nov;92(10-11):349-54</RefSource>
<PMID Version="1">24183239</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2013 Nov 25;203(4):673-89</RefSource>
<PMID Version="1">24247431</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2005 Aug 5;280(31):28653-62</RefSource>
<PMID Version="1">15939738</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008841">Actin Cytoskeleton</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001369">Axons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004331">Drosophila melanogaster</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017956">Photoreceptor Cells, Invertebrate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011392">Proline</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011554">Pseudopodia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017386">Sequence Homology, Amino Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051300">Wiskott-Aldrich Syndrome Protein Family</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4165403</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24687913</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>277-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4354</ELocationID>
<Abstract>
<AbstractText>The development of therapeutic resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs, ie erlotinib or gefitinib) has been the major clinical problem when treating lung adenocarcinoma patients with these agents. However, its mechanisms have not necessarily been well studied to this date. Autophagy has been recently considered to play pivotal roles in escaping from the effects of anti-neoplastic agents. Therefore, in this study, we examined its roles in the development of resistance to EGFR-TKIs in lung adenocarcinoma. We first established erlotinib-resistant cell lines (PC9/ER) from parental PC9 cells by exposing the cells to erlotinib. In PC9/ER, autophagy-related LC3A expression came to be up-regulated and constitutive activation of LC3A-mediated autophagy became more pronounced through the process of acquiring therapeutic resistance. In addition, inhibition of LC3A or autophagy restores sensitivity to EGFR-TKIs in PC9/ER. LC3A was also activated at the transcriptional level in de novo resistant cells via demethylation of the MAP1LC3A gene. We then evaluated the status of LC3A in 169 lung adenocarcinoma patients using immunohistochemistry. LC3A immunoreactivity was only detected in carcinoma cells (89/169 patients), not in non-tumoural cells. In addition, LC3A immunoreactivity was significantly correlated with progression-free survival (p = 0.0039) and overall survival (p = 0.0040) of 35 patients treated with EGFR-TKIs. The results of our present study demonstrated that LC3A-mediated autophagy in carcinoma cells was involved in the development of resistance to EGFR-TKIs, and that LC3A could serve as a promising therapeutic target for overcoming resistance to EGFR-TKIs and a novel predictor of response to EGFR-TKIs in lung adenocarcinoma patients.</AbstractText>
<CopyrightInformation>Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nihira</LastName>
<ForeName>Kaito</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, School of Medicine, Tohoku University, Sendai, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miki</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iida</LastName>
<ForeName>Shinya</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Narumi</LastName>
<ForeName>Sodai</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ono</LastName>
<ForeName>Katsuhiko</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iwabuchi</LastName>
<ForeName>Erina</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ise</LastName>
<ForeName>Kazue</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mori</LastName>
<ForeName>Kazushige</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saito</LastName>
<ForeName>Mikiyoshi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ebina</LastName>
<ForeName>Masahito</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Ikuro</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Maemondo</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yamada-Okabe</LastName>
<ForeName>Hisafumi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kondo</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sasano</LastName>
<ForeName>Hironobu</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C466626">light chain 3, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J4T82NDH7E</RegistryNumber>
<NameOfSubstance UI="C400278">erlotinib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>S65743JHBS</RegistryNumber>
<NameOfSubstance UI="C419708">gefitinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C538231">Adenocarcinoma of lung</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008869">Microtubule-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">DNA methylation</Keyword>
<Keyword MajorTopicYN="N">EGFR tyrosine kinase inhibitors</Keyword>
<Keyword MajorTopicYN="N">autophagy</Keyword>
<Keyword MajorTopicYN="N">drug resistance</Keyword>
<Keyword MajorTopicYN="N">lung cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24930886</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.</ArticleTitle>
<Pagination>
<MedlinePgn>239-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4390</ELocationID>
<Abstract>
<AbstractText>Endometrial cancer is the most frequently occurring malignancy of the female genital tract in Western countries. Although in many cases surgically curable, about 30% of the tumours represent an aggressive and untreatable disease. In an attempt to establish a reliable prognostic marker for endometrial carcinomas disregarding their histological diversity, we investigated the expression of KPNA2, a mediator of nucleocytoplasmic transport, and other cell proliferation-associated proteins and their correlation with cancer progression. We analysed patient tissue microarrays (TMAs) assembled from 527 endometrial cancer tissue specimens and uterus samples from a Trp53 knockout mouse model of endometrial cancer. Our data show that KPNA2 expression was significantly up-regulated in human endometrial carcinomas and associated with higher tumour grade (p = 0.026), higher FIGO stage (p = 0.027), p53 overexpression (p &lt; 0.001), activation of the PI3K/AKT pathway, and epithelial-mesenchymal transition. Increased nuclear KPNA2 immunoreactivity was identified as a novel predictor of overall survival, independent of well-established prognostic factors in Cox regression analyses (hazard ratio 1.7, 95% CI 1.13-2.56, p = 0.01). No significant association between KPNA2 expression and endometrial cancer subtype was detected. In the mouse model, KPNA2 showed increased expression levels from precancerous (EmgD, EIC) to far-advanced invasive lesions. We further investigated the cell proliferation capacity after siRNA-mediated KPNA2 knockdown in the human endometrial cancer cell line MFE-296. KPNA2 silencing led to decreased proliferation of the cancer cells, suggesting interplay of the protein with the cell cycle. Taken together, increased expression of KPNA2 is an independent prognostic marker for poor survival. The mechanism of enhanced nucleocytoplasmic transport by KPNA2 overexpression seems a common event in aggressive cancers since we have shown a significant correlation of KPNA2 expression and tumour aggressiveness in a large variety of other solid tumour entities. Introducing KPNA2 immunohistochemistry in routine diagnostics may allow for the identification of patients who need more aggressive treatment regimens.</AbstractText>
<CopyrightInformation>Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ikenberg</LastName>
<ForeName>Kristian</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Valtcheva</LastName>
<ForeName>Nadejda</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brandt</LastName>
<ForeName>Simone</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Christine E</ForeName>
<Initials>CE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Noske</LastName>
<ForeName>Aurelia</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rechsteiner</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rueschoff</LastName>
<ForeName>Jan H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Caduff</LastName>
<ForeName>Rosmarie</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dellas</LastName>
<ForeName>Athanassios</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Obermann</LastName>
<ForeName>Ellen</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fink</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fuchs</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krek</LastName>
<ForeName>Wilhelm</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moch</LastName>
<ForeName>Holger</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frew</LastName>
<ForeName>Ian J</ForeName>
<Initials>IJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wild</LastName>
<ForeName>Peter J</ForeName>
<Initials>PJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490630">KPNA2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490631">Kpna2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D028901">alpha Karyopherins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016889">Endometrial Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D028901">alpha Karyopherins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EMT</Keyword>
<Keyword MajorTopicYN="N">KPNA2</Keyword>
<Keyword MajorTopicYN="N">Snail</Keyword>
<Keyword MajorTopicYN="N">biomarker</Keyword>
<Keyword MajorTopicYN="N">endometrial cancer</Keyword>
<Keyword MajorTopicYN="N">importin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25042889</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-9896</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>234</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pathology</Title>
<ISOAbbreviation>J. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>228-38</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4402</ELocationID>
<Abstract>
<AbstractText>The premalignant lesions of pancreatic cancer, pancreatic intraepithelial neoplasia (PanIN), have a high frequency of mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), and genetic alterations in the retinoblastoma (Rb)-E2 factor (E2F) and transformed 3T3 cell double minute 2 (MDM2)-p53 pathways accelerate development of pancreatic ductal adenocarcinoma. The viral oncoprotein SV40 large T antigen (TAg) can inhibit the effects of the Rb family of molecules and of p53 on these pathways, and targeted expression of TAg in mouse pancreas is associated with the development of endocrine or acinar cell tumours. In this study, to determine whether the viral oncoprotein promotes pancreatic duct carcinogenesis initiated by oncogenic KRAS, we generated mice expressing temperature-sensitive SV40 large T antigen (tsTAg) on pancreatic epithelial cells in the presence or absence of Kras(G12D) . Mice with pancreas-specific tsTAg expression developed acinar cell dysplasia by 22 weeks without PanIN formation, while mice expressing both tsTAg and Kras(G12D) developed highly aggressive adenocarcinoma with a ductal cell phenotype within a short period, and died within 3 weeks. The tumours resembled human pancreatic ductal adenocarcinoma (PDAC) at the histological level, and oncogenic Kras and tsTAg synergistically activated E2f and Sre transcription in established PDAC cell lines. These results suggest that tsTAg synergistically promotes Kras(G12D) -associated PDAC formation, and our study identifies a new mouse model of PDAC that may allow a better understanding of the mechanism of carcinogenesis in pancreatic carcinoma, which shows a catastrophic clinical course.</AbstractText>
<CopyrightInformation>Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yamaguchi</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Molecular Medicine Team, Research Centre for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ikehara</LastName>
<ForeName>Sanae</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nakanishi</LastName>
<ForeName>Hayao</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ikehara</LastName>
<ForeName>Yuzuru</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Pathol</MedlineTA>
<NlmUniqueID>0204634</NlmUniqueID>
<ISSNLinking>0022-3417</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000957">Antigens, Viral, Tumor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000957">Antigens, Viral, Tumor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021441">Carcinoma, Pancreatic Ductal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016283">Proto-Oncogene Proteins p21(ras)</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">KrasG12D</Keyword>
<Keyword MajorTopicYN="N">genetically engineered mouse model</Keyword>
<Keyword MajorTopicYN="N">temperature-sensitive T antigen</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23625689</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines.</ArticleTitle>
<Pagination>
<MedlinePgn>765-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22032</ELocationID>
<Abstract>
<AbstractText>Previous studies in head and neck squamous cell carcinoma (HNSCC) cell lines have revealed that the Ah receptor (AHR) plays a significant role in mediating the "aggressive" phenotype of these cells, which includes enhanced inflammatory signaling (e.g., IL6) and migratory potential. Here we sought to identify putative novel targets of the AHR associated with enhanced tumor invasiveness. Global gene expression analysis identified a number of genes that are repressed upon treatment of OSC-19 or HN30 cells with an AHR antagonist. Three growth factors were targets of AHR activity; amphiregulin (AREG), epiregulin (EREG), and platelet-derived growth factor A (PDGFA) were repressed by an AHR antagonist and further examined. Quantitative PCR analysis, ELISA, and siRNA-mediated knock down of AHR revealed an attenuation of basal and/or induced levels of expression of these growth factors in two HNSCC lines, following AHR antagonism. In silico analysis revealed that these growth factors possess dioxin-like response elements. Two other AHR ligands, 6-formylindolo[3,2-b]carbazole and benzo(a)pyrene (BP) also elicited similar responses. In conclusion, this study identified AREG, EREG, and PDGFA as growth factor targets of AHR activity associated with metastatic phenotype of HNSCC cells, suggesting that attenuation of AHR activity may be a therapeutic strategy.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>John</LastName>
<ForeName>Kaarthik</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Center for Molecular Toxicology and Carcinogenesis and the Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, Pennsylvania; DuPont Haskell Global Centers for Health and Environmental Sciences, Newark, Delaware.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lahoti</LastName>
<ForeName>Tejas S</ForeName>
<Initials>TS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>Kelly</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hughes</LastName>
<ForeName>Jarod M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Perdew</LastName>
<ForeName>Gary H</ForeName>
<Initials>GH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>ES004869</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>ES019964</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C511621">2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001391">Azo Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C587880">EREG protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D066260">Epiregulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010982">Platelet-Derived Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018336">Receptors, Aryl Hydrocarbon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C075278">platelet-derived growth factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>103107-01-3</RegistryNumber>
<NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C535575">Carcinoma, squamous cell of head and neck</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001391">Azo Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D066260">Epiregulin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016222">Fibroblast Growth Factor 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010982">Platelet-Derived Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018336">Receptors, Aryl Hydrocarbon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">AHR</Keyword>
<Keyword MajorTopicYN="N">antagonist</Keyword>
<Keyword MajorTopicYN="N">aryl hydrocarbon receptor</Keyword>
<Keyword MajorTopicYN="N">dioxin</Keyword>
<Keyword MajorTopicYN="N">growth factors</Keyword>
<Keyword MajorTopicYN="N">head and neck cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23625726</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>Up-regulated cten by FGF2 contributes to FGF2-mediated cell migration.</ArticleTitle>
<Pagination>
<MedlinePgn>787-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22034</ELocationID>
<Abstract>
<AbstractText>Cten is a focal adhesion molecule that is expressed at very low levels in most normal tissues. Nonetheless, its expression has been found to increase dramatically in many types of cancer including colorectal, breast, gastric, and pancreatic cancer, suggesting that cten may play a critical role during tumorigenesis. To study the mechanisms that induce cten expression and the function of up-regulated cten, we examined the effects of several cancer-associated growth factors and cytokines on cten expression. We found that EGF, FGF2, NGF, PDGF, TGF-β, IGF-1, IL-6, and IL-13 were able to induce cten expression in a dose- and time-dependent manner. The Mek-Erk and PI3K-Akt pathways were two main signaling cascades responsible for cten up-regulation, whereas the Jak-Stat pathway could contribute to the increase in some conditions. Since many of these factors are known to promote cell migration, we hypothesized that up-regulated cten might contribute to this process. This hypothesis was investigated in FGF2-mediated cell migration. Silencing of cten not only reduced regular cell motility but also FGF2-mediated cell migration. Overexpression of cten promoted cell migration and FGF2 treatment failed to further enhance cell migration. Our findings that (1) cten is a common downstream molecule of these cancer-associated growth factors and cytokines; and that (2) up-regulated cten modulates cell migration induced by FGF2 and likely other growth factors as well, strongly suggest that cten could be a potential downstream therapeutic target for treating cancers associated with aberrant signaling of these growth factors and cytokines.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hung</LastName>
<ForeName>Shih-Ya</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>Center for Tissue Regeneration and Repair, Department of Biochemistry and Molecular Medicine, University of California-Davis, Sacramento, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shih</LastName>
<ForeName>Yi-Ping</ForeName>
<Initials>YP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Michelle</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lo</LastName>
<ForeName>Su Hao</ForeName>
<Initials>SH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA102537</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C074700">tensins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>103107-01-3</RegistryNumber>
<NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016222">Fibroblast Growth Factor 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008840">Microfilament Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FGF2</Keyword>
<Keyword MajorTopicYN="N">cell migration</Keyword>
<Keyword MajorTopicYN="N">cten</Keyword>
<Keyword MajorTopicYN="N">focal adhesion</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23625751</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>Downregulation of MED23 promoted the tumorigenecity of esophageal squamous cell carcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>833-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22041</ELocationID>
<Abstract>
<AbstractText>Esophageal squamous cell carcinoma (ESCC) is one of the most common tumors in the world. It is very urgent to develop new therapeutic strategies. MED23, a component of the mediator complex, is known as a hub to integrate various signaling pathways. However, the function of MED23 in ESCC remains unknown. Here, we found that the expression of MED23 was downregulated in the clinical ESCC samples and the expression of MED23 reversely correlated with tumor size and clinical stage. Moreover, overexpression of MED23 in ESCC cells inhibited cell growth dramatically, while downregulation of MED23 promoted the tumorigenecity of ESCC cells in vitro and in vivo. Mechanistically, knockdown the expression of MED23 inhibited cell apoptosis by downregulation of Bax, activated Caspase 3, activated Caspase 9 and upregulation of cyclinD1 and Bcl2. Taken together, our study revealed the suppressive role of MED23 in ESCC and MED23 might be an important therapeutic target in ESCC.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Jianxin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Qingqi</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Heng</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Chenxi</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yao</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C492159">MED23 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D056892">Mediator Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C562729">Esophageal Squamous Cell Carcinoma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004938">Esophageal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056892">Mediator Complex</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ESCC</Keyword>
<Keyword MajorTopicYN="N">cell growth and apoptosis</Keyword>
<Keyword MajorTopicYN="N">mediator MED23</Keyword>
<Keyword MajorTopicYN="N">tumorigenecity</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23661500</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>777-86</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22033</ELocationID>
<Abstract>
<AbstractText>Resistance to cisplatin-based chemotherapy is responsible for the majority of deaths from head and neck squamous cell carcinoma (HNSCC). In this study, using genome-wide gene expression analysis to investigate potential molecular mediators of HNSCC chemoresistance, we identified SERPINB2, a known inhibitor of extracellular serine proteinase urokinase-type plasminogen activator (uPA), as an important candidate. Whereas SERPINB2 is known to function as a suppressor of uPA molecular cascades, many of which play important roles in tumor invasion and metastasis, a role for SERPINB2 in cancer drug resistance has not been examined. By using quantitative real-time PCR and Western blot analysis, we determined that SERPINB2 mRNA and protein levels correlated with chemoresistance in HNSCC cell lines, and significantly lower SERPINB2 expression levels were observed in two cisplatin resistant HNSCC subclones compared to their isogenic drug-sensitive parental lines. Immunohistochemical analysis of HNSCC tumor tissues from patients treated with neoadjuvant cisplatin-based chemotherapy (n = 67 cases) revealed a significant association between SERPINB2 protein levels, tumor differentiation and patient relapse. Moreover, SERPINB2 down-regulation was a strong predictor of reduced overall survival in patients with HNSCC who received cisplatin-based chemotherapy (P = 0.001, log rank test). Studies using either siRNA-mediated down-regulation or forced over-expression of SERPINB2 in HNSCC cell lines confirmed a functional role for SERPINB2 in drug resistance. The findings were further supported using chemical inhibitors of STAT3 activity (a downstream effecter of uPAR signaling pathway), showing that STAT3 suppression altered HNSCC cell line cisplatin sensitivity. This is the first report on a role for SERPINB2 in acquired resistance to cisplatin in patients with HNSCC.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Zhiquan</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Medical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana; Department of Oral and Maxillofacial Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, P.R., China; Department of Cellular and Integrative Physiology and Indiana University Simon Cancer Center, Indianapolis, Indiana.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Haigang</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Qi</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Jingjing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Lili</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Chanbin</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Weiliang</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>House</LastName>
<ForeName>Michael G</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nephew</LastName>
<ForeName>Kenneth P</ForeName>
<Initials>KP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Zhongmin</ForeName>
<Initials>Z</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>U54CA113001</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>05</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017396">Plasminogen Activator Inhibitor 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017396">Plasminogen Activator Inhibitor 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">chemoresistance</Keyword>
<Keyword MajorTopicYN="N">chemotherapy</Keyword>
<Keyword MajorTopicYN="N">head and neck cancer</Keyword>
<Keyword MajorTopicYN="N">serpin peptidase inhibitor B2(SERPINB2)</Keyword>
<Keyword MajorTopicYN="N">uPAR signaling</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23661506</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>TPD52 represents a survival factor in ERBB2-amplified breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>807-19</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22038</ELocationID>
<Abstract>
<AbstractText>TPD52 and ERBB2 co-expression has been persistently reported in human breast cancer and animal models of this disease, but the significance of this is unknown. We identified significant positive associations between relative TPD52 and ERBB2 transcript levels in human diagnostic breast cancer samples, and maximal TPD52 expression in the hormone receptor (HR)- and ERBB2-positive sub-group. High-level TPD52 expression was associated with significantly reduced metastasis-free survival, within the overall cohort (log rank test, P = 8.6 × 10(-4), n = 375) where this was an independent predictor of metastasis-free survival (hazard ratio, 2.69, 95% confidence interval 1.59-4.54, P = 2.2 × 10(-4), n = 359), and the HR- and ERBB2-positive sub-group (log rank test, P = 0.035, n = 47). Transient TPD52 knock-down in the ERBB2-amplified breast cancer cell lines SK-BR-3 and BT-474 produced significant apoptosis, both singly and in combination with transient ERBB2 knock-down. Unlike ERBB2 knock-down, transient TPD52 knock-down produced no reduction in pAKT levels in SK-BR-3 or BT-474 cells. We then derived multiple SK-BR-3 cell lines in which TPD52 levels were stably reduced, and measured significant inverse correlations between pERBB2 and TPD52 levels in viable TPD52-depleted and control cell lines, all of which showed similar proliferative capacities. Our results therefore identify TPD52 as a survival factor in ERBB2-amplified breast cancer cells, and suggest complementary cellular functions for TPD52 and ERBB2.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Roslan</LastName>
<ForeName>Nuruliza</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Molecular Oncology Laboratory, Children's Cancer Research Unit, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia; The University of Sydney Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Westmead, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bièche</LastName>
<ForeName>Ivan</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bright</LastName>
<ForeName>Robert K</ForeName>
<Initials>RK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lidereau</LastName>
<ForeName>Rosette</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yuyan</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Byrne</LastName>
<ForeName>Jennifer A</ForeName>
<Initials>JA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>05</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C114751">TPD52 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005784">Gene Amplification</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008207">Lymphatic Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">HER2</Keyword>
<Keyword MajorTopicYN="N">Neu</Keyword>
<Keyword MajorTopicYN="N">PrLZ</Keyword>
<Keyword MajorTopicYN="N">gene amplification</Keyword>
<Keyword MajorTopicYN="N">tumor protein D52</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23765383</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-2744</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular carcinogenesis</Title>
<ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
</Journal>
<ArticleTitle>β-Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase.</ArticleTitle>
<Pagination>
<MedlinePgn>793-806</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22035</ELocationID>
<Abstract>
<AbstractText>Constitutive activation of STAT3 is frequently observed and closely linked with proliferation, survival, invasion, metastasis and angiogenesis in tumor cells. In the present study, we investigated whether β-caryophyllene oxide (CPO), a sesquiterpene isolated primarily from the essential oils of medicinal plants such as guava (Psidium guajava), and oregano (Origanum vulgare L.), can mediate its effect through interference with the STAT3 activation pathway in cancer cells. The effect of CPO on STAT3 activation, associated protein kinases and phosphatase, STAT3-regulated gene products and apoptosis was investigated using both functional proteomics tumor pathway technology platform and different tumor cell lines. We found that CPO suppressed constitutive STAT3 activation in multiple myeloma (MM), breast and prostate cancer cell lines, with a significant dose- and time-dependent effects observed in MM cells. The suppression was mediated through the inhibition of activation of upstream kinases c-Src and JAK1/2. Also, vanadate treatment reversed CPO-induced down-regulation of STAT3, suggesting the involvement of a tyrosine phosphatase. Indeed, we found that CPO induced the expression of tyrosine phosphatase SHP-1 that correlated with the down-regulation of constitutive STAT3 activation. Interestingly, deletion of SHP-1 gene by siRNA abolished the ability of CPO to inhibit STAT3 activation. The inhibition of STAT3 activation by CPO inhibited proliferation, induced apoptosis and abrogated the invasive potential of tumor cells. Our results suggest for the first time that CPO is a novel blocker of STAT3 signaling cascade and thus has an enormous potential for the treatment of various cancers harboring constitutively activated STAT3.</AbstractText>
<CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chulwon</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, Seoul, Republic of, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Somi K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kapoor</LastName>
<ForeName>Shweta</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Ansu</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vali</LastName>
<ForeName>Shireen</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abbasi</LastName>
<ForeName>Taher</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hoon</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sethi</LastName>
<ForeName>Gautam</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Kwang Seok</ForeName>
<Initials>KS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>06</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Carcinog</MedlineTA>
<NlmUniqueID>8811105</NlmUniqueID>
<ISSNLinking>0899-1987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C507924">JAK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C509249">PTPN6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>S2XU9K448U</RegistryNumber>
<NameOfSubstance UI="C515179">caryophyllene oxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004790">Enzyme Induction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053614">Janus Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012717">Sesquiterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">SHP-1</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">β-caryophyllene oxide</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25127718</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1472-6882</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BMC complementary and alternative medicine</Title>
<ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Annona muricata leaves induced apoptosis in A549 cells through mitochondrial-mediated pathway and involvement of NF-κB.</ArticleTitle>
<Pagination>
<MedlinePgn>299</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-14-299</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Annona muricata leaves have been reported to have antiproliferative effects against various cancer cell lines. However, the detailed mechanism has yet to be defined. The current study was designed to evaluate the molecular mechanisms of A. muricata leaves ethyl acetate extract (AMEAE) against lung cancer A549 cells.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The effect of AMEAE on cell proliferation of different cell lines was analyzed by MTT assay. High content screening (HCS) was applied to investigate the suppression of NF-κB translocation, cell membrane permeability, mitochondrial membrane potential (MMP) and cytochrome c translocation from mitochondria to cytosol. Reactive oxygen species (ROS) formation, lactate dehydrogenase (LDH) release and activation of caspase-3/7, -8 and -9 were measured while treatment. The western blot analysis also carried out to determine the protein expression of cleaved caspase-3 and -9. Flow cytometry analysis was used to determine the cell cycle distribution and phosphatidylserine externalization. Quantitative PCR analysis was performed to measure the gene expression of Bax and Bcl-2 proteins.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Cell viability analysis revealed the selective cytotoxic effect of AMEAE towards lung cancer cells, A549, with an IC50 value of 5.09 ± 0.41 μg/mL after 72 h of treatment. Significant LDH leakage and phosphatidylserine externalization were observed in AMEAE treated cells by fluorescence analysis. Treatment of A549 cells with AMEAE significantly elevated ROS formation, followed by attenuation of MMP via upregulation of Bax and downregulation of Bcl-2, accompanied by cytochrome c release to the cytosol. The incubation of A549 cells with superoxide dismutase and catalase significantly attenuated the cytotoxicity caused by AMEAE, indicating that intracellular ROS plays a pivotal role in cell death. The released cytochrome c triggered the activation of caspase-9 followed by caspase-3. In addition, AMEAE-induced apoptosis was accompanied by cell cycle arrest at G0/G1 phase. Moreover, AMEAE suppressed the induced translocation of NF-κB from cytoplasm to nucleus.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data showed for the first time that the ethyl acetate extract of Annona muricata inhibited the proliferation of A549 cells, leading to cell cycle arrest and programmed cell death through activation of the mitochondrial-mediated signaling pathway with the involvement of the NF-kB signalling pathway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moghadamtousi</LastName>
<ForeName>Soheil Zorofchian</ForeName>
<Initials>SZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kadir</LastName>
<ForeName>Habsah Abdul</ForeName>
<Initials>HA</Initials>
<AffiliationInfo>
<Affiliation>Biomolecular Research Group, Biochemistry Program, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia. habsah@um.edu.my.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Paydar</LastName>
<ForeName>Mohammadjavad</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rouhollahi</LastName>
<ForeName>Elham</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Karimian</LastName>
<ForeName>Hamed</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Complement Altern Med</MedlineTA>
<NlmUniqueID>101088661</NlmUniqueID>
<ISSNLinking>1472-6882</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-43-6</RegistryNumber>
<NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D031041">Annona</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053453">Caspase 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045304">Cytochromes c</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018515">Plant Leaves</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051028">bcl-2-Associated X Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25063738</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.</ArticleTitle>
<Pagination>
<MedlinePgn>232-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.019</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00366-8</ELocationID>
<Abstract>
<AbstractText>The role of microRNAs (miRNAs) in carcinogenesis as tumor suppressors or oncogenes has been widely reported. Epigenetic change is one of the mechanisms of transcriptional silencing of miRNAs in cancer. To identify lung cancer-related miRNAs that are mediated by histone modification, we conducted microarray analysis in the Calu-6 non-small cell lung cancer (NSCLC) cell line after treatment with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor. The expression level of miR-373 was enhanced by SAHA treatment in this cell line by microarray and the following quantitative RT-PCR analyses. Treatment with another HDAC inhibitor, Trichostatin A, restored the levels of miR-373 expression in A549 and Calu-6 cells, while demethylation drug treatment did not. Importantly, miR-373 was found to be down-regulated in NSCLC tissues and cell lines. Transfection of miR-373 into A549 and Calu-6 cells attenuated cell proliferation, migration, and invasion and reduced the expression of mesenchymal markers. Additional microarray analysis of miR-373-transfected cells and computational predictions identified IRAK2 and LAMP1 as targets of miR-373. Knockdown of these two genes showed similar biological effects to those of miR-373 overexpression. In clinical samples, overexpression of IRAK2 correlated with decreased disease-free survival of patients with non-adenocarcinoma. In conclusion, we found that miR-373 is silenced by histone modification in lung cancer cells and identified its function as a tumor suppressor and negative regulator of the mesenchymal phenotype through downstream IRAK2 and LAMP1 target genes. </AbstractText>
<CopyrightInformation>Published by Elsevier Ireland Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Seol</LastName>
<ForeName>Hyang Sook</ForeName>
<Initials>HS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea; Asan Center for Cancer Genome Discovery, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akiyama</LastName>
<ForeName>Yoshimitsu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shimada</LastName>
<ForeName>Shu</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Hee Jin</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Tae Im</ForeName>
<Initials>TI</Initials>
<AffiliationInfo>
<Affiliation>Asan Center for Cancer Genome Discovery, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chun</LastName>
<ForeName>Sung Min</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea; Asan Center for Cancer Genome Discovery, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Shree Ram</ForeName>
<Initials>SR</Initials>
<AffiliationInfo>
<Affiliation>Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. Electronic address: singhshr@mail.nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jang</LastName>
<ForeName>Se Jin</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea; Asan Center for Cancer Genome Discovery, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea. Electronic address: jangsejin@amc.seoul.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489116">LAMP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051907">Lysosome-Associated Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527114">MIRN373 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D053592">Interleukin-1 Receptor-Associated Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053592">Interleukin-1 Receptor-Associated Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051907">Lysosome-Associated Membrane Glycoproteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015999">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Histone deacetylase</Keyword>
<Keyword MajorTopicYN="N">IRAK2</Keyword>
<Keyword MajorTopicYN="N">LAMP1</Keyword>
<Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
<Keyword MajorTopicYN="N">Tumor suppressor</Keyword>
<Keyword MajorTopicYN="N">microRNA-373</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25063739</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG.</ArticleTitle>
<Pagination>
<MedlinePgn>201-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.026</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00373-5</ELocationID>
<Abstract>
<AbstractText>MicroRNAs (miRNAs) are a class of non-coding RNAs that post-transcriptionally inhibit gene expression. In this study, we discovered that microRNA-370 (miR-370) was down-regulated in endometrioid ovarian cancer cells. In IGROV1 and TOV112D endometrioid ovarian cancer cells, miR-370 suppressed cellular viability and colony formation. miR-370 also enhanced endometrioid ovarian cancer cell chemosensitivity to cDDP. Endoglin (ENG) was directly and negatively regulated by miR-370. In addition, hypermethylation was a potential mechanism of miR-370 epigenetic silencing. We conclude that miR-370 acts as a tumor suppressor in endometrioid ovarian cancer via ENG regulation. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Xiao-Ping</ForeName>
<Initials>XP</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynaecology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China; Department of Obstetrics and Gynaecology, Yancheng 1th People Hospital, Yancheng, Jiangsu Province, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>You-Guo</ForeName>
<Initials>YG</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynaecology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lan</LastName>
<ForeName>Jian-Yun</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynaecology, Yancheng 1th People Hospital, Yancheng, Jiangsu Province, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Zong-Ji</ForeName>
<Initials>ZJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Obstetrics and Gynaecology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China. Electronic address: zongjishen2013@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C064206">ENG protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C526503">MIRN370 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018269">Carcinoma, Endometrioid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Endoglin</Keyword>
<Keyword MajorTopicYN="N">Endometrioid ovarian cancer</Keyword>
<Keyword MajorTopicYN="N">MicroRNA</Keyword>
<Keyword MajorTopicYN="N">Target gene</Keyword>
<Keyword MajorTopicYN="N">miR-370</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25067787</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.</ArticleTitle>
<Pagination>
<MedlinePgn>211-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.024</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00371-1</ELocationID>
<Abstract>
<AbstractText>Although the role of p53 as a tumour suppressor in renal cell carcinoma (RCC) is unclear, our recent analysis suggests that increased wild-type p53 protein expression is associated with poor outcome. A growing body of evidence also suggests that p53 expression and increased co-expression of MDM2 are linked with poor prognosis in RCC. We have therefore examined whether an MDM2 antagonist; Nutlin-3, might rescue/increase p53 expression and induce growth inhibition or apoptosis in RCC cells that retain wild-type p53. We show that inhibition of p53 suppression by MDM2 in RCC cells promotes growth arrest and p53-dependent senescence - phenotypes known to mediate p53 tumour suppression in vivo. We propose that future investigations of therapeutic strategies for RCC should incorporate MDM2 antagonism as part of strategies aimed at rescuing/augmenting p53 tumour suppressor function. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Polański</LastName>
<ForeName>Radosław</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>p53/MDM2 Research Group, Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, University of Liverpool, Liverpool L3 9TA, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Noon</LastName>
<ForeName>Aidan P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo>
<Affiliation>p53/MDM2 Research Group, Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, University of Liverpool, Liverpool L3 9TA, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blaydes</LastName>
<ForeName>Jeremy</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Southampton Cancer Research UK Centre, University of Southampton School of Medicine, Southampton, Hampshire, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Phillips</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Southampton Cancer Research UK Centre, University of Southampton School of Medicine, Southampton, Hampshire, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rubbi</LastName>
<ForeName>Carlos P</ForeName>
<Initials>CP</Initials>
<AffiliationInfo>
<Affiliation>p53/MDM2 Research Group, Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, University of Liverpool, Liverpool L3 9TA, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parsons</LastName>
<ForeName>Keith</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Royal Liverpool University Hospital, Liverpool L7 8XP, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vlatković</LastName>
<ForeName>Nikolina</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>p53/MDM2 Research Group, Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, University of Liverpool, Liverpool L3 9TA, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Boyd</LastName>
<ForeName>Mark T</ForeName>
<Initials>MT</Initials>
<AffiliationInfo>
<Affiliation>p53/MDM2 Research Group, Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, University of Liverpool, Liverpool L3 9TA, UK. Electronic address: mboyd@liv.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C482205">nutlin 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C497206">MDM2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D051736">Proto-Oncogene Proteins c-mdm2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016922">Cell Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051736">Proto-Oncogene Proteins c-mdm2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">MDM2</Keyword>
<Keyword MajorTopicYN="N">Nutlin-3</Keyword>
<Keyword MajorTopicYN="N">Renal cell carcinoma</Keyword>
<Keyword MajorTopicYN="N">Senescence</Keyword>
<Keyword MajorTopicYN="N">Targeted therapy</Keyword>
<Keyword MajorTopicYN="N">p53</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25069038</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.</ArticleTitle>
<Pagination>
<MedlinePgn>272-80</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.033</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00384-X</ELocationID>
<Abstract>
<AbstractText>Metronomic cyclophosphamide (CPA) treatment activates robust innate anti-tumor immunity and induces major regression of large, implanted brain tumor xenografts when administered on an intermittent, every 6-day schedule, but not on a daily low-dose or a maximum-tolerated dose CPA schedule. Here, we used an implanted GL261 glioma model to compare five intermittent metronomic CPA schedules to elucidate the kinetics and schedule dependence of innate immune cell recruitment and tumor regression. Tumor-recruited natural killer cells induced by two every 6-day treatment cycles were significantly ablated 1 day after a third CPA treatment, but largely recovered several days later. Natural killer and other tumor-infiltrating innate immune cells peaked 12 days after the last CPA treatment on the every 6-day schedule, suggesting that drug-free intervals longer than 6 days may show increased efficacy. Metronomic CPA treatments spaced 9 or 12 days apart, or on an alternating 6 and 9 day schedule, induced extensive tumor regression, similar to the 6-day schedule; however, the tumor-infiltrating natural killer cell responses were not sustained, leading to rapid resumption of tumor growth after day 24, despite ongoing metronomic CPA treatment. Increasing the CPA dose prolonged the period of tumor regression on the every 9-day schedule, but natural killer cell activation was markedly decreased. Thus, while several intermittent metronomic CPA treatment schedules can activate innate immune cell recruitment leading to major tumor regression, sustained immune and anti-tumor responses are only achieved on the 6-day schedule. However, even with this schedule, some tumors eventually relapse, indicating a need for further improvements in this immunogenic metronomic therapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Junjie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell and Molecular Biology, Department of Biology, Boston University, 5 Cummington Mall, Boston, MA 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Waxman</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Division of Cell and Molecular Biology, Department of Biology, Boston University, 5 Cummington Mall, Boston, MA 02215, USA. Electronic address: djw@bu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA49248</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA049248</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8N3DW7272P</RegistryNumber>
<NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059250">Administration, Metronomic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018906">Antineoplastic Agents, Alkylating</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008813">Mice, Inbred ICR</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS616845 [Available on 10/28/15]</OtherID>
<OtherID Source="NLM">PMC4162810 [Available on 10/28/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chemotherapy schedule</Keyword>
<Keyword MajorTopicYN="N">GL261 glioma</Keyword>
<Keyword MajorTopicYN="N">Innate immune response</Keyword>
<Keyword MajorTopicYN="N">Metronomic chemotherapy</Keyword>
<Keyword MajorTopicYN="N">Natural killer cells</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079687</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Delivery of doxorubicin across the blood-brain barrier by ondansetron pretreatment: a study in vitro and in vivo.</ArticleTitle>
<Pagination>
<MedlinePgn>242-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.018</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00365-6</ELocationID>
<Abstract>
<AbstractText>Doxorubicin (Dox) has got a limited efficacy in the treatment of central nervous system tumors because of its poor penetration through blood-brain barrier mediated by MDR efflux transporters. We investigated the possibility that ondansetron (Ond) enhances Dox cytotoxicity in cell lines interfering with P-glycoprotein and increases Dox concentration in rat brain tissues. The MDR phenotype was studied using human hepatocellular carcinoma cell line PLC/PRF/5 (P5 and P1(0.5) clones), two subclones of NIH 3T3 cells (PSI-2 and PN1A) and two glioblastoma cell lines (A172, U87MG). Rats were pretreated with Ond before injection of Dox. Quantitative analysis of Dox was performed by mass spectrometry. Our in vitro experiments demonstrated that Ond at 10 µg/ml is not toxic to all cell lines. However, Ond reverses the MDR phenotype in P1(0.5) and PN1A cell lines. In addition, we showed that pretreatment with Ond increases Dox concentration in rat brain tissues, without increasing acute heart and renal toxicity. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sardi</LastName>
<ForeName>Iacopo</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Neuro-oncology Unit, Department of Paediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy; Department of Health Sciences, University of Florence, Florence, Italy. Electronic address: i.sardi@meyer.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fantappiè</LastName>
<ForeName>Ornella</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Second Medical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence University, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>la Marca</LastName>
<ForeName>Giancarlo</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Newborn Screening, Biochemistry and Pharmacology Laboratory, Paediatric Neurology Unit and Laboratories, Department of Neuroscience, Meyer Children's Hospital, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Giovannini</LastName>
<ForeName>Maria Grazia</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Department of Health Sciences, Section of Pharmacology and Clinical Oncology, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iorio</LastName>
<ForeName>Anna Lisa</ForeName>
<Initials>AL</Initials>
<AffiliationInfo>
<Affiliation>Neuro-oncology Unit, Department of Paediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy; Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>da Ros</LastName>
<ForeName>Martina</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Neuro-oncology Unit, Department of Paediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy; Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Malvagia</LastName>
<ForeName>Sabrina</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Newborn Screening, Biochemistry and Pharmacology Laboratory, Paediatric Neurology Unit and Laboratories, Department of Neuroscience, Meyer Children's Hospital, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cardellicchio</LastName>
<ForeName>Stefania</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Neuro-oncology Unit, Department of Paediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy; Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Giunti</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Neuro-oncology Unit, Department of Paediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy; Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Martino</LastName>
<ForeName>Maurizio</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Neuro-oncology Unit, Department of Paediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy; Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mazzanti</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Second Medical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence University, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020168">P-Glycoprotein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4AF302ESOS</RegistryNumber>
<NameOfSubstance UI="D017294">Ondansetron</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018432">Drug Resistance, Multiple</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D041681">NIH 3T3 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017294">Ondansetron</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020168">P-Glycoprotein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014018">Tissue Distribution</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Blood–brain barrier</Keyword>
<Keyword MajorTopicYN="N">Brain tumors</Keyword>
<Keyword MajorTopicYN="N">Doxorubicin</Keyword>
<Keyword MajorTopicYN="N">Multidrug resistance</Keyword>
<Keyword MajorTopicYN="N">Ondansetron</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079688</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>194-200</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.034</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00399-1</ELocationID>
<Abstract>
<AbstractText>The invasiveness of glioblastoma is a major cause of poor prognosis and relapse. However, the molecular mechanism controlling glioma cell invasion is poorly understood. Here, we report that receptor activator of nuclear factor kappa-B (NFκB) ligand (RANKL) promotes glioma cell invasion in vivo, but not in vitro. Unlike the invasiveness under in vitro culture conditions, in vivo xenograft studies revealed that LN229 cells expressing high endogenous RANKL generated more invasive tumors than U87MG cells expressing relatively low endogenous RANKL. Consistently, RANKL-overexpressing U87MG resulted in invasive tumors, whereas RANKL-depleted LN229 generated rarely invasive tumors. We found that the number of activated astrocytes was markedly increased in the periphery of RANKL-high invasive tumors. RANKL activated astrocytes through NFκB signaling and these astrocytes in turn secreted various factors which regulate glioma cell invasion. Among them, transforming growth factor β (TGF-β) signaling was markedly increased in glioblastoma specimens and xenograft tumors expressing high levels of RANKL. These results indicate that RANKL contributes to glioma invasion by modulating the peripheral microenvironment of the tumor, and that targeting RANKL signaling has important implications for the prevention of highly invasive glioblastoma. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jun-Kyum</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Xiong</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sohn</LastName>
<ForeName>Young-Woo</ForeName>
<Initials>YW</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Xun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jeon</LastName>
<ForeName>Hee-Young</ForeName>
<Initials>HY</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Eun-Jung</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ham</LastName>
<ForeName>Seok Won</ForeName>
<Initials>SW</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jeon</LastName>
<ForeName>Hye-Min</ForeName>
<Initials>HM</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>So-Young</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>Se-Yeong</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>Institute of Life Science and Natural Resources, Korea University, Seoul 136-713, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Jinlong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Specific Organs Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hak</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea; Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Jong Bae</ForeName>
<Initials>JB</Initials>
<AffiliationInfo>
<Affiliation>Specific Organs Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakano</LastName>
<ForeName>Ichiro</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Hyunggee</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Republic of Korea. Electronic address: hg-kim@korea.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053245">RANK Ligand</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505688">TNFSF11 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053245">RANK Ligand</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Astrocyte</Keyword>
<Keyword MajorTopicYN="N">Glioblastoma</Keyword>
<Keyword MajorTopicYN="N">RANKL signaling</Keyword>
<Keyword MajorTopicYN="N">Tumor-invasive microenvironment</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25086185</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>258-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.027</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00374-7</ELocationID>
<Abstract>
<AbstractText>Cancer cells with constitutive phosphatidylinositol 3-kinase (PI3K)/Akt pathway activation have been associated with overexpression of the lipogenic enzyme fatty acid synthase (FAS) as a means to provide lipids necessary for cell growth. In contrast, K-Ras-driven cancer cells suppress utilization of de novo synthesized fatty acids and rely on exogenously supplied fatty acids for cell growth and membrane phospholipid biosynthesis. Consistent with a differential need for de novo fatty acid synthesis, cancer cells with activated PI3K signaling were sensitive to suppression of FAS; whereas mutant K-Ras-driven cancer cells continued to proliferate with suppressed FAS. Surprisingly, in response to FAS suppression, we observed robust increases in both Akt and ERK phosphorylation. Akt phosphorylation was dependent on the insulin-like growth factor-1 receptor (IGF-1R)/PI3K pathway and mTOR complex 2. Intriguingly, K-Ras-mediated ERK activation was dependent on N-Ras. Pharmacological inhibition of PI3K and MEK in K-Ras-driven cancer cells resulted in increased sensitivity to FAS inhibition. These data reveal a surprising sensitivity of K-Ras-driven cancer cells to FAS suppression when stimulation of Akt and ERK was prevented. As K-Ras-driven cancers are notoriously difficult to treat, these findings have therapeutic implications. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yellen</LastName>
<ForeName>Paige</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, Hunter College, City University of New York, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Foster</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, Hunter College, City University of New York, New York, NY, USA. Electronic address: foster@genectr.hunter.cuny.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA046677</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-CA046677</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RR-03037</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>TL1RR024998</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054872">Fatty Acid Synthesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506614">PD 0325901</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>154447-36-6</RegistryNumber>
<NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>17397-89-6</RegistryNumber>
<NameOfSubstance UI="D002569">Cerulenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9N3CBB0BIQ</RegistryNumber>
<NameOfSubstance UI="D004159">Diphenylamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.85</RegistryNumber>
<NameOfSubstance UI="D064429">Fatty Acid Synthases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.25</RegistryNumber>
<NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002569">Cerulenin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002867">Chromones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004159">Diphenylamine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064429">Fatty Acid Synthases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054872">Fatty Acid Synthesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050155">Lipogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020930">MAP Kinase Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020935">MAP Kinase Signaling System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009025">Morpholines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS618293 [Available on 10/28/15]</OtherID>
<OtherID Source="NLM">PMC4170853 [Available on 10/28/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Akt</Keyword>
<Keyword MajorTopicYN="N">ERK</Keyword>
<Keyword MajorTopicYN="N">Fatty acid synthase</Keyword>
<Keyword MajorTopicYN="N">K-Ras</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25130168</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>353</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).</ArticleTitle>
<Pagination>
<MedlinePgn>153-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.06.022</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00440-6</ELocationID>
<Abstract>
<AbstractText>The mechanism underlying the aggressive behaviors of triple negative breast cancer (TNBC) is not well characterized yet. The association between cancer stem cell (CSC) population and the aggressive behaviors of TNBC has not been established. We found the CD44(+)/CD24(-) cell population was enriched in TNBC tissues and cell lines, with a higher capacity of proliferation, migration, invasion and tumorigenicity as well as lower adhesion ability. The CD44(+)/CD24(-) cell population with cancer stem cell-like properties may play an important role in the aggressive behaviors of TNBC. This discovery may lead to new therapeutic strategies targeting CD44(+)/CD24(-) cell population in TNBC. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Huihui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Shandong Cancer Hospital/Institute, Jinan, Shandong 250017, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Haijuan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Xiuqing</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Xiaoyan</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Chen</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhan</LastName>
<ForeName>Qimin</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qian</LastName>
<ForeName>Haili</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: qianhaili@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Binghe</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: binghxu@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051927">Antigens, CD24</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018960">Antigens, CD44</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497889">CD24 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051927">Antigens, CD24</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018960">Antigens, CD44</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018270">Carcinoma, Ductal, Breast</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008207">Lymphatic Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064726">Triple Negative Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CD44(+)/CD24(−).</Keyword>
<Keyword MajorTopicYN="N">Cancer stem cells</Keyword>
<Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25064842</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>New tumor suppressor CXXC finger protein 4 inactivates mitogen activated protein kinase signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>3322-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.07.014</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00563-8</ELocationID>
<Abstract>
<AbstractText>As a well-characterized master player in epigenetic regulatory network, EZH2 is widely implicated in the development of many malignancies. We previously found that EZH2 promoted Wnt/β-catenin activation through downregulation of CXXC4 expression. In this report, we demonstrated that CXXC4 inhibited MAPK signaling through binding to ERK-1/2 and abrogating the interaction of ERK 1/2 with MEK1/2. L183, the critical residue in CXXC4 ERK D domain, was found to be essential for CXXC4-ERK 1/2 interaction and the growth inhibitory effect of CXXC4 in human cancer cells. In summary, CXXC4 directly disrupted MEK1/2-ERK 1/2 interaction to inactivate MAPK signaling. L183 site is indispensable for the binding of CXXC4 to ERK1/2 and growth inhibitory effect of CXXC4. Therefore, EZH2 can activate MAPK signaling by inhibiting CXXC4 expression.</AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Haiqi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cancer Biology, Institute of Clinical Science, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Lifeng</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cancer Biology, Institute of Clinical Science, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lan</LastName>
<ForeName>Huiyin</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cancer Biology, Institute of Clinical Science, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Qi</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Yanning</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cancer Biology, Institute of Clinical Science, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jiaqiu</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yue</LastName>
<ForeName>Yongfang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cancer Biology, Institute of Clinical Science, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Hongchuan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Cancer Biology, Institute of Clinical Science, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Xian</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: wangxzju@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C418221">CXXC4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="C498409">EZH2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="D063151">Polycomb Repressive Complex 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.25</RegistryNumber>
<NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048049">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020930">MAP Kinase Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020935">MAP Kinase Signaling System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063151">Polycomb Repressive Complex 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060449">Wnt Signaling Pathway</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CXXC finger protein 4 (CXXC4)</Keyword>
<Keyword MajorTopicYN="N">Enhancer of zeste homologue 2 (EZH2)</Keyword>
<Keyword MajorTopicYN="N">Extracellular signal-regulated kinase (ERK)</Keyword>
<Keyword MajorTopicYN="N">Gastric carcinogenesis</Keyword>
<Keyword MajorTopicYN="N">MAP kinase (MEK)</Keyword>
<Keyword MajorTopicYN="N">Mitogen-activated protein kinase (MAPK)</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25080009</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.</ArticleTitle>
<Pagination>
<MedlinePgn>3333-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.07.021</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00570-5</ELocationID>
<Abstract>
<AbstractText>Understanding the resistance of glioma cells to chemotherapy has been an enormous challenge. In particular, mechanisms by which tumor cells acquire resistance to chemotherapy under hypoxic conditions are not fully understood. In this study, we have found that miR-497 is overexpressed in glioma and that hypoxia can induce the expression of miR-497 at the transcriptional level by binding with the hypoxia response element in the promoter. Ectopic overexpression of miR-497 promotes chemotherapy resistance in glioma cells by targeting PDCD4, a tumor suppressor that is involved in apoptosis. In contrast, the inhibition of miR-497 enhances apoptosis and increases the sensitivity of glioma cells to TMZ. These results suggest that miR-497 is a potential molecular target for glioma therapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lan</LastName>
<ForeName>Jin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xue</LastName>
<ForeName>Yajun</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Huairui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Sanhu</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Zhijian</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fang</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Cong</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lou</LastName>
<ForeName>Meiqing</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>The Affiliated First People's Hospital of Shanghai Jiaotong University, School of Medicine, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C559640">MIRN497 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C114487">PDCD4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7GR28W0FJI</RegistryNumber>
<NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>85622-93-1</RegistryNumber>
<NameOfSubstance UI="C047246">temozolomide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018906">Antineoplastic Agents, Alkylating</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015687">Cell Hypoxia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003606">Dacarbazine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016601">RNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020218">Response Elements</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Drug resistance</Keyword>
<Keyword MajorTopicYN="N">Glioma</Keyword>
<Keyword MajorTopicYN="N">PDCD4</Keyword>
<Keyword MajorTopicYN="N">miR-497</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093297</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hypoxia inducible factor-1α suppresses Peroxiredoxin 3 expression to promote proliferation of CCRCC cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3390-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.07.030</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00579-1</ELocationID>
<Abstract>
<AbstractText>Peroxiredoxin 3 (Prx3) is a mitochondrial member of the antioxidant family of thioredoxin peroxidases that uses mitochondrial thioredoxin 2 as a source of reducing equivalents to scavenge hydrogen peroxide (H2O2). Here, we report that the protein levels of Prx3 are significantly reduced in VHL-deficient clear cell renal cell carcinoma (CCRCC). Furthermore, stabilization of HIF-1α protein, caused either by VHL deficiency under normoxia, or by hypoxia, significantly reduced Prx3 expression. Luciferase-reporter and chromatin-immunoprecipitation assays indicated that HIF-1α binds to the hypoxia-responsive elements of PRDX3 promoter and represses its transcription. Finally, shRNA-based assays suggested that Prx3 downregulation is required for the HIF-1α-dependent proliferation of CCRCC cells. Taken together, our results shed new light onto the mechanism of HIF-1α-dependent proliferation in CCRCC cells.</AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xi</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Yao-Hui</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Department of Science and Education, Minghang Central Hospital, Shanghai 201100, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Dong-Yan</ForeName>
<Initials>DY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Qian-Yu</ForeName>
<Initials>QY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Li-Jin</ForeName>
<Initials>LJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ji</LastName>
<ForeName>Guo</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Jia-Cheng</ForeName>
<Initials>JC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hui-Zhen</ForeName>
<Initials>HZ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, PR China. Electronic address: zhanghuizhen1967@sina.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Qing</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China. Electronic address: weiqing1971@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.11.1.15</RegistryNumber>
<NameOfSubstance UI="C516115">PRDX3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.11.1.15</RegistryNumber>
<NameOfSubstance UI="D061105">Peroxiredoxin III</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C497446">VHL protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D051794">Von Hippel-Lindau Tumor Suppressor Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015687">Cell Hypoxia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004794">Enzyme Repression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061105">Peroxiredoxin III</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020218">Response Elements</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051794">Von Hippel-Lindau Tumor Suppressor Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">HIF-1α</Keyword>
<Keyword MajorTopicYN="N">Proliferation</Keyword>
<Keyword MajorTopicYN="N">Prx3</Keyword>
<Keyword MajorTopicYN="N">VHL</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25117453</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Zinc finger MYND-type containing 8 promotes tumour angiogenesis via induction of vascular endothelial growth factor-A expression.</ArticleTitle>
<Pagination>
<MedlinePgn>3409-16</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.07.033</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00582-1</ELocationID>
<Abstract>
<AbstractText>Zinc finger, MYND-type containing 8 (ZMYND8) encodes a receptor for activated C-kinase protein. Here, we report that ZMYND8 promotes angiogenesis in prostate cancer xenografts in zebrafish, as well as tube formation in human umbilical vascular endothelial cell (HUVEC) cultures. Using transcriptome analyses, we found upregulation of ZMYND8 expression in both zebrafish prostate cancer xenografts and prostate cancer samples from patients. In vitro and in vivo ZMYND8 knockdown suppressed angiogenesis, whereas ZMYND8 overexpression enhanced angiogenesis. Notably, ZMYND8 induced vegfa mRNA expression selectively in prostate cancer xenografts. Integrated analysis of human and zebrafish transcriptomes, which identified ZMYND8, might be a powerful strategy to determine also other molecular targets for inhibiting prostate cancer progression. </AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kuroyanagi</LastName>
<ForeName>Junya</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shimada</LastName>
<ForeName>Yasuhito</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Systems Pharmacology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Mie University Medical Zebrafish Research Center, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Bioinformatics, Mie University Life Science Research Center, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Omics Medicine, Mie University Industrial Technology Innovation Institute, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Beibei</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ariyoshi</LastName>
<ForeName>Michiko</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Umemoto</LastName>
<ForeName>Noriko</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Systems Pharmacology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishimura</LastName>
<ForeName>Yuhei</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Systems Pharmacology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Mie University Medical Zebrafish Research Center, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Bioinformatics, Mie University Life Science Research Center, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Omics Medicine, Mie University Industrial Technology Innovation Institute, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>Toshio</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Systems Pharmacology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Mie University Medical Zebrafish Research Center, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Bioinformatics, Mie University Life Science Research Center, 2-174 Edobashi, Tsu, Mie 514-8507, Japan; Department of Omics Medicine, Mie University Industrial Technology Innovation Institute, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. Electronic address: tanaka@doc.medic.mie-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C076645">receptors for activated C kinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061307">Human Umbilical Vein Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">DNA microarray</Keyword>
<Keyword MajorTopicYN="N">Prostate cancer</Keyword>
<Keyword MajorTopicYN="N">Tumour vessels</Keyword>
<Keyword MajorTopicYN="N">Xenotransplantation</Keyword>
<Keyword MajorTopicYN="N">Zebrafish</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128584</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>PDE7A1 hydrolyzes cCMP.</ArticleTitle>
<Pagination>
<MedlinePgn>3469-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.08.005</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00606-1</ELocationID>
<Abstract>
<AbstractText>The degradation and biological role of the cyclic pyrimidine nucleotide cCMP is largely elusive. We investigated nucleoside 3',5'-cyclic monophosphate (cNMP) specificity of six different recombinant phosphodiesterases (PDEs) by using a highly-sensitive HPLC-MS/MS detection method. PDE7A1 was the only enzyme that hydrolyzed significant amounts of cCMP. Enzyme kinetic studies using purified GST-tagged truncated PDE7A1 revealed a cCMP KM value of 135 ± 19 μM. The Vmax for cCMP hydrolysis reached 745 ± 27 nmol/(minmg), which is about 6-fold higher than the corresponding velocity for adenosine 3',5'-cyclic monophosphate (cAMP) degradation. In summary, PDE7A is a high-speed and low-affinity PDE for cCMP.</AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Monzel</LastName>
<ForeName>Maike</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kuhn</LastName>
<ForeName>Maike</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bähre</LastName>
<ForeName>Heike</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Core Facility Mass Spectrometry and Metabolomics, Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seifert</LastName>
<ForeName>Roland</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schneider</LastName>
<ForeName>Erich H</ForeName>
<Initials>EH</Initials>
<AffiliationInfo>
<Affiliation>Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497936">3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009574">Nitro Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3616-08-8</RegistryNumber>
<NameOfSubstance UI="D003563">Cyclic CMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.4.17</RegistryNumber>
<NameOfSubstance UI="D054708">Cyclic Nucleotide Phosphodiesterases, Type 7</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.4.17</RegistryNumber>
<NameOfSubstance UI="C517458">PDE7A protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000242">Cyclic AMP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003563">Cyclic CMP</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054708">Cyclic Nucleotide Phosphodiesterases, Type 7</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006868">Hydrolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007700">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009574">Nitro Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010726">Phosphodiesterase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015290">Second Messenger Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061987">Sf9 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018411">Spodoptera</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013379">Substrate Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cyclic CMP</Keyword>
<Keyword MajorTopicYN="N">Cyclic nucleotides</Keyword>
<Keyword MajorTopicYN="N">Enzyme kinetics</Keyword>
<Keyword MajorTopicYN="N">HPLC–MS</Keyword>
<Keyword MajorTopicYN="N">Phosphodiesterase</Keyword>
<Keyword MajorTopicYN="N">Second messenger</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25131931</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.</ArticleTitle>
<Pagination>
<MedlinePgn>3491-500</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.08.008</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00609-7</ELocationID>
<Abstract>
<AbstractText>The aberrant expression of PSMD10 has important functions in various malignancies. This study showed that PSMD10 was highly expressed and inversely correlated with the expression of miR-605 in intrahepatic cholangiocarcinoma (ICC) specimens. MiR-605 directly targeted and repressed PSMD10 expression. In addition, over-expression of miR-605 inhibited ICC cell progression both in vitro and in vivo. This effect of miR-605 on ICC cells was similar to that of PSMD10 knock-down by RNAi. Moreover, restoration of PSMD10 could reverse the phenotypic alteration caused by miR-605 in ICC cells. These results suggest a new therapeutic strategy in ICC by restoring miR-605, which is regulated by p53. </AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jianwei</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tian</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Dajiang</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jian</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Peng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Shuguo</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xiaowu</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Shuguang</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China. Electronic address: sgwang90@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C556602">MIRN605 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C403591">PSMD10 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.25.1</RegistryNumber>
<NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C535533">Intrahepatic cholangiocarcinoma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020413">3' Untranslated Regions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001650">Bile Duct Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001653">Bile Ducts, Intrahepatic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018281">Cholangiocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046988">Proteasome Endopeptidase Complex</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Intrahepatic cholangiocarcinoma</Keyword>
<Keyword MajorTopicYN="N">Invasion</Keyword>
<Keyword MajorTopicYN="N">Proteasome 26S subunit non-ATPase 10</Keyword>
<Keyword MajorTopicYN="N">miR-605</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25131932</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Paired related homeobox protein-like 1 (Prrxl1) controls its own expression by a transcriptional autorepression mechanism.</ArticleTitle>
<Pagination>
<MedlinePgn>3475-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.08.006</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00607-3</ELocationID>
<Abstract>
<AbstractText>The homeodomain factor paired related homeobox protein-like 1 (Prrxl1) is crucial for proper assembly of dorsal root ganglia (DRG)-dorsal spinal cord (SC) pain-sensing circuit. By performing chromatin immunoprecipitation with either embryonic DRG or dorsal SC, we identified two evolutionarily conserved regions (i.e. proximal promoter and intron 4) of Prrxl1 locus that show tissue-specific binding of Prrxl1. Transcriptional assays confirm the identified regions can mediate repression by Prrxl1, while gain-of-function studies in Prrxl1 expressing ND7/23 cells indicate Prrxl1 can down-regulate its own expression. Altogether, our results suggest that Prrxl1 uses distinct regulatory regions to repress its own expression in DRG and dorsal SC.</AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Monteiro</LastName>
<ForeName>César B</ForeName>
<Initials>CB</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Biologia Experimental, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal; Morfofisiologia do Sistema Somatosensitivo, IBMC - Instituto de Biologia Celular e Molecular, 4150-180 Porto, Portugal. Electronic address: cesar48.48@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Costa</LastName>
<ForeName>Mariana F</ForeName>
<Initials>MF</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Biologia Experimental, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal; Morfofisiologia do Sistema Somatosensitivo, IBMC - Instituto de Biologia Celular e Molecular, 4150-180 Porto, Portugal. Electronic address: marianafacosta@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reguenga</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Biologia Experimental, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal; Morfofisiologia do Sistema Somatosensitivo, IBMC - Instituto de Biologia Celular e Molecular, 4150-180 Porto, Portugal. Electronic address: cregueng@med.up.pt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lima</LastName>
<ForeName>Deolinda</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Biologia Experimental, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal; Morfofisiologia do Sistema Somatosensitivo, IBMC - Instituto de Biologia Celular e Molecular, 4150-180 Porto, Portugal. Electronic address: limad@med.up.pt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Castro</LastName>
<ForeName>Diogo S</ForeName>
<Initials>DS</Initials>
<AffiliationInfo>
<Affiliation>Molecular Neurobiology, IGC - Instituto Gulbenkian de Ciência, 2780-156 Oeiras, Portugal. Electronic address: dscastro@igc.gulbenkian.pt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Monteiro</LastName>
<ForeName>Filipe A</ForeName>
<Initials>FA</Initials>
<AffiliationInfo>
<Affiliation>Departamento de Biologia Experimental, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal; Morfofisiologia do Sistema Somatosensitivo, IBMC - Instituto de Biologia Celular e Molecular, 4150-180 Porto, Portugal. Electronic address: filipem@med.up.pt.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C433766">Prrxl1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025461">Feedback, Physiological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005727">Ganglia, Spinal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020033">Protein Isoforms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Autorepression</Keyword>
<Keyword MajorTopicYN="N">Chromatin immunoprecipitation</Keyword>
<Keyword MajorTopicYN="N">Dorsal root ganglia</Keyword>
<Keyword MajorTopicYN="N">Dorsal spinal cord</Keyword>
<Keyword MajorTopicYN="N">Paired related homeobox protein-like 1</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24913304</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1432-1335</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of cancer research and clinical oncology</Title>
<ISOAbbreviation>J. Cancer Res. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.</ArticleTitle>
<Pagination>
<MedlinePgn>1689-704</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-014-1727-y</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Head and neck squamous cell carcinoma (HNSCC) cell lines with cytoplasmically sequestered mutant p53 (p53(mut_c)) are frequently more resistant to cisplatin (CDDP) than cells with mutant but nuclear p53 (p53(mut_n)). The aim of the study was to identify underlying mechanisms implicated in CDDP resistance of HNSCC cells carrying cytoplasmic p53(mut).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Microarray analysis, quantitative reverse transcription polymerase chain reaction, Western blot analysis and immunocytochemistry were used to identify and evaluate candidate genes involved in CDDP resistance of p53(mut_c) cells. RNAi knockdown or treatment with inhibitors together with flow cytometry-based methods was used for functional assessment of the identified candidate genes. Cellular metabolic activity was assessed with the XTT assay, and the redox capacity of cells was evaluated by measuring cellular glutathione (GSH) levels.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Upregulation of ABCC2 and ABCG2 transporters was observed in CDDP-resistant p53(mut_c) HNSCC cells. Furthermore, p53(mut_c) cells exhibited a pronounced side population that could be suppressed by RNAi knockdown of ABCG2 as well as treatment with the ATP-binding-cassette transporter inhibitors imatinib, MK571 and tariquidar. Metabolic activity and cellular GSH levels were higher in CDDP-resistant p53(mut_c) cells, consistent with a higher capacity to fend off cytotoxic oxidative effects such as those caused by CDDP treatment. Finally, ABCC2/G2 inhibition of HNSCC cells with MK571 markedly enhanced CDDP sensitivity of HNSCC cells.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The observations in this study point to a major role of p53(mut_c) in conferring a stem cell like phenotype to HNSCC cells that is associated with ABCC2/G2 overexpression, high GSH and metabolic activity levels as well as CDDP resistance.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tonigold</LastName>
<ForeName>Manuel</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head and Neck Surgery, University Hospital Giessen and Marburg, Campus Marburg, Baldingerstrasse, 35033, Marburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rossmann</LastName>
<ForeName>Annette</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meinold</LastName>
<ForeName>Marie</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bette</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Märken</LastName>
<ForeName>Melanie</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Henkenius</LastName>
<ForeName>Katharina</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bretz</LastName>
<ForeName>Anne C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Giel</LastName>
<ForeName>Gavin</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cai</LastName>
<ForeName>Chengzhong</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rodepeter</LastName>
<ForeName>Fiona R</ForeName>
<Initials>FR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beneš</LastName>
<ForeName>Vladimir</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grénman</LastName>
<ForeName>Reidar</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carey</LastName>
<ForeName>Thomas E</ForeName>
<Initials>TE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lage</LastName>
<ForeName>Hermann</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stiewe</LastName>
<ForeName>Thorsten</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Neubauer</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Werner</LastName>
<ForeName>Jochen A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brendel</LastName>
<ForeName>Cornelia</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mandic</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
<NlmUniqueID>7902060</NlmUniqueID>
<ISSNLinking>0171-5216</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C116614">ABCG2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D027425">Multidrug Resistance-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C119001">multidrug resistance-associated protein 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>GAN16C9B8O</RegistryNumber>
<NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018528">ATP-Binding Cassette Transporters</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003593">Cytoplasm</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005978">Glutathione</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D027425">Multidrug Resistance-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24916171</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>01</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1432-1335</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of cancer research and clinical oncology</Title>
<ISOAbbreviation>J. Cancer Res. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.</ArticleTitle>
<Pagination>
<MedlinePgn>1705-13</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-014-1734-z</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Mammalian target of rapamycin inhibitor has exhibited promising anticancer activity for the treatment of renal cell carcinoma (RCC). However, many patients acquire resistance to therapeutic agents leading to treatment failure. The objective of this study was to determine whether treatment with YM155, a novel small molecule inhibitor of survivin, could reverse rapamycin resistance in a rapamycin-resistant RCC.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We induced a rapamycin-resistant clear cell carcinoma cell line (Caki-1-RapR). We showed that survivin gene expression was significantly up-regulated in Caki-1-RapR compared with that in its parent cells (Caki-1). Therefore, we hypothesized that targeting of survivin in Caki-1-RapR could reverse the resistant phenotype in tumor cells, thereby enhancing the therapeutic efficacy of rapamycin. We used both in vitro and in vivo models to test the efficacy of YM155 either as a single agent or in combination with rapamycin.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In Caki-1-RapR cells, YM155 significantly decreased survivin gene and protein expression levels and cell proliferation in a dose-dependent manner in vitro. In addition, YM155 treatment significantly reversed rapamycin resistance in cancer cells. In a nude mouse tumor xenograft model, YM155 significantly inhibited the growth of Caki-1-RapR tumor. In addition, YM155 significantly enhanced the antitumor effects of rapamycin in Caki-1-RapR tumor.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest a potentially novel strategy to use YM155 to overcome the resistance in tumor cells, thereby enhancing the effectiveness of molecular target therapy in RCC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Koike</LastName>
<ForeName>Hidekazu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, 371-8511, Japan, hkoike@gunma-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nitta</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sekine</LastName>
<ForeName>Yoshitaka</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Arai</LastName>
<ForeName>Seiji</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Furuya</LastName>
<ForeName>Yosuke</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nomura</LastName>
<ForeName>Masashi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matsui</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shibata</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ito</LastName>
<ForeName>Kazuto</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oyama</LastName>
<ForeName>Tetsunari</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Kazuhiro</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
<NlmUniqueID>7902060</NlmUniqueID>
<ISSNLinking>0171-5216</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C107489">BIRC5 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051034">Inhibitor of Apoptosis Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C523798">YM 155</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051034">Inhibitor of Apoptosis Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009285">Naphthoquinones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043030</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7517</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Fructose-1,6-bisphosphatase opposes renal carcinoma progression.</ArticleTitle>
<Pagination>
<MedlinePgn>251-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13557</ELocationID>
<Abstract>
<AbstractText>Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is characterized by elevated glycogen levels and fat deposition. These consistent metabolic alterations are associated with normoxic stabilization of hypoxia-inducible factors (HIFs) secondary to von Hippel-Lindau (VHL) mutations that occur in over 90% of ccRCC tumours. However, kidney-specific VHL deletion in mice fails to elicit ccRCC-specific metabolic phenotypes and tumour formation, suggesting that additional mechanisms are essential. Recent large-scale sequencing analyses revealed the loss of several chromatin remodelling enzymes in a subset of ccRCC (these included polybromo-1, SET domain containing 2 and BRCA1-associated protein-1, among others), indicating that epigenetic perturbations are probably important contributors to the natural history of this disease. Here we used an integrative approach comprising pan-metabolomic profiling and metabolic gene set analysis and determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) is uniformly depleted in over six hundred ccRCC tumours examined. Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for ccRCC patients. Our data further indicate that FBP1 inhibits ccRCC progression through two distinct mechanisms. First, FBP1 antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin, thereby inhibiting a potential Warburg effect. Second, in pVHL (the protein encoded by the VHL gene)-deficient ccRCC cells, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in a catalytic-activity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain. This unique dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qiu</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>David S M</ForeName>
<Initials>DS</Initials>
<AffiliationInfo>
<Affiliation>1] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Howard Hughes Medical Institute, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Walton</LastName>
<ForeName>Zandra E</ForeName>
<Initials>ZE</Initials>
<AffiliationInfo>
<Affiliation>1] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ochocki</LastName>
<ForeName>Joshua D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mathew</LastName>
<ForeName>Lijoy K</ForeName>
<Initials>LK</Initials>
<AffiliationInfo>
<Affiliation>1] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Howard Hughes Medical Institute, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mancuso</LastName>
<ForeName>Anthony</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>1] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [3] Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gade</LastName>
<ForeName>Terence P F</ForeName>
<Initials>TP</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Keith</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>1] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nissim</LastName>
<ForeName>Itzhak</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Pediatrics, Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Division of Child Development and Metabolic Disease, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Simon</LastName>
<ForeName>M Celeste</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>1] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [2] Howard Hughes Medical Institute, Philadelphia, Pennsylvania 19104, USA [3] Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA104838</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>DK053761</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 CA016520</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK053761</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>53-59-8</RegistryNumber>
<NameOfSubstance UI="D009249">NADP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.11</RegistryNumber>
<NameOfSubstance UI="D006597">Fructose-Bisphosphatase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Cancer. 2014 Sep;14(9):575</RefSource>
<PMID Version="1">25145476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Urol. 2014 Sep;11(9):482</RefSource>
<PMID Version="1">25091010</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051792">Basic Helix-Loop-Helix Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006597">Fructose-Bisphosphatase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006019">Glycolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009249">NADP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013552">Swine</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS603220 [Available on 03/11/15]</OtherID>
<OtherID Source="NLM">PMC4162811 [Available on 03/11/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25043050</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>513</Volume>
<Issue>7517</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins.</ArticleTitle>
<Pagination>
<MedlinePgn>256-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13466</ELocationID>
<Abstract>
<AbstractText>Aberrant regulation of RNA stability has an important role in many disease states. Deregulated post-transcriptional modulation, such as that governed by microRNAs targeting linear sequence elements in messenger RNAs, has been implicated in the progression of many cancer types. A defining feature of RNA is its ability to fold into structures. However, the roles of structural mRNA elements in cancer progression remain unexplored. Here we performed an unbiased search for post-transcriptional modulators of mRNA stability in breast cancer by conducting whole-genome transcript stability measurements in poorly and highly metastatic isogenic human breast cancer lines. Using a computational framework that searches RNA sequence and structure space, we discovered a family of GC-rich structural cis-regulatory RNA elements, termed sRSEs for structural RNA stability elements, which are significantly overrepresented in transcripts displaying reduced stability in highly metastatic cells. By integrating computational and biochemical approaches, we identified TARBP2, a double-stranded RNA-binding protein implicated in microRNA processing, as the trans factor that binds the sRSE family and similar structural elements--collectively termed TARBP2-binding structural elements (TBSEs)--in transcripts. TARBP2 is overexpressed in metastatic cells and metastatic human breast tumours and destabilizes transcripts containing TBSEs. Endogenous TARBP2 promotes metastatic cell invasion and colonization by destabilizing amyloid precursor protein (APP) and ZNF395 transcripts, two genes previously associated with Alzheimer's and Huntington's disease, respectively. We reveal these genes to be novel metastasis suppressor genes in breast cancer. The cleavage product of APP, extracellular amyloid-α peptide, directly suppresses invasion while ZNF395 transcriptionally represses a pro-metastatic gene expression program. The expression levels of TARBP2, APP and ZNF395 in human breast carcinomas support their experimentally uncovered roles in metastasis. Our findings establish a non-canonical and direct role for TARBP2 in mammalian gene expression regulation and reveal that regulated RNA destabilization through protein-mediated binding of mRNA structural elements can govern cancer progression.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Goodarzi</LastName>
<ForeName>Hani</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Systems Cancer Biology, Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Systems Cancer Biology, Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Buss</LastName>
<ForeName>Colin G</ForeName>
<Initials>CG</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Systems Cancer Biology, Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fish</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Systems Cancer Biology, Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tavazoie</LastName>
<ForeName>Saeed</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Molecular Biophysics, and Department of Systems Biology, Columbia University, New York, New York 10032, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tavazoie</LastName>
<ForeName>Sohail F</ForeName>
<Initials>SF</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Systems Cancer Biology, Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>GEO</DataBankName>
<AccessionNumberList>
<AccessionNumber>GSE49649</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 HG003219</GrantID>
<Acronym>HG</Acronym>
<Agency>NHGRI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C484332">ZNF395 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136628-24-5</RegistryNumber>
<NameOfSubstance UI="C068106">trans-activation responsive RNA-binding protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Cancer. 2014 Sep;14(9):578</RefSource>
<PMID Version="1">25145481</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016564">Amyloid beta-Protein Precursor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020871">RNA Stability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016601">RNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096478</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis.</ArticleTitle>
<Pagination>
<MedlinePgn>4558-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.404</ELocationID>
<Abstract>
<AbstractText>Characteristically, prostate cancer (PCa) cells exhibit marked decrease in intracellular zinc; however, the mechanism responsible is not clearly understood. HOXB13 is involved in PCa progression and is overexpressed in castration-resistant PCa. DNA microarray analysis of LNCaP Pca cells showed that ZnT zinc output transporters were strikingly upregulated among androgen-independent HOXB13 target genes. Furthermore, exogenous HOXB13 caused intracellular zinc concentrations to fall in PCa cells, stimulated NF-κB-mediated signaling by reducing inhibitor of NF-κB alpha (IκBα) and enhanced the nuclear translocation of RelA/p65. Human prostate tumors also exhibited strong inverse correlation between the protein expressions of HOXB13 and IκBα. Consequently, HOXB13 stimulated PCa cell invasion, and this was inhibited by the suppression of ZnT4. In addition, studies in a PC3 orthotopic mouse model of PCa metastasis showed that HOXB13 is a strong metastatic stimulator. Taken together, these results show that HOXB13 promotes PCa invasion and metastasis by decreasing intracellular zinc levels, thus stimulating NF-κB signals, and suggest that HOXB13 acts as a modulator of intracellular zinc levels that promotes the malignant characteristics of PCa. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Y-R</ForeName>
<Initials>YR</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>I-J</ForeName>
<Initials>IJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>T W</ForeName>
<Initials>TW</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>K K</ForeName>
<Initials>KK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Statistics, College of Natural Sciences, Chonnam National University, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>K I</ForeName>
<Initials>KI</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C484414">HOXB13 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020672">I-kappa B Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052002">NF-kappa B p50 Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C489548">NFKB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>139874-52-5</RegistryNumber>
<NameOfSubstance UI="C069722">NF-kappaB inhibitor alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J41CSQ7QDS</RegistryNumber>
<NameOfSubstance UI="D015032">Zinc</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020672">I-kappa B Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052002">NF-kappa B p50 Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015032">Zinc</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096482</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression.</ArticleTitle>
<Pagination>
<MedlinePgn>4548-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.402</ELocationID>
<Abstract>
<AbstractText>Although epidemiological and preclinical studies have shown the preventative effects of n-3 polyunsaturated fatty acids (PUFAs) on breast cancer, inconsistencies still remain in the data and the underlying mechanisms remain unclear. In this study, we identified mammalian target of rapamycin (mTOR) signaling, which plays an essential role in cell proliferation and breast tumorigenesis, as a target of n-3 PUFAs. In breast cancer cell lines, n-3 PUFAs rapidly and efficiently suppress both mTOR complex 1 (mTORC1) and mTORC2 and their downstream signaling, and subsequently inhibit cell proliferation and angiogenesis while promoting apoptosis. Further study indicates that stabilization of the mTOR-raptor complex by n-3 PUFAs may contribute to their inhibitory effect on mTORC1. Importantly, four complementary and well-controlled animal models were utilized to identify the role and molecular target of n-3 PUFAs in the prevention of breast carcinogenesis and progression, namely: (1) chemically induced mammary tumor rats with a high dietary intake of n-3 PUFAs; (2) nude mice implanted with mammary tumor cell lines stably expressing fat-1, a desaturase that catalyzes the conversion of n-6 to n-3 PUFAs and produces n-3 PUFAs endogenously; (3) fat-1 transgenic severe combined immune deficiency mice implanted with breast tumor cells; and (4) the fat-1 transgenic mouse mammary tumor virus-polyoma virus middle T oncogene double-hybrid mice, a model of aggressive breast cancer. In summary, dietary and endogenous n-3 PUFAs abrogate the activity of mTORC1/2 pathways in vitro and in vivo and prevent breast carcinogenesis, tumor growth and metastasis. Taken together, our findings convincingly clarify the causal relationship between n-3 PUFAs and breast cancer prevention and establish mTORC1/2 as a target of n-3 PUFAs. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jia</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lai</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Q</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ren</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Q</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>College of Life Sciences, Nankai University, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wan</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy and Neurobiology, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dai</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Reproductive Medicine and Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bai</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C576554">TOR complex 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C576553">mechanistic target of rapamycin complex 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>684-93-5</RegistryNumber>
<NameOfSubstance UI="D008770">Methylnitrosourea</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002273">Carcinogens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015525">Fatty Acids, Omega-3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015674">Mammary Neoplasms, Animal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008770">Methylnitrosourea</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046912">Multiprotein Complexes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24276246</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Phosphatidylethanolamine-binding protein 4 is associated with breast cancer metastasis through Src-mediated Akt tyrosine phosphorylation.</ArticleTitle>
<Pagination>
<MedlinePgn>4589-98</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.408</ELocationID>
<Abstract>
<AbstractText>Metastasis is responsible for more than 90% of the mortality observed among patients with breast cancer. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a novel member of the PEBP family and functions as an anti-apoptotic molecule. Here, we found that the metastatic MDA-MB-231 breast cancer cells expressed much higher levels of hPEBP4 than the nonmetastatic MCF-7 breast cancer cells and that the expression levels of hPEBP4 were positively correlated with the metastasis of clinical breast cancer. The hPEBP4 overexpression in the MDA-MB-231 cells significantly promoted cell invasion in vitro and increased the development of lymph node metastasis in vivo. Conversely, the silencing of hPEBP4 suppressed the cell-invasive ability both in vitro and in vivo. Further investigation showed that hPEBP4 promoted the expression or activity of the metastasis-related proteinases MMP (matrix metalloproteinase) 2, MMP9 and MMP13. This hPEBP4-potentiated cell invasion and MMP expression is due to an increase in Akt activation. Knockdown of Akt restored hPEBP4-induced breast tumor metastasis in the hPEBP4-MDA-MB-231 xenograft mouse model. Moreover, we found that hPEBP4 functioned as a scaffolding molecule and enhanced the association of Akt with Src to promote Akt tyrosine phosphorylation, a prerequisite for the full activation of Akt, in a phosphatidylethanolamine-binding domain-dependent manner. Given the present information about human breast cancer, these functional data from cell culture and animal studies suggest that, in human breast cancer hPEBP4 is a novel and clinically relevant metastasis accelerator gene and may be a new diagnostic marker and therapeutic target for breast cancer metastasis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Q</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, PR China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>11</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C518018">PE-binding protein 4, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D049488">Phosphatidylethanolamine Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>42HK56048U</RegistryNumber>
<NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="C507079">MMP13 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D053509">Matrix Metalloproteinase 13</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.35</RegistryNumber>
<NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.35</RegistryNumber>
<NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053509">Matrix Metalloproteinase 13</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020780">Matrix Metalloproteinase 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049488">Phosphatidylethanolamine Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046888">Tissue Array Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014443">Tyrosine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24662828</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes.</ArticleTitle>
<Pagination>
<MedlinePgn>4613-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.66</ELocationID>
<Abstract>
<AbstractText>It has emerged recently that exosomes are potential carriers of pro-tumorigenic factors that participate in oncogenesis. However, whether oncogenic transcription factors are transduced by exosomes is unknown. Hypoxia-inducible factor-1α (HIF1α) transcriptionally regulates numerous key aspects of tumor development and progression by promoting a more aggressive tumor phenotype, characterized by increased proliferation and invasiveness coupled with neoangiogenesis. It has been shown that the principal oncoprotein of Epstein-Barr virus (EBV), latent membrane protein 1 (LMP1), drives oncogenic processes and tumor progression of the highly invasive EBV malignancy, nasopharyngeal carcinoma (NPC). We now demonstrate that endogenous HIF1α is detectable in exosomes and that LMP1 significantly increases levels of HIF1α in exosomes. HIF1 recovered from exosomes retains DNA-binding activity and is transcriptionally active in recipient cells after exosome uptake. We also show that treatment of EBV-negative cells with LMP1-exosomes increases migration and invasiveness of NP cell lines in functional assays, which correlates with the phenotype associated with epithelial-mesenchymal transition (EMT). In addition, we provide evidence that HIF1α itself participates in exosome-mediated pro-metastatic effects in recipient cells, as exosome-mediated delivery of active and inactive forms of HIF1α results in reciprocal changes in the expression of E- and N-cadherins associated with EMT. Further, immunohistochemical analysis of NPC tumor tissues revealed direct correlation between protein levels of LMP1 and of the endosome/exosome marker tetraspanin, CD63, which suggests an increase in exosome formation in this EBV-positive malignancy. We hypothesize that exosome-mediated transfer of functional pro-metastatic factors by LMP1-positive NPC cells to surrounding tumor cells promotes cancer progression. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Aga</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>1] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA [2] Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bentz</LastName>
<ForeName>G L</ForeName>
<Initials>GL</Initials>
<AffiliationInfo>
<Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raffa</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Medicina Clinica e Molecolare, Università di Roma La Sapienza, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Torrisi</LastName>
<ForeName>M R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Dipartimento di Medicina Clinica e Molecolare, Università di Roma La Sapienza, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kondo</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wakisaka</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshizaki</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pagano</LastName>
<ForeName>J S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shackelford</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA [2] Department of Cell Biology and Physioligy, University of North Carolina, Chapel Hill, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>2P01-CA19014-26</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 CA019014</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060149">Antigens, CD63</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C554586">CD63 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C037662">EBV-associated membrane antigen, Epstein-Barr virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C538339">Nasopharyngeal carcinoma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2006 Oct 15;66(20):9870-7</RefSource>
<PMID Version="1">17047048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2006 May;6(5):392-401</RefSource>
<PMID Version="1">16572188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2007 Oct 1;121(7):1494-506</RefSource>
<PMID Version="1">17546597</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2007 Sep 1;13(17):4993-5000</RefSource>
<PMID Version="1">17785549</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Cycle. 2008 Jul 15;7(14):2090-6</RefSource>
<PMID Version="1">18635960</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Metastasis Rev. 2009 Jun;28(1-2):177-83</RefSource>
<PMID Version="1">19259624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proteomics. 2009 May;9(10):2820-35</RefSource>
<PMID Version="1">19415654</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Expert Rev Proteomics. 2009 Jun;6(3):267-83</RefSource>
<PMID Version="1">19489699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Genomics. 2009;10:556</RefSource>
<PMID Version="1">19930720</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33</RefSource>
<PMID Version="1">20304794</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Proteomics. 2010 Sep 10;73(10):1907-20</RefSource>
<PMID Version="1">20601276</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biol. 2010 Sep 20;190(6):1079-91</RefSource>
<PMID Version="1">20837771</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20370-5</RefSource>
<PMID Version="1">21059916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Soc Trans. 2011 Apr;39(2):559-62</RefSource>
<PMID Version="1">21428939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2011 Dec;85(24):12844-54</RefSource>
<PMID Version="1">21976651</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Dev Biol. 2011;55(7-9):879-87</RefSource>
<PMID Version="1">22161843</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Cancer Biol. 2012 Apr;22(2):127-36</RefSource>
<PMID Version="1">22249142</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem Pharmacol. 2012 Jun 1;83(11):1484-94</RefSource>
<PMID Version="1">22230477</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2012 Jul;1820(7):940-8</RefSource>
<PMID Version="1">22503788</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Med. 2012 Jun;18(6):883-91</RefSource>
<PMID Version="1">22635005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Virol. 2012 Aug;2(4):453-8</RefSource>
<PMID Version="1">22858118</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Signal. 2012 Sep 25;5(243):ra70</RefSource>
<PMID Version="1">23012657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Adh Migr. 2012 Jul-Aug;6(4):365-73</RefSource>
<PMID Version="1">22796940</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Mol Cell Cardiol. 2012 Dec;53(6):848-57</RefSource>
<PMID Version="1">23085511</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7</RefSource>
<PMID Version="1">23589885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2013 Aug 28;337(1):1-7</RefSource>
<PMID Version="1">23689138</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):E2925-33</RefSource>
<PMID Version="1">23818640</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2000 May;11(5):1829-43</RefSource>
<PMID Version="1">10793155</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 1999 Dec 1;94(11):3791-9</RefSource>
<PMID Version="1">10572093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2013;8(11):e79636</RefSource>
<PMID Version="1">24244532</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2000 Sep 1;275(35):26765-71</RefSource>
<PMID Version="1">10837481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2000 Oct;113 Pt 19:3365-74</RefSource>
<PMID Version="1">10984428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Biol Cell. 2002 Mar;13(3):767-81</RefSource>
<PMID Version="1">11907260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 2002 Dec 15;270(2):211-26</RefSource>
<PMID Version="1">12379326</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2004 Jan 15;377(Pt 2):407-17</RefSource>
<PMID Version="1">14556650</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2004 Jun;24(12):5223-34</RefSource>
<PMID Version="1">15169887</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1998 Aug 7;273(32):20121-7</RefSource>
<PMID Version="1">9685355</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42</RefSource>
<PMID Version="1">16493418</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood Cells Mol Dis. 2006 Mar-Apr;36(2):315-21</RefSource>
<PMID Version="1">16487731</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2007 Jun;9(6):654-9</RefSource>
<PMID Version="1">17486113</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060149">Antigens, CD63</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004247">DNA</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055354">Exosomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004854">Herpesvirus 4, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009303">Nasopharyngeal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014763">Viral Matrix Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014945">Wound Healing</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS560269</OtherID>
<OtherID Source="NLM">PMC4162459</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24662831</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>4568-78</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.32</ELocationID>
<Abstract>
<AbstractText>Our goal in this work was to illustrate the Epstein-Barr virus (EBV)-modulated global biochemical profile and provide a novel metabolism-related target to improve the therapeutic regimen of nasopharyngeal carcinoma (NPC). We used a metabolomics approach to investigate EBV-modulated metabolic changes, and found that the exogenous overexpression of the EBV-encoded latent membrane protein 1 (LMP1) significantly increased glycolysis. The deregulation of several glycolytic genes, including hexokinase 2 (HK2), was determined to be responsible for the reprogramming of LMP1-mediated glucose metabolism in NPC cells. The upregulation of HK2 elevated aerobic glycolysis and facilitated proliferation by blocking apoptosis. More importantly, HK2 was positively correlated with LMP1 in NPC biopsies, and high HK2 levels were significantly associated with poor overall survival of NPC patients following radiation therapy. Knockdown of HK2 effectively enhanced the sensitivity of LMP1-overexpressing NPC cells to irradiation. Finally, c-Myc was demonstrated to be required for LMP1-induced upregulation of HK2. The LMP1-mediated attenuation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis resulted in the stabilization of c-Myc. These findings indicate a close relationship between EBV and glycolysis in NPC. Notably, LMP1 is the key regulator of the reprogramming of EBV-mediated glycolysis in NPC cells. Given the importance of EBV-mediated deregulation of glycolysis, anti-glycolytic therapy might represent a worthwhile avenue of exploration in the treatment of EBV-related cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Z-Y</ForeName>
<Initials>ZY</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China [4] The First Hospital of Changsha City, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China [4] Metabolic Syndrome Research Center, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China [4] Center For Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tao</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yi</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Clinical Biochemical Laboratory, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Pathology Department, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Pathology Department, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>You</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Radiation Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA [2] Endocrinology Department, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Deng</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Metabolic Syndrome Research Center, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Metabolic Syndrome Research Center, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bode</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>The Hormel Institute, University of Minnesota, Austin, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>The Hormel Institute, University of Minnesota, Austin, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>L-Q</ForeName>
<Initials>LQ</Initials>
<AffiliationInfo>
<Affiliation>Center For Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C037662">EBV-associated membrane antigen, Epstein-Barr virus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011838">Radiation-Sensitizing Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D006593">Hexokinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C538339">Nasopharyngeal carcinoma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Dec 1;71(23):7291-300</RefSource>
<PMID Version="1">21987722</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2012 Jan;11(1):14-23</RefSource>
<PMID Version="1">22234809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):561-6</RefSource>
<PMID Version="1">21300483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Cancer Biol. 2012 Apr;22(2):144-53</RefSource>
<PMID Version="1">22249143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 Mar 30;149(1):49-62</RefSource>
<PMID Version="1">22401813</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9593-8</RefSource>
<PMID Version="1">22647604</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11818-23</RefSource>
<PMID Version="1">22752304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(7):e42072</RefSource>
<PMID Version="1">22848707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2012 Aug 17;150(4):685-96</RefSource>
<PMID Version="1">22901803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2012 Dec;1826(2):370-84</RefSource>
<PMID Version="1">22750268</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2013 Feb;87(3):1301-11</RefSource>
<PMID Version="1">23152522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2013 Aug 10;31(23):2861-9</RefSource>
<PMID Version="1">23857969</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2013 Aug 12;24(2):213-28</RefSource>
<PMID Version="1">23911236</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Virology. 2013 Sep;444(1-2):301-9</RefSource>
<PMID Version="1">23876457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2002 Mar 1;277(9):7610-8</RefSource>
<PMID Version="1">11751859</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2004 Jun;24(12):5223-34</RefSource>
<PMID Version="1">15169887</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2004 Oct;4(10):757-68</RefSource>
<PMID Version="1">15510157</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2004 Dec 3;16(5):819-30</RefSource>
<PMID Version="1">15574336</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2005 Jul 1;11(13):4658-65</RefSource>
<PMID Version="1">16000558</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2005 Oct 20;24(46):6917-24</RefSource>
<PMID Version="1">16007144</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402</RefSource>
<PMID Version="1">16798876</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cold Spring Harb Symp Quant Biol. 2005;70:363-74</RefSource>
<PMID Version="1">16869773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2006 Oct 15;66(20):9870-7</RefSource>
<PMID Version="1">17047048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Mol Immunol. 2007 Jun;4(3):185-96</RefSource>
<PMID Version="1">17601372</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Exp Med Biol. 2007;597:173-87</RefSource>
<PMID Version="1">17633026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2007 Nov;27(21):7381-93</RefSource>
<PMID Version="1">17785433</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Pathog. 2007 Nov;3(11):e166</RefSource>
<PMID Version="1">17997602</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2008 Feb;8(2):83-93</RefSource>
<PMID Version="1">18094723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2008 Jul 8;265(2):226-38</RefSource>
<PMID Version="1">18353539</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FASEB J. 2008 Aug;22(8):2809-20</RefSource>
<PMID Version="1">18381814</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Virol. 2008 Oct;82(20):10175-87</RefSource>
<PMID Version="1">18684838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2009 Jan 30;284(5):3001-11</RefSource>
<PMID Version="1">19033437</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Pathog. 2010 Jan;6(1):e1000719</RefSource>
<PMID Version="1">20062526</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10696-701</RefSource>
<PMID Version="1">20498071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Neuroimmune Pharmacol. 2010 Sep;5(3):271-7</RefSource>
<PMID Version="1">20369303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2010 Dec 3;330(6009):1340-4</RefSource>
<PMID Version="1">21127244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2011 Jan 18;19(1):17-30</RefSource>
<PMID Version="1">21251613</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5</RefSource>
<PMID Version="1">21289278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2011 Mar 4;144(5):646-74</RefSource>
<PMID Version="1">21376230</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Apr 15;71(8):2815-20</RefSource>
<PMID Version="1">21487041</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2011 May;11(5):325-37</RefSource>
<PMID Version="1">21508971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Pathog. 2011 Jul;7(7):e1002124</RefSource>
<PMID Version="1">21779165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Aug 26;286(34):29872-81</RefSource>
<PMID Version="1">21690090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2011 Aug 26;333(6046):1154-7</RefSource>
<PMID Version="1">21798897</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(11):e24647</RefSource>
<PMID Version="1">22096476</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D006019">Glycolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004854">Herpesvirus 4, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006593">Hexokinase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055432">Metabolomics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009303">Nasopharyngeal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016271">Proto-Oncogene Proteins c-myc</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011838">Radiation-Sensitizing Agents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014763">Viral Matrix Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4162460</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24662835</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>37</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>4579-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.45</ELocationID>
<Abstract>
<AbstractText>The antiestrogen tamoxifen is a well-tolerated, effective treatment for estrogen receptor-α-positive (ER+) breast cancer, but development of resistance eventually limits its use. Here we show that expression of MAGEA2, and related members of this cancer-testis antigen family, is upregulated in tamoxifen-resistant tumor cells. Expression of MAGEA2 in tumor lines grown in vitro or as xenografts led to continued proliferation in the presence of tamoxifen. At the molecular level, we demonstrate that MAGEA2 protein localizes to the nucleus and forms complexes with p53 and ERα, resulting in repression of the p53 pathway but increased ER-dependent signaling. In a series of ER+, tamoxifen-treated breast cancer patients, we show a highly significant (P=0.006) association between MAGEA (melanoma-associated antigen) expression and reduced overall survival, confirming the clinical significance of our observations. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>P-P</ForeName>
<Initials>PP</Initials>
<AffiliationInfo>
<Affiliation>Centre for Tumor Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yeoh</LastName>
<ForeName>C C</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Centre for Tumor Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahmad</LastName>
<ForeName>A S</ForeName>
<Initials>AS</Initials>
<AffiliationInfo>
<Affiliation>Center for Epidemiology Mathematics and Statistics, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chelala</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Center for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gillett</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Breast Pathology Research Group, Guy's Hospital, King's College London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Speirs</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Centre for Tumor Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hurst</LastName>
<ForeName>H C</ForeName>
<Initials>HC</Initials>
<AffiliationInfo>
<Affiliation>Centre for Tumor Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004965">Estrogen Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C574803">MageA2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058950">Melanoma-Specific Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>094ZI81Y45</RegistryNumber>
<NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2002 Feb;71(3):269-80</RefSource>
<PMID Version="1">12002345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2011 Jul 1;17(13):4309-19</RefSource>
<PMID Version="1">21565982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer. 2003 Feb;39(3):300-8</RefSource>
<PMID Version="1">12565981</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(3):e17876</RefSource>
<PMID Version="1">21437249</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Chem. 2011 Mar;57(3):421-30</RefSource>
<PMID Version="1">21245367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Dec 15;70(24):10362-70</RefSource>
<PMID Version="1">21056992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Pharmacol. 2010 Dec;10(6):620-8</RefSource>
<PMID Version="1">20926342</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell. 2010 Sep 24;39(6):963-74</RefSource>
<PMID Version="1">20864041</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2010 Jan 20;28(3):509-18</RefSource>
<PMID Version="1">19949017</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2009 Nov 18;28(22):3591-601</RefSource>
<PMID Version="1">19798054</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Sci. 2009 Nov;100(11):2014-21</RefSource>
<PMID Version="1">19719775</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Cancer. 2009 Sep 15;101(6):875-8</RefSource>
<PMID Version="1">19672259</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13493-8</RefSource>
<PMID Version="1">19651608</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2009 Sep;9(9):631-43</RefSource>
<PMID Version="1">19701242</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Genomics. 2008;9:239</RefSource>
<PMID Version="1">18498629</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2008 May;13(5):454-63</RefSource>
<PMID Version="1">18455128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer. 2003 Feb;39(3):309-16</RefSource>
<PMID Version="1">12565982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Endocrinology. 2003 Mar;144(3):1032-44</RefSource>
<PMID Version="1">12586780</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2002 Feb;2(2):101-12</RefSource>
<PMID Version="1">12635173</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Cell Biol. 2003 Apr;15(2):164-71</RefSource>
<PMID Version="1">12648672</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9</RefSource>
<PMID Version="1">12826609</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):207-21</RefSource>
<PMID Version="1">14672741</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2004 Aug 4;23(15):3051-60</RefSource>
<PMID Version="1">15241475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 1993 Dec;106 ( Pt 4):1377-88</RefSource>
<PMID Version="1">8126115</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 1994 Dec;9(12):3407-15</RefSource>
<PMID Version="1">7970699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Exp Med. 1995 Sep 1;182(3):689-98</RefSource>
<PMID Version="1">7544395</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 1995 Oct 20;97(1):107-16</RefSource>
<PMID Version="1">7585469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2005 May 14-20;365(9472):1687-717</RefSource>
<PMID Version="1">15894097</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2005 Aug;5(8):615-25</RefSource>
<PMID Version="1">16034368</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11160-5</RefSource>
<PMID Version="1">16847267</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2007 Sep;7(9):713-22</RefSource>
<PMID Version="1">17721435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2007 Oct 15;67(20):9954-62</RefSource>
<PMID Version="1">17942928</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res. 2007;9(5):306</RefSource>
<PMID Version="1">17980055</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2008 Jan 15;14(2):405-11</RefSource>
<PMID Version="1">18223215</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1650-5</RefSource>
<PMID Version="1">18216244</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004965">Estrogen Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047628">Estrogen Receptor alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056945">Hep G2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058950">Melanoma-Specific Antigens</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013629">Tamoxifen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4162461</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25061176</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1528-0020</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>124</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Blood</Title>
<ISOAbbreviation>Blood</ISOAbbreviation>
</Journal>
<ArticleTitle>The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.</ArticleTitle>
<Pagination>
<MedlinePgn>1765-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-03-560862</ELocationID>
<Abstract>
<AbstractText>Glycosylation is a stepwise procedure of covalent attachment of oligosaccharide chains to proteins or lipids, and alterations in this process, especially increased sialylation, have been associated with malignant transformation and metastasis. The role of altered sialylation in multiple myeloma (MM) cell trafficking has not been previously investigated. In the present study we identified high expression of β-galactoside α-2,3-sialyltransferase, ST3GAL6, in MM cell lines and patients. This gene plays a key role in selectin ligand synthesis in humans through the generation of functional sialyl Lewis X. In MRC IX patients, high expression of this gene is associated with inferior overall survival. In this study we demonstrate that knockdown of ST3GAL6 results in a significant reduction in levels of α-2,3-linked sialic acid on the surface of MM cells with an associated significant reduction in adhesion to MM bone marrow stromal cells and fibronectin along with reduced transendothelial migration in vitro. In support of our in vitro findings, we demonstrate significantly reduced homing and engraftment of ST3GAL6 knockdown MM cells to the bone marrow niche in vivo, along with decreased tumor burden and prolonged survival. This study points to the importance of altered glycosylation, particularly sialylation, in MM cell adhesion and migration. </AbstractText>
<CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Glavey</LastName>
<ForeName>Siobhan V</ForeName>
<Initials>SV</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Hematology, National University of Ireland, Galway and Galway University Hospital, Galway, Ireland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Manier</LastName>
<ForeName>Salomon</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Natoni</LastName>
<ForeName>Alessandro</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, National University of Ireland, Galway and Galway University Hospital, Galway, Ireland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sacco</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moschetta</LastName>
<ForeName>Michele</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reagan</LastName>
<ForeName>Michaela R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Murillo</LastName>
<ForeName>Laura S</ForeName>
<Initials>LS</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, National University of Ireland, Galway and Galway University Hospital, Galway, Ireland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sahin</LastName>
<ForeName>Ilyas</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Ping</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mishima</LastName>
<ForeName>Yuji</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Wenjing</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morgan</LastName>
<ForeName>Gareth</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Joshi</LastName>
<ForeName>Lokesh</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Glycoscience Research Group, National University of Ireland, Galway, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roccaro</LastName>
<ForeName>Aldo M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ghobrial</LastName>
<ForeName>Irene M</ForeName>
<Initials>IM</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Dwyer</LastName>
<ForeName>Michael E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, National University of Ireland, Galway and Galway University Hospital, Galway, Ireland; Glycoscience Research Group, National University of Ireland, Galway, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA154648</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Blood</MedlineTA>
<NlmUniqueID>7603509</NlmUniqueID>
<ISSNLinking>0006-4971</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.99.-</RegistryNumber>
<NameOfSubstance UI="D012799">Sialyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.99.4</RegistryNumber>
<NameOfSubstance UI="C033572">beta-galactoside alpha-2,3-sialyltransferase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>GZP2782OP0</RegistryNumber>
<NameOfSubstance UI="D019158">N-Acetylneuraminic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2007 Apr 1;67(7):2982-9</RefSource>
<PMID Version="1">17409404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Apr 1;109(7):2708-17</RefSource>
<PMID Version="1">17119115</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Dec 15;110(13):4417-26</RefSource>
<PMID Version="1">17761832</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2008 Nov;8(11):874-87</RefSource>
<PMID Version="1">18846099</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Haematol. 2009 May;145(3):350-68</RefSource>
<PMID Version="1">19298595</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Apr 30;113(18):4341-51</RefSource>
<PMID Version="1">19139079</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Jun 25;113(26):6669-80</RefSource>
<PMID Version="1">19401561</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunol Rev. 2009 Jul;230(1):51-74</RefSource>
<PMID Version="1">19594629</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunol Rev. 2009 Jul;230(1):97-113</RefSource>
<PMID Version="1">19594631</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2009 Jul 16;114(3):619-29</RefSource>
<PMID Version="1">19443661</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochim Biophys Acta. 2010 Jun;1800(6):545-55</RefSource>
<PMID Version="1">20332015</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Cancer Biol. 2010 Jun;20(3):169-77</RefSource>
<PMID Version="1">20452433</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2010 Dec 11;376(9757):1989-99</RefSource>
<PMID Version="1">21131037</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Jan 15;71(2):473-83</RefSource>
<PMID Version="1">21224350</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Dec 15;71(24):7683-93</RefSource>
<PMID Version="1">22025563</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2012 Feb 9;119(6):1468-78</RefSource>
<PMID Version="1">22096244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2012 Jul 5;120(1):20-30</RefSource>
<PMID Version="1">22535658</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Proteomics. 2012 Jul;11(7):M112.017558</RefSource>
<PMID Version="1">22457533</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2012 Aug 2;120(5):1015-26</RefSource>
<PMID Version="1">22700726</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Chem Biol. 2012 Jul;8(7):661-8</RefSource>
<PMID Version="1">22683610</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2012 Dec 28;287(53):44490-7</RefSource>
<PMID Version="1">23275522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2013 Mar 18;587(6):782-7</RefSource>
<PMID Version="1">23416306</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2013 Apr 1;19(7):1705-16</RefSource>
<PMID Version="1">23444218</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2013 Apr 15;19(8):1981-93</RefSource>
<PMID Version="1">23446997</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2013 Oct;12(10):1935-46</RefSource>
<PMID Version="1">23974695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2013;8(12):e83719</RefSource>
<PMID Version="1">24386263</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Immunity. 2001 Jul;15(1):115-26</RefSource>
<PMID Version="1">11485743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 2002 Apr;109(7):939-50</RefSource>
<PMID Version="1">11927621</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2003 Feb 15;101(4):1530-4</RefSource>
<PMID Version="1">12393500</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2003 Sep 15;102(6):2060-7</RefSource>
<PMID Version="1">12763924</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2004 May 25;101(21):8132-7</RefSource>
<PMID Version="1">15141079</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 1994 May;102(5):773-80</RefSource>
<PMID Version="1">7513740</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1995 Sep 29;270(39):22677-80</RefSource>
<PMID Version="1">7559387</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 1996 Aug 2;271(31):18732-42</RefSource>
<PMID Version="1">8702529</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 1996 Nov 1;88(9):3546-54</RefSource>
<PMID Version="1">8896422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Annu Rev Physiol. 2005;67:147-73</RefSource>
<PMID Version="1">15709955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2005 Jun 16;435(7044):969-73</RefSource>
<PMID Version="1">15959517</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50</RefSource>
<PMID Version="1">16199517</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2006 Jan 1;66(1):184-91</RefSource>
<PMID Version="1">16397231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2006 Sep 15;281(37):27016-28</RefSource>
<PMID Version="1">16847058</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001854">Bone Marrow Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061307">Human Umbilical Vein Endothelial Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019158">N-Acetylneuraminic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012799">Sialyltransferases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017154">Stromal Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D057705">Transendothelial and Transepithelial Migration</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4162107</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25214559</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju204</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju204</ELocationID>
<Abstract>
<AbstractText>Ibrutinib, which irreversibly inhibits Bruton tyrosine kinase, was evaluated for antitumor activity in a panel of non-small cell lung cancer (NSCLC) cell lines and found to selectively inhibit growth of NSCLC cells carrying mutations in the epidermal growth factor receptor (EGFR) gene, including T790M mutant and erlotinib-resistant H1975 cells. Ibrutinib induced dose-dependent inhibition of phosphor-EGFR at both Y1068 and Y1173 sites, suggesting ibrutinib functions as an EGFR inhibitor. Survival was analyzed by Kaplan-Meier estimation and log-rank test. All statistical tests were two-sided. In vivo study showed that ibrutinib statistically significantly suppressed H1975 tumor growth and prolonged survival of the tumor bearing mice (n = 5 per group). The mean survival times for solvent- and erlotinib-treated mice were both 17.8 days (95% confidence interval [CI] = 14.3 to 21.3 days), while the mean survival time for ibrutinib-treated mice was 29.8 days (95% CI = 26.0 to 33.6 days, P = .008). Our results indicate that ibrutinib could be a candidate drug for treatment of EGFR-mutant NSCLC, including erlotinib-resistant tumors. </AbstractText>
<CopyrightInformation>© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Wen</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Haibo</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Shuhong</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dai</LastName>
<ForeName>Bingbing</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ou</LastName>
<ForeName>Zhishuo</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Liang</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Heymach</LastName>
<ForeName>John V</ForeName>
<Initials>JV</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gold</LastName>
<ForeName>Kathryn A</ForeName>
<Initials>KA</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Minna</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roth</LastName>
<ForeName>Jack A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hofstetter</LastName>
<ForeName>Wayne L</ForeName>
<Initials>WL</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Swisher</LastName>
<ForeName>Stephen G</ForeName>
<Initials>SG</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fang</LastName>
<ForeName>Bingliang</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG). bfang@mdanderson.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA-016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA070907</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA124951</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551803">PCI 32765</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2ZD004190S</RegistryNumber>
<NameOfSubstance UI="D013912">Threonine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>AE28F7PNPL</RegistryNumber>
<NameOfSubstance UI="D008715">Methionine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J4T82NDH7E</RegistryNumber>
<NameOfSubstance UI="C400278">erlotinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Natl Cancer Inst. 2014 Sep;106(9). pii: dju250. doi: 10.1093/jnci/dju250</RefSource>
<PMID Version="1">25214562</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008715">Methionine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013912">Threonine</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4200057 [Available on 09/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25215487</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4172</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>158</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Cell</Title>
<ISOAbbreviation>Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>A dual program for translation regulation in cellular proliferation and differentiation.</ArticleTitle>
<Pagination>
<MedlinePgn>1281-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.08.011</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)01042-3</ELocationID>
<Abstract>
<AbstractText>A dichotomous choice for metazoan cells is between proliferation and differentiation. Measuring tRNA pools in various cell types, we found two distinct subsets, one that is induced in proliferating cells, and repressed otherwise, and another with the opposite signature. Correspondingly, we found that genes serving cell-autonomous functions and genes involved in multicellularity obey distinct codon usage. Proliferation-induced and differentiation-induced tRNAs often carry anticodons that correspond to the codons enriched among the cell-autonomous and the multicellularity genes, respectively. Because mRNAs of cell-autonomous genes are induced in proliferation and cancer in particular, the concomitant induction of their codon-enriched tRNAs suggests coordination between transcription and translation. Histone modifications indeed change similarly in the vicinity of cell-autonomous genes and their corresponding tRNAs, and in multicellularity genes and their tRNAs, suggesting the existence of transcriptional programs coordinating tRNA supply and demand. Hence, we describe the existence of two distinct translation programs that operate during proliferation and differentiation. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gingold</LastName>
<ForeName>Hila</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tehler</LastName>
<ForeName>Disa</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christoffersen</LastName>
<ForeName>Nanna R</ForeName>
<Initials>NR</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nielsen</LastName>
<ForeName>Morten M</ForeName>
<Initials>MM</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Asmar</LastName>
<ForeName>Fazila</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kooistra</LastName>
<ForeName>Susanne M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christophersen</LastName>
<ForeName>Nicolaj S</ForeName>
<Initials>NS</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Christensen</LastName>
<ForeName>Lise Lotte</ForeName>
<Initials>LL</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borre</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sørensen</LastName>
<ForeName>Karina D</ForeName>
<Initials>KD</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Andersen</LastName>
<ForeName>Lars D</ForeName>
<Initials>LD</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Andersen</LastName>
<ForeName>Claus L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark; Department of Surgery, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hulleman</LastName>
<ForeName>Esther</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Oncology, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center, 1007 MB Amsterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wurdinger</LastName>
<ForeName>Tom</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center, 1007 MB Amsterdam, the Netherlands; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ralfkiær</LastName>
<ForeName>Elisabeth</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Helin</LastName>
<ForeName>Kristian</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark; Center for Epigenetics, University of Copenhagen, 2200 Copenhagen, Denmark; The Danish Stem Cell Center (Danstem), University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grønbæk</LastName>
<ForeName>Kirsten</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Orntoft</LastName>
<ForeName>Torben</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Waszak</LastName>
<ForeName>Sebastian M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dahan</LastName>
<ForeName>Orna</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pedersen</LastName>
<ForeName>Jakob Skou</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department for Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark; Bioinformatics Research Centre, Aarhus University Hospital, 8000 Aarhus, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lund</LastName>
<ForeName>Anders H</ForeName>
<Initials>AH</Initials>
<AffiliationInfo>
<Affiliation>Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark. Electronic address: anders.lund@bric.ku.dk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pilpel</LastName>
<ForeName>Yitzhak</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: pilpel@weizmann.ac.il.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell</MedlineTA>
<NlmUniqueID>0413066</NlmUniqueID>
<ISSNLinking>0092-8674</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000926">Anticodon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003062">Codon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9014-25-9</RegistryNumber>
<NameOfSubstance UI="D012343">RNA, Transfer</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Cell. 2014 Sep 11;158(6):1238-9</RefSource>
<PMID Version="1">25215483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>EMBO J. 2014 Sep 17;33(18):1981-3</RefSource>
<PMID Version="1">25216676</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000926">Anticodon</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002454">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003062">Codon</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014176">Protein Biosynthesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012343">RNA, Transfer</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25215490</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4172</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>158</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Cell</Title>
<ISOAbbreviation>Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage.</ArticleTitle>
<Pagination>
<MedlinePgn>1324-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.07.040</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00990-8</ELocationID>
<Abstract>
<AbstractText>The P7C3 class of aminopropyl carbazole chemicals fosters the survival of neurons in a variety of rodent models of neurodegeneration or nerve cell injury. To uncover its mechanism of action, an active derivative of P7C3 was modified to contain both a benzophenone for photocrosslinking and an alkyne for CLICK chemistry. This derivative was found to bind nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme involved in the conversion of nicotinamide into nicotinamide adenine dinucleotide (NAD). Administration of active P7C3 chemicals to cells treated with doxorubicin, which induces NAD depletion, led to a rebound in intracellular levels of NAD and concomitant protection from doxorubicin-mediated toxicity. Active P7C3 variants likewise enhanced the activity of the purified NAMPT enzyme, providing further evidence that they act by increasing NAD levels through its NAMPT-mediated salvage. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Gelin</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Ting</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nijhawan</LastName>
<ForeName>Deepak</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA; Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Theodoropoulos</LastName>
<ForeName>Pano</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Naidoo</LastName>
<ForeName>Jacinth</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yadavalli</LastName>
<ForeName>Sivaramakrishnan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mirzaei</LastName>
<ForeName>Hamid</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pieper</LastName>
<ForeName>Andrew A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ready</LastName>
<ForeName>Joseph M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA. Electronic address: joseph.ready@utsouthwestern.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McKnight</LastName>
<ForeName>Steven L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA. Electronic address: steven.mcknight@utsouthwestern.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5-R01-MH087986</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 MH087986</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cell</MedlineTA>
<NlmUniqueID>0413066</NlmUniqueID>
<ISSNLinking>0092-8674</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C552520">P7C3 compound</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0U46U6E8UK</RegistryNumber>
<NameOfSubstance UI="D009243">NAD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.12</RegistryNumber>
<NameOfSubstance UI="D054409">Nicotinamide Phosphoribosyltransferase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.12</RegistryNumber>
<NameOfSubstance UI="C085455">nicotinamide phosphoribosyltransferase, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002227">Carbazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053858">Metabolic Networks and Pathways</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009243">NAD</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054409">Nicotinamide Phosphoribosyltransferase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS619251 [Available on 09/11/15]</OtherID>
<OtherID Source="NLM">PMC4163014 [Available on 09/11/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25058467</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-7035</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>154</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Clinical immunology (Orlando, Fla.)</Title>
<ISOAbbreviation>Clin. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>In vitro evaluation of intestinal epithelial TLR activation in preventing food allergic responses.</ArticleTitle>
<Pagination>
<MedlinePgn>91-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2014.07.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1521-6616(14)00169-7</ELocationID>
<Abstract>
<AbstractText>Alterations in the gut microbiota composition are associated with food allergy. Toll-like receptors (TLRs) respond to microbial stimuli. We studied the effects of the ligation of TLRs on intestinal epithelial cells (IECs) in preventing an allergic effector response. IEC monolayers (T84 cells) were co-cultured with CD3/28-activated PBMCs from healthy controls or atopic patients and simultaneously apically exposed to TLR2, TLR4 or TLR9 ligands. The barrier integrity of T84 cell monolayers was significantly reduced upon co-culture with PBMCs of food allergic subjects compared to healthy subjects. Apical exposure of IECs to a TLR9 ligand prevented PBMC-induced epithelial barrier disruption. Using PBMCs from food allergic subjects, apical TLR9 activation on IECs increased the IFN-γ/IL-13 and IL-10/IL-13 ratio, while suppressing pro-inflammatory IL-6, IL-8 and TNF-α production in an IEC-dependent manner. Hence, the activation of apical TLR9 on IECs, potentially by microbiota-derived signals, may play an important role in the prevention of allergic inflammation. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>de Kivit</LastName>
<ForeName>Sander</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA. Electronic address: sander_dekivit@rush.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tobin</LastName>
<ForeName>Mary C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>DeMeo</LastName>
<ForeName>Mark T</ForeName>
<Initials>MT</Initials>
<AffiliationInfo>
<Affiliation>Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fox</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Garssen</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Pharmacology, Utrecht Institute Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands; Department of Immunology, Nutricia Research, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Forsyth</LastName>
<ForeName>Christopher B</ForeName>
<Initials>CB</Initials>
<AffiliationInfo>
<Affiliation>Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Keshavarzian</LastName>
<ForeName>Ali</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA; Division of Pharmacology, Utrecht Institute Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Landay</LastName>
<ForeName>Alan L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL, USA; Division of Pharmacology, Utrecht Institute Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Clin Immunol</MedlineTA>
<NlmUniqueID>100883537</NlmUniqueID>
<ISSNLinking>1521-6616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018920">Coculture Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005512">Food Hypersensitivity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007413">Intestinal Mucosa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007963">Leukocytes, Mononuclear</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cytokines;</Keyword>
<Keyword MajorTopicYN="N">Food allergy;</Keyword>
<Keyword MajorTopicYN="N">Intestinal epithelial cells;</Keyword>
<Keyword MajorTopicYN="N">PBMC;</Keyword>
<Keyword MajorTopicYN="N">Toll-like receptors</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25063444</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-7035</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>154</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Clinical immunology (Orlando, Fla.)</Title>
<ISOAbbreviation>Clin. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8.</ArticleTitle>
<Pagination>
<MedlinePgn>116-26</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2014.07.005</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1521-6616(14)00172-7</ELocationID>
<Abstract>
<AbstractText>Resistance to chemotherapy is the major cause of colorectal cancer (CRC) treatment failure. The cytokine IL-22, which is produced by T cells and NK cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in chemoresistance has not been investigated. We found that IL-22 levels in tumor tissues and peripheral blood were associated with chemoresistance and indicate poor prognosis for patients who received FOLFOX chemotherapy. In CRC cells, IL-22 was able to attenuate the cytotoxic and apoptosis-inducing effects of 5-FU and OXA by activating the STAT3 pathway and subsequently increasing the expression of anti-apoptotic genes. In addition, IL-22 conferred resistance to 5-FU and OXA by inducing IL-8 autocrine expression through STAT3 activation. Our findings identify IL-22 as a novel chemoresistance cytokine and may be a useful prognostic biomarker for CRC patients receiving FOLFOX chemotherapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Tingyu</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: wtyscu@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Zhongchuan</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: zhongchuanwang@aliyun.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yun</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: aeolus304@sina.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mei</LastName>
<ForeName>Zubing</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: herrmayor@126.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Guanghui</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: wgh_0625@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Zhonglin</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: xhgclzl@126.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Ang</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: light_0315@126.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Xuguang</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: huxuguangxinhua@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Long</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: longcuidr@126.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Yili</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: nathanyang@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Chen-Ying</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Shanghai, 200092, China. Electronic address: cyliu_eric@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Clin Immunol</MedlineTA>
<NlmUniqueID>100883537</NlmUniqueID>
<ISSNLinking>1521-6616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C415368">interleukin-22</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>Q573I9DVLP</RegistryNumber>
<NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Protocol" UI="C410216">Folfox protocol</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019898">Autocrine Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016209">Interleukin-8</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007378">Interleukins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002955">Leucovorin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009944">Organoplatinum Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017211">Treatment Failure</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chemoresistance</Keyword>
<Keyword MajorTopicYN="N">Interleukin 22</Keyword>
<Keyword MajorTopicYN="N">Interleukin 8</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24811246</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2568</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>59</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Digestive diseases and sciences</Title>
<ISOAbbreviation>Dig. Dis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2.</ArticleTitle>
<Pagination>
<MedlinePgn>2477-87</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-014-3184-5</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MicroRNAs (miRNAs) belong to a group of small non-coding RNA with differential expression in tumors, including hepatocellular carcinoma (HCC).</AbstractText>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study investigates the involvement of miR-125b in HCC.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Clinical analysis of miR-125b was performed using data derived from miRNA profiling and qPCR. Phenotypic changes of liver cell lines were examined after ectopic miR-125b expression. Lastly, bioinformatics analysis coupled with luciferase reporter assay was used to reveal the cellular target of miR-125b.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A down-regulation of miR-125b was found in HCC tumors and cultured cells. Patients having tumors with ≥twofold reduction in miR-125b compared to adjacent non-tumor tissues contributed to 23 out of 49 HCC cases (46.9 %), while this down-regulation was usually found in patients with tumor venous infiltration and recurrence. miR-125b expression was also negatively correlated with increased serum AFP level and poor overall survival of patients. Ectopic expression of miR-125b led to alleviated tumor phenotypes of HCC cells. Among the 110 bioinformatically predicated candidates, 31 of them negatively correlated with miR-125b in HCC tumors for which one of them named eukaryotic translation initiation factor 5A2 (eIF5A2), known also as a liver oncofetal molecule, was validated to be a direct target of miR-125b in HCC.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study has evidenced for the negative correlation of tumor miR-125b expression with poor prognosis of HCC patients. Expression of miR-125b can reverse the tumorigenic properties of cultured HCC cells via suppressing the tumorigenic molecule eIF5A2, thus postulating restoration of miR-125b level as a way to counteract liver tumorigenesis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tsang</LastName>
<ForeName>Felice H</ForeName>
<Initials>FH</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Au</LastName>
<ForeName>Victor</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Wen-Jing</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shek</LastName>
<ForeName>Felix H</ForeName>
<Initials>FH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Angela M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Luk</LastName>
<ForeName>John M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Sheung-Tat</ForeName>
<Initials>ST</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Poon</LastName>
<ForeName>Ronnie T P</ForeName>
<Initials>RT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Nikki P</ForeName>
<Initials>NP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dig Dis Sci</MedlineTA>
<NlmUniqueID>7902782</NlmUniqueID>
<ISSNLinking>0163-2116</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C531888">MIRN125 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010448">Peptide Initiation Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C425967">eIF-5A2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010448">Peptide Initiation Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24825593</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2568</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>59</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Digestive diseases and sciences</Title>
<ISOAbbreviation>Dig. Dis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis.</ArticleTitle>
<Pagination>
<MedlinePgn>2444-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-014-3193-4</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Colitis-associated cancer (CAC) is the serious complication of ulcerative colitis (UC), and molecular markers to evaluate the individual risk are required. MicroRNA-124a (miR - 124a) is known to have tumor-suppressive function and be methylation-silenced during exposure to chronic inflammation.</AbstractText>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">We analyzed whether higher methylation levels of miR-124a genes correlated with the higher epidemiologic risk of CAC development in UC patients.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Forty UC patients without CAC, four patients with CAC or dysplasia, eight sporadic colorectal cancer (S-CRC) patients, and 12 healthy volunteers (HV) were studied. Methylation status of miR-124a genes (miR-124a-1, -2, and -3) was analyzed by methylation-specific polymerase chain reaction (MSP), and methylation levels were quantified by real-time MSP. Expression of cyclin-dependent kinase 6 (CDK6), a target of miR-124a, was analyzed by immunohistochemistry.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Three miR-124a genes were methylated in all neoplastic tissues (CAC, dysplasia, and S-CRC), and CDK6 was highly expressed in those tissues. Regarding disease extent, mean methylation levels of miR-124a-3 in HV, non-pancolitis, and pancolitis were 2.0, 5.3, and 12.3%, respectively, and were significantly higher in pancolitis than in HV (p &lt; 0.01). Regarding disease duration, mean methylation levels in short-term and long-standing UC patients were 2.5 and 13.2%, respectively. Long-standing UC patients had significantly higher methylation levels than HV (p &lt; 0.01). Moreover, UC patients with both pancolitis and long-standing had 7.4-fold higher methylation levels than those without these risk factors.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MiR-124a genes are methylated during carcinogenesis in UC patients. The methylation level of miR-124a-3 is a promising marker for estimating individual risk for CAC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ueda</LastName>
<ForeName>Yuko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan, i-yuko@umail.plala.or.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ando</LastName>
<ForeName>Takayuki</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nanjo</LastName>
<ForeName>Sohachi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ushijima</LastName>
<ForeName>Toshikazu</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sugiyama</LastName>
<ForeName>Toshiro</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dig Dis Sci</MedlineTA>
<NlmUniqueID>7902782</NlmUniqueID>
<ISSNLinking>0163-2116</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C509207">MIRN124 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003093">Colitis, Ulcerative</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019175">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25117438</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>451</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>A genetic screen in Drosophila for regulators of human prostate cancer progression.</ArticleTitle>
<Pagination>
<MedlinePgn>548-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2014.08.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(14)01421-1</ELocationID>
<Abstract>
<AbstractText>To uncover the mechanism by which human prostate cancer progresses, we performed a genetic screen for regulators of human prostate cancer progression using the Drosophila accessory gland, a functional homolog of the mammalian prostate. Cell growth and migration of secondary cells in the adult male accessory gland were found to be regulated by paired, N-cadherin, and E-cadherin, which are Drosophila homologues of regulators of human prostate cancer progression. Using this screening system, we also identified three genes that promoted growth and migration of secondary cells in the accessory gland. The human homologues of these candidate genes - MRGBP, CNPY2, and MEP1A - were found to be expressed in human prostate cancer model cells and to promote replication and invasiveness in these cells. These findings suggest that the development of the Drosophila accessory gland and human prostate cancer cell growth and invasion are partly regulated through a common mechanism. The screening system using the Drosophila accessory gland can be a useful tool for uncovering the mechanisms of human prostate cancer progression. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ito</LastName>
<ForeName>Saya</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kajii-cho, 465, Kyoto City, Kyoto 602-8566, Japan. Electronic address: itosaya@koto.kpu-m.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ueda</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kajii-cho, 465, Kyoto City, Kyoto 602-8566, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ueno</LastName>
<ForeName>Akihisa</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kajii-cho, 465, Kyoto City, Kyoto 602-8566, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakagawa</LastName>
<ForeName>Hideo</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kajii-cho, 465, Kyoto City, Kyoto 602-8566, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Taniguchi</LastName>
<ForeName>Hidefumi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kajii-cho, 465, Kyoto City, Kyoto 602-8566, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kayukawa</LastName>
<ForeName>Naruhiro</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kajii-cho, 465, Kyoto City, Kyoto 602-8566, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miki</LastName>
<ForeName>Tsuneharu</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kajii-cho, 465, Kyoto City, Kyoto 602-8566, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C479739">C20orf20 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C502333">CNPY2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.-</RegistryNumber>
<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.18</RegistryNumber>
<NameOfSubstance UI="C053833">meprin A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005088">Exocrine Glands</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008666">Metalloendopeptidases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Accessory gland</Keyword>
<Keyword MajorTopicYN="N">Drosophila</Keyword>
<Keyword MajorTopicYN="N">Prostate cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25117446</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>451</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>556-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2014.08.014</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(14)01420-X</ELocationID>
<Abstract>
<AbstractText>Arsenic trioxide (As2O3) has shown therapeutic effects in some leukemias and solid cancers. However, the molecular mechanisms of its anticancer efficacy have not been clearly elucidated, particularly in solid cancers. Our previous data showed that As2O3 induced apoptosis of human papillomavirus (HPV) 16 DNA-immortalized human cervical epithelial cells and cervical cancer cells and inhibited the expression of HPV oncogenes in these cells. In the present study, we systemically examined the effects of As2O3 on five human cervical cancer cell lines and explored the possible molecular mechanisms. MTT assay showed that HPV-negative C33A cells were more sensitive to growth inhibition induced by As2O3 than HPV-positive cervical cancer cells, and HPV 18-positive HeLa and C4-I cells were more sensitive to As2O3 than HPV 16-positive CaSki and SiHa cells. After As2O3 treatment, both mRNA and protein levels of HPV E6 and E7 obviously decreased in all HPV positive cell lines. In contrast, p53 and Rb protein levels increased in all tested cell lines. Transcription factor AP-1 protein expression decreased significantly in HeLa, CaSki and C33A cells with ELISA method. These results suggest that As2O3 is a potential anticancer drug for cervical cancer. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Hongtao</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, School of Medicine, Southeast University, Nanjing 210009, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Peng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, School of Medicine, Southeast University, Nanjing 210009, China. Electronic address: jiezheng54@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001152">Arsenicals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C068651">E6 protein, Human papillomavirus type 16</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009856">Oncogene Proteins, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050725">Papillomavirus E7 Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016160">Retinoblastoma Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1327-53-3</RegistryNumber>
<NameOfSubstance UI="C006632">arsenic trioxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001152">Arsenicals</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052162">Human papillomavirus 16</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009856">Oncogene Proteins, Viral</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010087">Oxides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050725">Papillomavirus E7 Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030361">Papillomavirus Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016160">Retinoblastoma Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018808">Transcription Factor AP-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002583">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Arsenic trioxide</Keyword>
<Keyword MajorTopicYN="N">Cervical cancer cells</Keyword>
<Keyword MajorTopicYN="N">Human papillomavirus</Keyword>
<Keyword MajorTopicYN="N">Viral oncogenes E6/E7</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25124663</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>451</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Regulation of IL-6 and IL-8 production by reciprocal cell-to-cell interactions between tumor cells and stromal fibroblasts through IL-1α in ameloblastoma.</ArticleTitle>
<Pagination>
<MedlinePgn>491-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2014.07.137</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(14)01400-4</ELocationID>
<Abstract>
<AbstractText>Ameloblastoma is an odontogenic benign tumor that occurs in the jawbone, which invades bone and reoccurs locally. This tumor is treated by wide surgical excision and causes various problems, including changes in facial countenance and mastication disorders. Ameloblastomas have abundant tumor stroma, including fibroblasts and immune cells. Although cell-to-cell interactions are considered to be involved in the pathogenesis of many diseases, intercellular communications in ameloblastoma have not been fully investigated. In this study, we examined interactions between tumor cells and stromal fibroblasts via soluble factors in ameloblastoma. We used a human ameloblastoma cell line (AM-3 ameloblastoma cells), human fibroblasts (HFF-2 fibroblasts), and primary-cultured fibroblasts from human ameloblastoma tissues, and analyzed the effect of ameloblastoma-associated cell-to-cell communications on gene expression, cytokine secretion, cellular motility and proliferation. AM-3 ameloblastoma cells secreted higher levels of interleukin (IL)-1α than HFF-2 fibroblasts. Treatment with conditioned medium from AM-3 ameloblastoma cells upregulated gene expression and secretion of IL-6 and IL-8 of HFF-2 fibroblasts and primary-cultured fibroblast cells from ameloblastoma tissues. The AM3-stimulated production of IL-6 and IL-8 in fibroblasts was neutralized by pretreatment of AM-3 cells with anti-IL-1α antibody and IL-1 receptor antagonist. Reciprocally, cellular motility of AM-3 ameloblastoma cells was stimulated by HFF-2 fibroblasts in IL-6 and IL-8 dependent manner. In conclusion, ameloblastoma cells and stromal fibroblasts behave interactively via these cytokines to create a microenvironment that leads to the extension of ameloblastomas. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fuchigami</LastName>
<ForeName>Takao</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Department of Oral and Maxillofacial Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kibe</LastName>
<ForeName>Toshiro</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Oral and Maxillofacial Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Koyama</LastName>
<ForeName>Hirofumi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kishida</LastName>
<ForeName>Shosei</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iijima</LastName>
<ForeName>Mikio</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nishizawa</LastName>
<ForeName>Yoshiaki</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Kagoshima University Faculty of Medicine, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hijioka</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Oral and Maxillofacial Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fujii</LastName>
<ForeName>Tomomi</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Oral and Maxillofacial Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ueda</LastName>
<ForeName>Masahiro</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Natural Science Centre for Research and Education, Kagoshima University, 1-21-24 Koorimoto, Kagoshima 890-8580, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakamura</LastName>
<ForeName>Norifumi</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Oral and Maxillofacial Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kiyono</LastName>
<ForeName>Tohru</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Virology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuouku, Tokyo 104-0045, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kishida</LastName>
<ForeName>Michiko</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry and Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. Electronic address: kmichiko@m2.kufm.kagoshima-u.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053582">Interleukin-1alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000564">Ameloblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002450">Cell Communication</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053582">Interleukin-1alpha</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016209">Interleukin-8</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007573">Jaw Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017472">Receptors, Interleukin-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017154">Stromal Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">AM-3</Keyword>
<Keyword MajorTopicYN="N">Ameloblastoma</Keyword>
<Keyword MajorTopicYN="N">Fibroblast</Keyword>
<Keyword MajorTopicYN="N">Interleukin</Keyword>
<Keyword MajorTopicYN="N">Microenvironment</Keyword>
<Keyword MajorTopicYN="N">Reciprocal interaction</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128825</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>451</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Modulation of cytokine expression in human macrophages by endocrine-disrupting chemical Bisphenol-A.</ArticleTitle>
<Pagination>
<MedlinePgn>592-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2014.08.031</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(14)01446-6</ELocationID>
<Abstract>
<AbstractText>Exposure to environmental endocrine-disrupting chemical Bisphenol-A (BPA) is often associated with dysregulated immune homeostasis, but the mechanisms remain unclear. In the present study, the effects of BPA on the cytokines responses of human macrophages were investigated. Treatment with BPA increased pro-inflammation cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production, but decreased anti-inflammation cytokines interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) production in THP1 macrophages, as well as in primary human macrophages. BPA effected cytokines expression through estrogen receptor α/β (ERα/β)-dependent mechanism with the evidence of ERα/β antagonist reversed the expression of cytokines. We also identified that activation of extracellular regulated protein kinases (ERK)/nuclear factor κB (NF-κB) signal cascade marked the effects of BPA on cytokines expression. Our results indicated that BPA effected inflammatory responses of macrophages via modulating of cytokines expression, and provided a new insight into the link between exposure to BPA and human health. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yanzhen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mei</LastName>
<ForeName>Chenfang</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, Guangzhou 510095, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Hongsheng</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zeng</LastName>
<ForeName>Guoqu</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Jianhui</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Meiying</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Applied Microbiology Southern China, Guangzhou 510070, PR China; Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Institute of Microbiology, Guangzhou 510070, PR China. Electronic address: xumy@gdim.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506487">estrogen receptor alpha, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>130068-27-8</RegistryNumber>
<NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>MLT3645I99</RegistryNumber>
<NameOfSubstance UI="C006780">bisphenol A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001559">Benzhydryl Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047628">Estrogen Receptor alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016753">Interleukin-10</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010636">Phenols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Bisphenol-A</Keyword>
<Keyword MajorTopicYN="N">Cytokine</Keyword>
<Keyword MajorTopicYN="N">Inflammation</Keyword>
<Keyword MajorTopicYN="N">Macrophage</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128827</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>451</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>5</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>PGE2-induced colon cancer growth is mediated by mTORC1.</ArticleTitle>
<Pagination>
<MedlinePgn>587-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2014.08.032</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(14)01447-8</ELocationID>
<Abstract>
<AbstractText>The inflammatory prostaglandin E2 (PGE2) cytokine plays a key role in the development of colon cancer. Several studies have shown that PGE2 directly induces the growth of colon cancer cells and furthermore promotes tumor angiogenesis by increasing the production of the vascular endothelial growth factor (VEGF). The signaling intermediaries implicated in these processes have however not been fully characterized. In this report, we show that the mechanistic target of rapamycin complex 1 (mTORC1) plays an important role in PGE2-induced colon cancer cell responses. Indeed, stimulation of LS174T cells with PGE2 increased mTORC1 activity as observed by the augmentation of S6 ribosomal protein phosphorylation, a downstream effector of mTORC1. The PGE2 EP4 receptor was responsible for transducing the signal to mTORC1. Moreover, PGE2 increased colon cancer cell proliferation as well as the growth of colon cancer cell colonies grown in matrigel and blocking mTORC1 by rapamycin or ATP-competitive inhibitors of mTOR abrogated these effects. Similarly, the inhibition of mTORC1 by downregulation of its component raptor using RNA interference blocked PGE2-induced LS174T cell growth. Finally, stimulation of LS174T cells with PGE2 increased VEGF production which was also prevented by mTORC1 inhibition. Taken together, these results show that mTORC1 is an important signaling intermediary in PGE2 mediated colon cancer cell growth and VEGF production. They further support a role for mTORC1 in inflammation induced tumor growth. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dufour</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Visceral Surgery, University Hospital of Lausanne, Pavillon 4, Av. de Beaumont, 1011 Lausanne, Switzerland. Electronic address: Marc.dufour@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Faes</LastName>
<ForeName>Seraina</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Visceral Surgery, University Hospital of Lausanne, Pavillon 4, Av. de Beaumont, 1011 Lausanne, Switzerland. Electronic address: Seraina.faes@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dormond-Meuwly</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Visceral Surgery, University Hospital of Lausanne, Pavillon 4, Av. de Beaumont, 1011 Lausanne, Switzerland. Electronic address: Anne.meuwly-Dormond@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Demartines</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Visceral Surgery, University Hospital of Lausanne, Pavillon 4, Av. de Beaumont, 1011 Lausanne, Switzerland. Electronic address: Demartines@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dormond</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Department of Visceral Surgery, University Hospital of Lausanne, Pavillon 4, Av. de Beaumont, 1011 Lausanne, Switzerland. Electronic address: Olivier.dormond@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C576553">mechanistic target of rapamycin complex 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K7Q1JQR04M</RegistryNumber>
<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046912">Multiprotein Complexes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Colon cancer</Keyword>
<Keyword MajorTopicYN="N">PGE(2)</Keyword>
<Keyword MajorTopicYN="N">Rapamycin</Keyword>
<Keyword MajorTopicYN="N">Signaling</Keyword>
<Keyword MajorTopicYN="N">mTORC1</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24990856</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1490</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>307</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Regulatory, integrative and comparative physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.</ArticleTitle>
<Pagination>
<MedlinePgn>R693-703</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpregu.00422.2013</ELocationID>
<Abstract>
<AbstractText>20-Hydroxyeicosatetraenoic acid (20-HETE), Cyp4a-derived eicosanoid, is a lipid mediator that promotes tumor growth, as well as causing detrimental effects in cerebral circulation. We determined whether concurrent inhibition of cyclooxygenase-2 (COX-2) and 20-HETE affects colon tumor growth and ischemic stroke outcomes. The expression of Cyp4a and COXs and production of 20-HETE and PGE2 were determined in murine colon carcinoma (MC38) cells. We then examined the effects of combined treatment with rofecoxib, a potent COX-2 inhibitor, and HET0016, a potent Cyp4a inhibitor, on the growth and proliferation of MC38 cells. Subsequently, we tested the effects of HET0016 plus rofecoxib in MC38 tumor and ischemic stroke models. Cyp4a and COXs are highly expressed in MC38 cells. Respectively, HET0016 and rofecoxib inhibited 20-HETE and PGE2 formation in MC38 cells. Moreover, rofecoxib combined with HET0016 had greater inhibitory effects on the growth and proliferation of MC38 cells than did rofecoxib alone. Importantly, rofecoxib combined with HET0016 provided greater inhibition on tumor growth than did rofecoxib alone in MC38 tumor-bearing mice. Prolonged treatment with rofecoxib selectively induced circulating 20-HETE levels and caused cerebrovascular damage after ischemic stroke, whereas therapy with rofecoxib and HET0016 attenuated 20-HETE levels and reduced rofecoxib-induced cerebrovascular damage and stroke outcomes during anti-tumor therapy. Thus these results demonstrate that combination therapy with rofecoxib and HET0016 provides a new treatment of colon tumor, which can not only enhance the anti-tumor efficacy of rofecoxib, but also reduce rofecoxib-induced cerebrovascular damage and stroke outcomes. </AbstractText>
<CopyrightInformation>Copyright © 2014 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Georgia Regents University, Augusta, Georgia; Department of Orthopedics, Puren Hospital, Wuhan University of Science and Technology, Wuhan, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hoda</LastName>
<ForeName>Md Nasrul</ForeName>
<Initials>MN</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Laboratory, Imaging &amp; Radiologic Sciences, College of Allied Health Sciences, Georgia Regents University, Augusta, Georgia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Xuan</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Medicine and Genetics, Georgia Regents University, Augusta, Georgia; Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Weiguo</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Georgia Regents University, Augusta, Georgia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Pengcheng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Huangshi Central Hospital, Hubei Polytechnic University and Hubei Key Laboratory of Kidney Disease, Pathogenesis, and Intervention, Huangshi, Hubei, China; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Maddipati</LastName>
<ForeName>Krishna Rao</ForeName>
<Initials>KR</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and WSU Lipidomics Core, Wayne State University, Detroit, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Seki</LastName>
<ForeName>Tsugio</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Georgia Regents University, Augusta, Georgia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ergul</LastName>
<ForeName>Adviye</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Georgia Regents University, Augusta, Georgia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Mong-Heng</ForeName>
<Initials>MH</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology, Georgia Regents University, Augusta, Georgia; mwang@gru.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>NS-054688</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>S10-RR-027926</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Regul Integr Comp Physiol</MedlineTA>
<NlmUniqueID>100901230</NlmUniqueID>
<ISSNLinking>0363-6119</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052246">Cyclooxygenase 2 Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006893">Hydroxyeicosatetraenoic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007783">Lactones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013450">Sulfones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0QTW8Z7MCR</RegistryNumber>
<NameOfSubstance UI="C116926">rofecoxib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>79551-86-3</RegistryNumber>
<NameOfSubstance UI="C055987">20-hydroxy-5,8,11,14-eicosatetraenoic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.15.3</RegistryNumber>
<NameOfSubstance UI="D042926">Cytochrome P-450 CYP4A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.-</RegistryNumber>
<NameOfSubstance UI="C077623">Ptgs2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K7Q1JQR04M</RegistryNumber>
<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002545">Brain Ischemia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D052246">Cyclooxygenase 2 Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042926">Cytochrome P-450 CYP4A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006893">Hydroxyeicosatetraenoic Acids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007783">Lactones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020521">Stroke</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013450">Sulfones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4214836 [Available on 09/15/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">HET0016</Keyword>
<Keyword MajorTopicYN="N">rofecoxib</Keyword>
<Keyword MajorTopicYN="N">stroke</Keyword>
<Keyword MajorTopicYN="N">tumor growth</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24975213</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1365-2141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>167</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>British journal of haematology</Title>
<ISOAbbreviation>Br. J. Haematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>69-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.13013</ELocationID>
<Abstract>
<AbstractText>PIM kinases (PIM1, 2 and 3) are involved in cell proliferation and survival signalling and are emerging targets for the therapy of various malignancies. We found that a significant proportion of primary acute myeloid leukaemia (AML) samples showed PIM1 and PIM2 expression by quantitative reverse transcription polymerase chain reaction. Therefore, we investigated the effects of a novel ATP-competitive pan-PIM inhibitor, AZD1897, on AML cell growth and survival. PIM inhibition showed limited single agent activity in AML cell lines and primary AML cells, including those with or without FLT3-internal tandem duplication (ITD) mutation. However, significant synergy was seen when AZD1897 was combined with the Akt inhibitor AZD5363, a compound that is in early-phase clinical trials. AML cells from putative leukaemia stem cell subsets, including CD34+38- and CD34+38+ fractions, were equivalently affected by dual PIM/Akt inhibition when compared with bulk tumour cells. Analysis of downstream signalling pathways showed that combined PIM/Akt inhibition downregulated mTOR outputs (phosphorylation of 4EBP1 and S6) and markedly reduced levels of the anti-apoptotic protein MCL1. The combination of PIM and Akt inhibition holds promise for the treatment of AML. </AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Meja</LastName>
<ForeName>Koremu</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Haematology, University College London Cancer Institute, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stengel</LastName>
<ForeName>Chloe</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sellar</LastName>
<ForeName>Rob</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huszar</LastName>
<ForeName>Dennis</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Davies</LastName>
<ForeName>Barry R</ForeName>
<Initials>BR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gale</LastName>
<ForeName>Rosemary E</ForeName>
<Initials>RE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Linch</LastName>
<ForeName>David C</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khwaja</LastName>
<ForeName>Asim</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Haematol</MedlineTA>
<NlmUniqueID>0372544</NlmUniqueID>
<ISSNLinking>0007-1048</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051573">Proto-Oncogene Proteins c-pim-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C406031">proto-oncogene proteins pim</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051573">Proto-Oncogene Proteins c-pim-1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">apoptosis</Keyword>
<Keyword MajorTopicYN="N">kinase</Keyword>
<Keyword MajorTopicYN="N">leukaemia</Keyword>
<Keyword MajorTopicYN="N">oncogenes</Keyword>
<Keyword MajorTopicYN="N">therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24995804</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1365-2141</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>167</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>British journal of haematology</Title>
<ISOAbbreviation>Br. J. Haematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.</ArticleTitle>
<Pagination>
<MedlinePgn>87-99</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.13011</ELocationID>
<Abstract>
<AbstractText>While childhood acute lymphoblastic leukaemia (ALL) is now highly curable, the dismal prognosis for children who relapse warrants novel therapeutic approaches. Previously, using an integrated genomic analysis of matched diagnosis-relapse paired samples, we identified overactivation of the Wnt pathway as a possible mechanism of recurrence. To validate these findings and document whether Wnt inhibition may sensitize cells to chemotherapy, we analysed the expression of activated β-catenin (and its downstream target BIRC5) using multiparameter phosphoflow cytometry and tested the efficacy of a recently developed Wnt inhibitor, iCRT14, in ALL cell lines and patient samples. We observed increased activation of β-catenin at relapse in 6/10 patients. Furthermore, treatment of leukaemic cell lines with iCRT14 led to significant downregulation of Wnt target genes and combination with traditional chemotherapeutic drugs resulted in a synergistic decrease in viability as well as a significant increase in apoptotic cell death. Finally, pre-treatment of purified blasts from patients with relapsed leukaemia with the Wnt inhibitor followed by exposure to prednisolone, restored chemosensitivity in these cells. Our results demonstrate that overactivation of the Wnt pathway may contribute to chemoresistance in relapsed childhood ALL and that Wnt-inhibition may be a promising therapeutic approach. </AbstractText>
<CopyrightInformation>© 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dandekar</LastName>
<ForeName>Smita</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>NYU Langone Medical Center, NYU Cancer Institute, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Romanos-Sirakis</LastName>
<ForeName>Eleny</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pais</LastName>
<ForeName>Faye</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bhatla</LastName>
<ForeName>Teena</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>Courtney</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bourgeois</LastName>
<ForeName>Wallace</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hunger</LastName>
<ForeName>Stephen P</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raetz</LastName>
<ForeName>Elizabeth A</ForeName>
<Initials>EA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hermiston</LastName>
<ForeName>Michelle L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dasgupta</LastName>
<ForeName>Ramanuj</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morrison</LastName>
<ForeName>Debra J</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carroll</LastName>
<ForeName>William L</ForeName>
<Initials>WL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5 P30 CA16087-30</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA140729</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA140729</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA155125-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA152838-02</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 GM066704</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA98413</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA98543</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U24 CA114766</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Haematol</MedlineTA>
<NlmUniqueID>0372544</NlmUniqueID>
<ISSNLinking>0007-1048</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer. 2009 Nov;45(16):2759-67</RefSource>
<PMID Version="1">19729298</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2009 Oct 1;461(7264):614-20</RefSource>
<PMID Version="1">19759537</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2010;5(2):e9370</RefSource>
<PMID Version="1">20186325</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2010 Mar 26;327(5973):1650-3</RefSource>
<PMID Version="1">20339075</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2010 Jun 15;16(12):3153-62</RefSource>
<PMID Version="1">20530697</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS Lett. 2010 Sep 24;584(18):3923-8</RefSource>
<PMID Version="1">20804755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Chem Biol. 2010 Nov;6(11):829-36</RefSource>
<PMID Version="1">20890287</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):5954-63</RefSource>
<PMID Version="1">21393571</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pediatr Blood Cancer. 2011 Aug;57(2):210-6</RefSource>
<PMID Version="1">21337680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2011 Nov 10;118(19):5218-26</RefSource>
<PMID Version="1">21921043</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Jan 12;481(7380):157-63</RefSource>
<PMID Version="1">22237106</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Leukemia. 2012 Feb;26(2):271-9</RefSource>
<PMID Version="1">21844871</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2012 May 10;30(14):1663-9</RefSource>
<PMID Version="1">22412151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2012 May 31;119(22):5201-10</RefSource>
<PMID Version="1">22496163</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Lett. 2013 Jun 1;333(1):9-17</RefSource>
<PMID Version="1">23333798</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15710-5</RefSource>
<PMID Version="1">24019458</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2014 Apr 24;33(17):2169-78</RefSource>
<PMID Version="1">23728349</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2000 Aug 1;14(15):1837-51</RefSource>
<PMID Version="1">10921899</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2000 Sep 1;96(5):1921-5</RefSource>
<PMID Version="1">10961895</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2000 Sep 1;96(5):1926-32</RefSource>
<PMID Version="1">10961896</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2001 Dec 15;61(24):8664-7</RefSource>
<PMID Version="1">11751382</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hematol J. 2000;1(1):3-6</RefSource>
<PMID Version="1">11920163</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2002 Aug 15;21(36):5548-56</RefSource>
<PMID Version="1">12165853</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res. 2003;5(2):63-8</RefSource>
<PMID Version="1">12631383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3422-7</RefSource>
<PMID Version="1">12626754</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2003 May 22;423(6938):409-14</RefSource>
<PMID Version="1">12717450</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23</RefSource>
<PMID Version="1">14973184</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2004 Mar 5;303(5663):1483-7</RefSource>
<PMID Version="1">15001769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cell Biol. 2004 Apr;24(7):2890-904</RefSource>
<PMID Version="1">15024077</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7</RefSource>
<PMID Version="1">15067127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2004 Aug 12;351(7):657-67</RefSource>
<PMID Version="1">15306667</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7</RefSource>
<PMID Version="1">15314234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1998 Sep 4;281(5382):1509-12</RefSource>
<PMID Version="1">9727977</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 1995 Nov 15;86(10):3861-8</RefSource>
<PMID Version="1">7579354</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Genet. 2004 Sep;5(9):691-701</RefSource>
<PMID Version="1">15372092</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Genet. 1999 Jan;15(1):1-3</RefSource>
<PMID Version="1">10087922</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 1999 Apr 1;398(6726):422-6</RefSource>
<PMID Version="1">10201372</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11464-9</RefSource>
<PMID Version="1">10500199</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Cell Biol. 2004 Dec;16(6):681-7</RefSource>
<PMID Version="1">15530781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2004 Dec 30;351(27):2817-26</RefSource>
<PMID Version="1">15591335</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Immunol. 2005 Jan;5(1):21-30</RefSource>
<PMID Version="1">15630426</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2005 Apr 14;434(7035):843-50</RefSource>
<PMID Version="1">15829953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2005 Aug 11;24(34):5396-400</RefSource>
<PMID Version="1">16007226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Pediatr Blood Cancer. 2006 Jul;47(1):4-13</RefSource>
<PMID Version="1">16534789</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Apr 15;109(8):3462-9</RefSource>
<PMID Version="1">17148581</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2007 Jun;28(6):1133-9</RefSource>
<PMID Version="1">17341657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Blood. 2007 Jun 15;109(12):5463-72</RefSource>
<PMID Version="1">17317856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Haematol. 2007 Aug;138(3):338-48</RefSource>
<PMID Version="1">17614820</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2008 Aug 20;26(24):3971-8</RefSource>
<PMID Version="1">18711187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Leukemia. 2008 Dec;22(12):2142-50</RefSource>
<PMID Version="1">18818707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioorg Med Chem Lett. 2009 Jul 15;19(14):3825-7</RefSource>
<PMID Version="1">19410457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Jan 15;70(2):440-6</RefSource>
<PMID Version="1">20068163</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051153">Wnt Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060449">Wnt Signaling Pathway</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS634496</OtherID>
<OtherID Source="NLM">PMC4207443</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Wnt inhibition</Keyword>
<Keyword MajorTopicYN="N">acute lymphoblastic leukaemia</Keyword>
<Keyword MajorTopicYN="N">chemosensitivity</Keyword>
<Keyword MajorTopicYN="N">phosphoflow cytometry</Keyword>
<Keyword MajorTopicYN="N">relapse</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24860972</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>08</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-2399</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>42</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Experimental hematology</Title>
<ISOAbbreviation>Exp. Hematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.</ArticleTitle>
<Pagination>
<MedlinePgn>783-92.e1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exphem.2014.05.007</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0301-472X(14)00203-3</ELocationID>
<Abstract>
<AbstractText>The hypoxic microenvironment of the bone marrow, known as the hypoxic niche, supports hematopoietic stem cell quiescence and maintains long-term repopulation activity. Hypoxia also affects the expansion of progenitor cells and enhances erythropoiesis and megakaryopoiesis. In contrast to the known effects of hypoxia on normal hematopoiesis, the effects of the hypoxic environment of the bone marrow on the pathogenesis of myeloproliferative neoplasms (MPNs) have not been well studied. In the present study, we investigated the role of the hypoxic environment in the pathophysiology of MPNs, focusing on JAK2V617F, a major driver of mutation in Philadelphia-negative MPNs. We found that the activity of JAK2V617F was suppressed in hypoxic conditions not only in JAK2V617F-positive leukemia cells, but also in primary peripheral blood mononuclear cells from patients with polycythemia vera. Concomitant with the inhibition of JAK2V617F activity, hypoxia increased the expression of p27/KIP1, the primary negative regulator of the cell cycle, and inhibited cell cycle progression in JAK2V617F-positive leukemia cell lines. The spontaneous erythroid colony formation of primary cells from polycythemia vera patients was also suppressed under hypoxic conditions. We also revealed that the hypoxia-induced overproduction of reactive oxygen species played a crucial role in the inhibition of JAK2V617F through the oxidation and inhibition of SHP-2, a protein tyrosine phosphatase that contains SH-2, which is required for JAK2 activation. In conclusion, a hypoxic environment may modulate JAK2-positive MPN cell fate and disease progression through the suppression of SHP-2 function and the subsequent suppression of JAK2V617F activity. </AbstractText>
<CopyrightInformation>Copyright © 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mitsumori</LastName>
<ForeName>Toru</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nozaki</LastName>
<ForeName>Yumi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kawashima</LastName>
<ForeName>Ichiro</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Takeo</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shobu</LastName>
<ForeName>Yuki</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nakajima</LastName>
<ForeName>Kei</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morishita</LastName>
<ForeName>Soji</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Komatsu</LastName>
<ForeName>Norio</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kirito</LastName>
<ForeName>Keita</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan. Electronic address: kirito@yamanashi.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>05</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Exp Hematol</MedlineTA>
<NlmUniqueID>0402313</NlmUniqueID>
<ISSNLinking>0301-472X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C436291">CDKN1B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147604-94-2</RegistryNumber>
<NameOfSubstance UI="D050760">Cyclin-Dependent Kinase Inhibitor p27</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="C507924">JAK2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C516724">PTPN11 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D054592">Protein Tyrosine Phosphatase, Non-Receptor Type 11</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019943">Amino Acid Substitution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015687">Cell Hypoxia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050760">Cyclin-Dependent Kinase Inhibitor p27</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019337">Hematologic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053614">Janus Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007963">Leukocytes, Mononuclear</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020125">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011087">Polycythemia Vera</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054592">Protein Tyrosine Phosphatase, Non-Receptor Type 11</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202028</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-8140</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>206</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of cell biology</Title>
<ISOAbbreviation>J. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Dlg1 controls planar spindle orientation in the neuroepithelium through direct interaction with LGN.</ArticleTitle>
<Pagination>
<MedlinePgn>707-17</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.201405060</ELocationID>
<Abstract>
<AbstractText>Oriented cell divisions are necessary for the development of epithelial structures. Mitotic spindle orientation requires the precise localization of force generators at the cell cortex via the evolutionarily conserved LGN complex. However, polarity cues acting upstream of this complex in vivo in the vertebrate epithelia remain unknown. In this paper, we show that Dlg1 is localized at the basolateral cell cortex during mitosis and is necessary for planar spindle orientation in the chick neuroepithelium. Live imaging revealed that Dlg1 is required for directed spindle movements during metaphase. Mechanistically, we show that direct interaction between Dlg1 and LGN promotes cortical localization of the LGN complex. Furthermore, in human cells dividing on adhesive micropatterns, homogenously localized Dlg1 recruited LGN to the mitotic cortex and was also necessary for proper spindle orientation. We propose that Dlg1 acts primarily to recruit LGN to the cortex and that Dlg1 localization may additionally provide instructive cues for spindle orientation.</AbstractText>
<CopyrightInformation>© 2014 Saadaoui et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Saadaoui</LastName>
<ForeName>Mehdi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, F-75005 Paris, France Institut National de la Santé et de la Recherche Medicale, U1024, F-75005 Paris, France Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8197, F-75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Machicoane</LastName>
<ForeName>Mickaël</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Membrane Traffic and Cell Division Laboratory, Institut Pasteur, F-75015 Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Associée 2582, F-75015 Paris, France Cellule Pasteur-Université Pierre et Marie Curie, Université Pierre et Marie Curie, F-75015 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>di Pietro</LastName>
<ForeName>Florencia</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, F-75005 Paris, France Institut National de la Santé et de la Recherche Medicale, U1024, F-75005 Paris, France Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8197, F-75005 Paris, France Institute of Doctoral Studies (IFD), Sorbonne Universités, Université Pierre et Marie Curie-Université Paris 6, F-75252 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Etoc</LastName>
<ForeName>Fred</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, F-75005 Paris, France Institut National de la Santé et de la Recherche Medicale, U1024, F-75005 Paris, France Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8197, F-75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Echard</LastName>
<ForeName>Arnaud</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Membrane Traffic and Cell Division Laboratory, Institut Pasteur, F-75015 Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Associée 2582, F-75015 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morin</LastName>
<ForeName>Xavier</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Institut de Biologie de l'École Normale Supérieure, Ecole Normale Supérieure, F-75005 Paris, France Institut National de la Santé et de la Recherche Medicale, U1024, F-75005 Paris, France Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8197, F-75005 Paris, France xavier.morin@ens.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cell Biol</MedlineTA>
<NlmUniqueID>0375356</NlmUniqueID>
<ISSNLinking>0021-9525</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C513314">DLG1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C102754">GPSM2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016764">Cell Polarity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002642">Chick Embryo</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004848">Epithelium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008938">Mitosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008941">Spindle Apparatus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4164945 [Available on 03/15/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202031</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-8140</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>206</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of cell biology</Title>
<ISOAbbreviation>J. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Concentration of Sec12 at ER exit sites via interaction with cTAGE5 is required for collagen export.</ArticleTitle>
<Pagination>
<MedlinePgn>751-62</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.201312062</ELocationID>
<Abstract>
<AbstractText>Mechanisms for exporting variably sized cargo from the endoplasmic reticulum (ER) using the same machinery remain poorly understood. COPII-coated vesicles, which transport secretory proteins from the ER to the Golgi apparatus, are typically 60-90 nm in diameter. However, collagen, which forms a trimeric structure that is too large to be accommodated by conventional transport vesicles, is also known to be secreted via a COPII-dependent process. In this paper, we show that Sec12, a guanine-nucleotide exchange factor for Sar1 guanosine triphosphatase, is concentrated at ER exit sites and that this concentration of Sec12 is specifically required for the secretion of collagen VII but not other proteins. Furthermore, Sec12 recruitment to ER exit sites is organized by its direct interaction with cTAGE5, a previously characterized collagen cargo receptor component, which functions together with TANGO1 at ER exit sites. These findings suggest that the export of large cargo requires high levels of guanosine triphosphate-bound Sar1 generated by Sec12 localized at ER exit sites. </AbstractText>
<CopyrightInformation>© 2014 Saito et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Saito</LastName>
<ForeName>Kota</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan ksaito@mol.f.u-tokyo.ac.jp.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamashiro</LastName>
<ForeName>Koh</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shimazu</LastName>
<ForeName>Noriko</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tanabe</LastName>
<ForeName>Tomoya</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kontani</LastName>
<ForeName>Kenji</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Katada</LastName>
<ForeName>Toshiaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cell Biol</MedlineTA>
<NlmUniqueID>0375356</NlmUniqueID>
<ISSNLinking>0021-9525</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497396">ARNT protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C109278">CTAGE5 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024143">Collagen Type VII</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020662">Guanine Nucleotide Exchange Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C118971">PREB protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C517555">SEC16A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>138391-32-9</RegistryNumber>
<NameOfSubstance UI="D051784">Aryl Hydrocarbon Receptor Nuclear Translocator</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>86-01-1</RegistryNumber>
<NameOfSubstance UI="D006160">Guanosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="C493083">SAR1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D020559">Monomeric GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000951">Antigens, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051784">Aryl Hydrocarbon Receptor Nuclear Translocator</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022181">COP-Coated Vesicles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024143">Collagen Type VII</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004721">Endoplasmic Reticulum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006056">Golgi Apparatus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020662">Guanine Nucleotide Exchange Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006160">Guanosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019169">Jurkat Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020559">Monomeric GTP-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033921">Vesicular Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4164946 [Available on 03/15/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25202032</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1540-8140</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>206</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of cell biology</Title>
<ISOAbbreviation>J. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Expression of HSF2 decreases in mitosis to enable stress-inducible transcription and cell survival.</ArticleTitle>
<Pagination>
<MedlinePgn>735-49</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.201402002</ELocationID>
<Abstract>
<AbstractText>Unless mitigated, external and physiological stresses are detrimental for cells, especially in mitosis, resulting in chromosomal missegregation, aneuploidy, or apoptosis. Heat shock proteins (Hsps) maintain protein homeostasis and promote cell survival. Hsps are transcriptionally regulated by heat shock factors (HSFs). Of these, HSF1 is the master regulator and HSF2 modulates Hsp expression by interacting with HSF1. Due to global inhibition of transcription in mitosis, including HSF1-mediated expression of Hsps, mitotic cells are highly vulnerable to stress. Here, we show that cells can counteract transcriptional silencing and protect themselves against proteotoxicity in mitosis. We found that the condensed chromatin of HSF2-deficient cells is accessible for HSF1 and RNA polymerase II, allowing stress-inducible Hsp expression. Consequently, HSF2-deficient cells exposed to acute stress display diminished mitotic errors and have a survival advantage. We also show that HSF2 expression declines during mitosis in several but not all human cell lines, which corresponds to the Hsp70 induction and protection against stress-induced mitotic abnormalities and apoptosis.</AbstractText>
<CopyrightInformation>© 2014 Elsing et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Elsing</LastName>
<ForeName>Alexandra N</ForeName>
<Initials>AN</Initials>
<AffiliationInfo>
<Affiliation>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aspelin</LastName>
<ForeName>Camilla</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Björk</LastName>
<ForeName>Johanna K</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bergman</LastName>
<ForeName>Heidi A</ForeName>
<Initials>HA</Initials>
<AffiliationInfo>
<Affiliation>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Himanen</LastName>
<ForeName>Samu V</ForeName>
<Initials>SV</Initials>
<AffiliationInfo>
<Affiliation>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kallio</LastName>
<ForeName>Marko J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland VTT Health, VTT Technical Research Centre of Finland, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Roos-Mattjus</LastName>
<ForeName>Pia</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sistonen</LastName>
<ForeName>Lea</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland lea.sistonen@abo.fi.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Cell Biol</MedlineTA>
<NlmUniqueID>0375356</NlmUniqueID>
<ISSNLinking>0021-9525</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C073438">heat shock transcription factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>142297-91-4</RegistryNumber>
<NameOfSubstance UI="C070389">HSF2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance UI="D012319">RNA Polymerase II</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018840">HSP70 Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006360">Heat-Shock Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018869">Heat-Shock Response</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008938">Mitosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008940">Mitotic Index</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012319">RNA Polymerase II</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4164949 [Available on 03/15/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25092866</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>BRCA1 pathway function in basal-like breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3828-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.01646-13</ELocationID>
<Abstract>
<AbstractText>Sporadic basal-like cancers (BLCs) are a common subtype of breast cancer that share multiple biological properties with BRCA1-mutated breast tumors. Despite being BRCA1(+/+), sporadic BLCs are widely viewed as phenocopies of BRCA1-mutated breast cancers, because they are hypothesized to manifest a BRCA1 functional defect or breakdown of a pathway(s) in which BRCA1 plays a major role. The role of BRCA1 in the repair of double-strand DNA breaks by homologous recombination (HR) is its best understood function and the function most often implicated in BRCA1 breast cancer suppression. Therefore, it is suspected that sporadic BLCs exhibit a defect in HR. To test this hypothesis, multiple DNA damage repair assays focused on several types of repair were performed on a group of cell lines classified as sporadic BLCs and on controls. The sporadic BLC cell lines failed to exhibit an overt HR defect. Rather, they exhibited defects in the repair of stalled replication forks, another BRCA1 function. These results provide insight into why clinical trials of poly(ADP-ribose) polymerase (PARP) inhibitors, which require an HR defect for efficacy, have been unsuccessful in sporadic BLCs, unlike cisplatin, which elicits DNA damage that requires stalled fork repair and has shown efficacy in sporadic BLCs. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hill</LastName>
<ForeName>Sarah J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Clark</LastName>
<ForeName>Allison P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Silver</LastName>
<ForeName>Daniel P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Livingston</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA david_livingston@dfci.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1F30CA167895-01</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01CA080111</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50CA089393</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA136512</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009153">Mutagens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>AT5C31J09G</RegistryNumber>
<NameOfSubstance UI="D008741">Methyl Methanesulfonate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019313">BRCA1 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053903">DNA Breaks, Double-Stranded</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004261">DNA Replication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008741">Methyl Methanesulfonate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009153">Mutagens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018295">Neoplasms, Basal Cell</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059767">Recombinational DNA Repair</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187718 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25113560</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Plakophilin-2 promotes tumor development by enhancing ligand-dependent and -independent epidermal growth factor receptor dimerization and activation.</ArticleTitle>
<Pagination>
<MedlinePgn>3843-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00758-14</ELocationID>
<Abstract>
<AbstractText>Epidermal growth factor (EGF) receptor (EGFR) has been implicated in tumor development and invasion. Dimerization and autophosphorylation of EGFR are the critical events for EGFR activation. However, the regulation of EGF-dependent and EGF-independent dimerization and phosphorylation of EGFR has not been fully understood. Here, we report that cytoplasmic protein plakophilin-2 (PKP2) is a novel positive regulator of EGFR signaling. PKP2 specifically interacts with EGFR via its N-terminal head domain. Increased PKP2 expression enhances EGF-dependent and EGF-independent EGFR dimerization and phosphorylation. Moreover, PKP2 knockdown reduces EGFR phosphorylation and attenuates EGFR-mediated signal activation, resulting in a significant decrease in proliferation and migration of cancer cells and tumor development. Our results indicate that PKP2 is a novel activator of the EGFR signaling pathway and a potential new drug target for inhibiting tumor growth. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Arimoto</LastName>
<ForeName>Kei-ichiro</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA karimoto@ucsd.edu d7zhang@ucsd.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Burkart</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Ming</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ran</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weng</LastName>
<ForeName>Stephanie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Dong-Er</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA Department of Pathology and Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA karimoto@ucsd.edu d7zhang@ucsd.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01CA177305</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01HL091549</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495337">PKP2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051191">Plakophilins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Mol Cell Biol. 2014 Oct;34(20):3778-9</RefSource>
<PMID Version="1">25113561</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051191">Plakophilins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055503">Protein Multimerization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187709 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135475</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol. Cell. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>CTCF controls HOXA cluster silencing and mediates PRC2-repressive higher-order chromatin structure in NT2/D1 cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3867-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00567-14</ELocationID>
<Abstract>
<AbstractText>HOX cluster genes are activated sequentially in their positional order along the chromosome during vertebrate development. This phenomenon, known as temporal colinearity, depends on transcriptional silencing of 5' HOX genes. Chromatin looping was recently identified as a conserved feature of silent HOX clusters, with CCCTC-binding factor (CTCF) binding sites located at the loop bases. However, the potential contribution of CTCF to HOX cluster silencing and the underlying mechanism have not been established. Here, we demonstrate that the HOXA locus is organized by CTCF into chromatin loops and that CTCF depletion causes significantly enhanced activation of HOXA3 to -A7, -A9 to -A11, and -A13 in response to retinoic acid, with the highest effect observed for HOXA9. Our subsequent analyses revealed that CTCF facilitates the stabilization of Polycomb repressive complex 2 (PRC2) and trimethylated lysine 27 of histone H3 (H3K27me3) at the human HOXA locus. Our results reveal that CTCF functions as a controller of HOXA cluster silencing and mediates PRC2-repressive higher-order chromatin structure. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Miao</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Guang-Nian</ForeName>
<Initials>GN</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lv</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Guoyou</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Lily Yan</ForeName>
<Initials>LY</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People's Republic of China Shenzhen Institute of Research and Innovation, The University of Hong Kong, Shenzhen, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hao</LastName>
<ForeName>De-Long</ForeName>
<Initials>DL</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Junwen</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People's Republic of China Center for Genomic Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People's Republic of China Shenzhen Institute of Research and Innovation, The University of Hong Kong, Shenzhen, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>De-Pei</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China iudp@pumc.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Chih-Chuan</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C109778">CCCTC-binding factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>157907-48-7</RegistryNumber>
<NameOfSubstance UI="C088144">HoxA protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5688UTC01R</RegistryNumber>
<NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.43</RegistryNumber>
<NameOfSubstance UI="D063151">Polycomb Repressive Complex 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056426">Genetic Loci</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008968">Molecular Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063151">Polycomb Repressive Complex 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055550">Protein Stability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017384">Sequence Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4187707 [Available on 04/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24698102</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1600-0463</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>122</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</Title>
<ISOAbbreviation>APMIS</ISOAbbreviation>
</Journal>
<ArticleTitle>Elevated expression of pleiotrophin in lymphocytic leukemia CD19+ B cells.</ArticleTitle>
<Pagination>
<MedlinePgn>905-13</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/apm.12229</ELocationID>
<Abstract>
<AbstractText>Pleiotrophin (PTN) has been demonstrated to be strongly expressed in many fetal tissues, but seldom in healthy adult tissues. While PTN has been reported to be expressed in many types of tumors as well as at high serum concentrations in patients with many types of cancer, to date, there has been no report that PTN is expressed in leukemia, especially in lymphocytic leukemia. We isolated the CD19(+) subset of B cells from peripheral blood from healthy adults, B-cell acute lymphocytic leukemia (B-ALL) patients, and B-cell chronic lymphocytic leukemia (B-CLL) patients and examined these cells for PTN mRNA and protein expression. We used immunocytochemistry, western blotting, and enzyme-linked immunosorbent assay to show that PTN protein is highly expressed in CD19(+) B cells from B-ALL and B-CLL patients, but barely expressed in B cells from healthy adults. We also examined PTN expression at the nucleic acid level using reverse transcription polymerase chain reaction (RT-PCR) and northern blotting and detected a high levels of PTN transcripts in the CD19(+) B cells from both groups of leukemia patients, but very few in the CD19(+) B cells from the healthy controls. Interestingly, the quantity of the PTN transcripts correlated with the severity of disease. Moreover, suppression of PTN activity with an anti-PTN antibody promoted apoptosis of cells from leukemia patients and cell lines SMS-SB and JVM-2. This effect of the anti-PTN antibody suggests that PTN may be a new target for the treatment of lymphocytic leukemia. </AbstractText>
<CopyrightInformation>© 2014 APMIS. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Du</LastName>
<ForeName>Chun-Xian</ForeName>
<Initials>CX</Initials>
<AffiliationInfo>
<Affiliation>Department of Respiratory Medicine, The Zhongnan Hospital, Wuhan University, Wuhan, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Lan</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Qin-Lian</ForeName>
<Initials>QL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>Xin-Ti</ForeName>
<Initials>XT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Denmark</Country>
<MedlineTA>APMIS</MedlineTA>
<NlmUniqueID>8803400</NlmUniqueID>
<ISSNLinking>0903-4641</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>134034-50-7</RegistryNumber>
<NameOfSubstance UI="C066845">pleiotrophin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018941">Antigens, CD19</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007945">Leukemia, Lymphoid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">B-cell chronic lymphocytic leukemia</Keyword>
<Keyword MajorTopicYN="N">Cluster of differentiation 19 positive B cells</Keyword>
<Keyword MajorTopicYN="N">acute B lymphoblastic leukemia</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24698341</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1600-0463</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>122</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</Title>
<ISOAbbreviation>APMIS</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiadhesive and antibiofilm activity of hyaluronic acid against bacteria responsible for respiratory tract infections.</ArticleTitle>
<Pagination>
<MedlinePgn>1013-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/apm.12254</ELocationID>
<Abstract>
<AbstractText>To address the problem of limited efficacy of existing antibiotics in the treatment of bacterial biofilm, it is necessary to find alternative remedies. One candidate could be hyaluronic acid; this study therefore aimed to evaluate the in vitro antiadhesive and antibiofilm activity of hyaluronic acid toward bacterial species commonly isolated from respiratory infections. Interference exerted on bacterial adhesion was evaluated by using Hep-2 cells, while the antibiofilm activity was assessed by means of spectrophotometry after incubation of biofilm with hyaluronic acid and staining with crystal violet. Our data suggest that hyaluronic acid is able to interfere with bacterial adhesion to a cellular substrate in a concentration-dependent manner, being notably active when assessed as pure substance. Moreover, we found that Staphylococcus aureus biofilm was more sensitive to the action of hyaluronic acid than biofilm produced by Haemophilus influenzae and Moraxella catarrhalis. In conclusion, hyaluronic acid is characterized by notable antiadhesive properties, while it shows a moderate activity against bacterial biofilm. As bacterial adhesion to oral cells is the first step for colonization, these results further sustain the role of hyaluronic acid in prevention of respiratory infections. </AbstractText>
<CopyrightInformation>© 2014 APMIS. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Drago</LastName>
<ForeName>Lorenzo</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy; Laboratory of Technical Medical Sciences, Department of Biomedical Science for Health, University of Milan, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cappelletti</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Vecchi</LastName>
<ForeName>Elena</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pignataro</LastName>
<ForeName>Lorenzo</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Torretta</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mattina</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Denmark</Country>
<MedlineTA>APMIS</MedlineTA>
<NlmUniqueID>8803400</NlmUniqueID>
<ISSNLinking>0903-4641</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9004-61-9</RegistryNumber>
<NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001422">Bacterial Adhesion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018441">Biofilms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006193">Haemophilus influenzae</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006820">Hyaluronic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001936">Moraxella (Branhamella) catarrhalis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012141">Respiratory Tract Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000382">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013211">Staphylococcus aureus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hyaluronic acid</Keyword>
<Keyword MajorTopicYN="N">bacterial biofilm</Keyword>
<Keyword MajorTopicYN="N">respiratory tract infections</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24939568</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1600-0463</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>122</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</Title>
<ISOAbbreviation>APMIS</ISOAbbreviation>
</Journal>
<ArticleTitle>Two plasmid-encoded genes of enteropathogenic Escherichia coli strain K798 promote invasion and survival within HEp-2 cells.</ArticleTitle>
<Pagination>
<MedlinePgn>922-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/apm.12234</ELocationID>
<Abstract>
<AbstractText>Enteropathogenic Escherichia coli (EPEC) are considered to be extracellular pathogens, inducing attaching and effacing lesions following their attachment to the surface of eukaryotic cells; however, in vitro and in vivo invasion by EPEC has been reported in several studies. A cloned 4.6 kb fragment of EPEC plasmid pLV501 has been shown to facilitate invasion of E. coli K-12, and here we further investigate the nature of this process. Two of the three complete open reading frames contained within the plasmid fragment have been cloned to E. coli, and in HEp-2 adherence assays both tniA2 and pecM were shown to be expressed during the first 3 h of infection from a plac promoter. Escherichia coli transformants carrying pecM alone or in combination with tniA2 were able to both survive intracellularly and escape eukaryotic cells to re-establish themselves within the medium, whereas those bacterial cells carrying tniA2 alone could not be isolated from within HEp-2 cells after 24 h of infection, but were present in the previously sterile medium surrounding the cells. Bacteria carrying pecM and tniA2 adhered to HEp-2 cells with sites of adhesion characterized by underlying actin polymerization. The invasive potential conferred by these genes may give EPEC strains a survival advantage during prolonged infection. </AbstractText>
<CopyrightInformation>© 2014 APMIS. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Burska</LastName>
<ForeName>Urszula L</ForeName>
<Initials>UL</Initials>
<AffiliationInfo>
<Affiliation>School of Medical Sciences, University of Bradford, Bradford, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fletcher</LastName>
<ForeName>Jonathan N</ForeName>
<Initials>JN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>02</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Denmark</Country>
<MedlineTA>APMIS</MedlineTA>
<NlmUniqueID>8803400</NlmUniqueID>
<ISSNLinking>0903-4641</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029968">Escherichia coli Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054308">Enteropathogenic Escherichia coli</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029968">Escherichia coli Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010957">Plasmids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014774">Virulence</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EPEC</Keyword>
<Keyword MajorTopicYN="N">HEp-2 cells</Keyword>
<Keyword MajorTopicYN="N">PecM</Keyword>
<Keyword MajorTopicYN="N">TniA2</Keyword>
<Keyword MajorTopicYN="N">invasion</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25230493</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1934-578X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Natural product communications</Title>
<ISOAbbreviation>Nat Prod Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Application of microalgal fucoxanthin for the reduction of colon cancer risk: inhibitory activity of fucoxanthin against beta-glucuronidase and DLD-1 cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>921-4</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Intestinal bacterial beta-glucuronidases are capable of retoxifying compounds that have been detoxified by liver glucuronidation and are also known to accelerate colon cancer invasion and metastasis. In this study, fucoxanthin extracted from the microalga Phaeodactylum tricornutum was investigated for its inhibitory activity against Escherichia coli beta-glucuronidase and DLD-1 cancer cells. Fucoxanthin inhibited beta-glucuronidase in a concentration-dependent manner with an IC50 value of 2.32 mM and a mixed inhibition type. Fucoxanthin had more potent inhibitory activity on beta-glucuronidase at 37 degrees C and in alkaline conditions. Fucoxanthin also inhibited the beta-glucuronidase activity of DLD-1 cancer cells at a concentration of 20-50 microM. The presence of beta-glucuronidase and substrate in the medium decreased the inhibitory activity of fucoxanthin against DLD-1 cancer cells. Therefore, microalgal fucoxanthin might prevent colon cancer because of its strong beta-glucuronidase inhibitory activity and could be utilized as a novel functional ingredient of food and pharmaceutical supplements.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kawee-Ai</LastName>
<ForeName>Arthitaya</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sang Moo</ForeName>
<Initials>SM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Prod Commun</MedlineTA>
<NlmUniqueID>101477873</NlmUniqueID>
<ISSNLinking>1555-9475</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024341">Xanthophylls</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>06O0TC0VSM</RegistryNumber>
<NameOfSubstance UI="C025164">fucoxanthin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.2.1.31</RegistryNumber>
<NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005966">Glucuronidase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058086">Microalgae</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024341">Xanthophylls</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25230495</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1934-578X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Natural product communications</Title>
<ISOAbbreviation>Nat Prod Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Cytotoxic alkaloids from leaves and twigs of Dasymaschalon sootepense.</ArticleTitle>
<Pagination>
<MedlinePgn>929-32</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Bioassay-guided fractionation of the cytotoxic ethyl acetate fraction of the sequential methanol extract from the leaves and twigs of Dasymaschalon sootepense led to the isolation of a new 7-hydroxy aporphine alkaloid, 6a,7-dehydrodasymachaline (1) along with the five known compounds (-)-nordicentrine (2), dicentrinone (3), (-)-sinactine (4), aristolactam AII (5) and epiberberine (6). Their structures were elucidated by spectroscopic methods. This is the first report of alkaloids 1-2 and 5-6 from the genus Dasymaschalon. Compounds 1 and 5 showed cytotoxicity against a panel of cancer cell lines.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hongthong</LastName>
<ForeName>Sakchai</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuhakarn</LastName>
<ForeName>Chutima</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reutrakul</LastName>
<ForeName>Vichai</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jariyawat</LastName>
<ForeName>Surawat</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piyachaturawat</LastName>
<ForeName>Pawinee</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nuntasaen</LastName>
<ForeName>Narong</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jaipetch</LastName>
<ForeName>Thaworn</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Prod Commun</MedlineTA>
<NlmUniqueID>101477873</NlmUniqueID>
<ISSNLinking>1555-9475</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000470">Alkaloids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000470">Alkaloids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029061">Annonaceae</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25230508</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1934-578X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Natural product communications</Title>
<ISOAbbreviation>Nat Prod Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Synthesis and biological evaluation of oseltamivir analogues from shikimic acid.</ArticleTitle>
<Pagination>
<MedlinePgn>977-80</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>New oseltamivir analogues were designed and synthesized, starting from shikimic acid. Biological evaluation against three human cancer cell lines (KB, MCF7 and Lu-1) showed that many of them exhibited cytotoxic activity. Azides 5 are more active than the corresponding amines 6. Thus, the reduction of the azide group into amine led to the loss of cytotoxicity. The compounds with a cyclohexanemethyloxy group at C-3 were more active than the other investigated compounds belonging to the same series. This cyclohexanemethyloxy group seems to be critical for the cytotoxic activity of this class of compounds. The synthetic oseltamivir analogues 6a-e had no inhibition activity, even at the concentration of 50 microM when they were evaluated for their in vitro influenza A neuraminidase inhibitory activity by an enzymatic assay.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Van Hung</ForeName>
<Initials>VH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pham</LastName>
<ForeName>Van Cuong</ForeName>
<Initials>VC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Do</LastName>
<ForeName>Thi Thao</ForeName>
<Initials>TT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mai</LastName>
<ForeName>Huong Doan Thi</ForeName>
<Initials>HD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Le</LastName>
<ForeName>Nguyen Thanh</ForeName>
<Initials>NT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vu</LastName>
<ForeName>Van Nam</ForeName>
<Initials>VN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tran</LastName>
<ForeName>Van Hieu</ForeName>
<Initials>VH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Thi Minh Hang</ForeName>
<Initials>TM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dehaen</LastName>
<ForeName>Wim</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chau</LastName>
<ForeName>Van Minh</ForeName>
<Initials>VM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Prod Commun</MedlineTA>
<NlmUniqueID>101477873</NlmUniqueID>
<ISSNLinking>1555-9475</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>29MS2WI2NU</RegistryNumber>
<NameOfSubstance UI="D012765">Shikimic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053139">Oseltamivir</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012765">Shikimic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24096486</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.</ArticleTitle>
<Pagination>
<MedlinePgn>4664-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.405</ELocationID>
<Abstract>
<AbstractText>Increased microRNA-10b (miR-10b) expression in the cancer cells in pancreatic ductal adenocarcinoma (PDAC) is a marker of disease aggressiveness. In the present study, we determined that plasma miR-10b levels are significantly increased in PDAC patients by comparison with normal controls. By gene profiling, we identified potential targets downregulated by miR-10b, including Tat-interacting protein 30 (TIP30). Immunoblotting and luciferase reporter assays confirmed that TIP30 was a direct miR-10b target. Downregulation of TIP30 by miR-10b or siRNA-mediated silencing of TIP30 enhanced epidermal growth factor (EGF)-dependent invasion. The actions of miR-10b were abrogated by expressing a modified TIP30 cDNA resistant to miR-10b. EGF-induced EGF receptor (EGFR) tyrosine phosphorylation and extracellular signal-regulated kinase phosphorylation were enhanced by miR-10b, and these effects were mimicked by TIP30 silencing. The actions of EGF in the presence of miR-10b were blocked by EGFR kinase inhibition with erlotinib and by dual inhibition of PI3K (phosphatidylinositol 3'-kinase) and MEK. Moreover, miR-10b, EGF and transforming growth factor-beta (TGF-β) combined to markedly increase cell invasion, and this effect was blocked by the combination of erlotinib and SB505124, a type I TGF-β receptor inhibitor. miR-10b also enhanced the stimulatory effects of EGF and TGF-β on cell migration and epithelial-mesenchymal transition (EMT) and decreased the expression of RAP2A, EPHB2, KLF4 and NF1. Moreover, miR-10b overexpression accelerated pancreatic cancer cell (PCC) proliferation and tumor growth in an orthotopic model. Thus, plasma miR-10b levels may serve as a diagnostic marker in PDAC, whereas intra-tumoral miR-10b promotes PCC proliferation and invasion by suppressing TIP30, which enhances EGFR signaling, facilitates EGF-TGF-β cross-talk and enhances the expression of EMT-promoting genes, whereas decreasing the expression of several metastasis-suppressing genes. Therefore, therapeutic targeting of miR-10b in PDAC may interrupt growth-promoting deleterious EGF-TGF-β interactions and antagonize the metastatic process at various levels. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ouyang</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gore</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Deitz</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Korc</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Departments of Medicine, Biochemistry and Molecular Biology, Indiana University School of Medicine, the Melvin and Bren Simon Cancer Center and the Pancreatic Cancer Signature Center, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R37 CA075059</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37-CA-075059</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C547183">MIRN10 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.-</RegistryNumber>
<NameOfSubstance UI="D000123">Acetyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="C111246">HTATIP2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J4T82NDH7E</RegistryNumber>
<NameOfSubstance UI="C400278">erlotinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Chem. 2008 Oct;54(10):1716-24</RefSource>
<PMID Version="1">18719196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2008 Dec 1;14(23):7614-23</RefSource>
<PMID Version="1">19047086</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Res. 2009 Jan;19(1):89-102</RefSource>
<PMID Version="1">19050696</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2009 Feb 27;284(9):5731-41</RefSource>
<PMID Version="1">19073608</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Cell Res. 2009 Feb 15;315(4):683-96</RefSource>
<PMID Version="1">19278030</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2009 Mar 15;69(6):2195-200</RefSource>
<PMID Version="1">19276373</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2009 May;174(5):1931-9</RefSource>
<PMID Version="1">19349353</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Biochem J. 2009 Jul 1;421(1):119-31</RefSource>
<PMID Version="1">19356148</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2009 Jun 12;324(5933):1457-61</RefSource>
<PMID Version="1">19460966</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90</RefSource>
<PMID Version="1">19597153</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Trends Cell Biol. 2009 Aug;19(8):385-94</RefSource>
<PMID Version="1">19648010</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Prev Res (Phila). 2009 Sep;2(9):807-13</RefSource>
<PMID Version="1">19723895</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2010 Jan 1;126(1):73-80</RefSource>
<PMID Version="1">19551852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2009 Dec 1;27(34):5848-56</RefSource>
<PMID Version="1">19884536</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2010 Mar 12;285(11):7986-94</RefSource>
<PMID Version="1">20075075</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Chem. 2010 Apr;56(4):603-12</RefSource>
<PMID Version="1">20093556</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Biotechnol. 2010 Apr;28(4):341-7</RefSource>
<PMID Version="1">20351690</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Commun. 2011;2:513</RefSource>
<PMID Version="1">22027593</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(10):e26815</RefSource>
<PMID Version="1">22053213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Crit Rev Eukaryot Gene Expr. 2011;21(2):115-29</RefSource>
<PMID Version="1">22077151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</RefSource>
<PMID Version="1">22237781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(5):e36753</RefSource>
<PMID Version="1">22586492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2012 Sep 15;131(6):E884-96</RefSource>
<PMID Version="1">22573479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2012 Aug;14(8):793-801</RefSource>
<PMID Version="1">22797597</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Surg Oncol. 2012 Sep;19(9):3065-71</RefSource>
<PMID Version="1">22322955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2012 Sep 11;22(3):304-17</RefSource>
<PMID Version="1">22975374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Cell. 2012 Sep 11;22(3):318-30</RefSource>
<PMID Version="1">22975375</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS J. 2012 Oct;279(20):3800-12</RefSource>
<PMID Version="1">22883469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Dis. 2012;3:e398</RefSource>
<PMID Version="1">23034333</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Cell Biol. 2004 Aug;16(4):400-6</RefSource>
<PMID Version="1">15261672</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 1986 Jul;83(14):5141-4</RefSource>
<PMID Version="1">3014534</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Invest. 1992 Oct;90(4):1352-60</RefSource>
<PMID Version="1">1401070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 1993 Oct;24(10):1127-34</RefSource>
<PMID Version="1">8104858</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 1993 Dec;105(6):1846-56</RefSource>
<PMID Version="1">8253361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Surg Oncol Clin N Am. 1998 Jan;7(1):25-41</RefSource>
<PMID Version="1">9443985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 1995 Nov;1(11):1413-20</RefSource>
<PMID Version="1">9815939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Biochem. 2005 Aug 1;95(5):918-31</RefSource>
<PMID Version="1">15861394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2006 Mar 1;20(5):515-24</RefSource>
<PMID Version="1">16510870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2006 Apr;6(4):259-69</RefSource>
<PMID Version="1">16557279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2006 May 15;20(10):1218-49</RefSource>
<PMID Version="1">16702400</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Hum Pathol. 2007 Feb;38(2):293-8</RefSource>
<PMID Version="1">17097132</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Colorectal Dis. 2010 Jun;25(6):687-94</RefSource>
<PMID Version="1">20339854</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2010 Jul 2;285(27):20541-6</RefSource>
<PMID Version="1">20444703</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13450-5</RefSource>
<PMID Version="1">20624982</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Cancer. 2010 Sep;10(9):618-29</RefSource>
<PMID Version="1">20720570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Nov 1;70(21):8822-31</RefSource>
<PMID Version="1">20978205</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Sci. 2010 Sep;101(9):1997-2004</RefSource>
<PMID Version="1">20550523</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2010 Dec 15;70(24):10224-33</RefSource>
<PMID Version="1">21159643</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cancer Res Clin Oncol. 2011 Jan;137(1):73-80</RefSource>
<PMID Version="1">20238226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2011 Mar 18;286(11):9373-81</RefSource>
<PMID Version="1">21252234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2011 May 1;17(9):2725-33</RefSource>
<PMID Version="1">21220473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neoplasia. 2011 Jul;13(7):601-10</RefSource>
<PMID Version="1">21750654</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Adv Exp Med Biol. 2011;700:15-27</RefSource>
<PMID Version="1">21755469</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Biol Ther. 2011 Aug 1;12(3):198-207</RefSource>
<PMID Version="1">21613822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Gastroenterology. 2011 Sep;141(3):1091-101</RefSource>
<PMID Version="1">21699781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2012 Oct;11(10):2138-48</RefSource>
<PMID Version="1">22869556</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Tumour Biol. 2012 Oct;33(5):1455-65</RefSource>
<PMID Version="1">22528944</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2012 Nov 15;491(7424):399-405</RefSource>
<PMID Version="1">23103869</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Oncol. 2013 Jan;25(1):76-84</RefSource>
<PMID Version="1">23197193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2013 May 2;32(18):2273-81, 2281e.1-12</RefSource>
<PMID Version="1">22733137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2013 May 16;497(7449):383-7</RefSource>
<PMID Version="1">23636329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Signal. 2013 Jul 16;6(284):ra58</RefSource>
<PMID Version="1">23861540</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Res. 2013 Oct;23(10):1157-8</RefSource>
<PMID Version="1">23835474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2002 Oct 1;62(19):5611-7</RefSource>
<PMID Version="1">12359775</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Cancer Ther. 2002 Jan;1(3):161-7</RefSource>
<PMID Version="1">12467210</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Surg. 2003 Jan;237(1):74-85</RefSource>
<PMID Version="1">12496533</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2003 Dec 15;63(24):8763-7</RefSource>
<PMID Version="1">14695192</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Gastroenterol. 2003;38(12):1162-6</RefSource>
<PMID Version="1">14714254</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32</RefSource>
<PMID Version="1">15040445</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2011 Sep 1;17(17):5812-21</RefSource>
<PMID Version="1">21652542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Cancer Res. 2011 Sep 1;17(17):5527-9</RefSource>
<PMID Version="1">21816909</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Surgery. 2011 Nov;150(5):916-22</RefSource>
<PMID Version="1">22018284</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2007 Mar 1;120(5):1046-54</RefSource>
<PMID Version="1">17149698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2007 May 2;297(17):1901-8</RefSource>
<PMID Version="1">17473300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Aug 16;448(7155):807-10</RefSource>
<PMID Version="1">17676035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Surg. 2007 Oct;194(4 Suppl):S84-6</RefSource>
<PMID Version="1">17903452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2007 Oct 11;449(7163):682-8</RefSource>
<PMID Version="1">17898713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Cancer. 2008 Aug 15;123(4):810-6</RefSource>
<PMID Version="1">18528861</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2008 Jul 3;454(7200):56-61</RefSource>
<PMID Version="1">18548003</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8</RefSource>
<PMID Version="1">18663219</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2008 Sep 26;321(5897):1801-6</RefSource>
<PMID Version="1">18772397</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000123">Acetyltransferases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021441">Carcinoma, Pancreatic Ductal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016212">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS560246</OtherID>
<OtherID Source="NLM">PMC3979498</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24141770</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>PTEN functions as a melanoma tumor suppressor by promoting host immune response.</ArticleTitle>
<Pagination>
<MedlinePgn>4632-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2013.409</ELocationID>
<Abstract>
<AbstractText>Cancer cells acquire several traits that allow for their survival and progression, including the ability to evade the host immune response. However, the mechanisms by which cancer cells evade host immune responses remain largely elusive. Here we study the phenomena of immune evasion in malignant melanoma cells. We find that the tumor suppressor phosphatase and tensin homolog (PTEN) is an important regulator of the host immune response against melanoma cells. Mechanistically, PTEN represses the expression of immunosuppressive cytokines by blocking the phosphatidylinositide 3-kinase (PI3K) pathway. In melanoma cells lacking PTEN, signal transducer and activator of transcription 3 activates the transcription of immunosuppressive cytokines in a PI3K-dependent manner. Furthermore, conditioned media from PTEN-deficient, patient-derived short-term melanoma cultures and established melanoma cell lines blocked the production of the interleukin-12 (IL-12) in human monocyte-derived dendritic cells. Inhibition of IL-12 production was rescued by restoring PTEN or using neutralizing antibodies against the immunosuppressive cytokines. Furthermore, we report that PTEN, as an alternative mechanism to promote the host immune response against cancer cells, represses the expression of programmed cell death 1 ligand, a known repressor of the host immune response. Finally, to establish the clinical significance of our results, we analyzed malignant melanoma patient samples with or without brisk host responses. These analyses confirmed that PTEN loss is associated with a higher percentage of malignant melanoma samples with non-brisk host responses compared with samples with brisk host responses. Collectively, these results establish that PTEN functions as a melanoma tumor suppressor in part by regulating the host immune response against melanoma cells and highlight the importance of assessing PTEN status before recruiting melanoma patients for immunotherapies. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Pathology, Yale University School of Medicine, New Haven, CT, USA [2] Department of Oral and Maxillofacial Surgery, College of Stomatology, Hebei Medical University, Shijiazhuang, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Richards</LastName>
<ForeName>J-Ae</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aung</LastName>
<ForeName>P P</ForeName>
<Initials>PP</Initials>
<AffiliationInfo>
<Affiliation>Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Emley</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kluger</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dogra</LastName>
<ForeName>S K</ForeName>
<Initials>SK</Initials>
<AffiliationInfo>
<Affiliation>Singapore Institute of Clinical Sciences, Agency for Science Technology and Research (A*STAR), Brenner Center for Molecular Medicine, Singapore, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mahalingam</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wajapeyee</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>10</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007108">Immune Tolerance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051059">PTEN Phosphohydrolase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019139">Tumor Escape</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24681955</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5594</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>33</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Oncogene</Title>
<ISOAbbreviation>Oncogene</ISOAbbreviation>
</Journal>
<ArticleTitle>SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4697-708</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/onc.2014.71</ELocationID>
<Abstract>
<AbstractText>Melanoma is one of the most aggressive types of human cancer, characterized by enhanced heterogeneity and resistance to conventional therapy at advanced stages. We and others have previously shown that HEDGEHOG-GLI (HH-GLI) signaling is required for melanoma growth and for survival and expansion of melanoma-initiating cells (MICs). Recent reports indicate that HH-GLI signaling regulates a set of genes typically expressed in embryonic stem cells, including SOX2 (sex-determining region Y (SRY)-Box2). Here we address the function of SOX2 in human melanomas and MICs and its interaction with HH-GLI signaling. We find that SOX2 is highly expressed in melanoma stem cells. Knockdown of SOX2 sharply decreases self-renewal in melanoma spheres and in putative melanoma stem cells with high aldehyde dehydrogenase activity (ALDH(high)). Conversely, ectopic expression of SOX2 in melanoma cells enhances their self-renewal in vitro. SOX2 silencing also inhibits cell growth and induces apoptosis in melanoma cells. In addition, depletion of SOX2 progressively abrogates tumor growth and leads to a significant decrease in tumor-initiating capability of ALDH(high) MICs upon xenotransplantation, suggesting that SOX2 is required for tumor initiation and for continuous tumor growth. We show that SOX2 is regulated by HH signaling and that the transcription factors GLI1 and GLI2, the downstream effectors of HH-GLI signaling, bind to the proximal promoter region of SOX2 in primary melanoma cells. In functional studies, we find that SOX2 function is required for HH-induced melanoma cell growth and MIC self-renewal in vitro. Thus SOX2 is a critical factor for self-renewal and tumorigenicity of MICs and an important mediator of HH-GLI signaling in melanoma. These findings could provide the basis for novel therapeutic strategies based on the inhibition of SOX2 for the treatment of a subset of human melanomas. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Santini</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pietrobono</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pandolfi</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Montagnani</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>D'Amico</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Penachioni</LastName>
<ForeName>J Y</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vinci</LastName>
<ForeName>M C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borgognoni</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Plastic Surgery Unit, S.M. Annunziata Hospital-Regional Melanoma Referral Center, Istituto Toscano Tumori, Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stecca</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori (CRL-ITT), Florence, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Oncogene</MedlineTA>
<NlmUniqueID>8711562</NlmUniqueID>
<ISSNLinking>0950-9232</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C400551">GLI1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527782">SOX2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055748">SOXB1 Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.2.1.3</RegistryNumber>
<NameOfSubstance UI="D000444">Aldehyde Dehydrogenase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2012 Oct;30(10):2100-13</RefSource>
<PMID Version="1">22887839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2012 Oct;44(10):1111-6</RefSource>
<PMID Version="1">22941189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2012 Nov 22;31(47):4898-911</RefSource>
<PMID Version="1">22286766</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mod Pathol. 2013 Jan;26(1):44-53</RefSource>
<PMID Version="1">22899289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2013 Mar;34(3):550-9</RefSource>
<PMID Version="1">23222817</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2013 Jun 15;73(12):3796-807</RefSource>
<PMID Version="1">23596255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2013;8(7):e69064</RefSource>
<PMID Version="1">23935925</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2013 Sep 1;73(17):5544-55</RefSource>
<PMID Version="1">23867475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2013 Oct;32(40):4737-47</RefSource>
<PMID Version="1">23146903</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Signal. 2013 Dec;25(12):2734-42</RefSource>
<PMID Version="1">24036214</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO Mol Med. 2014 Jan;6(1):66-79</RefSource>
<PMID Version="1">24178749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2013 Dec;31(12):2607-19</RefSource>
<PMID Version="1">23940081</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Carcinogenesis. 2014 Apr;35(4):942-50</RefSource>
<PMID Version="1">24325912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Aspects Med. 2014 Oct;39:33-49</RefSource>
<PMID Version="1">24145241</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Neurosci. 2003 Jan;6(1):21-7</RefSource>
<PMID Version="1">12469128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2003 Jan 1;17(1):126-40</RefSource>
<PMID Version="1">12514105</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuron. 2003 Aug 28;39(5):749-65</RefSource>
<PMID Version="1">12948443</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neuron. 2003 Sep 11;39(6):937-50</RefSource>
<PMID Version="1">12971894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 1997 Jul;124(13):2537-52</RefSource>
<PMID Version="1">9216996</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2005 Jan 15;19(2):214-23</RefSource>
<PMID Version="1">15625189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2005 May 6;121(3):465-77</RefSource>
<PMID Version="1">15882627</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2005 May 15;65(10):4320-33</RefSource>
<PMID Version="1">15899824</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2005 Oct 15;65(20):9328-37</RefSource>
<PMID Version="1">16230395</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Biol Chem. 2006 May 12;281(19):13374-81</RefSource>
<PMID Version="1">16547000</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2006 Aug 25;126(4):663-76</RefSource>
<PMID Version="1">16904174</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Cancer. 2007 Mar;43(5):935-46</RefSource>
<PMID Version="1">17320377</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900</RefSource>
<PMID Version="1">17392427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Cell Biol. 2007 Jun;9(6):625-35</RefSource>
<PMID Version="1">17515932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell. 2007 Nov 30;131(5):861-72</RefSource>
<PMID Version="1">18035408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19879-84</RefSource>
<PMID Version="1">18077420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 2007 Dec 21;318(5858):1917-20</RefSource>
<PMID Version="1">18029452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2008 Jan 17;451(7176):345-9</RefSource>
<PMID Version="1">18202660</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2009 Mar 18;28(6):663-76</RefSource>
<PMID Version="1">19214186</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2009 Jan;27(1):165-74</RefSource>
<PMID Version="1">18927476</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2009 Jan;27(1):40-8</RefSource>
<PMID Version="1">18948646</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Immunol Methods. 2009 Aug 15;347(1-2):70-8</RefSource>
<PMID Version="1">19567251</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2009 Sep;27(9):2175-84</RefSource>
<PMID Version="1">19591226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Cell Sci. 2009 Oct 1;122(Pt 19):3502-10</RefSource>
<PMID Version="1">19723802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Neurosci. 2009 Oct;12(10):1248-56</RefSource>
<PMID Version="1">19734891</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2009 Nov;41(11):1238-42</RefSource>
<PMID Version="1">19801978</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Chromosomes Cancer. 2010 Jan;49(1):9-16</RefSource>
<PMID Version="1">19787784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Pathol. 2010 Feb;176(2):903-13</RefSource>
<PMID Version="1">20042675</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2010 Jul;130(7):1877-86</RefSource>
<PMID Version="1">20376064</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2010 Jul 1;466(7302):133-7</RefSource>
<PMID Version="1">20596026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Death Differ. 2010 Aug;17(8):1345-53</RefSource>
<PMID Version="1">20489730</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2010 Aug 4;29(15):2659-74</RefSource>
<PMID Version="1">20581802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO J. 2010 Aug 4;29(15):2646-58</RefSource>
<PMID Version="1">20581804</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2010 Aug 4;102(15):1148-59</RefSource>
<PMID Version="1">20660365</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Invest Dermatol. 2010 Dec;130(12):2799-808</RefSource>
<PMID Version="1">20739950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2010 Dec;28(12):2141-50</RefSource>
<PMID Version="1">20945330</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Genomics. 2011;12:11</RefSource>
<PMID Version="1">21211035</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2474-9</RefSource>
<PMID Version="1">21282657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Dermatol. 2011 Apr;20(4):339-45</RefSource>
<PMID Version="1">21410764</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 2011 Apr 15;71(8):3098-109</RefSource>
<PMID Version="1">21393506</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Invest. 2011 May;91(5):647-64</RefSource>
<PMID Version="1">21445060</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2011;6(4):e18784</RefSource>
<PMID Version="1">21526207</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Stem Cell. 2011 May 6;8(5):552-65</RefSource>
<PMID Version="1">21549329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Genet. 2011 Jun;43(6):607-11</RefSource>
<PMID Version="1">21532573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>ACS Chem Biol. 2011 Jun 17;6(6):573-81</RefSource>
<PMID Version="1">21344919</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cell Stem Cell. 2011 Oct 4;9(4):317-29</RefSource>
<PMID Version="1">21982232</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Invest. 2011 Dec;91(12):1796-804</RefSource>
<PMID Version="1">21931300</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Development. 2012 Jan;139(2):397-410</RefSource>
<PMID Version="1">22186729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncotarget. 2012 Jan;3(1):22-30</RefSource>
<PMID Version="1">22289880</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lab Invest. 2012 Mar;92(3):362-70</RefSource>
<PMID Version="1">22184093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>EMBO Mol Med. 2012 Mar;4(3):218-33</RefSource>
<PMID Version="1">22294553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2012 Mar 15;31(11):1354-65</RefSource>
<PMID Version="1">21822303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mol Ther. 2012 May;20(5):1056-62</RefSource>
<PMID Version="1">22354376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncogene. 2012 May 3;31(18):2270-82</RefSource>
<PMID Version="1">21927024</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS One. 2012;7(5):e36762</RefSource>
<PMID Version="1">22675422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2012 Aug;40(14):6725-40</RefSource>
<PMID Version="1">22561374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Stem Cells. 2012 Sep;30(9):1808-18</RefSource>
<PMID Version="1">22730244</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000444">Aldehyde Dehydrogenase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055748">SOXB1 Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4180644</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25233593</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1934-578X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Natural product communications</Title>
<ISOAbbreviation>Nat Prod Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of anti-melanoma activities of (1S,2E,4R,6E,8R,11S,12R)-8,12-epoxy-2,6-cembradiene-4,11-diol, (1S,2E,4R,6E,8S,11R,12S)-8,11-epoxy-4,12-epoxy-2,6-cembradiene and (1S,4R,13S)-cembra-2E,7E,11E-trien-4,13-diol from the Red Sea soft coral Sarcophyton glaucum.</ArticleTitle>
<Pagination>
<MedlinePgn>1143-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Three natural cembranoids from the Red Sea soft coral Sarcophyton glaucum namely (1S,2E,4R,6E,8R,11S,12R)-8,12-epoxy-2,6-cembradiene-4,11-diol, (1S,2E,4R,6E,8S,11R,12S)-8,11-epoxy-4,12-epoxy-2,6-cembradiene and (1S,4R,13S)-cembra-2E,7E,11E-trien-4,13-diol were evaluated for their inhibitory effects on mouse melanoma B16F10 cell growth. Results show that all the cembranoids strongly inhibit viability of melanoma cells particularly during 48 -72 hrs treatment and also inhibit de novo DNA synthesis and PARP activity and stimulate fragmentation of DNA. (1S,2E,4R,6E,8R,11S,12R)-8,12-epoxy-2,6-cembradiene-4,11-diol was not cytotoxic to monkey kidney CV-1 cells at the concentration that produces the anti-melanoma effects which indicates that this compound may be a good candidate for further development. (1S,2E,4R,6E,8S,11R,12S)-8,11-epoxy-4,12-epoxy-2,6-cembradiene and (1S,4R,13S)-cembra-2E,7E,11E-trien-4,13-diol were found to be cytotoxic to healthy cells.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Szymanski</LastName>
<ForeName>Pawel T</ForeName>
<Initials>PT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahmed</LastName>
<ForeName>Safwat A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Radwan</LastName>
<ForeName>Mohamed M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khalifa</LastName>
<ForeName>Sherief I</ForeName>
<Initials>SI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fahmy</LastName>
<ForeName>Hesham</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Nat Prod Commun</MedlineTA>
<NlmUniqueID>101477873</NlmUniqueID>
<ISSNLinking>1555-9475</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="C491508">poly(ADP-ribose)polymerase-1, mouse</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D037421">Anthozoa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004261">DNA Replication</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004353">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D019156">Indian Ocean</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011065">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24950257</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1744-7593</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Expert opinion on drug delivery</Title>
<ISOAbbreviation>Expert Opin Drug Deliv</ISOAbbreviation>
</Journal>
<ArticleTitle>Cytotoxic enhancement of hexapeptide-conjugated micelles in EGFR high-expressed cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1537-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1517/17425247.2014.930433</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to develop the hexapeptide-conjugated active targeting micelles for delivery of doxorubicin (DOX) and paclitaxel (PTX) to EGFR high-expressed cancer cells.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A hexapeptide, which mimicked the EGFR, was applied as a targeting ligand. The active targeting micelles were prepared using the synthesized poly(D,L-lactide-co-glycolide)-PEG copolymer conjugated with the hexapeptide. The micelles were used for encapsulating DOX and/or PTX, and the cellular uptake, in vitro drug release and cellular viability of drug-loaded peptide-conjugated and peptide-free micelles were investigated.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The particle size of drug-loaded peptide-conjugated and peptide-free micelles was &lt; 150 nm with narrow size distribution. The uptake of peptide-conjugated micelles was more efficient in EGFR high-expressed MDA-MB-468 and SKOV3 cells than in EGFR low-expressed HepG2 cells. The in vitro release of DOX and PTX was faster in pH 4.0 (500 U lipase) than in pH 7.4 release medium. The cytotoxicity in terms of IC50 of DOX/PTX-loaded peptide-conjugated micelles was 4.8-folds lower than that of peptide-free micelles and 18.2-folds lower than DOX/PTX drug solution in SOKV3 cells.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The peptide-conjugated micelles acted as a nanocarrier to increase intracellular accumulation of anticancer drugs in EGFR high-expressed SKOV3 cancer cells to enhance cell cytotoxicity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Wen Jen</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo>
<Affiliation>National Taiwan University, Graduate Institute of Pharmaceutical Sciences, School of Pharmacy , No. 33 Lin San S. Rd, Taipei 100 , Taiwan +886 2 33668765 ; +886 2 23916126 ; wjlin@ntu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kao</LastName>
<ForeName>Li Ting</ForeName>
<Initials>LT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Expert Opin Drug Deliv</MedlineTA>
<NlmUniqueID>101228421</NlmUniqueID>
<ISSNLinking>1742-5247</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008823">Micelles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C043435">polylactic acid-polyglycolic acid copolymer</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>26009-03-0</RegistryNumber>
<NameOfSubstance UI="D011100">Polyglycolic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33069-62-4</RegistryNumber>
<NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33X04XA5AT</RegistryNumber>
<NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D004337">Drug Carriers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008823">Micelles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010316">Particle Size</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011100">Polyglycolic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EGFR</Keyword>
<Keyword MajorTopicYN="N">doxorubicin</Keyword>
<Keyword MajorTopicYN="N">hexapeptide</Keyword>
<Keyword MajorTopicYN="N">micelles</Keyword>
<Keyword MajorTopicYN="N">paclitaxel</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25238096</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1097-4180</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>41</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Immunity</Title>
<ISOAbbreviation>Immunity</ISOAbbreviation>
</Journal>
<ArticleTitle>The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors.</ArticleTitle>
<Pagination>
<MedlinePgn>389-401</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.08.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00309-4</ELocationID>
<Abstract>
<AbstractText>Adaptation of malignant cells to the hostile milieu present in tumors is an important determinant of their survival and growth. However, the interaction between tumor-linked stress and antitumor immunity remains poorly characterized. Here, we show the critical role of the cellular stress sensor C/EBP-homologous protein (Chop) in the accumulation and immune inhibitory activity of tumor-infiltrating myeloid-derived suppressor cells (MDSCs). MDSCs lacking Chop had decreased immune-regulatory functions and showed the ability to prime T cell function and induce antitumor responses. Chop expression in MDSCs was induced by tumor-linked reactive oxygen and nitrogen species and regulated by the activating-transcription factor-4. Chop-deficient MDSCs displayed reduced signaling through CCAAT/enhancer-binding protein-β, leading to a decreased production of interleukin-6 (IL-6) and low expression of phospho-STAT3. IL-6 overexpression restored immune-suppressive activity of Chop-deficient MDSCs. These findings suggest the role of Chop in tumor-induced tolerance and the therapeutic potential of targeting Chop in MDSCs for cancer immunotherapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Thevenot</LastName>
<ForeName>Paul T</ForeName>
<Initials>PT</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sierra</LastName>
<ForeName>Rosa A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raber</LastName>
<ForeName>Patrick L</ForeName>
<Initials>PL</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Al-Khami</LastName>
<ForeName>Amir A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Trillo-Tinoco</LastName>
<ForeName>Jimena</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zarreii</LastName>
<ForeName>Parisa</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ochoa</LastName>
<ForeName>Augusto C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Del Valle</LastName>
<ForeName>Luis</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rodriguez</LastName>
<ForeName>Paulo C</ForeName>
<Initials>PC</Initials>
<AffiliationInfo>
<Affiliation>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA; Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. Electronic address: prodri1@lsuhsc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P20 RR021970</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20GM103501</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P20GM103518</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 CA162133</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21CA162133</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Immunity</MedlineTA>
<NlmUniqueID>9432918</NlmUniqueID>
<ISSNLinking>1074-7613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C081452">Atf4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022782">CCAAT-Enhancer-Binding Protein-beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497250">Ddit3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026361">Reactive Nitrogen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494087">Stat3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>145891-90-3</RegistryNumber>
<NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-12-7</RegistryNumber>
<NameOfSubstance UI="D051742">Transcription Factor CHOP</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Immunity. 2014 Sep 18;41(3):341-2</RefSource>
<PMID Version="1">25238087</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051701">Activating Transcription Factor 4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001854">Bone Marrow Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016026">Bone Marrow Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022782">CCAAT-Enhancer-Binding Protein-beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042783">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022423">Myeloid Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D026361">Reactive Nitrogen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051742">Transcription Factor CHOP</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019139">Tumor Escape</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS625838 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4171711 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25172487</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-induced NLRP3 inflammasome activation.</ArticleTitle>
<Pagination>
<MedlinePgn>3676-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1401448</ELocationID>
<Abstract>
<AbstractText>NLRP3 is a key component of caspase-activating macromolecular protein complexes called inflammasomes. It has been found that DHX33 is a cytosolic dsRNA sensor for the NLRP3 inflammasome, which induces caspase-1-dependent production of IL-1β and IL-18 upon activation. However, how the cytosolic dsRNAs induce the interaction between DHX33 and the NLRP3 inflammasome remains unknown. In this study, we report that TRIM33, a member of the tripartite motif (TRIM) family, can bind DHX33 directly and induce DHX33 ubiquitination via the lysine 218 upon dsRNA stimulation. Knocking down of TRIM33 abolished the dsRNA-induced NLRP3 inflammasome activation in both THP-1-derived macrophages and human monocyte-derived macrophages. The ubiquitination of DHX33 by TRIM33 is lysine 63 specific and is required for the formation of the DHX33-NLRP3 inflammasome complex. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Weng</LastName>
<ForeName>Leiyun</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Baylor Institute for Immunology Research, Baylor Research Institute, Baylor Scott and White Health, Dallas, TX 75204;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mitoma</LastName>
<ForeName>Hiroki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Baylor Institute for Immunology Research, Baylor Research Institute, Baylor Scott and White Health, Dallas, TX 75204;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tricot</LastName>
<ForeName>Coline</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Baylor Institute for Immunology Research, Baylor Research Institute, Baylor Scott and White Health, Dallas, TX 75204;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bao</LastName>
<ForeName>Musheng</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Baylor Institute for Immunology Research, Baylor Research Institute, Baylor Scott and White Health, Dallas, TX 75204;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Baylor Institute for Immunology Research, Baylor Research Institute, Baylor Scott and White Health, Dallas, TX 75204;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Zhiqiang</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Baylor Institute for Immunology Research, Baylor Research Institute, Baylor Scott and White Health, Dallas, TX 75204; Immunobiology and Transplant Research, Houston Methodist Hospital and Houston Methodist Research Institute, Texas Medical Center, Houston, TX 77030; and zzhang@houstonmethodist.org liuyo@medimmune.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yong-Jun</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo>
<Affiliation>Baylor Institute for Immunology Research, Baylor Research Institute, Baylor Scott and White Health, Dallas, TX 75204; MedImmune, LLC, Gaithersburg, MD 20878 zzhang@houstonmethodist.org liuyo@medimmune.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R37 AI091947</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U19 AI082715</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508585">IL1B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C453881">NLRP3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C511956">TRIM33 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.36</RegistryNumber>
<NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="C568925">DHX33 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020170">Caspase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053487">DEAD-box RNA Helicases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058847">Inflammasomes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012330">RNA, Double-Stranded</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054875">Ubiquitination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS620365 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4170004 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25187660</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>193</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms.</ArticleTitle>
<Pagination>
<MedlinePgn>3257-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1301886</ELocationID>
<Abstract>
<AbstractText>Sensing of nucleic acids by TLRs is crucial in the host defense against viruses and bacteria. Unc-93 homolog B1 (UNC93B1) regulates the trafficking of nucleic acid-sensing TLRs from the endoplasmic reticulum to endolysosomes, where the TLRs encounter their respective ligands and become activated. In this article, we show that a carboxyl-terminal tyrosine-based sorting motif (YxxΦ) in UNC93B1 differentially regulates human nucleic acid-sensing TLRs in a receptor- and ligand-specific manner. Destruction of YxxΦ abolished TLR7, TLR8, and TLR9 activity toward nucleic acids in human B cells and monocytes, whereas TLR8 responses toward small molecules remained intact. YxxΦ in UNC93B1 influenced the subcellular localization of human UNC93B1 via both adapter protein complex (AP)1- and AP2-dependent trafficking pathways. However, loss of AP function was not causal for altered TLR responses, suggesting AP-independent functions of YxxΦ in UNC93B1. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Association of Immunologists, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pelka</LastName>
<ForeName>Karin</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Phulphagar</LastName>
<ForeName>Kshiti</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zimmermann</LastName>
<ForeName>Jana</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry I and Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stahl</LastName>
<ForeName>Rainer</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schmid-Burgk</LastName>
<ForeName>Jonathan L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Medicine, University Hospital, University of Bonn, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schmidt</LastName>
<ForeName>Tobias</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Medicine, University Hospital, University of Bonn, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spille</LastName>
<ForeName>Jan-Hendrik</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Institute of Physical and Theoretical Chemistry, University of Bonn, 53121 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Labzin</LastName>
<ForeName>Larisa I</ForeName>
<Initials>LI</Initials>
<AffiliationInfo>
<Affiliation>Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Agrawal</LastName>
<ForeName>Sudhir</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Idera Pharmaceuticals, Cambridge, MA 02139;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kandimalla</LastName>
<ForeName>Ekambar R</ForeName>
<Initials>ER</Initials>
<AffiliationInfo>
<Affiliation>Idera Pharmaceuticals, Cambridge, MA 02139;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Casanova</LastName>
<ForeName>Jean-Laurent</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; Howard Hughes Medical Institute, New York, NY 10065; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, 75015 Paris, France; Paris Descartes University, Imagine Institute, 75015 Paris, France; Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children, Public Assistance-Paris Hospitals, 75015 Paris, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hornung</LastName>
<ForeName>Veit</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Medicine, University Hospital, University of Bonn, 53127 Bonn, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marshak-Rothstein</LastName>
<ForeName>Ann</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Höning</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry I and Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Latz</LastName>
<ForeName>Eicke</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany; Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655; and German Center for Neurodegenerative Diseases, 53175 Bonn, Germany eicke.latz@uni-bonn.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 AR050256</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01-AR050256</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033961">Adaptor Protein Complex 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033962">Adaptor Protein Complex 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C454130">UNC93B1 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033961">Adaptor Protein Complex 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033962">Adaptor Protein Complex 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020816">Amino Acid Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D026901">Membrane Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009000">Monocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS620007 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4170058 [Available on 10/01/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25175026</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-4164</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Molecular cell</Title>
<ISOAbbreviation>Mol. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity.</ArticleTitle>
<Pagination>
<MedlinePgn>916-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2014.07.019</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1097-2765(14)00612-1</ELocationID>
<Abstract>
<AbstractText>Ras-driven cancer cells upregulate basal autophagy that degrades and recycles intracellular proteins and organelles. Autophagy-mediated proteome degradation provides free amino acids to support metabolism and macromolecular synthesis, which confers a survival advantage in starvation and promotes tumorigenesis. While the degradation of isolated protein substrates by autophagy has been implicated in controlling cellular function, the extent and specificity by which autophagy remodels the cellular proteome and the underlying functional consequences were unknown. Here we compared the global proteome of autophagy-functional and -deficient Ras-driven cancer cells, finding that autophagy affects the majority of the proteome yet is highly selective. While levels of vesicle trafficking proteins important for autophagy are preserved during starvation-induced autophagy, deleterious inflammatory response pathway components are eliminated even under basal conditions, preventing cytokine-induced paracrine cell death. This reveals the global, functional impact of autophagy-mediated proteome remodeling on cell survival and identifies critical autophagy substrates that mediate this process. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mathew</LastName>
<ForeName>Robin</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903; Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ, 08854.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khor</LastName>
<ForeName>Sinan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903; Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ, 08854.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hackett</LastName>
<ForeName>Sean R</ForeName>
<Initials>SR</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Washington Road, Princeton, NJ 08544.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rabinowitz</LastName>
<ForeName>Joshua D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Washington Road, Princeton, NJ 08544.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perlman</LastName>
<ForeName>David H</ForeName>
<Initials>DH</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biology, the Lewis-Sigler Institute for Integrative Genomics, and the Princeton Proteomics and Mass Spectrometry Core, Princeton University, Washington Road, Princeton, NJ 08544.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>White</LastName>
<ForeName>Eileen</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903; Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ, 08854. Electronic address: epwhite@cinj.rutgers.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA130893</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA130893</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA163591</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA163591</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R37 CA53370</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC1 CA147961</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>RC1 CA147961</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell</MedlineTA>
<NlmUniqueID>9802571</NlmUniqueID>
<ISSNLinking>1097-2765</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020543">Proteome</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001343">Autophagy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007113">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020543">Proteome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022161">Transport Vesicles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS618875 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4169768 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25219500</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-4164</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Molecular cell</Title>
<ISOAbbreviation>Mol. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.</ArticleTitle>
<Pagination>
<MedlinePgn>904-15</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2014.08.010</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1097-2765(14)00643-1</ELocationID>
<Abstract>
<AbstractText>Most colorectal cancers (CRCs) containing activated BRAF (BRAF[V600E]) have a CpG island methylator phenotype (CIMP) characterized by aberrant hypermethylation of many genes, including the mismatch repair gene MLH1. MLH1 silencing results in microsatellite instability and a hypermutable phenotype. Through an RNAi screen, here we identify the transcriptional repressor MAFG as the pivotal factor required for MLH1 silencing and CIMP in CRCs containing BRAF(V600E). In BRAF-positive human CRC cell lines and tumors, MAFG is bound at the promoters of MLH1 and other CIMP genes, and recruits a corepressor complex that includes its heterodimeric partner BACH1, the chromatin remodeling factor CHD8, and the DNA methyltransferase DNMT3B, resulting in hypermethylation and transcriptional silencing. BRAF(V600E) increases BRAF/MEK/ERK signaling resulting in phosphorylation and elevated levels of MAFG, which drives DNA binding. Analysis of transcriptionally silenced CIMP genes in KRAS-positive CRCs indicates that different oncoproteins direct the assembly of distinct repressor complexes on common promoters. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fang</LastName>
<ForeName>Minggang</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA; Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ou</LastName>
<ForeName>Jianhong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hutchinson</LastName>
<ForeName>Lloyd</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Green</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA; Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA. Electronic address: michael.green@umassmed.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 GM033977</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01GM033977</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mol Cell</MedlineTA>
<NlmUniqueID>9802571</NlmUniqueID>
<ISSNLinking>1097-2765</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C102108">BACH1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050976">Basic-Leucine Zipper Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C523331">CHD8 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051856">Fanconi Anemia Complementation Group Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C103944">MAFG protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C501486">MLH1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051259">MafG Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.37</RegistryNumber>
<NameOfSubstance UI="D004248">DNA (Cytosine-5-)-Methyltransferase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.37</RegistryNumber>
<NameOfSubstance UI="C120396">DNA methyltransferase 3B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050976">Basic-Leucine Zipper Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018899">CpG Islands</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004248">DNA (Cytosine-5-)-Methyltransferase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019175">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051856">Fanconi Anemia Complementation Group Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051259">MafG Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS627196 [Available on 09/18/15]</OtherID>
<OtherID Source="NLM">PMC4170521 [Available on 09/18/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24917306</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1097-0142</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>120</Volume>
<Issue>19</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer</Title>
<ISOAbbreviation>Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.</ArticleTitle>
<Pagination>
<MedlinePgn>2986-95</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.28853</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin-induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A dose of metaformin was administered (1500-2250 mg/day) to 31 patients with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2-sided. P values of &lt; .05 were considered statistically significant.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Preoperative metformin treatment decreased DNA synthesis in sera and significantly reduced the Ki-67 (mean proportional decrease, 44.2%; 95% confidence interval [95% CI], 35.4-53.0 [P &lt; .001]) and topoisomerase IIα (mean proportional decrease, 36.4%; 95% CI, 26.7-46.0 [P &lt; .001]) labeling indices. Levels of phospho-ribosomal protein S6 and phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) were found to be significantly decreased and phospho-adenosine monophosphate-activated protein kinase and p27 levels were significantly increased. Preoperative metformin use caused significant decreases in circulating factors, including insulin, glucose, insulin-like growth factor 1, and leptin. DNA synthesis-stimulating activity in patient sera was significantly decreased during metformin administration.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An antidiabetic dose of metformin inhibited endometrial cancer cell growth in vivo, an effect likely due to its effect on humoral factor(s). This translational study provides considerable rationale to initiate large clinical trials.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mitsuhashi</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kiyokawa</LastName>
<ForeName>Takako</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Yasunori</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shozu</LastName>
<ForeName>Makio</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
<ISSNLinking>0008-543X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018809">Proliferating Cell Nuclear Antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D038601">Ribosomal Protein S6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C413374">p27 antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="C535150">MAPK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.12.2</RegistryNumber>
<NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.99.1.3</RegistryNumber>
<NameOfSubstance UI="D004250">DNA Topoisomerases, Type II</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 5.99.1.3</RegistryNumber>
<NameOfSubstance UI="C087861">DNA topoisomerase II alpha</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055372">AMP-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000951">Antigens, Neoplasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018269">Carcinoma, Endometrioid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017024">Chemotherapy, Adjuvant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004250">DNA Topoisomerases, Type II</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016889">Endometrial Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007004">Hypoglycemic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019394">Ki-67 Antigen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020935">MAP Kinase Signaling System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008687">Metformin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019950">Mitogen-Activated Protein Kinase 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020929">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020360">Neoadjuvant Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060787">Neoplasm Grading</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018809">Proliferating Cell Nuclear Antigen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038601">Ribosomal Protein S6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">endometrial cancer</Keyword>
<Keyword MajorTopicYN="N">growth inhibition</Keyword>
<Keyword MajorTopicYN="N">in vivo</Keyword>
<Keyword MajorTopicYN="N">insulin resistance</Keyword>
<Keyword MajorTopicYN="N">metformin</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24997324</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>279</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Genotoxicity testing of peptides: folate deprivation as a marker of exaggerated pharmacology.</ArticleTitle>
<Pagination>
<MedlinePgn>419-27</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2014.06.022</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(14)00251-8</ELocationID>
<Abstract>
<AbstractText>The incidence of micronucleated-cells is considered to be a marker of a genotoxic event and can be caused by direct- or indirect-DNA reactive mechanisms. In particular, small increases in the incidence of micronuclei, which are not associated with toxicity in the target tissue or any structurally altering properties of the compound, trigger the suspicion that an indirect mechanism could be at play. In a bone marrow micronucleus test of a synthetic peptide (a dual agonist of the GLP-1 and GIP receptors) that had been integrated into a regulatory 13-week repeat-dose toxicity study in the rat, small increases in the incidence of micronuclei had been observed, together with pronounced reductions in food intake and body weight gain. Because it is well established that folate plays a crucial role in maintaining genomic integrity and pronounced reductions in food intake and body weight gain were observed, folate levels were determined from plasma samples initially collected for toxicokinetic analytics. A dose-dependent decrease in plasma folate levels was evident after 4 weeks of treatment at the mid and high dose levels, persisted until the end of the treatment duration of 13-weeks and returned to baseline levels during the recovery period of 4 weeks. Based on these properties, and the fact that the compound tested (peptide) per se is not expected to reach the nucleus and cause DNA damage, the rationale is supported that the elevated incidence of micronucleated polychromatic erythrocytes is directly linked to the exaggerated pharmacology of the compound resulting in a decreased folate level.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Guérard</LastName>
<ForeName>Melanie</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>F. Hoffmann-La Roche Ltd., Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 183, 4070 Basel, Switzerland. Electronic address: melanie.guerard@roche.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zeller</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>F. Hoffmann-La Roche Ltd., Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 183, 4070 Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Festag</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>F. Hoffmann-La Roche Ltd., Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 183, 4070 Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schubert</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>F. Hoffmann-La Roche Ltd., Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 183, 4070 Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Singer</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>F. Hoffmann-La Roche Ltd., Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 183, 4070 Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Müller</LastName>
<ForeName>Lutz</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>F. Hoffmann-La Roche Ltd., Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 183, 4070 Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009153">Mutagens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011964">Receptors, Gastrointestinal Hormone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C041086">gastric inhibitory polypeptide receptor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001831">Body Temperature</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001854">Bone Marrow Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002869">Chromosome Aberrations</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004435">Eating</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004920">Erythropoiesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005494">Folic Acid Deficiency</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044342">Malnutrition</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015162">Micronucleus Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009152">Mutagenicity Tests</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009153">Mutagens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011964">Receptors, Gastrointestinal Hormone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012486">Salmonella typhimurium</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Folate</Keyword>
<Keyword MajorTopicYN="N">Integration</Keyword>
<Keyword MajorTopicYN="N">Micronuclei</Keyword>
<Keyword MajorTopicYN="N">Peptide</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24998975</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>279</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis.</ArticleTitle>
<Pagination>
<MedlinePgn>322-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2014.06.018</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(14)00247-6</ELocationID>
<Abstract>
<AbstractText>Bladder cancer is highly recurrent following specific transurethral resection and intravesical chemotherapy, which has prompted continuing efforts to develop novel therapeutic agents and early-stage diagnostic tools. Specific changes in protein expression can provide a diagnostic marker. In our present study, we investigated changes in protein expression during urothelial carcinogenesis. The carcinogen BBN was used to induce mouse bladder tumor formation. Mouse bladder mucosa proteins were collected and analyzed by 2D electrophoresis from 6 to 20 weeks after commencing continuous BBN treatment. By histological examination, the connective layer of the submucosa showed gradual thickening and the number of submucosal capillaries gradually increased after BBN treatment. At 12-weeks after the start of BBN treatment, the urothelia became moderately dysplastic and tumors arose after 20-weeks of treatment. These induced bladder lesions included carcinoma in situ and connective tissue invasive cancer. In protein 2D analysis, the sequentially downregulated proteins from 6 to 20 weeks included GSTM1, L-lactate dehydrogenase B chain, keratin 8, keratin 18 and major urinary proteins 2 and 11/8. In contrast, the sequentially upregulated proteins identified were GSTO1, keratin 15 and myosin light polypeptide 6. Western blotting confirmed that GSTM1 and NQO-1 were decreased, while GSTO1 and Sp1 were increased, after BBN treatment. In human bladder cancer cells, 5-aza-2'-deoxycytidine increased the GSTM1 mRNA and protein expression. These data suggest that the downregulation of GSTM1 in the urothelia is a biomarker of bladder carcinogenesis and that this may be mediated by DNA CpG methylation.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chuang</LastName>
<ForeName>Jing-Jing</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dai</LastName>
<ForeName>Yuan-Chang</ForeName>
<Initials>YC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Chiayi Christian Hospital, Chiayi, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Yung-Lun</ForeName>
<Initials>YL</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yang-Yi</ForeName>
<Initials>YY</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Wei-Han</ForeName>
<Initials>WH</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Hong-Lin</ForeName>
<Initials>HL</Initials>
<AffiliationInfo>
<Affiliation>Institute of Bioinformatics and Structural Biology &amp; Department of Medical Sciences, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yi-Wen</ForeName>
<Initials>YW</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi, Taiwan. Electronic address: ywlss@mail.ncyu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3817-11-6</RegistryNumber>
<NameOfSubstance UI="D002085">Butylhydroxybutylnitrosamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>776B62CQ27</RegistryNumber>
<NameOfSubstance UI="C014347">decitabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.5.1.18</RegistryNumber>
<NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.5.1.18</RegistryNumber>
<NameOfSubstance UI="C117740">glutathione S-transferase M1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>M801H13NRU</RegistryNumber>
<NameOfSubstance UI="D001374">Azacitidine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001374">Azacitidine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002085">Butylhydroxybutylnitrosamine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002273">Carcinogens</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004396">Coloring Agents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015180">Electrophoresis, Gel, Two-Dimensional</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005982">Glutathione Transferase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009092">Mucous Membrane</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019032">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001743">Urinary Bladder</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001749">Urinary Bladder Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Biomarker</Keyword>
<Keyword MajorTopicYN="N">Bladder cancer</Keyword>
<Keyword MajorTopicYN="N">DNA CpG methylation</Keyword>
<Keyword MajorTopicYN="N">Glutathione S-transferase</Keyword>
<Keyword MajorTopicYN="N">Nitrosamines</Keyword>
<Keyword MajorTopicYN="N">Protein 2D electrophoresis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25019461</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>279</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Additive and synergistic antiandrogenic activities of mixtures of azol fungicides and vinclozolin.</ArticleTitle>
<Pagination>
<MedlinePgn>455-66</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2014.06.025</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(14)00254-3</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Many pesticides including pyrethroids and azole fungicides are suspected to have an endocrine disrupting property. At present, the joint activity of compound mixtures is only marginally known. Here we tested the hypothesis that the antiandrogenic activity of mixtures of azole fungicides can be predicted by the concentration addition (CA) model.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The antiandrogenic activity was assessed in MDA-kb2 cells. Following assessing single compounds activities mixtures of azole fungicides and vinclozolin were investigated. Interactions were analyzed by direct comparison between experimental and estimated dose-response curves assuming CA, followed by an analysis by the isobole method and the toxic unit approach.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The antiandrogenic activity of pyrethroids deltamethrin, cypermethrin, fenvalerate and permethrin was weak, while the azole fungicides tebuconazole, propiconazole, epoxiconazole, econazole and vinclozolin exhibited strong antiandrogenic activity. Ten binary and one ternary mixture combinations of five antiandrogenic fungicides were assessed at equi-effective concentrations of EC25 and EC50. Isoboles indicated that about 50% of the binary mixtures were additive and 50% synergistic. Synergism was even more frequently indicated by the toxic unit approach.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data lead to the conclusion that interactions in mixtures follow the CA model. However, a surprisingly high percentage of synergistic interactions occurred. Therefore, the mixture activity of antiandrogenic azole fungicides is at least additive.</AbstractText>
<AbstractText Label="PRACTICE" NlmCategory="UNASSIGNED">Mixtures should also be considered for additive antiandrogenic activity in hazard and risk assessment.</AbstractText>
<AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Our evaluation provides an appropriate "proof of concept", but whether it equally translates to in vivo effects should further be investigated.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Christen</LastName>
<ForeName>Verena</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences, Gründenstrasse 40, CH-4132 Muttenz, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Crettaz</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Federal Office of Public Health, Division Chemical Products, 3003 Bern, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fent</LastName>
<ForeName>Karl</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences, Gründenstrasse 40, CH-4132 Muttenz, Switzerland; ETH Zürich, Department of Environmental System Sciences, Institute of Biogeochemistry and Pollution Dynamics, Universitätsstrasse 16, CH-8092 Zürich, Switzerland. Electronic address: karl.fent@fhnw.ch.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001393">Azoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005659">Fungicides, Industrial</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011722">Pyrethrins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50471-44-8</RegistryNumber>
<NameOfSubstance UI="C025643">vinclozolin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000465">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000726">Androgen Antagonists</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001393">Azoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005659">Fungicides, Industrial</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007306">Insecticides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010080">Oxazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011722">Pyrethrins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011944">Receptors, Androgen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Antiandrogenicity</Keyword>
<Keyword MajorTopicYN="N">Azol fungicides</Keyword>
<Keyword MajorTopicYN="N">Concentration addition</Keyword>
<Keyword MajorTopicYN="N">Mixture activity</Keyword>
<Keyword MajorTopicYN="N">Pyrethroids</Keyword>
<Keyword MajorTopicYN="N">Synergism</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25034532</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0333</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>279</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Toxicology and applied pharmacology</Title>
<ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>253-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2014.06.030</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0041-008X(14)00259-2</ELocationID>
<Abstract>
<AbstractText>Glioblastoma multiforme (GBM) is the most lethal and aggressive astrocytoma of primary brain tumors in adults. Although there are many clinical trials to induce the cell death of glioblastoma cells, most glioblastoma cells have been reported to be resistant to TRAIL-induced apoptosis. Here, we showed that gingerol as a major component of ginger can induce TRAIL-mediated apoptosis of glioblastoma. Gingerol increased death receptor (DR) 5 levels in a p53-dependent manner. Furthermore, gingerol decreased the expression level of anti-apoptotic proteins (survivin, c-FLIP, Bcl-2, and XIAP) and increased pro-apoptotic protein, Bax and truncate Bid, by generating reactive oxygen species (ROS). We also found that the sensitizing effects of gingerol in TRAIL-induced cell death were blocked by scavenging ROS or overexpressing anti-apoptotic protein (Bcl-2). Therefore, we showed the functions of gingerol as a sensitizing agent to induce cell death of TRAIL-resistant glioblastoma cells. This study gives rise to the possibility of applying gingerol as an anti-tumor agent that can be used for the purpose of combination treatment with TRAIL in TRAIL-resistant glioblastoma tumor therapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Dae-Hee</ForeName>
<Initials>DH</Initials>
<AffiliationInfo>
<Affiliation>Departments of Surgery and Pharmacology and Cell Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: leedneo@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Dong-Wook</ForeName>
<Initials>DW</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, Immunology, and Cancer Biology, University of VA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jung</LastName>
<ForeName>Chang-Hwa</ForeName>
<Initials>CH</Initials>
<AffiliationInfo>
<Affiliation>Division of Metabolism and Functionality Research, Korea Food Research Institute, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Yong J</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo>
<Affiliation>Departments of Surgery and Pharmacology and Cell Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Daeho</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Republic of Korea. Electronic address: daehopark@gist.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
<NlmUniqueID>0416575</NlmUniqueID>
<ISSNLinking>0041-008X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002396">Catechols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005233">Fatty Alcohols</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053220">Receptors, TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>925QK2Z900</RegistryNumber>
<NameOfSubstance UI="C007845">gingerol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053179">Caspase 7</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053179">Caspase 7</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002396">Catechols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005233">Fatty Alcohols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053220">Receptors, TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053221">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Gingerol</Keyword>
<Keyword MajorTopicYN="N">Glioblastoma</Keyword>
<Keyword MajorTopicYN="N">Reactive oxygen species (ROS)</Keyword>
<Keyword MajorTopicYN="N">Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)</Keyword>
<Keyword MajorTopicYN="N">p53</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25138022</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-0103</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>351</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pharmacology and experimental therapeutics</Title>
<ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>Coadministrating luteolin minimizes the side effects of the aromatase inhibitor letrozole.</ArticleTitle>
<Pagination>
<MedlinePgn>270-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.114.216754</ELocationID>
<Abstract>
<AbstractText>Aromatase inhibitors (AIs) have been used as adjuvant therapeutic agents for breast cancer. Their adverse side effect on blood lipid is well documented. Some natural compounds have been shown to be potential AIs. In the present study, we compared the efficacy of the flavonoid luteolin to the clinically approved AI letrozole (Femara; Novartis Pharmaceuticals, East Hanover, NJ) in a cell and a mouse model. In the in vitro experimental results for aromatase inhibition, the Ki values of luteolin and letrozole were estimated to be 2.44 µM and 0.41 nM, respectively. Both letrozole and luteolin appeared to be competitive inhibitors. Subsequently, an animal model was used for the comparison. Aromatase-expressing MCF-7 cells were transplanted into ovariectomized athymic mice. Luteolin was given by mouth at 5, 20, and 50 mg/kg, whereas letrozole was administered by intravenous injection. Similar to letrozole, luteolin administration reduced plasma estrogen concentrations and suppressed the xenograft proliferation. The regulation of cell cycle and apoptotic proteins-such as a decrease in the expression of Bcl-xL, cyclin-A/D1/E, CDK2/4, and increase in that of Bax-was about the same in both treatments. The most significant disparity was on blood lipids. In contrast to letrozole, luteolin increased fasting plasma high-density lipoprotein concentrations and produced a desirable blood lipid profile. These results suggested that the flavonoid could be a coadjuvant therapeutic agent without impairing the action of AIs. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Fengjuan</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Tsz Yan</ForeName>
<Initials>TY</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Shu-mei</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chow</LastName>
<ForeName>Simon</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cheung</LastName>
<ForeName>Wing-hoi</ForeName>
<Initials>WH</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Franky L</ForeName>
<Initials>FL</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Shiuan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Leung</LastName>
<ForeName>Lai K</ForeName>
<Initials>LK</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-7781-3099</Identifier>
<AffiliationInfo>
<Affiliation>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, China (F.L.); Biochemistry Programme, School of Life Sciences, Faculty of Science (F.L), Food and Nutritional Sciences Programme , School of Life Sciences, Faculty of Science (T.Y.W., L.K.L.), Department of Orthopaedics and Traumatology, Faculty of Medicine (Si.C., W.C.), and School of Biomedical Sciences, Faculty of Medicine (F.L.C.), The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Food Science, National Chiayi University, Chiayi City, Taiwan, Republic of China (S.L.); and Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, California (Sh.C.) laikleung@cuhk.edu.hk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pharmacol Exp Ther</MedlineTA>
<NlmUniqueID>0376362</NlmUniqueID>
<ISSNLinking>0022-3565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4TI98Z838E</RegistryNumber>
<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7LKK855W8I</RegistryNumber>
<NameOfSubstance UI="C067431">letrozole</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>KUX1ZNC9J2</RegistryNumber>
<NameOfSubstance UI="D047311">Luteolin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047072">Aromatase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004958">Estradiol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008075">Lipoproteins, HDL</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047311">Luteolin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014230">Triazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25246820</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">2005-8330</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>15</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Korean journal of radiology : official journal of the Korean Radiological Society</Title>
<ISOAbbreviation>Korean J Radiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Intratumoral heterogeneity of breast cancer xenograft models: texture analysis of diffusion-weighted MR imaging.</ArticleTitle>
<Pagination>
<MedlinePgn>591-604</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3348/kjr.2014.15.5.591</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether there is a relationship between texture analysis parameters of apparent diffusion coefficient (ADC) maps and histopathologic features of MCF-7 and MDA-MB-231 xenograft models.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">MCF-7 estradiol (+), MCF-7 estradiol (-), and MDA-MB-231 xenograft models were made with approval of the animal care committee. Twelve tumors of MCF-7 estradiol (+), 9 tumors of MCF-7 estradiol (-), and 6 tumors in MDA-MB-231 were included. Diffusion-weighted MR images were obtained on a 9.4-T system. An analysis of the first and second order texture analysis of ADC maps was performed. The texture analysis parameters and histopathologic features were compared among these groups by the analysis of variance test. Correlations between texture parameters and histopathologic features were analyzed. We also evaluated the intraobserver agreement in assessing the texture parameters.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">MCF-7 estradiol (+) showed a higher standard deviation, maximum, skewness, and kurtosis of ADC values than MCF-7 estradiol (-) and MDA-MB-231 (p &lt; 0.01 for all). The contrast of the MCF-7 groups was higher than that of the MDA-MB-231 (p = 0.004). The correlation (COR) of the texture analysis of MCF-7 groups was lower than that of MDA-MB-231 (p &lt; 0.001). The histopathologic analysis showed that Ki-67mean and Ki-67diff of MCF-7 estradiol (+) were higher than that of MCF-7 estradiol (-) or MDA-MB-231 (p &lt; 0.05). The microvessel density (MVD)mean and MVDdiff of MDA-MB-231 were higher than those of MCF-7 groups (p &lt; 0.001). A diffuse-multifocal necrosis was more frequently found in MDA-MB-231 (p &lt; 0.001). The proportion of necrosis moderately correlated with the contrast (r = -0.438, p = 0.022) and strongly with COR (r = 0.540, p = 0.004). Standard deviation (r = 0.622, r = 0.437), skewness (r = 0.404, r = 0.484), and kurtosis (r = 0.408, r = 0.452) correlated with Ki-67mean and Ki-67diff (p &lt; 0.05 for all). COR moderately correlated with Ki-67diff (r = -0.388, p = 0.045). Skewness (r = -0.643, r = -0.464), kurtosis (r = -0.581, r = -0.389), contrast (r = -0.473, r = -0.549) and COR (r = 0.588, r = 0.580) correlated with MVDmean and MVDdiff (p &lt; 0.05 for all).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The texture analysis of ADC maps may help to determine the intratumoral spatial heterogeneity of necrosis patterns, amount of cellular proliferation and the vascularity in MCF-7 and MDA-MB-231 xenograft breast cancer models.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yun</LastName>
<ForeName>Bo La</ForeName>
<Initials>BL</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 110-744, Korea. ; Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Nariya</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 110-744, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Mulan</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 110-744, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jang</LastName>
<ForeName>Min Hye</ForeName>
<Initials>MH</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>So Yeon</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Ho Chul</ForeName>
<Initials>HC</Initials>
<AffiliationInfo>
<Affiliation>Department of Computer Science and Engineering, Seoul National University, Seoul 151-744, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Bohyoung</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>In Chan</ForeName>
<Initials>IC</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 110-744, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moon</LastName>
<ForeName>Woo Kyung</ForeName>
<Initials>WK</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 110-744, Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Korea (South)</Country>
<MedlineTA>Korean J Radiol</MedlineTA>
<NlmUniqueID>100956096</NlmUniqueID>
<ISSNLinking>1229-6929</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4TI98Z838E</RegistryNumber>
<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1636-47</RefSource>
<PMID Version="1">21617975</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phys Med Biol. 2014 Jan 20;59(2):R65-R127</RefSource>
<PMID Version="1">24374985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Korean J Radiol. 2012 Jan-Feb;13(1):82-9</RefSource>
<PMID Version="1">22247640</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Magn Reson Med. 2012 Mar;67(3):778-85</RefSource>
<PMID Version="1">22135228</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Magn Reson Imaging. 2012 May;35(5):1098-107</RefSource>
<PMID Version="1">22170753</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>World J Surg Oncol. 2012;10:126</RefSource>
<PMID Version="1">22741544</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Breast Cancer. 2012 Oct;12(5):331-9</RefSource>
<PMID Version="1">23040001</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Exp Biol Med (Maywood). 2012 Nov;237(11):1273-80</RefSource>
<PMID Version="1">23239438</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AJR Am J Roentgenol. 2013 Feb;200(2):314-20</RefSource>
<PMID Version="1">23345352</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur Radiol. 2013 Aug;23(8):2156-64</RefSource>
<PMID Version="1">23455763</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Invest Radiol. 2013 Oct;48(10):722-8</RefSource>
<PMID Version="1">23669588</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2013 Sep 19;501(7467):355-64</RefSource>
<PMID Version="1">24048068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Magn Reson Med Sci. 2013;12(3):193-9</RefSource>
<PMID Version="1">23857151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nature. 2000 Aug 17;406(6797):747-52</RefSource>
<PMID Version="1">10963602</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Magn Reson Imaging. 2002 Aug;16(2):172-8</RefSource>
<PMID Version="1">12203765</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Magn Reson Med. 2003 Jul;50(1):92-8</RefSource>
<PMID Version="1">12815683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Genes Dev. 2004 Sep 1;18(17):2095-107</RefSource>
<PMID Version="1">15314031</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Science. 1976 Oct 1;194(4260):23-8</RefSource>
<PMID Version="1">959840</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Radiology. 1986 Nov;161(2):401-7</RefSource>
<PMID Version="1">3763909</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Res. 1987 Aug 15;47(16):4355-60</RefSource>
<PMID Version="1">3607768</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Magn Reson Imaging. 1997 Nov-Dec;7(6):1016-26</RefSource>
<PMID Version="1">9400844</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AJR Am J Roentgenol. 2007 Jun;188(6):1622-35</RefSource>
<PMID Version="1">17515386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Anticancer Res. 2007 Jul-Aug;27(4B):2155-9</RefSource>
<PMID Version="1">17695498</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Magn Reson Med. 2007 Sep;58(3):562-71</RefSource>
<PMID Version="1">17763361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Nucl Med. 2008 Dec;49(12):1973-9</RefSource>
<PMID Version="1">18997052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Neoplasia. 2009 Feb;11(2):102-25</RefSource>
<PMID Version="1">19186405</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Environ Health Perspect. 2009 Jun;117(6):928-34</RefSource>
<PMID Version="1">19590685</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Comput Assist Tomogr. 2009 Jul-Aug;33(4):626-30</RefSource>
<PMID Version="1">19638862</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Magn Reson Imaging. 2009 Sep;30(3):615-20</RefSource>
<PMID Version="1">19711411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):618-25</RefSource>
<PMID Version="1">19683403</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Radiol. 2010 Apr;83(988):296-309</RefSource>
<PMID Version="1">20335440</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>NMR Biomed. 2010 Jul;23(6):619-23</RefSource>
<PMID Version="1">20232453</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Radiology. 2010 Oct;257(1):56-63</RefSource>
<PMID Version="1">20851939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Magn Reson Imaging. 2011 Jan;33(1):102-9</RefSource>
<PMID Version="1">21182127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Magn Reson Med Sci. 2010;9(4):195-207</RefSource>
<PMID Version="1">21187689</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Nucl Med. 2011 Mar;52(3):369-78</RefSource>
<PMID Version="1">21321270</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Magn Reson Med. 2011 May;65(5):1437-47</RefSource>
<PMID Version="1">21287591</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Mol Sci. 2013;14(11):21943-59</RefSource>
<PMID Version="1">24196357</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Radiol. 2013 Dec;82(12):e782-9</RefSource>
<PMID Version="1">24034833</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Radiology. 2011 Oct;261(1):182-92</RefSource>
<PMID Version="1">21828186</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000530">radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D038524">Diffusion Magnetic Resonance Imaging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004958">Estradiol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007090">Image Interpretation, Computer-Assisted</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019394">Ki-67 Antigen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014183">Transplantation, Heterologous</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4170160</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Animal</Keyword>
<Keyword MajorTopicYN="N">Breast neoplasms</Keyword>
<Keyword MajorTopicYN="N">Computer-assisted</Keyword>
<Keyword MajorTopicYN="N">Diffusion magnetic resonance imaging</Keyword>
<Keyword MajorTopicYN="N">Image interpretation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25060692</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-8600</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>63</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Metabolism: clinical and experimental</Title>
<ISOAbbreviation>Metab. Clin. Exp.</ISOAbbreviation>
</Journal>
<ArticleTitle>Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1352-62</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metabol.2014.06.016</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0026-0495(14)00183-8</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patatin-like phospholipase domain containing 3 (PNPLA3, adiponutrin) has been identified as a modifier of lipid metabolism. To better understand the physiological role of PNPLA3/adiponutrin, we have investigated its regulation in intact mice and human hepatocytes under various nutritional/metabolic conditions.</AbstractText>
<AbstractText Label="MATERIAL/METHODS" NlmCategory="METHODS">PNPLA3 gene expression was determined by real-time PCR in liver of C57BL/6 mice after dietary treatments and in HepG2 cells exposed to various nutritional/metabolic stimuli. Intracellular lipid content was determined in HepG2 cells after siRNA-mediated knockdown of PNPLA3.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In vivo, mice fed a high-carbohydrate (HC) liquid diet had elevated hepatic lipid content, and PNPLA3 mRNA and protein expression, compared to chow-fed mice. Elevated expression was completely abrogated by addition of unsaturated lipid emulsion to the HC diet. By contrast, in mice with high-fat diet-induced steatosis, Pnpla3 expression did not differ compared to low-fat fed mice. In HepG2 cells, Pnpla3 expression was reversibly suppressed by glucose depletion and increased by glucose refeeding, but unchanged by addition of insulin and glucagon. Several unsaturated fatty acids each significantly decreased Pnpla3 mRNA, similar to lipid emulsion in vivo. However, Pnpla3 knockdown in HepG2 cells did not alter total lipid content in high glucose- or oleic acid-treated cells.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results provide evidence that PNPLA3 expression is an early signal/signature of carbohydrate-induced lipogenesis, but its expression is not associated with steatosis per se. Under lipogenic conditions due to high-carbohydrate feeding, certain unsaturated fatty acids can effectively suppress both lipogenesis and PNPLA3 expression, both in vivo and in a hepatocyte cell line.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hao</LastName>
<ForeName>Lei</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA 16802 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ito</LastName>
<ForeName>Kyoko</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA 16802 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Kuan-Hsun</ForeName>
<Initials>KH</Initials>
<AffiliationInfo>
<Affiliation>Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA 16802 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sae-tan</LastName>
<ForeName>Sudathip</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Food Science, The Pennsylvania State University, University Park, PA 16802 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lambert</LastName>
<ForeName>Joshua D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Food Science, The Pennsylvania State University, University Park, PA 16802 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ross</LastName>
<ForeName>A Catharine</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA 16802 USA; Center for Immunology and Infectious Disease, The Pennsylvania State University, University Park, PA 16802 USA. Electronic address: acr6@psu.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>NIH AT004678</GrantID>
<Acronym>AT</Acronym>
<Agency>NCCAM NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>NIHCA90214</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AT004678</GrantID>
<Acronym>AT</Acronym>
<Agency>NCCAM NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA090214</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Metabolism</MedlineTA>
<NlmUniqueID>0375267</NlmUniqueID>
<ISSNLinking>0026-0495</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C436316">adiponutrin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-92-5</RegistryNumber>
<NameOfSubstance UI="D005934">Glucagon</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059305">Diet, High-Fat</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004040">Dietary Carbohydrates</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005234">Fatty Liver</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005934">Glucagon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056945">Hep G2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D022781">Hepatocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008055">Lipids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050155">Lipogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D065626">Non-alcoholic Fatty Liver Disease</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS608533 [Available on 10/01/15]</OtherID>
<OtherID Source="NLM">PMC4175036 [Available on 10/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Glucose</Keyword>
<Keyword MajorTopicYN="N">Lipid emulsion</Keyword>
<Keyword MajorTopicYN="N">Nonalcoholic fatty liver disease</Keyword>
<Keyword MajorTopicYN="N">Patatin-like phospholipase domain containing 3</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25249531</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2310-6972</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>60</Volume>
<Issue>4</Issue>
<PubDate>
<MedlineDate>2014 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Biomedit͡sinskai͡a khimii͡a</Title>
<ISOAbbreviation>Biomed Khim</ISOAbbreviation>
</Journal>
<ArticleTitle>[The influence of docosahexaenoic acid moiety on cytotoxic activity of 1,2,4-thiadiazole derivatives].</ArticleTitle>
<Pagination>
<MedlinePgn>473-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Among 3-(2-aminopropyl)-1,2,4-thiadiazole derivatives contatining substitution-ready secondary amino group and exhibiting cytotoxic towards rat C 6 glioma cells three compounds with LD 50 values ranged from 6 to 48 мM were chosen. For these compounds amides with docosahexaenoic acid were synthetised and their cytotoxic activity was studied. It was shown that, although docosahexaenoic acid itself was not toxic for C 6 glioma cells, its addition to the amino derivatives of 1,2,4-thiadiazole increased or decreased resultant cytotoxicity. The effect depended on the structure of 1,2,4-thiadiazole substituents. The obtained data show that the acylation of cytotoxic compounds with docosahexaenoic acid does not necessarily lead to the increase of their activity, but sometimes can inactivate a compound. This fact should be taken into account, especially in the case of anti-cancer drug development. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Akimov</LastName>
<ForeName>M G</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gretskaia</LastName>
<ForeName>N M</ForeName>
<Initials>NM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Karnoukhova</LastName>
<ForeName>V A</ForeName>
<Initials>VA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Serkov</LastName>
<ForeName>I V</ForeName>
<Initials>IV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Proshin</LastName>
<ForeName>A N</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shtratnikova</LastName>
<ForeName>V Iu</ForeName>
<Initials>VIu</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bezuglov</LastName>
<ForeName>V V</ForeName>
<Initials>VV</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Biomed Khim</MedlineTA>
<NlmUniqueID>101196966</NlmUniqueID>
<ISSNLinking>2310-6905</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000577">Amides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003603">Cytotoxins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013830">Thiadiazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>25167-62-8</RegistryNumber>
<NameOfSubstance UI="D004281">Docosahexaenoic Acids</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000577">Amides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003603">Cytotoxins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004281">Docosahexaenoic Acids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015195">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009457">Neuroglia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013830">Thiadiazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherAbstract Language="rus" Type="Publisher">
<AbstractText>Abstract available from the publisher.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">1,2,4-thiadiazoles</Keyword>
<Keyword MajorTopicYN="N">docosahexaenoic acid</Keyword>
<Keyword MajorTopicYN="N">rat C6 glioma</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25072260</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination.</ArticleTitle>
<Pagination>
<MedlinePgn>1338-49</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.426</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Surgery is considered to be the first line treatment for solid tumours. Recently, retrospective studies reported that general anaesthesia was associated with worse long-term cancer-free survival when compared with regional anaesthesia. This has important clinical implications; however, the mechanisms underlying those observations remain unclear. We aim to investigate the effect of anaesthetics isoflurane and propofol on prostate cancer malignancy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Prostate cancer (PC3) cell line was exposed to commonly used anaesthetic isoflurane and propofol. Malignant potential was assessed through evaluation of expression level of hypoxia-inducible factor-1α (HIF-1α) and its downstream effectors, cell proliferation and migration as well as development of chemoresistance.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We demonstrated that isoflurane, at a clinically relevant concentration induced upregulation of HIF-1α and its downstream effectors in PC3 cell line. Consequently, cancer cell characteristics associated with malignancy were enhanced, with an increase of proliferation and migration, as well as development of chemoresistance. Inhibition of HIF-1α neosynthesis through upper pathway blocking by a PI-3K-Akt inhibitor or HIF-1α siRNA abolished isoflurane-induced effects. In contrast, the intravenous anaesthetic propofol inhibited HIF-1α activation induced by hypoxia or CoCl2. Propofol also prevented isoflurane-induced HIF-1α activation, and partially reduced cancer cell malignant activities.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that modulation of HIF-1α activity by anaesthetics may affect cancer recurrence following surgery. If our data were to be extrapolated to the clinical setting, isoflurane but not propofol should be avoided for use in cancer surgery. Further work involving in vivo models and clinical trials is urgently needed to determine the optimal anaesthetic regimen for cancer patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>1] Section of Anaesthetics, Pain Medicine and Intensive Care, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK [2] Department of Anesthesiology, West China Second Hospital, Sichuan University, Chengdu, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Benzonana</LastName>
<ForeName>L L</ForeName>
<Initials>LL</Initials>
<AffiliationInfo>
<Affiliation>Section of Anaesthetics, Pain Medicine and Intensive Care, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Section of Anaesthetics, Pain Medicine and Intensive Care, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Watts</LastName>
<ForeName>H R</ForeName>
<Initials>HR</Initials>
<AffiliationInfo>
<Affiliation>Section of Anaesthetics, Pain Medicine and Intensive Care, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perry</LastName>
<ForeName>N J S</ForeName>
<Initials>NJ</Initials>
<AffiliationInfo>
<Affiliation>Section of Anaesthetics, Pain Medicine and Intensive Care, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bevan</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Section of Anaesthetics, Pain Medicine and Intensive Care, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018685">Anesthetics, Inhalation</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>15H5577CQD</RegistryNumber>
<NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>CYS9AKD70P</RegistryNumber>
<NameOfSubstance UI="D007530">Isoflurane</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>YI7VU623SF</RegistryNumber>
<NameOfSubstance UI="D015742">Propofol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018685">Anesthetics, Inhalation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007530">Isoflurane</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015742">Propofol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D043823">Taxoids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183852 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25077440</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray.</ArticleTitle>
<Pagination>
<MedlinePgn>1363-72</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.415</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Epithelial-mesenchymal transition (EMT) is characterised by the loss of cell-to-cell adhesion and gaining of mesenchymal phenotypes. Epithelial-mesenchymal transition is proposed to occur in various developmental processes and cancer progression. 'Cadherin switch', a process in which cells shift to express different isoforms of the cadherin transmembrane protein and usually refers to a switch from the expression of E-cadherin to N-cadherin, is one aspect of EMT and can have a profound effect on tumour invasion/metastasis. The aim of this study was to investigate the clinicopathological significance of EMT-related proteins and cadherin switch in extrahepatic cholangiocarcinoma (EHCC).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We investigated the association between altered expression of 12 EMT-related proteins and clinical outcomes in patients with EHCC (n=117) using immunohistochemistry on tissue microarrays.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Univariate and multivariate analyses revealed that, in addition to N classification (P=0.0420), the expression of E-cadherin (P=0.0208), N-cadherin (P=0.0038) and S100A4 (P=0.0157) was each an independent and a significant prognostic factor. We also demonstrated that cadherin switch was independently associated with poor prognosis (P=0.0143) in patients with EHCC.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results may provide novel information for selection of patients with EHCC who require adjuvant therapy and strict surveillance.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nitta</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Surgical Pathology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan [2] Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mitsuhashi</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Pathology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hatanaka</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Pathology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miyamoto</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oba</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Translational Research and Clinical Trial Center, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsuchikawa</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Pathology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hatanaka</LastName>
<ForeName>K C</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Pathology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hirano</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsuno</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgical Pathology, Hokkaido University Hospital, N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C513384">CDH1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C050361">CDH2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001650">Bile Duct Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017734">Bile Ducts, Extrahepatic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001653">Bile Ducts, Intrahepatic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015820">Cadherins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018281">Cholangiocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015999">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046888">Tissue Array Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183847 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25077442</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.</ArticleTitle>
<Pagination>
<MedlinePgn>1310-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.432</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cetuximab is often combined with radiotherapy in advanced SCCHN. Alternative routes bypassing inhibition of EGFR with cetuximab may overshadow the efficacy of this combination. We undertook this study to investigate a possible role of dasatinib in this scenario.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The SCC5, SCC25, SCC29, FaDu and A431 cell lines were assessed in vitro for cell proliferation under cetuximab and dasatinib treatments. In FaDu and A431 cells, dasatinib plus cetuximab resulted in higher proliferation than cetuximab alone. Then, FaDu and A431 cells were implanted into subcutaneous tissue of athymic mice that were irradiated with 30 Gy in 10 fractions over 2 weeks, and treated with cetuximab and dasatinib. Tumour growth, DNA synthesis and angiogenesis were determined. The EGFR, RAS-GTP activity, phosphorylated AKT, ERK1/2, SRC protein levels and VEGF secretion were determined in vitro.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The addition of dasatinib to cetuximab and radiotherapy increased tumour growth, DNA synthesis and angiogenesis that were associated with RAS, AKT and ERK1/2 activation, and SRC inhibition in FaDu and A431 cells.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In xenografts derived from these two cell lines, dasatinib did not improve the efficacy of cetuximab combined with radiotherapy. On the contrary, it worsened tumour control achieved by the combination of these two treatments.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Baro</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Llobet</LastName>
<ForeName>L I</ForeName>
<Initials>LI</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Figueras</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Skvortsova</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mesia</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Balart</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>1] Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain [2] Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C412373">AG 1879</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>PQX0D8J21J</RegistryNumber>
<NameOfSubstance UI="C411189">cetuximab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>RBZ1571X5H</RegistryNumber>
<NameOfSubstance UI="C488369">dasatinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004261">DNA Replication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019583">Dose Fractionation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013844">Thiazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000528">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000557">secretion</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019061">src-Family Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183853 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25093489</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>111</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>1400-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.435</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Insulin-like growth factor binding protein-2 (IGFBP-2) is significantly increased in the serum of patients with malignant gliomas. High plasma IGFBP-2 levels are correlated with poor prognosis in glioma patients. However, the exact role of exogenous IGFBP-2 in gliomas is unclear.</AbstractText>
<AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Using the MTT cell viability assay, cell cycle analysis, and the transwell migration assay, it was demonstrated that IGFBP-2 treatment stimulated proliferation and invasion in U87 and U251 cell lines and primary SU3 glioma cells. Western blot analysis and immunofluorescence staining revealed that IGFBP-2 promoted ERK phosphorylation and nuclear translocation. Moreover, blocking ERK activation using the inhibitor PD98059 markedly reduced the effects of IGFBP-2 in glioma cells. As IGFBP-2 has an integrin-binding domain, the contribution of integrin β1 to these IGFBP-2-mediated processes was examined. Neutralisation or knockdown of the expression of integrin β1 inhibited IGFBP-2-induced ERK activation, cell proliferation, and cell invasion. Significantly, IGFBP-2 induced temozolomide resistance in glioma cells in an integrin β1/ERK-dependent manner.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Exogenous IGFBP-2 induces proliferation, invasion, and chemoresistance in glioma cells via integrin β1/ERK signaling, suggesting that targeting this pathway could represent a potential therapeutic strategy for the treatment of gliomas. The identification of this pathway in glioma progression provides insight into the mechanism by which serum IGFBP-2 levels can predict the prognosis of glioma patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Master</LastName>
<ForeName>L M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Master</LastName>
<ForeName>Z W</ForeName>
<Initials>ZW</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019012">Antigens, CD29</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577903">IGFBP-2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018971">Insulin-Like Growth Factor Binding Protein 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7GR28W0FJI</RegistryNumber>
<NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>85622-93-1</RegistryNumber>
<NameOfSubstance UI="C047246">temozolomide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019012">Antigens, CD29</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018906">Antineoplastic Agents, Alkylating</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003606">Dacarbazine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048049">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018971">Insulin-Like Growth Factor Binding Protein 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D020935">MAP Kinase Signaling System</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046888">Tissue Array Analysis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4183856 [Available on 09/23/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24975049</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.</ArticleTitle>
<Pagination>
<MedlinePgn>1124-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12469</ELocationID>
<Abstract>
<AbstractText>Synovial sarcoma (SS) is a malignant soft-tissue tumor characterized by the recurrent chromosomal translocation SS18-SSX. Vascular endothelial growth factor (VEGF)-targeting anti-angiogenic therapy has been approved for soft-tissue sarcoma, including SS; however, the mechanism underlying the VEGF signal for sarcomagenesis in SS is unclear. Here, we show that SS18-SSX directs the VEGF signal outcome to cellular growth from differentiation. Synovial sarcoma cells secrete large amounts of VEGF under spheroid culture conditions in autocrine fashion. SS18-SSX knockdown altered the VEGF signaling outcome, from proliferation to tubular differentiation, without affecting VEGF secretion, suggesting that VEGF signaling promoted cell growth in the presence of SS18-SSX. Thus, VEGF inhibitors blocked both host angiogenesis and spheroid growth. Simultaneous treatment with VEGF and chemokine (C-X-C motif) (CXC) ligand 12 and CXC receptor 4 inhibitors and/or ifosfamide effectively suppressed tumor growth both in vitro and in vivo. SS18-SSX directs the VEGF signal outcome from endothelial differentiation to spheroid growth, and VEGF and CXC receptor 4 are critical therapeutic targets for SS.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wakamatsu</LastName>
<ForeName>Toru</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; Department of Orthopedics, Graduate School of Medicine, Osaka University, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Naka</LastName>
<ForeName>Norifumi</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sasagawa</LastName>
<ForeName>Satoru</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>Takaaki</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takenaka</LastName>
<ForeName>Satoshi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Araki</LastName>
<ForeName>Nobuhito</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ueda</LastName>
<ForeName>Takafumi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishizawa</LastName>
<ForeName>Yasuko</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yoshikawa</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Itoh</LastName>
<ForeName>Kazuyuki</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C587877">SS18-SSX1 fusion protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000588866">vascular endothelial growth factor receptor-2, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="C469428">bevacizumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>UM20QQM95Y</RegistryNumber>
<NameOfSubstance UI="D007069">Ifosfamide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007069">Ifosfamide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015514">Oncogene Proteins, Fusion</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019718">Receptors, CXCR4</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013584">Sarcoma, Synovial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018874">Spheroids, Cellular</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040301">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CXCR4</Keyword>
<Keyword MajorTopicYN="N">SS18-SSX</Keyword>
<Keyword MajorTopicYN="N">spheroid</Keyword>
<Keyword MajorTopicYN="N">synovial sarcoma</Keyword>
<Keyword MajorTopicYN="N">vascular endothelial growth factor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24975163</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>1212-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12470</ELocationID>
<Abstract>
<AbstractText>The alternative splicing of the extracellular domain of fibroblast growth factor receptor (FGFR)-2 generates the IIIb and IIIc isoforms. Expression of FGFR-2 IIIb correlates with vascular endothelial growth factor-A (VEGF-A) expression and venous invasion of pancreatic ductal adenocarcinoma (PDAC). By contrast, FGFR-2 IIIc expression correlates with faster development of liver metastasis after surgery, and increased proliferation rates and invasion of the cancer. In this study, we analyzed the expression and roles of total FGFR-2 (both isoforms) to determine the effectiveness of FGFR-2-targeting therapy for PDAC. Immunohistochemically, FGFR-2 was highly expressed in 25/48 (52.1%) PDAC cases, and correlated with advanced stage cancer. In FISH analysis, FGFR2 was amplified in 3/7 PDAC cell lines. We stably transfected an FGFR-2 shRNA targeting the IIIb and IIIc isoforms into FGFR2-amplified PDAC cells. The proliferation rates, migration, and invasion of FGFR-2-shRNA-transfected cells were lower than those of control cells in vitro. In response to FGF-2, FGFR-2-shRNA-transfected cells showed decreased phosphorylation of ERK compared with control cells. The FGFR-2-shRNA-transfected cells also expressed lower levels of vascular endothelial growth factor-A than control cells, and formed smaller s.c. tumors in nude mice. These findings suggest that FGFR-2 is a therapeutic target for inhibition in PDAC.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Matsuda</LastName>
<ForeName>Yoko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshimura</LastName>
<ForeName>Hisashi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Suzuki</LastName>
<ForeName>Taeko</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Uchida</LastName>
<ForeName>Eiji</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Naito</LastName>
<ForeName>Zenya</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ishiwata</LastName>
<ForeName>Toshiyuki</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C496353">FGFR2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D051497">Receptor, Fibroblast Growth Factor, Type 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021441">Carcinoma, Pancreatic Ductal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005784">Gene Amplification</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010179">Pancreas</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051497">Receptor, Fibroblast Growth Factor, Type 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FGFR-2 IIIb</Keyword>
<Keyword MajorTopicYN="N">FGFR-2 IIIc</Keyword>
<Keyword MajorTopicYN="N">fibroblast growth factor receptor-2 (FGFR-2)</Keyword>
<Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
<Keyword MajorTopicYN="N">short hairpin RNA</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24981602</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.</ArticleTitle>
<Pagination>
<MedlinePgn>1142-51</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12475</ELocationID>
<Abstract>
<AbstractText>We previously established that COX-2 overexpression promotes breast cancer progression and metastasis. As long-term use of COX-2 inhibitors (COX-2i) can promote thrombo-embolic events, we tested an alternative target, prostaglandin E2 receptor EP4 subtype (EP4), downstream of COX-2. Here we used the highly metastatic syngeneic murine C3L5 breast cancer model to test the role of EP4-expressing macrophages in vascular endothelial growth factor (VEGF)-C/D production, angiogenesis, and lymphangiogenesis in situ, the role of EP4 in stem-like cell (SLC) functions of tumor cells, and therapeutic effects of an EP4 antagonist RQ-15986 (EP4A). C3L5 cells expressed all EP receptors, produced VEGF-C/D, and showed high clonogenic tumorsphere forming ability in vitro, functions inhibited with COX-2i or EP4A. Treating murine macrophage RAW 264.7 cell line with COX-2i celecoxib and EP4A significantly reduced VEGF-A/C/D production in vitro, measured with quantitative PCR and Western blots. Orthotopic implants of C3L5 cells in C3H/HeJ mice showed rapid tumor growth, angiogenesis, lymphangiogenesis (CD31/LYVE-1 and CD31/PROX1 immunostaining), and metastasis to lymph nodes and lungs. Tumors revealed high incidence of EP4-expressing, VEGF-C/D producing macrophages identified with dual immunostaining of F4/80 and EP4 or VEGF-C/D. Celecoxib or EP4A therapy at non-toxic doses abrogated tumor growth, lymphangiogenesis, and metastasis to lymph nodes and lungs. Residual tumors in treated mice revealed markedly reduced VEGF-A/C/D and phosphorylated Akt/ERK proteins, VEGF-C/D positive macrophage infiltration, and proliferative/apoptotic cell ratios. Knocking down COX-2 or EP4 in C3L5 cells or treating cells in vitro with celecoxib or EP4A and treating tumor-bearing mice in vivo with the same drug reduced SLC properties of tumor cells including preferential co-expression of COX-2 and SLC markers ALDH1A, CD44, OCT-3/4, β-catenin, and SOX-2. Thus, EP4 is an excellent therapeutic target to block stem-like properties, angiogenesis, and lymphangiogenesis induced by VEGF-A/C/D secreted by cancer cells and tumor infiltrating macrophages.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Majumder</LastName>
<ForeName>Mousumi</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xin</LastName>
<ForeName>Xiping</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Ling</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Girish</LastName>
<ForeName>Gannareddy V</ForeName>
<Initials>GV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lala</LastName>
<ForeName>Peeyush K</ForeName>
<Initials>PK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C523467">(S)-4-(1-(5-chloro-2-(4-fluorophenyoxy) benzamido)ethyl) benzoic acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467480">vascular endothelial growth factor A, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>169590-42-5</RegistryNumber>
<NameOfSubstance UI="C105934">celecoxib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.-</RegistryNumber>
<NameOfSubstance UI="C077623">Ptgs2 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042583">Lymphangiogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008207">Lymphatic Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008325">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008809">Mice, Inbred C3H</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer stem cells</Keyword>
<Keyword MajorTopicYN="N">RQ-00015986</Keyword>
<Keyword MajorTopicYN="N">cyclooxygenase 2</Keyword>
<Keyword MajorTopicYN="N">macrophages</Keyword>
<Keyword MajorTopicYN="N">prostaglandin E2 receptor EP4 subtype</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24981766</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Expression of platelet-derived growth factor receptor β is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis.</ArticleTitle>
<Pagination>
<MedlinePgn>1116-23</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12476</ELocationID>
<Abstract>
<AbstractText>The lymphatic system plays important roles not only in the physiological processes, such as maintenance of tissue fluid homeostasis, but also in pathological processes including the lymph node metastasis of tumor cells. Therefore, understanding of the molecular mechanisms underlying lymphatic vessel formation is crucial. Previous studies have shown that proliferation and migration of lymphatic endothelial cells (LECs) are activated by multiple types of signals mediated by tyrosine kinase receptors such as vascular endothelial growth factor receptor (VEGFR) 3. Although signals mediated by platelet-derived growth factor receptor β (PDGFRβ) have been implicated in lymphangiogenesis, the mechanisms explaining how PDGFRβ expression is maintained in LECs remain to be fully elucidated. In the present study, we show that PDGFRβ expression in LECs is maintained by Prox1 transcription factor. Knockdown of Prox1 expression in human dermal LECs decreased the expression of PDGFRβ, leading to the lowered migration of human dermal LECs towards PDGF-BB. Furthermore, we found that PDGF signals play important roles in inflammatory lymphangiogenesis in a chronic aseptic peritonitis model. Intraperitoneal administration of imatinib, a potent inhibitor of PDGFRβ, and transduction of PDGFRβ/Fc chimeric protein by an adenoviral system both reduced inflammatory lymphangiogenesis induced by thioglycollate in mice. We also found that the expression of PDGFRβ/Fc reduced tumor lymphangiogenesis in a BxPC3 human pancreatic cancer xenograft model. These findings suggest that PDGFRβ is one of the key mediators of lymphatic vessel formation acting downstream of Prox1.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Miyazaki</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Human Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoshimatsu</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akatsu</LastName>
<ForeName>Yuichi</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mishima</LastName>
<ForeName>Koichi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fukayama</LastName>
<ForeName>Masashi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watabe</LastName>
<ForeName>Tetsuro</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miyazono</LastName>
<ForeName>Kohei</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020574">Proto-Oncogene Proteins c-sis</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C072194">platelet-derived growth factor BB</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C102225">prospero-related homeobox 1 protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>BKJ8M8G5HI</RegistryNumber>
<NameOfSubstance UI="C097613">imatinib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D020797">Receptor, Platelet-Derived Growth Factor beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061307">Human Umbilical Vein Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042583">Lymphangiogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042601">Lymphatic Vessels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020574">Proto-Oncogene Proteins c-sis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020797">Receptor, Platelet-Derived Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Inflammation</Keyword>
<Keyword MajorTopicYN="N">Prox1</Keyword>
<Keyword MajorTopicYN="N">lymphangiogenesis</Keyword>
<Keyword MajorTopicYN="N">platelet-derived growth factor</Keyword>
<Keyword MajorTopicYN="N">tumor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24981848</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface.</ArticleTitle>
<Pagination>
<MedlinePgn>1196-204</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12477</ELocationID>
<Abstract>
<AbstractText>Combretastatins interrupt blood flow of solid tumor vascular networks and lead to necrosis by blocking nutrients. However, tumors recover from tumor blood flow interruption-induced damage and develop viable rims. To investigate why cancer recurs and its prevention, we used a combretastatin derivative, Cderiv (=AC7700), and analyzed changes in tumor-host interface (T-HI) vessels, which were closest to cancer cells in the tumor margin after tumor vessel disruption, and the microenvironment surrounding them. Treatment with Cderiv (10 mg/kg) interrupted tumor blood flow in all regions of LY80 (a variant of Yoshida sarcoma) tumor, but not T-HI vessel blood flow. The same Cderiv dose given 72 h after 5 Gy irradiation stopped T-HI vessel blood flow and prevented cancer recurrence. Treatment in the reverse order, however, did not affect T-HI vessel blood flow. The greatest difference between the two treatments was the occurrence of gradual T-HI edema with the former. Severe T-HI edema compressed T-HI blood vessels, so that circulation stopped. Thus, the distance between a tumor margin and its nearest functioning host vessel became much larger, and the tumor marginal region became a microenvironment that lacked a nutritional supply. Cancer cells in tumor margins received nutrients through two circulation routes: tumor vessels and T-HI vessels. Our starvation methods, which involved treatment with Cderiv 72 h after 5 Gy irradiation, blocked both circulation routes and may have great potential as a clinical strategy to prevent cancer recurrence.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hori</LastName>
<ForeName>Katsuyoshi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Cancer Science, Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akita</LastName>
<ForeName>Hirotoshi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nonaka</LastName>
<ForeName>Hiroi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sumiyoshi</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taki</LastName>
<ForeName>Yasuyuki</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001632">Bibenzyls</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C571791">Cderiv</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001632">Bibenzyls</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059248">Chemoradiotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004487">Edema</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012039">Regional Blood Flow</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012517">Sarcoma, Yoshida</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Combretastatins</Keyword>
<Keyword MajorTopicYN="N">radiotherapy</Keyword>
<Keyword MajorTopicYN="N">tumor blood flow</Keyword>
<Keyword MajorTopicYN="N">tumor vessels</Keyword>
<Keyword MajorTopicYN="N">viable rim</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24988892</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation.</ArticleTitle>
<Pagination>
<MedlinePgn>1220-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12478</ELocationID>
<Abstract>
<AbstractText>Although it is known that ataxia-telangiectasia mutated (ATM) and interleukin 6 (IL-6) contribute to multiple drug resistance (MDR) in tumor chemotherapy, the exact role of ATM activation in MDR resulting from increased IL-6 expression is still unclear. In the present study, we demonstrate that the activation of the ATM-NF-kappaB pathway, resulting from increased IL-6 expression, plays a central role in augmented chemoresistance in lung cancer cell lines. This result was supported by the increased expressions of Bcl-2, Mcl-1, Bcl-xl, and the upregulation of MDR-associated protein ABCG2. The higher level of IL-6 reveals not only higher ATM/NF-kappaB activity but also increased expressions of ABCG2, Bcl-2, Mcl-1 and Bcl-xl. Most importantly, lung cancer cells themselves upregulated IL-6 secretion by activating the p38/NF-kappaB pathway through treatment with cisplatin and camptothecin. Taken together, these findings demonstrate that chemotherapeutic agents increase IL-6 expression, hence activating the ATM/NF-kappaB pathway, augmenting anti-apoptotic protein expression and contributing to MDR. This indicates that both IL-6 and ATM are potential targets for the treatment of chemotherapeutic resistance in lung cancer.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Hong Qiong</ForeName>
<Initials>HQ</Initials>
<AffiliationInfo>
<Affiliation>Department of Immunology, Basic Medicine Science, Medical College, Xiamen University, Xiamen, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Xiao Bo</ForeName>
<Initials>XB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ke</LastName>
<ForeName>Shi Zhong</ForeName>
<Initials>SZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Yi Na</ForeName>
<Initials>YN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yue Hua</ForeName>
<Initials>YH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yi Nan</ForeName>
<Initials>YN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Feng Guang</ForeName>
<Initials>FG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C434003">3-(4-methylphenylsulfonyl)-2-propenenitrile</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C116614">ABCG2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494811">BCL2L1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C579095">MCL1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C093642">SB 203580</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013450">Sulfones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051020">bcl-X Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C576324">ATM protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D064007">Ataxia Telangiectasia Mutated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>XT3Z54Z28A</RegistryNumber>
<NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018528">ATP-Binding Cassette Transporters</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064007">Ataxia Telangiectasia Mutated Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002166">Camptothecin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013450">Sulfones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051020">bcl-X Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Ataxia-telangiectasia mutated</Keyword>
<Keyword MajorTopicYN="N">NF-kappaB</Keyword>
<Keyword MajorTopicYN="N">chemotherapy</Keyword>
<Keyword MajorTopicYN="N">interleukin 6</Keyword>
<Keyword MajorTopicYN="N">multiple drug resistance</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24989082</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.</ArticleTitle>
<Pagination>
<MedlinePgn>1152-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12479</ELocationID>
<Abstract>
<AbstractText>MicroRNA (miRNA) can function as tumor suppressors or oncogenes, and also as potential specific cancer biomarkers; however, there are few published studies on miRNA in synovial sarcomas, and their function remains unclear. We transfected the OncomiR miRNA Precursor Virus Library into synovial sarcoma Fuji cells followed by a colony formation assay to identify miRNAs to confer an aggressive tumorigenicity, and identified miR-17-5p from the large colonies. MiR-17 was found to be induced by a chimeric oncoprotein SS18-SSX specific for synovial sarcoma, and all examined cases of human synovial sarcoma expressed miR-17, even at high levels in several cases. Overexpression of miR-17 in synovial sarcoma cells, Fuji and HS-SYII, increased colony forming ability in addition to cell growth, but not cell motility and invasion. Tumor volume formed in mice in vivo was significantly increased by miR-17 overexpression with a marked increase of MIB-1 index. According to PicTar and Miranda algorithms, which predicted CDKN1A (p21) as a putative target of miR-17, a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA. Indeed, p21 protein level was remarkably decreased by miR-17 overexpression in a p53-independent manner. It is noteworthy that miR-17 succeeded in suppressing doxorubicin-evoked higher expression of p21 and conferred the drug resistance. Meanwhile, introduction of anti-miR-17 in Fuji and HS-SYII cells significantly decreased cell growth, consistent with rescued expression of p21. Taken together, miR-17 promotes the tumor growth of synovial sarcomas by post-transcriptional suppression of p21, which may be amenable to innovative therapeutic targeting in synovial sarcoma.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Minami</LastName>
<ForeName>Yusuke</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kohsaka</LastName>
<ForeName>Shinji</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tsuda</LastName>
<ForeName>Masumi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yachi</LastName>
<ForeName>Kazuhiro</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hatori</LastName>
<ForeName>Nobuaki</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanino</LastName>
<ForeName>Mishie</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kimura</LastName>
<ForeName>Taichi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishihara</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Minami</LastName>
<ForeName>Akio</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iwasaki</LastName>
<ForeName>Norimasa</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>Shinya</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C524941">MIRN17 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C587877">SS18-SSX1 fusion protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C116512">SYT-SSX fusion protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020413">3' Untranslated Regions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015514">Oncogene Proteins, Fusion</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013584">Sarcoma, Synovial</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cyclin-dependent kinase inhibitor p21</Keyword>
<Keyword MajorTopicYN="N">SS18-SSX fusion protein</Keyword>
<Keyword MajorTopicYN="N">drug resistance</Keyword>
<Keyword MajorTopicYN="N">hsa-mir-17 microRNA</Keyword>
<Keyword MajorTopicYN="N">synovial sarcoma</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25040744</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Krüppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1109-15</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12483</ELocationID>
<Abstract>
<AbstractText>We previously reported that hypoxia-induced MDR in gastric cancer (GC) cells is hypoxia-inducible factor-1 (HIF-1)-dependent. However, the exact mechanisms are still unknown. Our previous study revealed that Krüppel-like factor 8 (KLF8), a novel transcription factor, was associated with malignant phenotype in GC cells. KLF8 is overexpressed in clear cell renal carcinoma lacking von Hippel-Lindau protein function, which resulted in HIF-1 stabilization. Given this association, we hypothesized that KLF8 contributed to hypoxia-induced MDR in GC cells. Initial experiments revealed that hypoxia could increase KLF8 and HIF-1α expressions in GC cells, and KLF8 levels in GC drug-resistant cell lines were higher than in parental cell lines. Subsequent experiments showed that in normoxia, exogenous KLF8 could promote the MDR phenotype; however, blocking KLF8 expression could effectively reverse the MDR phenotype induced by hypoxia. Overexpressed KLF8 increased resistance-associated gene MDR1 mRNA levels, Bcl-2 and P-gp protein levels, and decreased Bax and caspase-3 protein levels in GC cells, and knockout KLF8 reversed these effects. Dual luciferase reporter and ChIP assays showed that KLF8 could promote MDR1 transcriptional activity by combining with KLF8 binding sites located in the upstream of MDR1 transcriptional start site. These results suggest that KLF8 is involved in hypoxia-induced MDR through inhibiting apoptosis and increasing the drug release rate by directly regulating MDR1 transcription.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China; Department of Tuberculosis Control and Prevention, Xi'an Center for Disease Control and Prevention, Xi'an, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Xiao</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Rougang</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Changhao</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yafang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wei</LastName>
<ForeName>Yanling</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hongbo</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Lili</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C507402">KLF8 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020168">P-Glycoprotein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018435">P-Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015687">Cell Hypoxia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018432">Drug Resistance, Multiple</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020168">P-Glycoprotein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018435">P-Glycoproteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Gastric cancer cells</Keyword>
<Keyword MajorTopicYN="N">Krüppel-like factor 8</Keyword>
<Keyword MajorTopicYN="N">hypoxia</Keyword>
<Keyword MajorTopicYN="N">multidrug resistance</Keyword>
<Keyword MajorTopicYN="N">normoxia</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25060325</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1349-7006</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Cancer science</Title>
<ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis.</ArticleTitle>
<Pagination>
<MedlinePgn>1100-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12487</ELocationID>
<Abstract>
<AbstractText>Although numerous studies have shown the significance of cancer-specific aerobic glycolysis, how glycolysis contributes to tumor invasion, a critical phenomenon in metastasis, remains unclear. With regard to colorectal cancer (CRC), we studied two critical gate enzymes, hexokinase 2 (HK2), which is involved in glycolysis, and phosphorylated pyruvate dehydrogenase-E1α (p-PDH), which is involved in oxidative phosphorylation (OxPhos). Immunohistochemical analyses using anti-HK2 and p-PDH antibodies were performed on surgically resected CRC samples (n = 104), and the expression in invasive front lesions of tumors was assessed. Positive HK2 expression correlated with extensive tumor diameter (P = 0.0460), advanced tumor depth (P = 0.0395), and presence of lymph node metastasis (P = 0.0409). Expression of p-PDH tended to be higher in right-sided CRCs than in left-sided CRCs (P = 0.0883). In survival analysis, the combined evaluation of positive HK2 and negative p-PDH was associated with reduced recurrence-free survival (RFS) (P = 0.0169 in all stages and P = 0.0238 in Stage II and III patients, respectively). This evaluation could predict RFS more precisely than the independent evaluation. The present study indicated that high HK2 expression combined with low p-PDH expression in the invasive front lesions of CRC tumors is predictive of tumor aggressiveness and survival of CRC cases.</AbstractText>
<CopyrightInformation>© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hamabe</LastName>
<ForeName>Atsushi</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Hirofumi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Konno</LastName>
<ForeName>Masamitsu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Uemura</LastName>
<ForeName>Mamoru</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishimura</LastName>
<ForeName>Junichi</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hata</LastName>
<ForeName>Taishi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takemasa</LastName>
<ForeName>Ichiro</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mizushima</LastName>
<ForeName>Tsunekazu</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishida</LastName>
<ForeName>Naohiro</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kawamoto</LastName>
<ForeName>Koichi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koseki</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doki</LastName>
<ForeName>Yuichiro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mori</LastName>
<ForeName>Masaki</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ishii</LastName>
<ForeName>Hideshi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cancer Sci</MedlineTA>
<NlmUniqueID>101168776</NlmUniqueID>
<ISSNLinking>1347-9032</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.2.4.1</RegistryNumber>
<NameOfSubstance UI="D030481">Pyruvate Dehydrogenase (Lipoamide)</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.2.4.1</RegistryNumber>
<NameOfSubstance UI="C065640">pyruvate dehydrogenase E1alpha subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D006593">Hexokinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006593">Hexokinase</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007413">Intestinal Mucosa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015999">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010750">Phosphoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011499">Protein Processing, Post-Translational</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030481">Pyruvate Dehydrogenase (Lipoamide)</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
<Keyword MajorTopicYN="N">hexokinase</Keyword>
<Keyword MajorTopicYN="N">invasion</Keyword>
<Keyword MajorTopicYN="N">metastasis</Keyword>
<Keyword MajorTopicYN="N">pyruvate dehydrogenase</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24705984</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1420-9071</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>71</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Cellular and molecular life sciences : CMLS</Title>
<ISOAbbreviation>Cell. Mol. Life Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Critical role of extracellular vesicles in modulating the cellular effects of cytokines.</ArticleTitle>
<Pagination>
<MedlinePgn>4055-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-014-1618-z</ELocationID>
<Abstract>
<AbstractText>Under physiological and pathological conditions, extracellular vesicles (EVs) are present in the extracellular compartment simultaneously with soluble mediators. We hypothesized that cytokine effects may be modulated by EVs, the recently recognized conveyors of intercellular messages. In order to test this hypothesis, human monocyte cells were incubated with CCRF acute lymphoblastic leukemia cell line-derived EVs with or without the addition of recombinant human TNF, and global gene expression changes were analyzed. EVs alone regulated the expression of numerous genes related to inflammation and signaling. In combination, the effects of EVs and TNF were additive, antagonistic, or independent. The differential effects of EVs and TNF or their simultaneous presence were also validated by Taqman assays and ELISA, and by testing different populations of purified EVs. In the case of the paramount chemokine IL-8, we were able to demonstrate a synergistic upregulation by purified EVs and TNF. Our data suggest that neglecting the modulating role of EVs on the effects of soluble mediators may skew experimental results. On the other hand, considering the combined effects of cytokines and EVs may prove therapeutically useful by targeting both compartments at the same time. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Szabó</LastName>
<ForeName>Géza Tamás</ForeName>
<Initials>GT</Initials>
<AffiliationInfo>
<Affiliation>Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tarr</LastName>
<ForeName>Bettina</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pálóczi</LastName>
<ForeName>Krisztina</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Éder</LastName>
<ForeName>Katalin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lajkó</LastName>
<ForeName>Eszter</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kittel</LastName>
<ForeName>Ágnes</ForeName>
<Initials>Á</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tóth</LastName>
<ForeName>Sára</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>György</LastName>
<ForeName>Bence</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pásztói</LastName>
<ForeName>Mária</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Németh</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Osteikoetxea</LastName>
<ForeName>Xabier</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pállinger</LastName>
<ForeName>Éva</ForeName>
<Initials>É</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Falus</LastName>
<ForeName>András</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Szabó-Taylor</LastName>
<ForeName>Katalin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buzás</LastName>
<ForeName>Edit Irén</ForeName>
<Initials>EI</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Cell Mol Life Sci</MedlineTA>
<NlmUniqueID>9705402</NlmUniqueID>
<ISSNLinking>1420-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018932">Chemokine CCL2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016000">Cluster Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055354">Exosomes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016209">Interleukin-8</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25187431</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-0103</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>351</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pharmacology and experimental therapeutics</Title>
<ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>352-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.114.215418</ELocationID>
<Abstract>
<AbstractText>Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may be a mechanism(s) other than the EGFR pathway that mediates the tumoricidal effects. In the current study, we tested the efficacy of TD-19, a novel compound chemically modified from erlotinib, which has more potent apoptotic effects than erlotinib in EGFR wild-type NSCLC cell lines. TD-19 induced significant cell death and apoptosis in H358, H441, H460, and A549 cells, as evidenced by increased caspase-3 activity and cleavage of procaspase-9 and poly (ADP-ribose) polymerase. The apoptotic effect of TD-19 in H460 cells, which were resistant to erlotinib, was associated with downregulation of cancerous inhibitor of protein phosphatase 2A (CIP2A), increased protein phosphatase 2A (PP2A) activity, and decreased AKT phosphorylation, but minimal effects on EGFR phosphorylation. Overexpression of CIP2A partially protected the H460 cells from TD-19-induced apoptosis. Okadaic acid, a known PP2A inhibitor, significantly reduced TD-19-induced apoptosis, while forskolin, which increased PP2A activity, increased the apoptotic effect of TD-19. TD-19 inhibited the growth of H460 xenograft tumors by ∼80%. We conclude that TD-19 exerted tumoricidal effects on NSCLC cells. TD-19 provides proof that the CIP2A pathway may be a novel target for the treatment of EGFR wild-type NSCLC. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chao</LastName>
<ForeName>Ting-Ting</ForeName>
<Initials>TT</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Cheng-Yi</ForeName>
<Initials>CY</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lai</LastName>
<ForeName>Chih-Cheng</ForeName>
<Initials>CC</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yen-Lin</ForeName>
<Initials>YL</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tsai</LastName>
<ForeName>Yi-Ting</ForeName>
<Initials>YT</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Pao-Tzu</ForeName>
<Initials>PT</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Hen-I</ForeName>
<Initials>HI</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Yuh-Chin T</ForeName>
<Initials>YC</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shiau</LastName>
<ForeName>Chung-Wai</ForeName>
<Initials>CW</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan cwshiau@ym.edu.tw kfchen1970@ntu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Chong-Jen</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan cwshiau@ym.edu.tw kfchen1970@ntu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Kuen-Feng</ForeName>
<Initials>KF</Initials>
<AffiliationInfo>
<Affiliation>Medical Research Center (T.-T.C., C.-Y.W., Y.-T.T., P.-T.C.), Department of Internal Medicine (C.-Y.W., H.-I.L.), and Department of Pathology (Y.-L.C.), Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (C.-Y.W.); Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan (C.-C.L.); Department of Medicine, Duke University Medical Center, Durham, North Carolina (Y.-C.T.H.); Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan (C.-W.S.); and Department of Internal Medicine (C.-J.Y.) and Department of Medical Research and National Center of Excellence for Clinical Trial and Research (K.-F.C.), National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan cwshiau@ym.edu.tw kfchen1970@ntu.edu.tw.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pharmacol Exp Ther</MedlineTA>
<NlmUniqueID>0376362</NlmUniqueID>
<ISSNLinking>0022-3565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C500266">KIAA1524 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.16</RegistryNumber>
<NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J4T82NDH7E</RegistryNumber>
<NameOfSubstance UI="C400278">erlotinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001324">Autoantigens</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053453">Caspase 9</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011065">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054648">Protein Phosphatase 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24927871</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0945</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>97</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental and molecular pathology</Title>
<ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Dendritic cells transduced with CPEB4 induced antitumor immune response.</ArticleTitle>
<Pagination>
<MedlinePgn>273-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexmp.2014.06.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4800(14)00085-9</ELocationID>
<Abstract>
<AbstractText>Much evidence leads to the exploration of immunologic approaches for eliminating tumor cells. Cytoplasmic polyadenylation element binding protein 4 (CPEB4) is considered to be a novel therapeutical target for glioblastoma. In this study, we transduced DCs with CPEB4 to explore the immune response in vivo. We found that DCs transduced with recombinant adenovirus encoding CPEB4 could induce specific cytotoxic T lymphocytes (CTLs) to lyse glioma cells and augment the number of IFN-γ secreting T-cells in mice. In addition, the modified DCs could effectively protect mice from lethal challenges against glioma cells, reduce tumor growth and increase the mice life span. These results suggest that the DC transduced with CPEB4 may induce anti-tumor immunity against glioma cells and might be used as an efficient tumor vaccine in clinical applications. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Peng</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Orthopaedics, 309th Hospital of PLA, Beijing 100091, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nan</LastName>
<ForeName>Zhang</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Yongping</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The 476th Hospital of PLA, Fuzhou, Fujian 350025, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Hanchao</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The 476th Hospital of PLA, Fuzhou, Fujian 350025, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Chuangan</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The 476th Hospital of PLA, Fuzhou, Fujian 350025, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The 476th Hospital of PLA, Fuzhou, Fujian 350025, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Bangqing</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurosurgery, The 476th Hospital of PLA, Fuzhou, Fujian 350025, China. Electronic address: ytt83812280@sina.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Mol Pathol</MedlineTA>
<NlmUniqueID>0370711</NlmUniqueID>
<ISSNLinking>0014-4800</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C477604">Cpeb4 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000256">Adenoviridae</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019496">Cancer Vaccines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016601">RNA-Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Antitumor</Keyword>
<Keyword MajorTopicYN="N">CPEB4</Keyword>
<Keyword MajorTopicYN="N">Dendritic cells</Keyword>
<Keyword MajorTopicYN="N">Immune response</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25062904</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-0945</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>97</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental and molecular pathology</Title>
<ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Sineoculis homeobox homolog 1 protein is associated with breast cancer progression and survival outcome.</ArticleTitle>
<Pagination>
<MedlinePgn>247-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexmp.2014.07.005</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-4800(14)00102-6</ELocationID>
<Abstract>
<AbstractText>Sineoculis homeobox homolog 1 (SIX1) is one of the transcription factors that act as master regulators of development and is frequently dysregulated in cancer. This study explores the roles of SIX1 in tumor progression and as a prognostic determinant of breast cancer. Breast cancer specimens from 262 patients were selected for analysis of SIX1 protein by immunohistochemistry (IHC). The localization of SIX1 protein was detected in MDA-MB468 breast cancer cells using immunofluorescence (IF) staining. The survival rates were calculated by the Kaplan-Meier method, and the relationship between prognostic factors and patient survival was also analyzed by the Cox proportional hazard models. SIX1 protein mainly showed cytoplasmic/perinuclear staining pattern in breast cancer using IHC in paraffin embedded breast cancer tissues and IF in MDA-MB468 cancer cells. The strongly positive rate of SIX1 protein was 61.8% (162/262) in breast cancer and 23.1% (12/52) in ductal carcinoma in situ (DCIS), which was significantly higher than adjacent normal breast tissues (6.7%, 3/45). SIX1 overexpression was positively correlated with clinical stage, lymph node metastasis, Her2 expression status, and disease-free survival (DFS) and 5-year overall survival (OS) rates of patients with breast cancer. Moreover, patients with late stage breast cancer and high SIX1 expression had poorer survival rates than those with low SIX1 expression. Further analysis using a Cox proportional hazard regression model revealed that high SIX1 expression emerged as a significant independent hazard factor for the DFS and OS rates of patients with breast cancers along with Her2 status and clinical stage. SIX1 may potentially be used as an independent biomarker for prognostic evaluation of breast cancer. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jin</LastName>
<ForeName>Haidan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology &amp; Cancer Research Center, Yanbian University Medical College, Yanji 133002, China. Electronic address: haidan0423@sohu.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Minghua</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology &amp; Cancer Research Center, Yanbian University Medical College, Yanji 133002, China. Electronic address: mhcui@ybu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kong</LastName>
<ForeName>Jienan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology &amp; Cancer Research Center, Yanbian University Medical College, Yanji 133002, China. Electronic address: kongjienan@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Xuelian</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology &amp; Cancer Research Center, Yanbian University Medical College, Yanji 133002, China. Electronic address: 592362250@qq.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Zhenhua</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology &amp; Cancer Research Center, Yanbian University Medical College, Yanji 133002, China. Electronic address: zhlin720@ybu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Qiang</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, The Second Affiliated Hospital, Anhui Medical University, Hefei 230601, China. Electronic address: aydjohn@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Shuangping</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology &amp; Cancer Research Center, Yanbian University Medical College, Yanji 133002, China. Electronic address: liushp@ybu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Exp Mol Pathol</MedlineTA>
<NlmUniqueID>0370711</NlmUniqueID>
<ISSNLinking>0014-4800</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099236">SIX1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044584">Carcinoma, Ductal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Biomarker</Keyword>
<Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">Sineoculis homeobox homolog 1</Keyword>
<Keyword MajorTopicYN="N">Survival analysis</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25157435</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC.</ArticleTitle>
<Pagination>
<MedlinePgn>3703-12</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.08.016</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00618-8</ELocationID>
<Abstract>
<AbstractText>The involvement of miR-204 in lung cancer development is unclear. In our study, we analyzed the expression of miR-204 in tumor- and adjacent-tissue samples from 141 patients with non-small cell lung cancer (NSCLC). MiR-204 expression was decreased in tumor samples compared with non-cancerous tissue-derived controls. Moreover, miR-204 expression negatively correlated with homeobox protein SIX1 expression, tumor size and metastasis. MiR-204 silencing in miR-204-positive NSCLC cell lines promoted cell invasion and proliferation. Concomitantly, MiR-204 overexpression resulted in reduced cell proliferation and invasion, upregulated E-cadherin and downregulated N-cadherin and Vimentin expression. SIX1 was identified as a potential target of miR-204, and SIX1 silencing partially compromised the invasive and proliferative capacity of miR-204-deficient cells. Thus, miR-204 may be involved in the NSCLC development. </AbstractText>
<CopyrightInformation>Copyright © 2014. Published by Elsevier B.V.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xia</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Yi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China; Department of Thoracic and Cardiovascular Surgery, Huai'an Hospital Affiliated of Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an 223002, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>Teng</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Chunfeng</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Zhicheng</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Zhi</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>Xiaotong</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yijiang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China. Electronic address: YJChen@NJMU.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C549404">MIRN204 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099236">SIX1 protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020413">3' Untranslated Regions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Epithelial-to-mesenchymal transition</Keyword>
<Keyword MajorTopicYN="N">Invasion</Keyword>
<Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
<Keyword MajorTopicYN="N">Proliferation</Keyword>
<Keyword MajorTopicYN="N">SIX1</Keyword>
<Keyword MajorTopicYN="N">miR-204</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25171860</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>MicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>3732-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.08.021</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00623-1</ELocationID>
<Abstract>
<AbstractText>In the present study, we investigated the roles and molecular mechanisms of miR-320a in human nasopharyngeal carcinoma (NPC). miR-320a expression was strongly reduced in NPC tissues and cell lines. Overexpression of miR-320a significantly suppressed NPC cell growth, migration, invasion and tumor growth in a xenograft mouse model. A luciferase reporter assay revealed that miR-320a could directly bind to the 3' UTR of BMI-1. Overexpression of BMI-1 rescued miR-320a-mediated biological function. BMI-1 expression was found to be up-regulated and inversely correlated with miR-320a expression in NPC. Collectively, our data indicate that miR-320a plays a tumor suppressor role in the development and progression of NPC and may be a novel therapeutic target against NPC. </AbstractText>
<CopyrightInformation>Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>Xiaoming</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of E.N.T., The 88th Hospital of PLA, Tai'an, Shandong 271000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jianqiang</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of E.N.T., The 88th Hospital of PLA, Tai'an, Shandong 271000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Changbo</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of E.N.T., The 88th Hospital of PLA, Tai'an, Shandong 271000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lv</LastName>
<ForeName>Chunlei</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of E.N.T., The 88th Hospital of PLA, Tai'an, Shandong 271000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tian</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Orthopedics, The 88th Hospital of PLA, Tai'an, Shandong 271000, China. Electronic address: tianminpla88@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C069077">BMI1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C572916">MIRN320 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D063150">Polycomb Repressive Complex 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020413">3' Untranslated Regions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002277">Carcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009303">Nasopharyngeal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063150">Polycomb Repressive Complex 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BMI-1</Keyword>
<Keyword MajorTopicYN="N">Invasion</Keyword>
<Keyword MajorTopicYN="N">Nasopharyngeal carcinoma</Keyword>
<Keyword MajorTopicYN="N">Proliferation</Keyword>
<Keyword MajorTopicYN="N">miR-320a</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25171863</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>588</Volume>
<Issue>20</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6.</ArticleTitle>
<Pagination>
<MedlinePgn>3744-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2014.08.023</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0014-5793(14)00625-5</ELocationID>
<Abstract>
<AbstractText>Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is an important regulator of cell adhesion, invasion, and metastasis. The aim of this study was to evaluate the functional roles of CEACAM6 in lung adenocarcinoma and to identify miRNAs that inhibit the growth, migration, and invasion of lung adenocarcinoma cells by targeting CEACAM6. CEACAM6 expression is associated with poor prognosis of patients with lung adenocarcinoma, and CEACAM6 has important functional roles in controlling the growth, migration, and invasion of lung adenocarcinoma cells in vitro and in vivo. Furthermore, miR-29a can suppress the growth, migration, and invasion of lung adenocarcinoma cells by targeting CEACAM6. Therefore, miR-29a/CEACAM6 axis represents a potential therapeutic target for treatment of lung adenocarcinoma. </AbstractText>
<CopyrightInformation>Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Hye Sook</ForeName>
<Initials>HS</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Son</LastName>
<ForeName>Seung-Myoung</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, Chungbuk National University, Cheongju, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yun</LastName>
<ForeName>Jieun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Bioevaluation Center, Korea Research Institute of Bioscience and Biotechnology, Cheongwon, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jo</LastName>
<ForeName>Yeong Nang</ForeName>
<Initials>YN</Initials>
<AffiliationInfo>
<Affiliation>Bioevaluation Center, Korea Research Institute of Bioscience and Biotechnology, Cheongwon, South Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Ok-Jun</ForeName>
<Initials>OJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, Chungbuk National University, Cheongju, South Korea. Electronic address: ok5218@hanmail.net.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C504117">CEACAM6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C532045">MIRN29 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058851">GPI-Linked Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009374">Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Carcinoembryonic antigen-related cell adhesion molecule 6</Keyword>
<Keyword MajorTopicYN="N">Lung adenocarcinoma</Keyword>
<Keyword MajorTopicYN="N">MicroRNA 29a</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25258390</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>106</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/dju283</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">dju283</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tamoxifen is metabolically activated via a CYP2D6 enzyme system to the more potent hydroxylated derivatives 4-hydroxytamoxifen and endoxifen. This study addresses the pharmacological importance of endoxifen by simulating clinical scenarios in vitro.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Clinical levels of tamoxifen metabolites in postmenopausal breast cancer patients previously genotyped for CYP2D6 were used in vitro along with clinical estrogen levels (estrone and estradiol) in postmenopausal patients determined in previous studies. The biological effects on cell growth were evaluated in a panel of estrogen receptor-positive breast cancer cell lines via cell proliferation assays and real-time polymerase chain reaction (PCR). Data were analyzed with one- and two-way analysis of variance and Student's t test. All statistical tests were two-sided.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Postmenopausal levels of estrogen-induced proliferation of all test breast cancer cell lines (mean fold induction ± SD vs vehicle control: MCF-7 = 11 ± 1.74, P &lt; .001; T47D = 7.52 ± 0.72, P &lt; .001; BT474 = 1.75 ± 0.23, P &lt; .001; ZR-75-1 = 5.5 ± 1.95, P = .001. Tamoxifen and primary metabolites completely inhibited cell growth regardless of the CYP2D6 genotype in all cell lines (mean fold induction ± SD vs vehicle control: MCF-7 = 1.57 ± 0.38, P = .54; T47D = 1.17 ± 0.23, P = .79; BT474 = 0.96 ± 0.2, P = .98; ZR-75-1 = 0.86 ± 0.67, P = .99). Interestingly, tamoxifen and its primary metabolites were not able to fully inhibit the estrogen-stimulated expression of estrogen-responsive genes in MCF-7 cells (P &lt; .05 for all genes), but the addition of endoxifen was able to produce additional antiestrogenic effect on these genes.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results indicate that tamoxifen and other metabolites, excluding endoxifen, completely inhibit estrogen-stimulated growth in all cell lines, but additional antiestrogenic action from endoxifen is necessary for complete blockade of estrogen-stimulated genes. Endoxifen is of supportive importance for the therapeutic effect of tamoxifen in a postmenopausal setting.</AbstractText>
<CopyrightInformation>© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Maximov</LastName>
<ForeName>Philipp Y</ForeName>
<Initials>PY</Initials>
<AffiliationInfo>
<Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (PYM, REM, DJF, PB, VRK, CJ); Institute of Chemistry, Romanian Academy, Timisoara, Romania (RFC).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McDaniel</LastName>
<ForeName>Russell E</ForeName>
<Initials>RE</Initials>
<AffiliationInfo>
<Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (PYM, REM, DJF, PB, VRK, CJ); Institute of Chemistry, Romanian Academy, Timisoara, Romania (RFC).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fernandes</LastName>
<ForeName>Daphne J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (PYM, REM, DJF, PB, VRK, CJ); Institute of Chemistry, Romanian Academy, Timisoara, Romania (RFC).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bhatta</LastName>
<ForeName>Puspanjali</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (PYM, REM, DJF, PB, VRK, CJ); Institute of Chemistry, Romanian Academy, Timisoara, Romania (RFC).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Korostyshevskiy</LastName>
<ForeName>Valeriy R</ForeName>
<Initials>VR</Initials>
<AffiliationInfo>
<Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (PYM, REM, DJF, PB, VRK, CJ); Institute of Chemistry, Romanian Academy, Timisoara, Romania (RFC).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Curpan</LastName>
<ForeName>Ramona F</ForeName>
<Initials>RF</Initials>
<AffiliationInfo>
<Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (PYM, REM, DJF, PB, VRK, CJ); Institute of Chemistry, Romanian Academy, Timisoara, Romania (RFC).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jordan</LastName>
<ForeName>V Craig</ForeName>
<Initials>VC</Initials>
<AffiliationInfo>
<Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (PYM, REM, DJF, PB, VRK, CJ); Institute of Chemistry, Romanian Academy, Timisoara, Romania (RFC). vcj2@georgetown.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA051008</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020847">Estrogen Receptor Modulators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>094ZI81Y45</RegistryNumber>
<NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>110025-28-0</RegistryNumber>
<NameOfSubstance UI="C055492">4-hydroxy-N-desmethyltamoxifen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2DI9HA706A</RegistryNumber>
<NameOfSubstance UI="D004970">Estrone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4TI98Z838E</RegistryNumber>
<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="D019389">Cytochrome P-450 CYP2D6</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018931">Antineoplastic Agents, Hormonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019389">Cytochrome P-450 CYP2D6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004958">Estradiol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020847">Estrogen Receptor Modulators</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004970">Estrone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017698">Postmenopause</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012107">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013629">Tamoxifen</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272505</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>14</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Comparative study of Coptidis Rhizoma and Aconiti Kusnezoffii Radix on cell differentiation in lewis lung cancer].</ArticleTitle>
<Pagination>
<MedlinePgn>2732-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Coptidis Rhizoma and Aconiti Kusnezoffii Radix represent hot Chinese medicine and cold Chinese medicine respectively. The purpose of this study is to observe the differentiation effect of Coptidis Rhizoma and Aconiti Kusnezoffii Radix on lewis lung cancer and compare effect of hot Chinese medicine and cold Chinese medicine on tumor progression. In this study, the rat serum containing Coptidis Rhizoma or Aconiti Kusnezoffii Radix was prepared to treat lewis lung cancer cells in vitro, and effects of the serum containing Coptidis Rhizoma or Aconiti Kusnezoffii Radix on cell differentiation, proliferation, adhesion, succinic dehydrogenase (SDH) activity and gap-junction intercellular communication (GJIC) were investigated. In vivo, the subcutaneous implant model and pulmonary metastasis model of lewis lung cancer were established. Tumor bearing mice were taken water decoction of coptis chinensis or aconite by intragastric administration bid for four weeks, and the influences of coptis chinensis and aconite on tumor progression were evaluated by body temperature, blood oxygen saturation, red cell ATPase, blood rheology, intratumor hypoxia, capillary permeability and GJIC. The results showed that the serum containing aconite could induce cell differentiation, inhibit cell proliferation and migration, promote SDH activity and GJIC in lewis lung cancer cells. The serum containing Coptidis Rhizoma increased cell adhesion and decreased SDH activity and GJIC without cell differentiation although it also suppressed cell proliferation. Aconiti Kusnezoffii Radix water decoction could keep body temperature, blood oxygen saturation, red cell ATPase and blood rheology, and improve intratumor hypoxia, capillary permeability and GJIC in tumor bearing mice, which led to slower tumor growth and less metastasis. Coptidis Rhizoma water decoction decreased body temperature, blood oxygen saturation, red cell ATPase, blood rheology and GJIC, and promoted intratumor hypoxia and capillary permeability, which resulted to more tumor metastasis although it also prevented tumor growth. These results suggested that the hot Chinese medicine could induce tumor cell differentiation and prevent tumor poison invagination, which is better for tumor treatment than cold Chinese medicine.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Bei</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hou</LastName>
<ForeName>Xi-Dong</ForeName>
<Initials>XD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>Xiao-Xiao</ForeName>
<Initials>XX</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Gang-Gang</ForeName>
<Initials>GG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Lin-Xin</ForeName>
<Initials>LX</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Pei</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Du</LastName>
<ForeName>Gang-Jun</ForeName>
<Initials>GJ</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D031841">Aconitum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018827">Carcinoma, Lewis Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D030024">Curcuma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272506</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>14</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Proteomics research of bufalin-induced apoptosis in osteosarcoma cell lines].</ArticleTitle>
<Pagination>
<MedlinePgn>2739-43</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the apoptosis inducing effects of bufalin on various human osteosarcoma cells and the concerning molecular mechanisms.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">MTT assay was used to detect the growth inhibition rates of osteosarcoma cells U-20S, U-20S/MTX300, SaOS-2, IOR/OS9 treated with bufalin in different concentrations and times. The apoptosis of cells was observed flow cytometry 48 h following bufalin treatment. The proteomic techniques were used to separate and compare the treated and control groups 48 h after bufalin-incubation. Then, the proteomic results were validated by western blot.</AbstractText>
<AbstractText Label="RESULT" NlmCategory="RESULTS">Bufalin inhibited the growth of human osteosarcoma cells U20S, U20S/MTX300 (methotrexate resistant cells), SAOS2, IOR/OS9 in a dose- and time-dependent manner. The 72 h IC50 were (37.43 +/- 4.1), (32.24 +/- 5.3) nmol x L(-1) in U20S,U20S/MTX300 cells,respectivly. Flow cytometry showed that the apoptosis cells were increased following bufalin treatment. The protein expression profile showed 24 differentiated expression proteins. Among these proteins, the level of an anti-apoptotic protein, heat shock protein 27 (Hsp27) decreased significantly and the result was then validated by western blot. Ectopic expression of Hsp27 could reduce the bufalin-induced apoptosis remarkably in U20S and U20S/MTX300 cells.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Bufalin could inhibit the cell growth and induce apoptosis on human osteosarcoma cells. The effect of bufalin may be related to the joint intervention with multiple protein targets. Among them, downregulation of Hsp27 plays a critical role in the bufalin-induced apoptosis in human osteosarcoma cells.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Xian-Biao</ForeName>
<Initials>XB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wen</LastName>
<ForeName>Li-Li</ForeName>
<Initials>LL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Jun-Qiang</ForeName>
<Initials>JQ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liao</LastName>
<ForeName>Hong-Yi</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zou</LastName>
<ForeName>Chang-Ye</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Gang</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Jing-Nan</ForeName>
<Initials>JN</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002018">Bufanolides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>465-21-4</RegistryNumber>
<NameOfSubstance UI="C022777">bufalin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002018">Bufanolides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012516">Osteosarcoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D040901">Proteomics</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25107642</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.</ArticleTitle>
<Pagination>
<MedlinePgn>68-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.038</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00417-0</ELocationID>
<Abstract>
<AbstractText>Medulloblastoma (MB) expresses Src kinase, while aurora kinase A overexpression correlates with poor survival. We thus investigated novel combination treatment with dasatinib and AT9283, inhibitors of Src and aurora kinase, respectively, on MB growth in vitro and in vivo. Treatment with each drug significantly reduced cell viability and combined treatment markedly potentiated this response. AT9283 induced p53 expression, autophagy, and G2/M cell-cycle arrest, while combined treatment induced S phase arrest. Dasatinib treatment caused tumor regression in vivo. Activated Src was detected in 44% MB analyzed. We conclude that further evaluation of this combination therapy for MB is highly warranted. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Petersen</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, 1760 Haygood Drive, HSRB E-384, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jingbo</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, 1760 Haygood Drive, HSRB E-384, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Liangping</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, 1760 Haygood Drive, HSRB E-384, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hongying</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, 1760 Haygood Drive, HSRB E-384, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schneiderjan</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Yoon-Jae</ForeName>
<Initials>YJ</Initials>
<AffiliationInfo>
<Affiliation>Departments of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>MacDonald</LastName>
<ForeName>Tobey J</ForeName>
<Initials>TJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, 1760 Haygood Drive, HSRB E-384, Atlanta, GA 30322, USA. Electronic address: tobey.macdonald@emory.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 CA111835</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA111835</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C535237">1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8W8T17847W</RegistryNumber>
<NameOfSubstance UI="D014508">Urea</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D064096">Aurora Kinase A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>RBZ1571X5H</RegistryNumber>
<NameOfSubstance UI="C488369">dasatinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064096">Aurora Kinase A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001562">Benzimidazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016195">G2 Phase</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008527">Medulloblastoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013844">Thiazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014508">Urea</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS619532 [Available on 11/01/15]</OtherID>
<OtherID Source="NLM">PMC4179499 [Available on 11/01/15]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Aurora kinase</Keyword>
<Keyword MajorTopicYN="N">Dasatinib</Keyword>
<Keyword MajorTopicYN="N">Medulloblastoma</Keyword>
<Keyword MajorTopicYN="N">Survival</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25107643</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett's oesophagus.</ArticleTitle>
<Pagination>
<MedlinePgn>122-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.035</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00414-5</ELocationID>
<Abstract>
<AbstractText>Contemporary clinical management of Barrett's oesophagus has highlighted the lack of accurate predictive markers of disease progression to oesophageal cancer. This study aims to examine alterations in mitochondrial energy metabolism profiles across the entire disease progression sequence in Barrett's oesophagus. An in-vitro model was used to screen 84 genes associated with mitochondrial energy metabolism. Three energy metabolism genes (ATP12A, COX4I2, COX8C) were significantly altered across the in-vitro Barrett's disease sequence. In-vivo validations across the Barrett's sequence demonstrated differential expression of these genes. Tissue microarrays demonstrated significant alterations in both epithelial and stromal oxidative phosphorylation (ATP5B and Hsp60) and glycolytic (PKM2 and GAPDH) protein markers across the in-vivo Barrett's sequence. Levels of ATP5B in sequential follow up surveillance biopsy material segregated Barrett's non progressors and progressors to HGD and cancer. Utilising the Seahorse XF24 flux analyser, in-vitro Barrett's and adenocarcinoma cells exhibited altered levels of various oxidative parameters. We show for the first time that mitochondrial energy metabolism is differentially altered across the metaplasia-dysplasia-adenocarcinoma sequence and that oxidative phosphorylation profiles have predictive value in segregating Barrett's non progressors and progressors to adenocarcinoma. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Phelan</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>MacCarthy</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical Medicine, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Feighery</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Farrell</LastName>
<ForeName>N J</ForeName>
<Initials>NJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lynam-Lennon</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Doyle</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Toole</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ravi</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reynolds</LastName>
<ForeName>J V</ForeName>
<Initials>JV</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>O'Sullivan</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland. Electronic address: osullij4@tcd.ie.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 1.9.3.1</RegistryNumber>
<NameOfSubstance UI="C539675">COX4I2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.9.3.1</RegistryNumber>
<NameOfSubstance UI="C477826">COX8C protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.9.3.1</RegistryNumber>
<NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.3.10</RegistryNumber>
<NameOfSubstance UI="C088641">ATP12A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.3.10</RegistryNumber>
<NameOfSubstance UI="D017506">H(+)-K(+)-Exchanging ATPase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>S88TT14065</RegistryNumber>
<NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001471">Barrett Esophagus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003576">Electron Transport Complex IV</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004734">Energy Metabolism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006019">Glycolysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017506">H(+)-K(+)-Exchanging ATPase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008679">Metaplasia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010100">Oxygen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Barrett's metaplasia</Keyword>
<Keyword MajorTopicYN="N">Glycolysis</Keyword>
<Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword>
<Keyword MajorTopicYN="N">Mitochondrial energy metabolism</Keyword>
<Keyword MajorTopicYN="N">Oesophageal cancer</Keyword>
<Keyword MajorTopicYN="N">Oxidative phosphorylation</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25107644</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>N6-substituted adenosine analogues, a novel class of JAK2 inhibitors, potently block STAT3 signaling in human cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>43-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.043</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00422-4</ELocationID>
<Abstract>
<AbstractText>The JAK2/STAT3 signaling pathway plays a critical role in oncogenesis and malignancy, which makes it a promising anticancer target. We report four N(6)-substituted adenosine analogues (AAs) as potential JAK2/STAT3 inhibitors identified through a STAT3-based high-throughput drug screening system. These AAs exhibited selective anti-cancer activity on human cancer cells and xenograft tumors with constitutively activated STAT3. They rapidly and potently suppressed constitutive and IL-6/IFN-γ-induced JAK2/STAT3 signal activation. In addition, we finally proved that the STAT3 signal blockage by three of these AAs was dependent on specific JAK2 inhibition. These AAs may represent new targeted therapeutic agents for JAK2/STAT3 hyper-activated human cancers. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Peng</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Liwei</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Ximing</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, Université Paris Diderot, CNRS EAC4413, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Feng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Wenchao</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pan</LastName>
<ForeName>Yanlong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Du</LastName>
<ForeName>Yuping</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Jinbo</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China; Department of Molecular Genetics, Lerner Research Institute, The Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Qin</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Cell Biology, School of Life Sciences, Lanzhou University, Lanzhou 730000, China. Electronic address: qwang@lzu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K72T3FS567</RegistryNumber>
<NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000241">Adenosine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020169">Caspases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053614">Janus Kinase 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">JAK2 inhibitors</Keyword>
<Keyword MajorTopicYN="N">N(6)-Substituted adenosine analogues</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
<Keyword MajorTopicYN="N">Targeted therapy</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25109450</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization.</ArticleTitle>
<Pagination>
<MedlinePgn>132-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.048</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00427-3</ELocationID>
<Abstract>
<AbstractText>Given its contribution to malignant phenotypes of cancer, tumor hypoxia has been considered as a potential therapeutic problem. In the stressful microenvironment condition, hypoxia inducible factor 1 (HIF1) is well known to mediate the transcriptional adaptation of cells to hypoxia and acts as a central player for the process of hypoxia-driven malignant cancer progression. Here, we found that irradiation causes the HIF1α protein to stabilize, even in normoxia condition through activation of p38 MAPK, thereby promoting angiogenesis in tumor microenvironment and infiltrative property of glioma cells. Notably, irradiation reduced hydroxylation of HIF1α through destabilization of prolyl hydroxylases (PHD)-2. Moreover, radiation also decreased the half-life of protein von Hippel-Lindau (pVHL), which is a specific E3 ligase for HIF1α. Of note, inhibition of p38 MAPK attenuated radiation-induced stabilization of HIF1α through destabilization of PHD-2 and pVHL. In agreement with these results, targeting of either p38 MAPK, HIF1α, pVHL or PHD-2 effectively mitigated the radiation-induced tube formation of human brain-derived micro-vessel endothelial cells (HB-MEC) and infiltration of glioma cells. Taken together, our findings suggest that targeting HIF1α in combination with ionizing radiation might increase the efficacy of radiotherapy for glioma treatment. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Young-Heon</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yoo</LastName>
<ForeName>Ki-Chun</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cui</LastName>
<ForeName>Yan-Hong</ForeName>
<Initials>YH</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Uddin</LastName>
<ForeName>Nizam</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>Eun-Jung</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Min-Jung</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Radiation Exposure &amp; Therapeutics, National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>Seon-Young</ForeName>
<Initials>SY</Initials>
<AffiliationInfo>
<Affiliation>Radiation Health Research Institute, Korea Hydro &amp; Nuclear Power Co. LTD., Seoul 132-703, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>In-Gyu</ForeName>
<Initials>IG</Initials>
<AffiliationInfo>
<Affiliation>Department of Radiation Biology, Environmental Radiation Research Group, Korea Atomic Energy Research Institute, Daejeon 305-600, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suh</LastName>
<ForeName>Yongjoon</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea. Electronic address: hiswork@hanmail.net.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Su-Jae</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea. Electronic address: sj0420@hanyang.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007797">Laminin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011509">Proteoglycans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>119978-18-6</RegistryNumber>
<NameOfSubstance UI="C059485">matrigel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-34-5</RegistryNumber>
<NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.11.2</RegistryNumber>
<NameOfSubstance UI="C490190">EGLN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.11.29</RegistryNumber>
<NameOfSubstance UI="D064799">Hypoxia-Inducible Factor-Proline Dioxygenases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="C497446">VHL protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D051794">Von Hippel-Lindau Tumor Suppressor Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003094">Collagen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019583">Dose Fractionation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064799">Hypoxia-Inducible Factor-Proline Dioxygenases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007797">Laminin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011509">Proteoglycans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011839">Radiation, Ionizing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044767">Ubiquitin-Protein Ligases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051794">Von Hippel-Lindau Tumor Suppressor Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Angiogenesis</Keyword>
<Keyword MajorTopicYN="N">Hypoxia inducible factor 1 alpha</Keyword>
<Keyword MajorTopicYN="N">Infiltration of glioma cells</Keyword>
<Keyword MajorTopicYN="N">Ionizing radiation</Keyword>
<Keyword MajorTopicYN="N">p38 MAPK</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25111897</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>97-106</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.041</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00420-0</ELocationID>
<Abstract>
<AbstractText>The aberrant regulation of histone deacetylase 6 (HDAC6) contributes to malignant progression in various types of cancer, but the mechanism underlying gastric carcinogenesis remains unknown. Aberrant HDAC6 overexpression was observed in a subset of human gastric cancer cells. HDAC6 knockdown caused the significant inhibition of gastric cancer cell growth without affecting the transition of cell cycles or the processing of cell death. We demonstrate that an increase in epidermal growth factor receptor (EGFR) signaling through decreased EGFR degradation was mediated by HDAC6 in gastric carcinogenesis. These results establish a molecular mechanism responsible for oncogenic HDAC6, explaining how EGFR signaling induced by the growth factor is sustained during the malignant progression of gastric cancer. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Se Jin</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Jeong Kyu</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bae</LastName>
<ForeName>Hyun Jin</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eun</LastName>
<ForeName>Jung Woo</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Qingyu</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Hyung Seok</ForeName>
<Initials>HS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Woo Chan</ForeName>
<Initials>WC</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Hee Doo</ForeName>
<Initials>HD</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Eun Kyung</ForeName>
<Initials>EK</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Cancer Evolution Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>You</LastName>
<ForeName>Jueng Soo</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, School of Medicine, Konkuk University, Seoul 143-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Won Sang</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jung Young</ForeName>
<Initials>JY</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>Suk Woo</ForeName>
<Initials>SW</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Functional RNomics Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea; Cancer Evolution Research Center, The Catholic University of Korea, Seoul 137-701, Republic of Korea. Electronic address: swnam@catholic.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C097227">RABEP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="C433811">HDAC6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004705">Endocytosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011992">Endosomes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015971">Gene Expression Regulation, Enzymologic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033921">Vesicular Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EGF receptor</Keyword>
<Keyword MajorTopicYN="N">Endocytosis</Keyword>
<Keyword MajorTopicYN="N">Histone deacetylase 6</Keyword>
<Keyword MajorTopicYN="N">Rabaptin-5</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25111898</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.</ArticleTitle>
<Pagination>
<MedlinePgn>87-96</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.045</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00424-8</ELocationID>
<Abstract>
<AbstractText>Kruppel-like-factor 17 (KLF17) is a negative regulator of metastasis and epithelial-mesenchymal-transition (EMT). However, its expression is downregulated in metastatic breast cancer that contains p53 mutations. Here, we show that mutant-p53 plays a key role to suppress KLF17 and thereby enhances cancer progression, which defines novel gain-of-function (GOF) of mutant-p53. Mutant-p53 interacts with KLF17 and antagonizes KLF17 mediated EMT genes transcription. Depletion of KLF17 promotes cell viability, decreases apoptosis and induces drug resistance in metastatic breast cancer cells. KLF17 suppresses cell migration and invasion by decreasing CD44, PAI-1 and Cyclin-D1 expressions. Taken together, our results show that KLF17 is important for the suppression of metastasis and could be a potential therapeutic target during chemotherapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ali</LastName>
<ForeName>Amjad</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China. Electronic address: amjad_486@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shah</LastName>
<ForeName>Abdus Saboor</ForeName>
<Initials>AS</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahmad</LastName>
<ForeName>Ayaz</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China; Department of Biotechnology, Abdul Wali Khan University, Mardan, 23200, Pakistan. Electronic address: ahdayazb5@awkum.edu.pk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018960">Antigens, CD44</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530104">CCND1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C510638">KLF17 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017395">Plasminogen Activator Inhibitor 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C051321">SERPINE1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018960">Antigens, CD44</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002277">Carcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017395">Plasminogen Activator Inhibitor 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">Chemotherapy</Keyword>
<Keyword MajorTopicYN="N">Invasion</Keyword>
<Keyword MajorTopicYN="N">KLF17</Keyword>
<Keyword MajorTopicYN="N">Metastasis</Keyword>
<Keyword MajorTopicYN="N">Mutant p53</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128069</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Transcription factor OCT4 promotes cell cycle progression by regulating CCND1 expression in esophageal carcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>77-86</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.049</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00428-5</ELocationID>
<Abstract>
<AbstractText>The CCND1 gene is overexpressed in esophageal cancer and accelerates cell cycle progression. However, the mechanism whereby the upstream genes or factors directly regulate CCND1 expression remains unknown. By analyzing the 5'-UTR region of the CCND1 gene, we found that this region contains an octamer motif (ATTTTGCAT), which suggests that the expression of CCND1 might be directly associated with octamer-binding transcription factor 4 (OCT4). In this study, the wild-type and the octamer motif-mutanted CCND1 promoters were cloned, and their corresponding luciferase reporter vectors were then constructed to study the molecular mechanism by which OCT4 regulates the expression of CCND1 and influences the biological behaviors of esophageal cancer cells. The results indicated that suppressing the expression of CCND1 and OCT4 in esophageal cancer cells reduced cell proliferative and invasive abilities, induced cell cycle G1-phase arrest, and slowed the growth of xenografts in nude mice. Suppression of OCT4 expression significantly decreased the wild-type CCND1 promoter activity and down-regulated the expression of CCND1, but did not affect the activity of the mutant promoter. Whereas, suppression of CCND1 did not affect OCT4 expression, suggesting that OCT4 regulates CCND1 expression by activating the CCND1 promoter and subsequently promoting cell cycle progression. The results revealed and confirmed that OCT4 is the upstream factor that directly binds to the CCND1 promoter to regulate CCND1 expression, then to promote cell cycle progression and accelerate the proliferation and invasion of esophageal cancer cells. This finding may significantly contribute to elucidating the regulatory mechanism involved in the cell cycle progression of esophageal cancer cells and may aid in screening potential gene targets for the biological therapy of esophageal cancer. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Zhigang</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic Surgery, Shanghai Chest Hospital Esophageal Disease Center, Shanghai Jiao-Tong University, Shanghai 200030, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xinxin</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>School of Medicine, Shanghai Jiao-Tong University, Shanghai 200025, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Chunguang</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Cardiothoracic Surgery, Changhai Hospital, The Second Military Medical University, Shanghai 200168, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Su</LastName>
<ForeName>Yinghan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biology, Xi'an Jiaotong-Liverpool University, Suzhou 215123, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fang</LastName>
<ForeName>Wentao</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic Surgery, Shanghai Chest Hospital Esophageal Disease Center, Shanghai Jiao-Tong University, Shanghai 200030, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhong</LastName>
<ForeName>Chenxi</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Thoracic Surgery, Shanghai Chest Hospital Esophageal Disease Center, Shanghai Jiao-Tong University, Shanghai 200030, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ji</LastName>
<ForeName>Weidan</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital &amp; National Center of Liver Cancer, The Second Military Medical University, Shanghai 200438, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Qian</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital &amp; National Center of Liver Cancer, The Second Military Medical University, Shanghai 200438, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Su</LastName>
<ForeName>Changqing</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital &amp; National Center of Liver Cancer, The Second Military Medical University, Shanghai 200438, China. Electronic address: suchangqing@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530104">CCND1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050814">Octamer Transcription Factor-3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494173">POU5F1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020816">Amino Acid Motifs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002277">Carcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002455">Cell Division</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004938">Esophageal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050814">Octamer Transcription Factor-3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cell cycle</Keyword>
<Keyword MajorTopicYN="N">Cyclin</Keyword>
<Keyword MajorTopicYN="N">Esophageal cancer</Keyword>
<Keyword MajorTopicYN="N">Gene expression</Keyword>
<Keyword MajorTopicYN="N">Transcription factor</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128071</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo.</ArticleTitle>
<Pagination>
<MedlinePgn>189-99</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.009</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00437-6</ELocationID>
<Abstract>
<AbstractText>Supranutritional selenite has anti-cancer therapeutic effects in vivo; however, the detailed mechanisms underlying these effects are not clearly understood. Further studies would broaden our understanding of the anti-cancer effects of this compound and provide a theoretical basis for its clinical application. In this study, we primarily found that selenite exposure inhibited phosphorylation of cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB), leading to suppression of Bcl-2 in HCT116 and SW480 colorectal cancer (CRC) cells. Moreover, the selenite-induced inhibitory effect on PKD1 activation was involved in suppression of the CREB signalling pathway. Additionally, we discovered that selenite treatment can upregulate p38 MAPK phosphorylation, which results in inhibition of the PKD1/CREB/Bcl-2 survival pathway and triggers apoptosis. Finally, we established a colorectal cancer xenograft model and found that selenite treatment markedly inhibits tumour growth through the MAPK/PKD1/CREB/Bcl-2 pathway in vivo. Our results demonstrated that a supranutritional dose of selenite induced CRC cell apoptosis through inhibition of the PKD1/CREB/Bcl-2 axis both in vitro and in vivo. </AbstractText>
<CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hui</LastName>
<ForeName>Kaiyan</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Kejian</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Duan</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>An</LastName>
<ForeName>Jiajia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Pa</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ci</LastName>
<ForeName>Yali</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Lei</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Caimin</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China. Electronic address: cmxu@ibms.pumc.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C115163">CREB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050396">TRPP Cation Channels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C087882">polycystic kidney disease 1 protein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>F6A27P4Q4R</RegistryNumber>
<NameOfSubstance UI="D020887">Selenious Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017362">Cyclic AMP Response Element-Binding Protein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020887">Selenious Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050396">TRPP Cation Channels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">CREB</Keyword>
<Keyword MajorTopicYN="N">PKD1</Keyword>
<Keyword MajorTopicYN="N">Selenite</Keyword>
<Keyword MajorTopicYN="N">p38 MAPK</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25128652</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2.</ArticleTitle>
<Pagination>
<MedlinePgn>107-14</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.039</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00418-2</ELocationID>
<Abstract>
<AbstractText>Metastatic ovarian granulosa cell tumors (GCT) exhibit loss of betaglycan. Here we test the hypothesis that betaglycan blocks GCT metastasis by suppressing NFκB/TGFβ2-induced matrix metalloprotinease-2 (MMP2). Human GCT and a human GCT cell model demonstrated prominent MMP2 expression, which was dependent on NFκB activity and stimulated by TGFβ2 in an NFκB-dependent manner. Betaglycan suppressed both basal and TGFβ2-induced MMP2 expression and countered metastatic behaviors of GCT cells in non-adherent spheroid culture and in vivo xenograft models of metastasis. These data suggest that NFκB/TGFβ2 promotes, and betaglycan impedes, the early stages of GCT metastasis, when tumor cells first invade the peritoneum. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bilandzic</LastName>
<ForeName>Maree</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>MIMR-PHI Institute of Medical Research, Clayton, Vic. 3168, Australia. Electronic address: maree.bilandzic@mimr-phi.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Yao</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>MIMR-PHI Institute of Medical Research, Clayton, Vic. 3168, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahmed</LastName>
<ForeName>Nuzhat</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>MIMR-PHI Institute of Medical Research, Clayton, Vic. 3168, Australia; Women's Cancer Research Centre, Royal Women's Hospital, Parkville, Vic. 3052, Australia; Department of Obstetrics and Gynaecology, The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic. 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luwor</LastName>
<ForeName>Rodney B</ForeName>
<Initials>RB</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic. 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Hong Jian</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Surgery, The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic. 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Findlay</LastName>
<ForeName>Jock K</ForeName>
<Initials>JK</Initials>
<AffiliationInfo>
<Affiliation>MIMR-PHI Institute of Medical Research, Clayton, Vic. 3168, Australia; Women's Cancer Research Centre, Royal Women's Hospital, Parkville, Vic. 3052, Australia; Department of Obstetrics and Gynaecology, The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic. 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stenvers</LastName>
<ForeName>Kaye L</ForeName>
<Initials>KL</Initials>
<AffiliationInfo>
<Affiliation>MIMR-PHI Institute of Medical Research, Clayton, Vic. 3168, Australia; Department of Developmental Biology and Anatomy, Monash University, Clayton, Vic. 3168, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011509">Proteoglycans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018125">Receptors, Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053781">Transforming Growth Factor beta2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>145170-29-2</RegistryNumber>
<NameOfSubstance UI="C071736">betaglycan</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.24</RegistryNumber>
<NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006106">Granulosa Cell Tumor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020778">Matrix Metalloproteinase 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010537">Peritoneum</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011509">Proteoglycans</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018125">Receptors, Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053781">Transforming Growth Factor beta2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Betaglycan</Keyword>
<Keyword MajorTopicYN="N">Invasion</Keyword>
<Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
<Keyword MajorTopicYN="N">Spheroid</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25130169</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells.</ArticleTitle>
<Pagination>
<MedlinePgn>153-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00430-3</ELocationID>
<Abstract>
<AbstractText>Persistent activation of signal transducers and activator of transcription 3 (STAT3) has been closely related to growth, survival, proliferation, metastasis, and angiogenesis of various cancer cells, and thus its inhibition can be considered a potential therapeutic strategy. In this study, we investigated the role of bergamottin (BGM) obtained from grapefruit juice in abrogating the constitutive STAT3 activation in multiple myeloma (MM) cells. This suppression was mediated through the inhibition of phosphorylation of Janus-activated kinase (JAK) 1/2 and c-Src. Pervanadate reversed the BGM induced down-regulation of STAT3 activation, suggesting the involvement of a protein tyrosine phosphatase (PTP). Furthermore, BGM induced the expression of the tyrosine phosphatase SHP-1, and gene silencing of the SHP-1 by small interfering RNA abolished the ability of BGM to inhibit STAT3 activation, suggesting a critical role for SHP-1 in the action of BGM. BGM also downregulated the expression of STAT3-regulated gene products such as COX-2, VEGF, cyclin D1, survivin, IAP-1, Bcl-2, and Bcl-xl in MM cells. This correlated with induction of substantial apoptosis as indicated by an increase in the sub-G1 cell population and caspase-3 induced PARP cleavage. Also, this agent significantly potentiated the apoptotic effects of bortezomib and thalidomide in MM cells. Overall, these results suggest that BGM is a novel blocker of STAT3 activation pathway thus may have a potential in therapy of MM and other cancers. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Moo</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jong Hyun</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sethi</LastName>
<ForeName>Gautam</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, and Cancer Science Institute of Singapore, National University of Singapore, Singapore 117597.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Chulwon</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baek</LastName>
<ForeName>Seung Ho</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nam</LastName>
<ForeName>Dongwoo</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chung</LastName>
<ForeName>Won-Seok</ForeName>
<Initials>WS</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sung-Hoon</ForeName>
<Initials>SH</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shim</LastName>
<ForeName>Bum Sang</ForeName>
<Initials>BS</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Kwang Seok</ForeName>
<Initials>KS</Initials>
<AffiliationInfo>
<Affiliation>College of Korean Medicine, Kyung Hee University, 1 Hoegidong Dongdaemungu, Seoul 130-701, Korea. Electronic address: ksahn@khu.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011564">Furocoumarins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7380-40-7</RegistryNumber>
<NameOfSubstance UI="C068337">bergamottin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="C509249">PTPN6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D032083">Citrus paradisi</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011564">Furocoumarins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053824">Protein Tyrosine Phosphatase, Non-Receptor Type 6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">Bergamottin</Keyword>
<Keyword MajorTopicYN="N">Multiple myeloma</Keyword>
<Keyword MajorTopicYN="N">SHP-1</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25130171</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>172-80</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00429-7</ELocationID>
<Abstract>
<AbstractText>The aim of this study is to investigate the regulatory mechanism of leptin receptors (Ob-R) in pancreatic cancer. We found that the over-expression of hypoxia inducible factor (HIF-1)α and hypoxia up-regulated the expression of Ob-R in pancreatic cancer cells. When HIF-1α gene was silenced in vitro, the expression of Ob-R was significantly decreased. Xenograft mouse models showed that the inhibition of HIF-1α resulted in the concomitant decrease of Ob-R in vivo. In addition, HIF-1α expression was correlated with Ob-R in pancreatic cancer tissues by immunohistochemical staining. Clinical data showed that over-expression of HIF-1 was associated with pathological tumor node metastasis stage, lymph node metastasis and overall survival. HIF-1α directly bound to the hypoxia-responsive element (HRE) located in Ob-R gene promoter (-828/-832) and activated the transcription. Finally, we demonstrated that the silence of HIF-1α gene reversed the inhibitory effect of leptin/Ob-R in pancreatic cancer cells. Taken together, our results indicate that HIF-1α directly regulated Ob-R expression in pancreatic cancer, which might be a valuable therapeutic target for pancreatic cancer. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ren</LastName>
<ForeName>He</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jia</LastName>
<ForeName>Lingling</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Tiansuo</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Huan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Shaoguang</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jingcheng</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Ming</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>School of Public Health, Tianjin Medical University, Tianjin, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hao</LastName>
<ForeName>Jihui</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address: haojihui@tjmuch.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007797">Laminin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011509">Proteoglycans</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054411">Receptors, Leptin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>119978-18-6</RegistryNumber>
<NameOfSubstance UI="C059485">matrigel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-34-5</RegistryNumber>
<NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C562463">Pancreatic Carcinoma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003094">Collagen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020868">Gene Silencing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007797">Laminin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009368">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010957">Plasmids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011509">Proteoglycans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054411">Receptors, Leptin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Hypoxia inducible factor-1α (HIF-1α)</Keyword>
<Keyword MajorTopicYN="N">Leptin</Keyword>
<Keyword MajorTopicYN="N">Leptin receptor (Ob-R)</Keyword>
<Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25130172</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Activating transcription factor 4 mediates a multidrug resistance phenotype of esophageal squamous cell carcinoma cells through transactivation of STAT3 expression.</ArticleTitle>
<Pagination>
<MedlinePgn>142-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.044</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00423-6</ELocationID>
<Abstract>
<AbstractText>Multidrug resistance (MDR) is a major challenge to the clinical treatment of esophageal cancer. The stress response gene activating transcription factor 4 (ATF4) is involved in homeostasis and cellular protection. However, relatively little is known about the expression and function of ATF4 in esophageal squamous cell carcinoma (ESCC) MDR. In this study, we investigate the potential role and mechanisms of ATF4 in ESCC MDR. We demonstrated that overexpression of ATF4 promotes the MDR phenotype in ESCC cells, while depletion of ATF4 in the MDR ESCC cell line induces drug re-sensitization. We also demonstrated that ATF4 transactivates STAT3 expression by directly binding to the signal transducers and activators of transcription 3 (STAT3) promoter, resulting in MDR in ESCC cells. Significantly, inhibition of STAT3 by small interfering RNA (siRNA) or a selective inhibitor (JSI-124) reintroduces therapeutic sensitivity. In addition, increased Bcl-2, survivin, and MRP1 expression levels were observed in ATF4-overexpressing cells. In conclusion, ATF4 may promote MDR in ESCC cells through the up-regulation of STAT3 expression, and thus is an attractive therapeutic target to combat therapeutic resistance in ESCC. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Hongwu</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Xiong</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Fuzhou General Hospital of the Nanjing Military Command of the PLA, Fuzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Bin</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Bei</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Jianyong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Dermatology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Weibing</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Gerontology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Ziying</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Qiuqiong</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Meihua</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>Dayong</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China. Electronic address: sundayong1967@126.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Yagang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Guangzhou General Hospital of the Guangzhou Military Command of the People's Liberation Army (PLA), Guangzhou, China. Electronic address: yagang78@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497109">ATF4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C107489">BIRC5 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051034">Inhibitor of Apoptosis Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D027425">Multidrug Resistance-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C421109">multidrug resistance-associated protein 1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>145891-90-3</RegistryNumber>
<NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051701">Activating Transcription Factor 4</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018432">Drug Resistance, Multiple</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004938">Esophageal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051034">Inhibitor of Apoptosis Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D027425">Multidrug Resistance-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016297">Mutagenesis, Site-Directed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015533">Transcriptional Activation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Activating transcription factor 4</Keyword>
<Keyword MajorTopicYN="N">Esophageal squamous cell carcinoma</Keyword>
<Keyword MajorTopicYN="N">Multidrug resistance</Keyword>
<Keyword MajorTopicYN="N">Signal transducers and activators of transcription 3</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135221</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>A novel β-catenin signaling pathway activated by IL-1β leads to the onset of epithelial-mesenchymal transition in breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>164-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00444-3</ELocationID>
<Abstract>
<AbstractText>Interleukin 1β has been associated with tumor development, invasiveness and metastasis in various types of cancer. However, the molecular mechanisms underlying this association have not been clearly elucidated. The present study is the first to show, in breast cancer cells, that an IL-1β/IL-1RI/β-catenin signaling pathway induces β-catenin accumulation due to GSK3β inactivation by Akt phosphorylation. Translocation to the nucleus of accumulated β-catenin and formation of the TCF/Lef/β-catenin complex induce sequential expression of c-MYC, CCDN1, SNAIL1 and MMP2, leading to up-regulation of proliferation, migration and invasion; all of the processes shown to be required, in cancerous cells, to initiate transition from a non-invading to an invasive phenotype. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Perez-Yepez</LastName>
<ForeName>Eloy Andres</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Avenida Instituto Politécnico Nacional 2508, San Pedro Zacatenco, Mexico DF 07360, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ayala-Sumuano</LastName>
<ForeName>Jorge-Tonatiuh</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Institute of Neurobiology, Universidad Nacional Autónoma de México Campus Juriquilla, Blvd. Juriquilla 3001, Querétaro 76230, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lezama</LastName>
<ForeName>Ruth</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Av. Wilfrido Massieu y Calzada Miguel Stampa s/n, México DF 07738, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meza</LastName>
<ForeName>Isaura</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Avenida Instituto Politécnico Nacional 2508, San Pedro Zacatenco, Mexico DF 07360, Mexico. Electronic address: imeza@cinvestav.mx.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551918">2-methyl-2'-F-anandamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495270">CTNNB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508585">IL1B protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053284">Polyunsaturated Alkamides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C448280">glycogen synthase kinase 3 beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.26</RegistryNumber>
<NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021581">Active Transport, Cell Nucleus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038362">Glycogen Synthase Kinase 3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053284">Polyunsaturated Alkamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051176">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Breast cancer cell</Keyword>
<Keyword MajorTopicYN="N">IL-1RI/β-catenin signaling</Keyword>
<Keyword MajorTopicYN="N">IL-1β stimulation</Keyword>
<Keyword MajorTopicYN="N">Invasiveness</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135222</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>TIP30 nuclear translocation negatively regulates EGF-dependent cyclin D1 transcription in human lung adenocarcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>200-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.08.008</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00436-4</ELocationID>
<Abstract>
<AbstractText>Aberrant epidermal growth factor (EGF)-dependent signaling plays a key role in the progression of human carcinomas. We found that TIP30, a tumor suppressor protein, translocated into the nucleus of human lung adenocarcinoma cells following EGF treatment, and the selective inhibitors of EGFR signaling pathways blocked this effect. Chromatin immunoprecipitation assays revealed that TIP30 negatively regulated EGF-dependent transcriptional activation of CCND1 through a HDAC1-dependent mechanism. In lung adenocarcinoma patients, the level of nuclear TIP30 was inversely correlated with that of EGFR and cyclin D1. These findings suggest that nuclear TIP30-induced downregulation of cyclin D1 transcription antagonizes EGFR signaling and suppresses tumorigenesis. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shuai</LastName>
<ForeName>Shuai</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Xiao</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Oncology Department, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Junyi</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Shijun</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Fengsheng</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Luo</LastName>
<ForeName>Rongcheng</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China. Electronic address: luorc0101@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Aimin</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong 510315, China. Electronic address: liaimin2005@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C530104">CCND1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>136601-57-5</RegistryNumber>
<NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62229-50-9</RegistryNumber>
<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.-</RegistryNumber>
<NameOfSubstance UI="D000123">Acetyltransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.48</RegistryNumber>
<NameOfSubstance UI="C111246">HTATIP2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000123">Acetyltransferases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D021581">Active Transport, Cell Nucleus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019938">Cyclin D1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004815">Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cyclin D1</Keyword>
<Keyword MajorTopicYN="N">EGFR</Keyword>
<Keyword MajorTopicYN="N">HDAC1</Keyword>
<Keyword MajorTopicYN="N">Lung adenocarcinoma</Keyword>
<Keyword MajorTopicYN="N">TIP30</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25135223</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Strategy to enhance the anticancer efficacy of X-ray radiotherapy in melanoma cells by platinum complexes, the role of ROS-mediated signaling pathways.</ArticleTitle>
<Pagination>
<MedlinePgn>58-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.07.046</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00425-X</ELocationID>
<Abstract>
<AbstractText>Radiotherapy plays an important role in treatment of cancers with low toxicity to the surrounding normal tissues. However, it still fails to eradicate hypoxic tumors due to the occurrence of radioresistance. Therefore, the search for new radiation sensitizers is of great significance. Platinum (Pt) complexes have been identified as potential radiation sensitizers to increase the sensitivity of cancer cells to radiotherapy. In the present study, we have synthesized four Pt complexes containing (2 - benzimidazole [4, 5-f] - [1, 10] phenanthroline) ligand and found that they could effectively enhance the X-ray-induced growth inhibition against A375 human melanoma cells through induction of G2/M cell cycle arrest. In contrast, they showed much lower cytotoxicity toward human normal cells. The complexes also dramatically inhibited the TrxR activity and caused intracellular ROS overproduction, due to the Auger electron effect of heavy metal element under X-ray radiation. Excessive ROS triggered DNA damage and activated downstream signaling pathways, including the phosphorylation of p53 and p38MAPK, and down-regulation of phosphorylated AKT and ERK, finally resulted in increase of radiosensitivity and inhibition of tumor reproduction. Taken together, our results suggest that the synthetic Pt complexes could be further developed as sensitizers of X-ray radiotherapy. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Qiang</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China; Wu Jing Zong Dui Hospital of Guangdong Province, Guangzhou 510507, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lan</LastName>
<ForeName>Guoqiang</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Yangliang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Jiamin</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Yuanwei</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Wenjie</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Xiaoyan</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Cundong</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Tianfeng</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Jinan University, Guangzhou 510632, China. Electronic address: tchentf@jnu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>49DFR088MY</RegistryNumber>
<NameOfSubstance UI="D010984">Platinum</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000532">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010984">Platinum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011836">Radiation Tolerance</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011878">Radiotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D017382">Reactive Oxygen Species</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048051">p38 Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Auger electron effect</Keyword>
<Keyword MajorTopicYN="N">G2/M arrest</Keyword>
<Keyword MajorTopicYN="N">Platinum complexes</Keyword>
<Keyword MajorTopicYN="N">Radiotherapy</Keyword>
<Keyword MajorTopicYN="N">Sensitizers</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25153349</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1872-7980</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>354</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
<Title>Cancer letters</Title>
<ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>33-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.06.023</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00445-5</ELocationID>
<Abstract>
<AbstractText>Although NDRG2 has recently been found to be a candidate tumor suppressor, its precise role in the epithelial-mesenchymal transition (EMT) is not well understood. In the present study, we demonstrated that NDRG2 overexpression in MDA-MB-231 cells down-regulated the expression of Snail, a transcriptional repressor of E-cadherin and a key regulator of EMT, as well as the phosphorylation of signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor that is activated in many human malignancies including breast cancer. In addition, we confirmed that the expression of Snail and phospho-STAT3 was recovered when NDRG2 was knocked down by siRNA in MCF7 cells in which NDRG2 is endogenously expressed. Interestingly, MDA-MB-231-NDRG2 cells showed remarkably decreased Snail expression after treatment with JSI-124 (also known as cucurbitacin I) or Stattic, STAT3 inhibitors, compared to MDA-MB-231-mock cells. Moreover, STAT3 activation by EGF treatment induced higher Snail expression, and NDRG2 overexpression resulted in the inhibition of Snail expression in MDA-MB-231 cells stimulated by EGF in the absence or presence of STAT3 inhibitor. Treatment of MDA-MB-231 cells with STAT3 inhibitor led to a moderate decrease in wound healing and migration capacity, whereas STAT3 inhibitor treatment of MDA-MB-231-NDRG2 cells resulted in a significant attenuation of migration in both resting and EGF-stimulated cells. Collectively, our data demonstrate that the inhibition of STAT3 signaling by NDRG2 suppresses EMT progression of EMT via the down-regulation of Snail expression. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Myung-Jin</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>Jihyun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Young</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Myeong-Sok</ForeName>
<Initials>MS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>Jong-Seok</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University, Hyochangwongil 52, Yongsan-Gu, Seoul 140-742, Republic of Korea. Electronic address: jslim@sookmyung.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Ireland</Country>
<MedlineTA>Cancer Lett</MedlineTA>
<NlmUniqueID>7600053</NlmUniqueID>
<ISSNLinking>0304-3835</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C466228">NDRG2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C086988">snail family transcription factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D058750">Epithelial-Mesenchymal Transition</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061986">MCF-7 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014945">Wound Healing</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">EMT</Keyword>
<Keyword MajorTopicYN="N">NDRG2</Keyword>
<Keyword MajorTopicYN="N">STAT3</Keyword>
<Keyword MajorTopicYN="N">Snail</Keyword>
</KeywordList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265820</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0001-6837</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>71</Volume>
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 May-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Acta poloniae pharmaceutica</Title>
<ISOAbbreviation>Acta Pol Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>Water-soluble compounds of lettuce inhibit DNA damage and lipid peroxidation induced by glucose/serum deprivation in N2a cells.</ArticleTitle>
<Pagination>
<MedlinePgn>409-13</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Oxidative stress, increase of lipid peroxidation and resultant DNA damage are associated with pathophysiology of many human diseases such as acute and chronic CNS injuries and diseases, cancer, and also aging. This work was done to investigate whether water fraction from the hydroalcoholic extract of green leaf lettuce (Lactuca sativa L.) can protect N2a cells against glucose/serum deprivation (GSD)-induced lipid peroxidation and DNA fragmentation. The cells were cultivated for 12 h in GSD condition in the absence or presence of the lettuce fraction. The total antioxidant ability of the lettuce water fraction was determined using ferric reducing antioxidant power (FRAP) assay. The intracellular lipid peroxidation was evaluated by malondialdehyde (MDA) level. DNA damage was determined using single cell gel electrophoresis. Using FRAP assay, the antioxidant activity of lettuce water fraction was found to be 574 micromol/g, which is equivalent to 64.1 mg of pure ascorbic acid. Exposure of the cells to GSD condition led to a significant increase of MDA level and DNA fragmentation. Lettuce extract at 400 microg/mL could decrease the elevated intracellular lipid peroxidation and DNA damage. The present study demonstrates that lettuce exerts genoprotective effect through inhibition of oxidative stress.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Asadpour</LastName>
<ForeName>Elham</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ghorbani</LastName>
<ForeName>Ahmad</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sadeghnia</LastName>
<ForeName>Hamid R</ForeName>
<Initials>HR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Acta Pol Pharm</MedlineTA>
<NlmUniqueID>2985167R</NlmUniqueID>
<ISSNLinking>0001-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016895">Culture Media, Serum-Free</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012997">Solvents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>059QF0KO0R</RegistryNumber>
<NameOfSubstance UI="D014867">Water</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016895">Culture Media, Serum-Free</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018545">Lettuce</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009447">Neuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008517">Phytotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018515">Plant Leaves</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010946">Plants, Medicinal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012995">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012997">Solvents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014867">Water</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265847</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0939-5075</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>69</Volume>
<Issue>7-8</Issue>
<PubDate>
<MedlineDate>2014 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Zeitschrift für Naturforschung. C, Journal of biosciences</Title>
<ISOAbbreviation>Z. Naturforsch., C, J. Biosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Elatumic acid: a new ursolic acid congener from Omphalocarpum elatum Miers (Sapotaceae).</ArticleTitle>
<Pagination>
<MedlinePgn>276-82</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A new triterpene diastereomer, 1, of the previously reported 3beta,6beta,19alpha-trihydroxy-urs-12-en-28-oic acid-24-carboxylic acid methyl ester was obtained from the stem bark of Omphalocarpum elatum Miers (Sapotaceae) along with a-amyrin acetate (2), spinasterol (3), spinasterol 3-O-beta-D-glucopyranoside (4), and tormentic acid (5). The structures of the isolates were established on the basis of NMR and mass spectrometric data and by comparison with those previously reported in the literature. Compound 1 showed weak antibacterial activity against E. aerogenes ATCC13048 and EA3, K. pneumoniae ATCC29916, and P aeruginosa; it also displayed moderate cytotoxicity against CCRF-CEM, CEM/ADR5000, and MDA-MB231 cells.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sandjo</LastName>
<ForeName>Louis P</ForeName>
<Initials>LP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fru</LastName>
<ForeName>Chi G</ForeName>
<Initials>CG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuete</LastName>
<ForeName>Victor</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nana</LastName>
<ForeName>Frederic</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yeboah</LastName>
<ForeName>Samuel O</ForeName>
<Initials>SO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mapitse</LastName>
<ForeName>Renameditswe</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abegaz</LastName>
<ForeName>Berhanu M</ForeName>
<Initials>BM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Efferth</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Opatz</LastName>
<ForeName>Till</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ngadjui</LastName>
<ForeName>Bonaventure T</ForeName>
<Initials>BT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Z Naturforsch C</MedlineTA>
<NlmUniqueID>8912155</NlmUniqueID>
<ISSNLinking>0341-0382</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000592425">elatumic acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004354">Drug Screening Assays, Antitumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009682">Magnetic Resonance Spectroscopy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008826">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029632">Sapotaceae</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D021241">Spectrometry, Mass, Electrospray Ionization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25265853</PMID>
<DateCreated>
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0939-5075</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>69</Volume>
<Issue>7-8</Issue>
<PubDate>
<MedlineDate>2014 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Zeitschrift für Naturforschung. C, Journal of biosciences</Title>
<ISOAbbreviation>Z. Naturforsch., C, J. Biosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>In vitro antiproliferative effect of Helix aspersa hemocyanin on multiple malignant cell lines.</ArticleTitle>
<Pagination>
<MedlinePgn>325-34</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>As an extension of our studies on the antitumour properties of various hemocyanins, we sought to compare the antiproliferative effects of hemocyanins derived from two snail species: Helix lucorum (HIH) and Helix aspersa (HaH). This is the first report on the antitumour effects of HaH. We hypothesized that HaH has antitumour effects not only against bladder cancer, as previously shown with other hemocyanins, but also on other cancer cell lines. The antiproliferative properties of the mentioned hemocyanins were investigated in vitro on the following human cell lines: bladder cancer (CAL-29 and T-24), ovarian cancer (FraWü), acute monocytic leukemia (THP-1), prostate cancer (DU-145), glioma cancer (LN-18), and Burkitt's lymphoma (Daudi). The properties of HaH were compared to those of HlH, keyhole limpet hemocyanin (KLH), and two positive controls (doxorubicin and mitomycin C). An antiproliferative effect of the total molecule and one structural subunit of HaH, betac-HaH, against both bladder cancer cell lines, T-24 and CAL-29, was observed. The cytotoxic effect of HaH ranged between 15% and 60% among the other tested cell lines. The endotoxin contamination did not affect the efficacy of HaH. Therefore, HlH and HaH could be appropriate for more detailed investigations of their use as antitumour agents for the studied cancers.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Antonova</LastName>
<ForeName>Olga</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dolashka</LastName>
<ForeName>Pavlina</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Toncheva</LastName>
<ForeName>Draga</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rammensee</LastName>
<ForeName>Hans-Georg</ForeName>
<Initials>HG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Floetenmeyer</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stevanovic</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Z Naturforsch C</MedlineTA>
<NlmUniqueID>8912155</NlmUniqueID>
<ISSNLinking>0341-0382</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>9013-72-3</RegistryNumber>
<NameOfSubstance UI="D006433">Hemocyanin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006372">Helix (Snails)</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006433">Hemocyanin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046529">Microscopy, Electron, Transmission</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272817</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0001-6209</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>54</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jun</Month>
<Day>4</Day>
</PubDate>
</JournalIssue>
<Title>Wei sheng wu xue bao = Acta microbiologica Sinica</Title>
<ISOAbbreviation>Wei Sheng Wu Xue Bao</ISOAbbreviation>
</Journal>
<ArticleTitle>[MiR432* regulate the replication of coxsackievirus A16 in rhabdomyosarcoma cells].</ArticleTitle>
<Pagination>
<MedlinePgn>679-87</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">MicroRNAs (miRNAs) play an important role in infection and replication of virus in host cells. In this study, we examined miRNAs' effects on the replication of Coxsackievirus A16 (CA16) in rhabdomyosarcoma cells.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We constructed target gene of miRNAs screening system. We used 3'untranslated region (UTR) dual luciferase reporter analysis to identify putative miRNA targets in the CA16 virus genome. First, 12 segments of CA16 virus genome were inserted to the pMIR vector and the luciferase expression were assayed to identify the target gene of putative miRNA. The reporter gene expression of the cells transfected with the vector containing 5'-UTR was significantly downregulated. Then, using online analysis programs we screened the miRNAs that may target to 5'-UTR. Furthermore, Western blot and real-time PCR test were used to study the effect of miRNAs on viral replication.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The study showed that miR432 * could stimulate the replication of CA16 virus. On the contrary, miR432 * inhibitor could suppress CA16 virus replication.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cellular miRNAs could regulate the replication of CA16 virus in host cells. Our findings support the notion that the cellular miRNAs play an important role in the host and virus infection.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Zhuo</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tien</LastName>
<ForeName>Po</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Wei Sheng Wu Xue Bao</MedlineTA>
<NlmUniqueID>21610860R</NlmUniqueID>
<ISSNLinking>0001-6209</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020121">5' Untranslated Regions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C582553">MIRN432 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020413">3' Untranslated Regions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020121">5' Untranslated Regions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D029821">Enterovirus A, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004769">Enterovirus Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015967">Gene Expression Regulation, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012208">Rhabdomyosarcoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272885</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0001-6837</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>71</Volume>
<Issue>4</Issue>
<PubDate>
<MedlineDate>2014 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Acta poloniae pharmaceutica</Title>
<ISOAbbreviation>Acta Pol Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>Synthesis of some new carbonitriles and pyrazole coumarin derivatives with potent antitumor and antimicrobial activities.</ArticleTitle>
<Pagination>
<MedlinePgn>594-601</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>3-Acetyl-4-hydroxycoumarin (2) was reacted with some aldehydes (4-chlorobenzaldehyde, 4-bromobenzaldehyde, 5-methylfurfural) to afford the chalcones (3a-c). Cyclization of these chalcones with malononitrile in the presence of ammonium acetate afforded pyridine carbonitriles (4a-c), while the cyclization reaction of chalcones (3a-c) with ethyl cyanoacetate afforded the oxopyridine carbonitriles (5a-c). On the other hand, the chalcones (3a-c) reacted with hydrazine hydrate in alcohol to yield pyrazoles (6a-c), but when the same reaction is carried out in the presence of acetic acid, the acetyl pyrazole derivatives (7a-c) were obtained. Finally, the reaction of the chalcones (3a-c) with phenylhydrazine afforded phenylpyrazole derivatives (8a-c). The structures of synthesized compounds were confirmed by their micro analysis and spectral data (IR, NMR and MS). Twelve samples were evaluated for the human breast adenocarcinoma cytotoxicity, three of them showed moderate activity, the rest of the samples showed weak cytotoxic activity (very high IC50), but for the hepatocarcinoma cell lines four samples showed weak cytotoxic effect, while the rest of the compounds showed very weak effect. For antimicrobial study, three compounds proved to be the most promising against tested bacterial organisms.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hafez</LastName>
<ForeName>Omiama M Abdel</ForeName>
<Initials>OM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nassar</LastName>
<ForeName>Mahmoud I</ForeName>
<Initials>MI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>El-Kousy</LastName>
<ForeName>Salah M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abdel-Razik</LastName>
<ForeName>Ayman F</ForeName>
<Initials>AF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sherien</LastName>
<ForeName>M M Atalla</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>El-Ghonemy</LastName>
<ForeName>Mai M</ForeName>
<Initials>MM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Acta Pol Pharm</MedlineTA>
<NlmUniqueID>2985167R</NlmUniqueID>
<ISSNLinking>0001-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003374">Coumarins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000890">Anti-Infective Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003374">Coumarins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25272887</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0001-6837</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>71</Volume>
<Issue>4</Issue>
<PubDate>
<MedlineDate>2014 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Acta poloniae pharmaceutica</Title>
<ISOAbbreviation>Acta Pol Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>Utility of L-norephedrine in the semisynthesis of novel thiourea and thiazolidine derivatives as a new class of anticancer agents.</ArticleTitle>
<Pagination>
<MedlinePgn>615-23</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The natural alkaloid 1-norephedrine 1 was utlized in the synthesis of some novel thiourea derivatives 2, 5 and thiazolidinones 4a,b and 6, 7. Structures of the synthesized compounds were confirmed by analytical and spectral data. The synthesized compounds were evaluated in vitro for anticancer activity against the human breast (MCF-7), human liver (HEPG2) and human colon (HCT116) cancer cell lines. Thiazolidinone derivative 7 was the most active against all the cell lines with values IC50 = 2.60, 2.80 and 2.60 microg/mL compared with doxorubicin (IC50 = 5.40, 2.97 and 5.26 microg/mL). Thiazolidinone derivative 6 exhibited higher activity with IC50 value (3.20 microg/mL) against HCT116 when compared with doxorubicin with IC50 value (5.26 microg/mL) as positive control.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ghorab</LastName>
<ForeName>Mostafa M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alqasoumi</LastName>
<ForeName>Saleh I</ForeName>
<Initials>SI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abdel-Kader</LastName>
<ForeName>Maged S</ForeName>
<Initials>MS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alsaid</LastName>
<ForeName>Mansour S</ForeName>
<Initials>MS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Acta Pol Pharm</MedlineTA>
<NlmUniqueID>2985167R</NlmUniqueID>
<ISSNLinking>0001-6837</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053778">Thiazolidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33RU150WUN</RegistryNumber>
<NameOfSubstance UI="D010665">Phenylpropanolamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>GYV9AM2QAG</RegistryNumber>
<NameOfSubstance UI="D013890">Thiourea</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010665">Phenylpropanolamine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053778">Thiazolidines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013890">Thiourea</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25278611</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6205</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>3</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>85-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1250255</ELocationID>
<Abstract>
<AbstractText>Cancer genome characterization has revealed driver mutations in genes that govern ubiquitylation; however, the mechanisms by which these alterations promote tumorigenesis remain incompletely characterized. Here, we analyzed changes in the ubiquitin landscape induced by prostate cancer-associated mutations of SPOP, an E3 ubiquitin ligase substrate-binding protein. SPOP mutants impaired ubiquitylation of a subset of proteins in a dominant-negative fashion. Of these, DEK and TRIM24 emerged as effector substrates consistently up-regulated by SPOP mutants. We highlight DEK as a SPOP substrate that exhibited decreases in ubiquitylation and proteasomal degradation resulting from heteromeric complexes of wild-type and mutant SPOP protein. DEK stabilization promoted prostate epithelial cell invasion, which implicated DEK as an oncogenic effector. More generally, these results provide a framework to decipher tumorigenic mechanisms linked to dysregulated ubiquitylation. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Theurillat</LastName>
<ForeName>Jean-Philippe P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Harvard Medical School, Boston, MA 02115, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Udeshi</LastName>
<ForeName>Namrata D</ForeName>
<Initials>ND</Initials>
<AffiliationInfo>
<Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Errington</LastName>
<ForeName>Wesley J</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Svinkina</LastName>
<ForeName>Tanya</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baca</LastName>
<ForeName>Sylvan C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Harvard Medical School, Boston, MA 02115, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pop</LastName>
<ForeName>Marius</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Harvard Medical School, Boston, MA 02115, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wild</LastName>
<ForeName>Peter J</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo>
<Affiliation>Institute of Surgical Pathology, University Hospital Zurich, ZH 8091 Zurich, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Blattner</LastName>
<ForeName>Mirjam</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Groner</LastName>
<ForeName>Anna C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rubin</LastName>
<ForeName>Mark A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA. Institute for Precision Medicine of Weill Cornell and New York Presbyterian Hospital, New York, NY 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moch</LastName>
<ForeName>Holger</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Institute of Surgical Pathology, University Hospital Zurich, ZH 8091 Zurich, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Privé</LastName>
<ForeName>Gilbert G</ForeName>
<Initials>GG</Initials>
<AffiliationInfo>
<Affiliation>Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carr</LastName>
<ForeName>Steven A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo>
<Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Garraway</LastName>
<ForeName>Levi A</ForeName>
<Initials>LA</Initials>
<AffiliationInfo>
<Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Harvard Medical School, Boston, MA 02115, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115, USA. levi_garraway@dfci.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>10</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002868">Chromosomal Proteins, Non-Histone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C084738">Dek protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C509761">SPOP protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C555317">TRIM24 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.25.1</RegistryNumber>
<NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.3.2.19</RegistryNumber>
<NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002868">Chromosomal Proteins, Non-Histone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015513">Oncogene Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046988">Proteasome Endopeptidase Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044767">Ubiquitin-Protein Ligases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054875">Ubiquitination</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25079331</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-4687</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>514</Volume>
<Issue>7520</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>2</Day>
</PubDate>
</JournalIssue>
<Title>Nature</Title>
<ISOAbbreviation>Nature</ISOAbbreviation>
</Journal>
<ArticleTitle>Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity.</ArticleTitle>
<Pagination>
<MedlinePgn>54-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13556</ELocationID>
<Abstract>
<AbstractText>Cancers arise through a process of somatic evolution that can result in substantial sub-clonal heterogeneity within tumours. The mechanisms responsible for the coexistence of distinct sub-clones and the biological consequences of this coexistence remain poorly understood. Here we used a mouse xenograft model to investigate the impact of sub-clonal heterogeneity on tumour phenotypes and the competitive expansion of individual clones. We found that tumour growth can be driven by a minor cell subpopulation, which enhances the proliferation of all cells within a tumour by overcoming environmental constraints and yet can be outcompeted by faster proliferating competitors, resulting in tumour collapse. We developed a mathematical modelling framework to identify the rules underlying the generation of intra-tumour clonal heterogeneity. We found that non-cell-autonomous driving of tumour growth, together with clonal interference, stabilizes sub-clonal heterogeneity, thereby enabling inter-clonal interactions that can lead to new phenotypic traits. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Marusyk</LastName>
<ForeName>Andriy</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [3] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tabassum</LastName>
<ForeName>Doris P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] BBS Program, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Altrock</LastName>
<ForeName>Philipp M</ForeName>
<Initials>PM</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA [3] Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts 02138, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Almendro</LastName>
<ForeName>Vanessa</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [3] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Michor</LastName>
<ForeName>Franziska</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Polyak</LastName>
<ForeName>Kornelia</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [3] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA [4] BBS Program, Harvard Medical School, Boston, Massachusetts 02115, USA [5] Harvard Stem Cell Institute and the Broad Institute, Cambridge, Massachusetts 02138, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>U54 CA143798</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U54CA143798</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Nature</MedlineTA>
<NlmUniqueID>0410462</NlmUniqueID>
<ISSNLinking>0028-0836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017370">Interleukin-11</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002999">Clone Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017370">Interleukin-11</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS601972 [Available on 04/02/15]</OtherID>
<OtherID Source="NLM">PMC4184961 [Available on 04/02/15]</OtherID>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282873</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0024-7766</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>47</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Lymphology</Title>
<ISOAbbreviation>Lymphology</ISOAbbreviation>
</Journal>
<ArticleTitle>Novel characterization of bEnd.3 cells that express lymphatic vessel endothelial hyaluronan receptor-1.</ArticleTitle>
<Pagination>
<MedlinePgn>73-81</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Murine bEnd.3 endothelioma cell line has been widely used in vascular research and here we report the novel finding that bEnd.3 cells express lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) and vascular endothelial growth factor receptor-3 (VEGFR-3). Moreover, these cells express progenitor cell markers of Sca-1 and CD133. Upon stimulation with tumor necrosis factor-alpha (TNF-alpha), the bEnd.3 cells demonstrate enhanced formation of capillary-type tubes, which express LYVE-1. As the bEnd.3 cell line is derived from murine endothelioma, we further examined human tissues of endothelioma and identified lymphatic vessels in the tumor samples which express both LYVE-1 and podoplanin. Moreover, a significantly higher number of lymphatic vessels were detected in the endothelioma samples compared with normal control. Taken together, this study not only redefines bEnd.3 cells for vascular research, but also indicates a broader category of human diseases that are associated with lymphatics, such as endothelioma.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yuen</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leu</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tse</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>L L</ForeName>
<Initials>LL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Lymphology</MedlineTA>
<NlmUniqueID>0155112</NlmUniqueID>
<ISSNLinking>0024-7766</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C111385">AC133 antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000950">Antigens, Ly</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C119248">LYVE1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C074650">Ly6a protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C492273">Xlkd1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040321">Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000950">Antigens, Ly</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006023">Glycoproteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008202">Lymphangioma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D042601">Lymphatic Vessels</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013234">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D040321">Vascular Endothelial Growth Factor Receptor-3</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D033921">Vesicular Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282885</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Preparation and characterization of cucurbitacin B sodium deoxycholate/phospholipid-mixed oral fast dissolving film and antitumor activity study].</ArticleTitle>
<Pagination>
<MedlinePgn>1799-804</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A novel drug delivery system combining oral fast dissolving film with sodium deoxycholate/phospholipid mixed micelles was prepared to increase the absorption of cucurbitacin B that is a poor aqueous solubility substance. Encapsulation efficiency, particle size, zeta potential, polydispersity coefficient, investigated the morphology, disintegration time of oral fast dissolving film and the pharmacodynamic properties of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles before and after solidified in mice were evaluated and compared. The oral fast dissolving film prepared in this study showed a homogeneous pale yellow and could completely disintegrated in the 30 s. It could meet the requirements of rapidly disintegrating fully. The encapsulation efficiency, particle size, zeta potential, polydispersity coefficient of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles loaded in oral fast dissolving film were (43.36 +/- 2.12)%, (108.82 +/- 5.2) nm, (-34.18 +/- 1.07) mV, 0.088 +/- 0.012, respectively. The encapsulation efficiency, particle size, zeta potential, polydispersity coefficient of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles in solution were (41.26 +/- 2.22)%, (181.82 +/- 4.48) nm, (-30.67 +/- 0.81) mV, 0.092 +/- 0.012, respectively. The difference of pharmacodynamics among film of cucurbitacin B-loaded micelles, cucurbitacin B-loaded micelles and free cucurbitacin B in vivo was compared. Solubility of cucurbitacin B loaded in sodium deoxycholate/phospholipid-mixed micelles has also been greatly improved. The tumor inhibition rate of cucurbitacin B loaded in sodium deoxycholate/phospholipid-mixed micelles was significantly improved and did not change significantly before and after solidified. These showed that the sodium deoxycholate/phospholipid-mixed micelles could enhance the antitumor activities of cucurbitacin B and the stability of cucurbitacin B sodium deoxycholate/phospholipid-mixed micelles was improved significantly after solidified by oral fast dissolving film technology without pharmacodynamic properties changed significantly.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Chao</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Yun-Zhi</ForeName>
<Initials>YZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xun</LastName>
<ForeName>Ping-Hua</ForeName>
<Initials>PH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dai</LastName>
<ForeName>Ling</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Jin</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Hai-Long</ForeName>
<Initials>HL</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>005990WHZZ</RegistryNumber>
<NameOfSubstance UI="D003840">Deoxycholic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6199-67-3</RegistryNumber>
<NameOfSubstance UI="C041246">cucurbitacin B</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003840">Deoxycholic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004337">Drug Carriers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010743">Phospholipids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012995">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25282897</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1001-5302</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>39</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
<ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Effect of Buzhong Yiqi decoction on PI3K and AKT in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor].</ArticleTitle>
<Pagination>
<MedlinePgn>1869-73</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the effect of Buzhong Yiqi decoction on PI3K/AKT signaling pathway in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">Totally 60 nude mice were randomly divided into the blank control group, the tumor-bearing control group, the cisplatin group, the low-dose Buzhong Yiqi decoction group, the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group. After the corresponding interventions, efforts were made to measure the transplanted tumor volume and calculate the tumor inhibiting rate. The immunohistochemical method and real time PCR were used to detect the expression of PI3K and AKT level in nude mice spleen, stomach and lung.</AbstractText>
<AbstractText Label="RESULT" NlmCategory="RESULTS">Buzhong Yiqi decoction of different concentrations combined with cisplatin could inhibit the growth of the transplanted tumor, with the strongest inhibitory effect in the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group. All of the expressions of PI3K and AKT protein and gene in the spleen, stomach and lung increased, with the most significant increase in the tumor-bearing group. Along with the increase of the concentration of cisplatin and Buzhong Yiqi decoction, the expressions of PI3K and AKT gradually reduced. Compared with the tumor-bearing control group, there were statistical differences in spleen and stomach tissues (P &lt; 0.05). Compared with the cisplatin group, the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group showed statistical differences (P &lt; 0.05), but without statistical difference compared with the blank control group.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among nude mice with lung adenocarcinoma transplantation tumor, the PI3K and AKT protein and gene expressions in spleen, stomach and lung tissues increased, which might indicated the effect of cisplatin and Buzhong Yiqi decoction in reducing PI3K and AKT expressions and the relations between the reduction degree and the concentrations of Buzhong Yiqi decoction. Cisplatin combined with Buzhong Yiqi decoction could decrease the PI3K and AKT protein and gene expression in spleen, stomach and lung, and make the pathway closer to normal, so as to protect the functions of spleen, stomach and lung, there may be target spots of Buzhong Yiqi decoction in PI3K/AKT signal pathway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Ya-Li</ForeName>
<Initials>YL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yi</LastName>
<ForeName>Jia-Li</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jing</LastName>
<ForeName>Huan</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Chun-Ying</ForeName>
<Initials>CY</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
<NlmUniqueID>8913656</NlmUniqueID>
<ISSNLinking>1001-5302</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C538231">Adenocarcinoma of lung</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004365">Drugs, Chinese Herbal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051058">Oncogene Protein v-akt</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013154">Spleen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25289403</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2014</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Trametenolic acid B reverses multidrug resistance in breast cancer cells through regulating the expression level of P-glycoprotein.</ArticleTitle>
<Pagination>
<MedlinePgn>1037-44</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Trametenolic acid B (TAB) is the main active composition of Trametes lactinea (Berk.) Pat which possesses antitumor activities. There was no report its antitumor effect through regulating P-glycoprotein (P-gp) so far, due toP-gp over expression is one of the most important mechanisms contributing to the multiple drug resistance phenotype. The present aim was to investigate the effects of TAB on P-gp in multidrug-resistant cells;Paclitaxel-resistant cell line MDA-MB-231/Taxol was established by stepwise exposure for 10 months.MDA-MB-231 cells and MDA-MB-231/Taxol cells were treated with TAB, and their growth was evaluated using MTT assays. Paclitaxel accumulation in the cells was analyzed by high performance liquid chromatogram(HPLC). The activity of P-gp was detected by intracellular accumulation of rhodamine 123 (Rho123), and the protein expression of P-gp was evaluated using western blot. Results indicated that the IC50 of MDA-MB-231/Taxol to paclitaxel (Taxol) was 33 times higher than that of nature MDA-MB-231. TAB increased the intracellular concentration of Taxol and inhibited the activity of P-gp and suppressed the expression of P-gp in MDA-MB-231/Taxol cells. Our present results showed that TAB could reverse Taxol resistance in MDA-MB-231/Taxol cells,mainly inhibiting the activity of P-gp and down-regulating the expression level of P-gp, and then enhancing the accumulation of chemotherapy agents.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Qiaoyin</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Junzhi</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Haibo</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Hongbing</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yan</LastName>
<ForeName>Ximing</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zou</LastName>
<ForeName>Kun</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020168">P-Glycoprotein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018435">P-Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C586576">trametenolic acid B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33069-62-4</RegistryNumber>
<NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D018432">Drug Resistance, Multiple</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020168">P-Glycoprotein</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018435">P-Glycoproteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055454">Trametes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014315">Triterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25291942</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1433-6510</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>60</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Clinical laboratory</Title>
<ISOAbbreviation>Clin. Lab.</ISOAbbreviation>
</Journal>
<ArticleTitle>Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>1465-74</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The sex-determining region Y-box 17 (SOX17) is a member of the high mobility group (HMG) transcription factor family, which plays critical roles in the regulation of development and stem/precursor cell function. Recent evidence demonstrated that SOX17 acts as a tumor-suppressor gene, at least partly though repression of Wnt pathway activity.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Here we report that SOX17 methylation was detected in THP-1 and SKM-I cell lines and SOX17 mRNA levels was up-regulated by 5-aza-dC. To clarify the role of SOXI7 in MDS, methylation-specific PCR (MSP) was employed to examine the methylation status of SOX17 in 164 adult de novo MDS patients and 6 normal samples.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that SOX17 methylation was presented in 58.5% (n = 96) of these patients and none of the normal samples. Methylation was correlated significantly with World Health Organization (WHO) subtypes and international prognostic scoring system (IPSS) risk group. Patients with advanced stages of WHO subtypes (69.6% vs. 44.4%, p = 0.001) and higher risk IPSS subgroups (69.8% vs. 48.8%, p = 0.010) exhibited a significantly higher frequency of SOX17 methylation. Though multivariate analysis indicated that SOX17 methylation status was not the independent factor that impacted overall survival (OS) (HR = 0.097), there were significant differences in marrow blast levels and the IPSS risk subgroups between patients with and without SOX17 methylation.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that the hypermethylation of SOX17 promoter may be one of the early events in the development of MDS and predicts poor prognosis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Rong</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Xiao-Li</ForeName>
<Initials>XL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Hai-Yan</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peng</LastName>
<ForeName>Zhen-Ping</ForeName>
<Initials>ZP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Bo</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Tao</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Xiao-Qin</ForeName>
<Initials>XQ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Guo-Wei</ForeName>
<Initials>GW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Clin Lab</MedlineTA>
<NlmUniqueID>9705611</NlmUniqueID>
<ISSNLinking>1433-6510</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C109188">SOX17 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055760">SOXF Transcription Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016009">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019175">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005819">Genetic Markers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015999">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009190">Myelodysplastic Syndromes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055760">SOXF Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25204338</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-0103</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>351</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pharmacology and experimental therapeutics</Title>
<ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>Andrographolide prevents high-fat diet-induced obesity in C57BL/6 mice by suppressing the sterol regulatory element-binding protein pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>474-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.114.217968</ELocationID>
<Abstract>
<AbstractText>Sterol regulatory element-binding proteins (SREBPs) are major transcription factors regulating the expression of genes involved in biosynthesis of cholesterol, fatty acids, and triglycerides. We investigated the effect of the specific SREBP suppressor andrographolide, a natural compound isolated from Andrographis paniculata, on the regulation of SREBP signaling by use of Western blot, reporter gene assay, and quantitative real-time polymerase chain reaction analysis. In addition, the antiobesity effects of andrographolide were evaluated in C57BL/6 mice with high-fat diet (HFD)-induced obesity. Our results showed that andrographolide downregulated the expressions of SREBPs target genes and decreased cellular lipid accumulation in vitro. Further, andrographolide (100 mg/kg per day) attenuated HFD-induced body weight gain and fat accumulation in liver or adipose tissues, and improved serum lipid levels and insulin or glucose sensitivity in HFD-induced obese mice. Andrographolide effectively suppressed the respiratory quotient, energy expenditure, and oxygen consumption, which may have contributed to the decreased body-weight gain of the obese mice fed with a HFD. Consistently, andrographolide regulated SREBP target genes and metabolism-associated genes in liver or brown adipose tissue, which may have directly contributed to the lower lipid levels and enhanced insulin sensitivity. Taken together, our results indicated that andrographolide ameliorated lipid metabolism and improved glucose use in mice with HFD-induced obesity. Andrographolide has potential as a leading compound in the prevention or treatment of obesity and insulin resistance. </AbstractText>
<CopyrightInformation>Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Lili</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jinmei</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Song</LastName>
<ForeName>Baoliang</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Xu</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Wendong</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Binfeng</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Xiaowen</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qi</LastName>
<ForeName>Meng</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Qiming</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Qiaoling</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.) yangli7951@hotmail.com wangzht@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Zhengtao</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Shanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); Shanghai R&amp;D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China (L.D., J.L., B.Z., X.T., M.Q., Qim.Y., Qia.Y., L.Y., Z.W.); State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China (B.S., X.X.); Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California (W.H.); and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People's Republic of China (J.L.) yangli7951@hotmail.com wangzht@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pharmacol Exp Ther</MedlineTA>
<NlmUniqueID>0376362</NlmUniqueID>
<ISSNLinking>0022-3565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051779">Sterol Regulatory Element Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>410105JHGR</RegistryNumber>
<NameOfSubstance UI="C030419">andrographolide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002001">Adipose Tissue, Brown</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D059305">Diet, High-Fat</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004224">Diterpenes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004734">Energy Metabolism</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056945">Hep G2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008055">Lipids</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008820">Mice, Obese</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010101">Oxygen Consumption</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051779">Sterol Regulatory Element Binding Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015430">Weight Gain</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24919481</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">2168-6084</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>150</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>JAMA dermatology</Title>
<ISOAbbreviation>JAMA Dermatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays.</ArticleTitle>
<Pagination>
<MedlinePgn>901-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1001/jamadermatol.2013.9411</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pharaon</LastName>
<ForeName>Momen</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Dermatology, Archet 2 Hospital, Centre Hospitalier Universitaire (CHU) Nice, Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tichet</LastName>
<ForeName>Mélanie</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Team 11, Centre Méditerranéen de Médecin Moléculaire (C3M), Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lebrun-Frénay</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Pasteur Hospital, CHU Nice, Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tartare-Deckert</LastName>
<ForeName>Sophie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Team 11, Centre Méditerranéen de Médecin Moléculaire (C3M), Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Passeron</LastName>
<ForeName>Thierry</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Dermatology, Archet 2 Hospital, Centre Hospitalier Universitaire (CHU) Nice, Nice, France4INSERM, U1065, Team 12, C3M, Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>JAMA Dermatol</MedlineTA>
<NlmUniqueID>101589530</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039661">Integrin beta3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015676">Osteonectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C577241">SPARC protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C469407">natalizumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002465">Cell Movement</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D046169">Dermoscopy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039661">Integrin beta3</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009103">Multiple Sclerosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009506">Nevus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015676">Osteonectin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25318161</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0031-2991</ISSN>
<JournalIssue CitedMedium="Print">
<Issue>2</Issue>
<PubDate>
<MedlineDate>2014 Apr-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Patologicheskaia fiziologiia i èksperimental'naia terapiia</Title>
<ISOAbbreviation>Patol Fiziol Eksp Ter</ISOAbbreviation>
</Journal>
<ArticleTitle>[The role of genetic peculiarityes (of organisms) in the resistance to neoplastic processes in August line and Wistar population rats].</ArticleTitle>
<Pagination>
<MedlinePgn>37-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The probability of development of the Ehrlich's ascites carcinoma in young August and Wistar rats was investigated. The Ehrlich's carcinoma strain was derived in mice in the N.N. Blokhin Russian Cancer Research Center. The tumor was transplanted into rats intraperitonially. It was shown that the transplanted murine carcinomas did not arouse tumors in rats, but caused pathologic effects: abrupt growth impairment and partial loss in the August rats while in the Wistar rats the growth impairment was slight and there was no loss. Thus, the first, there was no tumor growth in rats and the second, the indicated effects of the murine tumor transplantation were more dramatic in the August rats than thouse in the Wistar rats.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pshennikova</LastName>
<ForeName>M G</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bakhtina</LastName>
<ForeName>L Yu</ForeName>
<Initials>LY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kalish</LastName>
<ForeName>S V</ForeName>
<Initials>SV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Budanova</LastName>
<ForeName>O P</ForeName>
<Initials>OP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Malyshev</LastName>
<ForeName>I Yu</ForeName>
<Initials>IY</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Patol Fiziol Eksp Ter</MedlineTA>
<NlmUniqueID>0376421</NlmUniqueID>
<ISSNLinking>0031-2991</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002286">Carcinoma, Ehrlich Tumor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013045">Species Specificity</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25280025</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0394-6320</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>27</Volume>
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 Jul-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>International journal of immunopathology and pharmacology</Title>
<ISOAbbreviation>Int J Immunopathol Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance.</ArticleTitle>
<Pagination>
<MedlinePgn>337-49</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Cancer stem cells possess the qualities of self-renewal, tumorigenesis and the ability to recapitulate a heterogeneous tumor. Our group was the first to isolate head and neck squamous cell carcinoma (HNSCC) stem cells using the cell surface marker CD44. CD44 is a trans-membrane glycoprotein with a multitude of key-functions that regulate cancer cell proliferation and metastasis. The variety of CD44 functions is due to tissue-specific patterns of glycosylation of the extracellular portion, and to the multiple protein isoforms (CD44 variants, CD44v) generated by alternative splicing. This study investigates the expression pattern of CD44 variants in HNSCC. Ten cell lines from the most common HNSCC locations and representative of various clinical outcomes were assayed by quantitative realtime PCR, flow cytometry and immunofluorescence comparatively with normal oral keratinocytes. The CD44 v4 and v6 were exclusively abundant in HNSCC while the isoform v1,2 was expressed in normal oral keratinocytes. Of interest, the highest level of CD44v6 expression was detected in advanced metastatic HNSCC, suggesting a link between CD44v6 expression and HNSCC metastasis, while the highest CD44v4 was detected in a stage IV HNSCC refractory to chemotherapy which developed recurrence. Oral-derived HNSCC expressed the highest CD44v4 and v6, and levels corresponded with staging, showing also an increasing tendency with recurrence and metastasis. CD44v were detected predominantly in smaller cells (a characteristic that has been associated with stem cell properties) or cells with mesenchymal morphology (a characteristic that has been associated with the migratory and invasive potential of epithelial tumor cells), suggesting that CD44v differential expression in HNSCC may be representative of the morphological changes inherent during tumor progression towards a more aggressive potential, and thus contributing to the individual tumor biology. The mechanism of CD44 variant involvement in HNSCC progression and metastasis is under investigation. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Athanassiou-Papaefthymiou</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shkeir</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Dentistry and Orthodontics, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Divi</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matossian</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Owen</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Czerwinski</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Papagerakis</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Dentistry and Orthodontics, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McHugh</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bradford</LastName>
<ForeName>C R</ForeName>
<Initials>CR</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Carey</LastName>
<ForeName>T E</ForeName>
<Initials>TE</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wolf</LastName>
<ForeName>G T</ForeName>
<Initials>GT</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Prince</LastName>
<ForeName>M E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Papagerakis</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, University of Michigan, Ann Arbor, MI , USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P50 CA097248</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 CA97248</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Italy</Country>
<MedlineTA>Int J Immunopathol Pharmacol</MedlineTA>
<NlmUniqueID>8911335</NlmUniqueID>
<ISSNLinking>0394-6320</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018960">Antigens, CD44</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C535575">Carcinoma, squamous cell of head and neck</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018960">Antigens, CD44</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005455">Fluorescent Antibody Technique</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009062">Mouth Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020033">Protein Isoforms</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25335385</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0869-2092</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>77</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Eksperimental'naia i klinicheskaia farmakologiia</Title>
<ISOAbbreviation>Eksp Klin Farmakol</ISOAbbreviation>
</Journal>
<ArticleTitle>[Neuroprotective effect of neuroglutam under conditions of activated free radical oxidation].</ArticleTitle>
<Pagination>
<MedlinePgn>16-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The neuroprotective properties of the novel glutamic acid derivative neiroglutam have been studied in vitro and in vivo. Neiroglutam demonstrated the protective action on 6-OH-dopamine neurotoxicity model &lt;MI&gt; in vitro, where free radical oxidation is a basic part of pathogenesis. In control rats, focal brain ischemia caused significant increase in thiobarbituric acid reactive species (TBARS) level and decrease in superoxide dismutase (SOD) enzyme activity. In two-year-old rats, preventive administration of the neiroglutam caused a significant reduction in the TBARS plasma concentration (34.5%, p &lt; 0.05), increased SOD activity, and increased the time of acid-induced hemolysis of erythrocytes (40%, p &lt; 0.05).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tiurenkov</LastName>
<ForeName>I N</ForeName>
<Initials>IN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Volotova</LastName>
<ForeName>E V</ForeName>
<Initials>EV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kurkin</LastName>
<ForeName>D V</ForeName>
<Initials>DV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bakulin</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Logvinov</LastName>
<ForeName>I O</ForeName>
<Initials>IO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Antipova</LastName>
<ForeName>T A</ForeName>
<Initials>TA</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Eksp Klin Farmakol</MedlineTA>
<NlmUniqueID>9215981</NlmUniqueID>
<ISSNLinking>0869-2092</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005609">Free Radicals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017392">Thiobarbituric Acid Reactive Substances</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3KX376GY7L</RegistryNumber>
<NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8HW4YBZ748</RegistryNumber>
<NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.15.1.1</RegistryNumber>
<NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002545">Brain Ischemia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004912">Erythrocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005609">Free Radicals</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018698">Glutamic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006461">Hemolysis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010084">Oxidation-Reduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016627">Oxidopamine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017392">Thiobarbituric Acid Reactive Substances</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25335412</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0507-4088</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>59</Volume>
<Issue>3</Issue>
<PubDate>
<MedlineDate>2014 May-Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Voprosy virusologii</Title>
<ISOAbbreviation>Vopr. Virusol.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Significance of modern methods for laboratory detection of rabies agents and identification of the zoonose immunological survey].</ArticleTitle>
<Pagination>
<MedlinePgn>5-10</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Analytical review of modern methods of the laboratory detection of rabies and findings of our research indicate high sensitivity and specificity of methods for rapid identification of rabies agents, such as ELISA, reverse-transcriptase PCR for identification of the rabies virus genome, and rabies virus isolation in rat Gasserian ganglion neurinoma, as well as their potential to be included into the State Quality Standard for early detection of rabies in animals to reduce the infection risk among humans and animals.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Guliukin</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Russia (Federation)</Country>
<MedlineTA>Vopr Virusol</MedlineTA>
<NlmUniqueID>0417337</NlmUniqueID>
<ISSNLinking>0507-4088</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000914">Antibodies, Viral</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012367">RNA, Viral</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011818">Rabies</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011820">Rabies virus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012668">Trigeminal Ganglion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015047">Zoonoses</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25340187</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1099-1573</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Phytotherapy research : PTR</Title>
<ISOAbbreviation>Phytother Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>1308-14</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Acute myeloid leukemia (AML) is a group of hematological malignancies defined by expanded clonal populations of immature progenitors (blasts) of myeloid phenotype in blood and bone marrow. Given a typical poor prognostic outlook, there is great need for novel agents with anti-AML activity. Devil’s club (Oplopanax horridus) is one of the most significant medicinal plants used among the indigenous people of Southeast Alaska and the coastal Pacific Northwest, with different linguistic groups utilizing various parts of the plant to treat many different conditions including cancer. Studies identifying medically relevant components in Devil’s club are limited. For this research study, samples were extracted in 70% ethanol before in vitro analysis, to assess effects on AML cell line viability as well as to study regulation of tyrosine phosphorylation and cysteine oxidation. The root extract displayed better in vitro anti-AML efficacy in addition to a noted anti-tyrosine kinase activity independent of an antioxidant effect. In vivo therapeutic studies using an immunocompetent murine model of AML further demonstrated that Devil’s club root extract improved the murine survival while decreasing immunosuppressive regulatory T cells and improving CD8+ T-cell functionality. This study defines for the first time an anti-AML efficacy for extracts of Devil’s club.</AbstractText>
<CopyrightInformation>Copyright © 2014 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>McGill</LastName>
<ForeName>Colin M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alba-Rodriguez</LastName>
<ForeName>Estefania J</ForeName>
<Initials>EJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Shuo</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benson</LastName>
<ForeName>Charles J</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ondrasik</LastName>
<ForeName>Regina M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fisher</LastName>
<ForeName>Lindsey N</ForeName>
<Initials>LN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Claxton</LastName>
<ForeName>David F</ForeName>
<Initials>DF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barth</LastName>
<ForeName>Brian M</ForeName>
<Initials>BM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Phytother Res</MedlineTA>
<NlmUniqueID>8904486</NlmUniqueID>
<ISSNLinking>0951-418X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D028002">Oplopanax</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008517">Phytotherapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010946">Plants, Medicinal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25342804</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6208</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>24</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Influenza A virus uses the aggresome processing machinery for host cell entry.</ArticleTitle>
<Pagination>
<MedlinePgn>473-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1257037</ELocationID>
<Abstract>
<AbstractText>During cell entry, capsids of incoming influenza A viruses (IAVs) must be uncoated before viral ribonucleoproteins (vRNPs) can enter the nucleus for replication. After hemagglutinin-mediated membrane fusion in late endocytic vacuoles, the vRNPs and the matrix proteins dissociate from each other and disperse within the cytosol. Here, we found that for capsid disassembly, IAV takes advantage of the host cell's aggresome formation and disassembly machinery. The capsids mimicked misfolded protein aggregates by carrying unanchored ubiquitin chains that activated a histone deacetylase 6 (HDAC6)-dependent pathway. The ubiquitin-binding domain was essential for recruitment of HDAC6 to viral fusion sites and for efficient uncoating and infection. That other components of the aggresome processing machinery, including dynein, dynactin, and myosin II, were also required suggested that physical forces generated by microtubule- and actin-associated motors are essential for IAV entry. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Banerjee</LastName>
<ForeName>Indranil</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry, Eidgenossische Technische Hochschule (ETH) Zurich, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miyake</LastName>
<ForeName>Yasuyuki</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nobs</LastName>
<ForeName>Samuel Philip</ForeName>
<Initials>SP</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Health Sciences, ETH Zurich, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schneider</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Health Sciences, ETH Zurich, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Horvath</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Synthetic and Systems Biology Unit, Biological Research Center, Szeged, Hungary.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kopf</LastName>
<ForeName>Manfred</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Institute of Molecular Health Sciences, ETH Zurich, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matthias</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Epigenetics, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. Faculty of Sciences, University of Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Helenius</LastName>
<ForeName>Ari</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry, Eidgenossische Technische Hochschule (ETH) Zurich, Switzerland. ari.helenius@bc.biol.ethz.ch yohei.yamauchi@bc.biol.ethz.ch.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamauchi</LastName>
<ForeName>Yohei</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Institute of Biochemistry, Eidgenossische Technische Hochschule (ETH) Zurich, Switzerland. ari.helenius@bc.biol.ethz.ch yohei.yamauchi@bc.biol.ethz.ch.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>144198-36-7</RegistryNumber>
<NameOfSubstance UI="C072084">dynactin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="C433811">HDAC6 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.1.98</RegistryNumber>
<NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="D024462">Myosin Type II</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.2</RegistryNumber>
<NameOfSubstance UI="D004398">Dyneins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Science. 2014 Oct 24;346(6208):427-8</RefSource>
<PMID Version="1">25342790</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002213">Capsid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004398">Dyneins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055786">Gene Knockout Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006655">Histone Deacetylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054884">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009980">Influenza A virus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007251">Influenza, Human</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008561">Membrane Fusion</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008869">Microtubule-Associated Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008870">Microtubules</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024462">Myosin Type II</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017510">Protein Folding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012261">Ribonucleoproteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025801">Ubiquitin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D053586">Virus Internalization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>

<?xml version='1.0' encoding='utf8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25323695</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>31</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-9203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>346</Volume>
<Issue>6209</Issue>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Science (New York, N.Y.)</Title>
<ISOAbbreviation>Science</ISOAbbreviation>
</Journal>
<ArticleTitle>Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.</ArticleTitle>
<Pagination>
<MedlinePgn>638-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1249830</ELocationID>
<Abstract>
<AbstractText>Small molecules are useful tools for probing the biological function and therapeutic potential of individual proteins, but achieving selectivity is challenging when the target protein shares structural domains with other proteins. The Bromo and Extra-Terminal (BET) proteins have attracted interest because of their roles in transcriptional regulation, epigenetics, and cancer. The BET bromodomains (protein interaction modules that bind acetyl-lysine) have been targeted by potent small-molecule inhibitors, but these inhibitors lack selectivity for individual family members. We developed an ethyl derivative of an existing small-molecule inhibitor, I-BET/JQ1, and showed that it binds leucine/alanine mutant bromodomains with nanomolar affinity and achieves up to 540-fold selectivity relative to wild-type bromodomains. Cell culture studies showed that blockade of the first bromodomain alone is sufficient to displace a specific BET protein, Brd4, from chromatin. Expansion of this approach could help identify the individual roles of single BET proteins in human physiology and disease. </AbstractText>
<CopyrightInformation>Copyright © 2014, American Association for the Advancement of Science.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Baud</LastName>
<ForeName>Matthias G J</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK. Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lin-Shiao</LastName>
<ForeName>Enrique</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK. Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cardote</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tallant</LastName>
<ForeName>Cynthia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pschibul</LastName>
<ForeName>Annica</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Kwok-Ho</ForeName>
<Initials>KH</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zengerle</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Garcia</LastName>
<ForeName>Jordi R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kwan</LastName>
<ForeName>Terence T-L</ForeName>
<Initials>TT</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferguson</LastName>
<ForeName>Fleur M</ForeName>
<Initials>FM</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ciulli</LastName>
<ForeName>Alessio</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee, DD1 5EH, UK. Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK. a.ciulli@dundee.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>PDB</DataBankName>
<AccessionNumberList>
<AccessionNumber>4QEU</AccessionNumber>
<AccessionNumber>4QEV</AccessionNumber>
<AccessionNumber>4QEW</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>097945/Z/11/Z</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>100476/Z/12/Z</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>BB/G023123/1</GrantID>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>BB/J001201/1</GrantID>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>10</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Science</MedlineTA>
<NlmUniqueID>0404511</NlmUniqueID>
<ISSNLinking>0036-8075</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C561695">(+)-JQ1 compound</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001381">Azepines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C441289">BRD4 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015335">Molecular Probes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>GMW67QNF9C</RegistryNumber>
<NameOfSubstance UI="D007930">Leucine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001381">Azepines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018360">Crystallography, X-Ray</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007930">Leucine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015335">Molecular Probes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015202">Protein Engineering</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014230">Triazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
